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Abstract
The design of new, improved NO-donor drugs is an important pharmacological objective
due to the biological importance of nitric oxide. N-Hydroxyguanidines represent a useful class of
NO donors where the mechanism of action is based on the biosynthetic pathway for NO.
Thirty new N-arylalkyl-N’-hydroxyguanidines were synthesized and their vasodilatation
activity examined by myography in rat aortic rings. The observed relaxations were reversed by
ODQ, which is an inhibitor of the guanylate cyclase, implying that this was an NO dependent
vasodilatation. The most active compounds were also tested in the isolated perfused kidney
(IPK) giving the vasodilatation properties. Preliminary results indicated that N-phenyl-N’-
hydroxyguanidine showed the best pharmacological profile with EC50 = 19.9 μM and ca. 100%
reversibility with ODQ. A series of N-phenylalkyl-N’-hydroxyguanidines were synthesised. NO
donor activity was found to be fairly constant up to three methylene groups, and then decreased.
Substitutions in the benzene ring of N-phenylethyl-N’-hydroxyguanidine demonstrated that
various electron-withdrawing and electron-donating groups in the para position did not
significantly affect the NO donor activity of this series of analogues. The nitro and
trifluoromethyl substituted compounds gave the best biological profiles. Additionally, a novel
heterocyclic, N–furfuryl-N’–hydroxyguanidine possessed very promising vasodilatation
properties. In general, almost all the N-arylalkyl-N’-hydroxyguanidines behaved as potent NO
donors in the rat aorta assay.
In order to establish the influence of the free NH2 group in the hydroxyguanidine
functionality on the vasodilatation properties, N,N-dimethyl and N-methyl-N’-
hydroxyguanidines were successfully synthesised. Unfortunately, they have not been tested yet in
the biological assay. However, their NMR spectra showed some unusual features and their
detailed analysis and X-ray data are presented herein.
In addition a series of hydroxamic acids was synthesised and the NO donor activity
investigated using the same biological methodology. It was found that the
3-phenylpropionohydroxamic acid was the most potent compound with EC50 = 6 μM and
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ODQ = 96%. However, behavior in the IPK indicated that hydroxamic acids did not undergo
the same biological pathway as in the rat aorta.
Two different types of enzyme-activated pro-drugs were designed using
N-hydroxyguanidines as the NO donating molecule. Synthetic studies towards these targets were
carried out using various synthetic approaches. The desired molecules have not yet been
synthesised but the chemistry explored so far has indicated potentially more successful
approaches that could be attempted.
THEORETICAL BACKGROUND
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1.1 Introduction
Before 1987, nitric oxide (NO) was mostly mentioned as a molecule that participated in
complex reactions which caused a “photochemical smog”. However, in 1987, two publications
indicated that the sought-after “endothelium-derived relaxing factor” (EDRF) was in fact NO.1
NO is small, diatomic, inorganic radical. Its physical and chemical properties have been well
known for many years, but its biological activity was discovered about twenty years ago. It is
known that a deficiency of endothelial NO causes the pathogenesis of vascular dysfunctions,
including coronary artery disease, atherosclerosis, hypertension, diabetic vasculapathy and others.
In addition, NO is involved in the inhibition of platelet aggregation, neurotransmission (Viagra
reverses impotence by enhancing a NO-stimulated pathway) and immune regulation.2-5 Due to
its instability, it is very difficult to introduce NO into biological systems. Therefore, the
development of synthetic agents that possess the ability to release NO under biological
conditions has become a very important issue. On the other hand, inappropriate production of
nitric oxide can also lead to a series of diseases such as neurodegeneration, rheumatic disorders,
septic shock and diabetes mellitus. The biochemical generation of NO is stimulated by nitric
oxide synthase (NOS).3, 6, 7 As a result, many research groups have started working on potential
NO donor drugs as well as on isoform-specific NOS inhibitors.
1.2 Nitric oxide formation
Since the importance of nitric oxide has been established in many physiological processes, an
enormous number of studies have been carried out in order to understand its mechanism of
action. In general, endogenous production of NO mainly proceeds via a two-step enzymatic
reaction shown in Scheme 1.1.1, 3, 8 In the first step, L-arginine (L-Arg) is hydroxylated to give the
stable intermediate Nω-hydroxy-L-arginine (NHA) and 1 mol of NADPH and O2 are utilized. In
the next step, NHA is further oxidized to citrulline and NO, with the consumption of 0.5 mol of
NADPH and 1 mol of O2. An enzyme-bound heme derives electrons from NADPH and
participates in oxygen activation in both steps.
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Scheme 1.13
The enzyme responsible for the production of NO is nitric oxide synthase (NOS). Three
isoforms of nitric oxide synthase have been identified. They are divided into groups based on
their location in the human body: neuronal (nNOS), inducible (iNOS) and endothelial (eNOS).
The most important properties of the NOS are summarized in Table 1.1.
Table 1.1 Properties of NOS isoforms3, 9
NOS Locations Characteristics Major BiologicalFunctions
nNOS (NOS-I) Brain, spinal cord, peripheral Constitutive,Ca2+ dependent Neuromediator
iNOS (NOS-II) Macrophages, other tissues Inducible,Ca2+ independent
Host defender,
cytotoxic
eNOS (NOS-III) Endothelium Constitutive,Ca2+ dependent
Vasodilator tone
modulator
Each of the isolated subtypes of NOS is associated with a different physiological function.
Neuronal NOS generates nitric oxide as a neurotransmitter which is crucial for brain
development, memory and learning. eNOS mediates endothelial production of NO and plays an
important role in vascular biology. It controls smooth muscle relaxation and inhibits platelet
aggregation. iNOS produces NO as a cytotoxic agent in activated macrophage cells. It helps the
immune system to fight against microorganisms and tumor cells. The constitutive isozymes
(nNOS and eNOS) generate relatively small amounts of NO and in order to be active they
require the presence of Ca2+ and calmodulin. However, iNOS produces relatively large amounts
of NO and already possesses bound Ca2+ and calmodulin.3, 9-11
THEORETICAL BACKGROUND
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Mammalian NOS are made up of an N-terminal oxygenase domain and C-terminal reductase
domain. NOS monomers are very large (~133-161 kD per monomer). The oxygenase region
binds iron protoporphyrine IX (heme), tetrahydrobiopterin (BH4) and L-arginine, while the
reductase region binds FMN, FAD and NADPH as shown in Figure 1.1. In order to possess
activity, two NOS polypeptides must form a homodimer, however, recently it has been reported
that they actually exist as tetramers of two NOS monomers connected by two calmodulins,
which promote electron transfer (ET) between them.9, 10, 12
Figure 1.1 The structure of NOS dimer and the path of electron transfer12
By cloning the subtypes of NOS it has been revealed that they share only 50% primary
sequence homology, possibly because they differ from each other in regulatory aspects.
However, interspecies similarity of each isozyme is rather high (81-93% identical). Based on the
crystal structures of the oxygenase domain of the murine iNOS monomer, murine and human
iNOS dimers, human and bovine eNOS dimers and rat brain nNOS, it has been found that
there is a high degree of similarity within the catalytic center between the NOS isoforms.
However, employing a novel approach to examine the active site of the three NOS using various
aryldiazenes indicated that the topologies of the active site of the three subtypes are actually
different.10 The size of the active site decreases in the order nNOS > iNOS > eNOS. Even
though the three isoforms of NOS possess a lot of similarities, the subtle structural differences
may still allow the development of subtype-specific inhibitors and substrates.4, 10, 12
NADPH FAD FMN CaMHOOC
BH4 Arg
Fe
Arg BH4
Fe
NADPHFMN FADCaM COOH
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The results of crystallographic studies indicated that the endogenous substrates (L-Arg and
NHA) of NOS bind to the enzyme close to the heme by a network of hydrogen bonds.
1.3 Chemical reactivity of nitrogen species
Due to its structure nitric oxide can undergo various chemical transformations. NO can be
oxidized and reduced leading to its conversion to various reactive nitrogen species (RNS). One
of the most important RNS is peroxynitrite. It is a strong oxidizing and nitrating agent which
causes molecular damage leading to disease-causing cellular dysfunction. Nitric oxide can react
with molecular oxygen (O2), superoxide anion (O2-) or transition metals (M) to produce RNS
such as N2O3, NO2, NO2-, NO3-, peroxynitrite (OONO-), and metal-nitrosyl adducts (Figure
1.2). Since NO reacts with superoxide anion to give peroxynitrite anion, the production of this
species is inevitably a source of hydroxyl (OH•) and nitrogen dioxide (NO•2) radicals. These
reactive species, when generated in high concentrations, can induce oxidative stress, and
therefore be the source of toxicity.2, 3
Figure 1.2 Chemical reactions of nitric oxide3
Nitrogen oxide can be rapidly oxidized, which leads to the nitrosonium ion (NO+). This
species reacts with nucleophiles such as alcohols (ROH), thiols (RSH) and secondary amines
(RR’NH) to generate RO-NO, RS-NO or RR’N-NO, respectively (Figure 1.3).
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Figure 1.3 Oxidation of NO3
NO can also undergo one-electron reduction to nitroxyl ion (NO-), which is rapidly
transformed to N2O under physiological conditions. Other competing reactions are illustrated in
Figure 1.4.
Figure 1.4 Reduction of NO3
1.4 Nitric oxide synthase inhibitors
Despite the fact, that NO is a free radical it plays an important role in many physiological
processes and its presence is crucial for the normal function of the human organism. However,
overproduction of nitric oxide in some cases may cause deleterious effects. As mentioned
before, iNOS produces a large amount of NO, which sometimes can lead to a variety of
diseases, including sepsis, tissue damage, arthritis and inflammation. Therefore, selective iNOS
inhibitors would be beneficial for the treatment of these pathological conditions.12-15 On the
other hand, it has been reported that NO overproduction by nNOS is responsible for
neurodegenaration during stroke, chronic headaches, Parkinson’s disease, Alzheimer’s disease,
and Huntington’s disease. Therefore, the development of potent nNOS inhibitors also would
bring an enormous advantage to medicinal chemistry and pharmacology. However, as previously
THEORETICAL BACKGROUND
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described the differences between various isoforms of NOS are not very significant and the
development of specific inhibitors is very demanding. In spite of this problem, several classes of
compounds have been recognized as potential NOS inhibitors.9, 12, 13, 15
1.4.1 L-Arginine and L-Arginine Derivatives
In general, derivatives of the endogenous substrate of NOS isoforms, L-arginine, can act as
inhibitors or substrates.14 Many analogues of L-arginine have been synthesized and investigated
as potential inhibitors of NOS. In fact, many derivatives of L-arginine are capable of inhibition
of NOS. Generally, they are modified at one or both of the terminal guanidine nitrogens, as
shown in Figure 1.5.3
n R1 R2 R3 name
3 NCH3 NH2 COOH L-NG-methyl-arginine (L-NMA) (1)
3 NNO2 NH2 COOH L-NG-nitro-arginine (L-NNA) (2)
3 NNH2 NH2 COOH L-NG-amino-arginine (3)
3 NCH2CH3 NH2 COOH L-NG-ethyl-arginine (4)
3 NCH2CHCH2 NH2 COOH L-NG-allyl-arginine (5)
3 NOCH3 NH2 COOH L-NG-methoxy-arginine (6)
3 NH CH3 COOH L-iminoethyl-omithine (L-NIO) (7)
3 NH SCH3 COOH S-methyl-L-thiocitrulline (L-SMTC) (8)
3 NH SCH2CH3 COOH S-ethyl-L-thiocitrulline (L-SETC) (9)
4 NH CH3 COOH L-iminoethyl-lysine (L-NIL) (10)
4 NH CH3 CH(OH)CH(OH)
N-[5(S)-amino-6,7-
dihydroxyhepnyl]ethanimidamide (11)
Figure 1.5 Structure of L-arginine analogues and amino acid-based NOS inhibitors3
IC50 and Ki values for these inhibitors against various NOS isoforms have been obtained. Most
of these compounds are potent inhibitors however they show rather poor selectivity for NOS
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subtypes. L-NMA (1) and L-NNA (2) are used as the prototypic inhibitors for in vitro and in vivo
testing due to their chemical stability, water solubility and low toxicity. They were found to be
more potent inhibitors of nNOS and eNOS than of iNOS. The first amino acid-based inhibitor
selective for iNOS (IC50= 5 µM) vs. eNOS (IC50= 138 µM) was L-NIL (10). Further
modifications of this compound, by replacing the carboxylic acid moiety with a vicinal glycol, led
to the analogue (11) which was 700-fold more selective for iNOS than for eNOS. Alternatively,
L-SMTC (8) and L-SETC (9) showed greater specificity for nNOS than iNOS or eNOS.3, 13, 14
1.4.2 Non-amino Acid Inhibitors
In general, derivatives of arginine can be considered as analogues of guanidine. Therefore
different amidine compounds (Figure 1.6) have been prepared and investigated as NOS
inhibitors.
Figure 1.6 Structures of guanidine derivatives and similar analogues3, 13
Guanidine itself is neither an inhibitor nor a substrate of NOS. However, methylguanidine
and ethylguanidine possess the ability to inhibit NOS, but they are much less selective than the
earlier described L-NMA. The only important molecule from this class of compounds is
aminoguanidine (Fig. 1.6-2, R=NH2). It has been reported that it plays a beneficial role in
various experimental models of inflammation and septic shock.
The simple alkyl isothioureas (ITU) have been known to be potent inhibitors of the three
human NOS subtypes since 2001. It has been found that substitution on the sulfur atom is
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critical for activity. On the other hand, modification of the nitrogen atoms resulted in the loss of
the inhibitory properties. Based on the reported 1/Ki values there is a borderline between the
size of the alkyl substituent and the compound’s activity. If the alkyl groups were too small
(R = H), too large (R = (CH2)3CH3) or too bulky (R = C(CH3)3), the inhibitor activity decreased
significantly. The optimal length chain for S-alkyl-ITU is between methyl and propyl. Overall,
the isopropyl group seemed to be the most beneficial alkyl group for the inhibitory potency.3, 12, 13
The simplest amidines, namely formamidine and acetamidine have been found not to be
NOS inhibitors. However, propionamidine and longer chain amidines revealed some activity
towards NOS inhibition. The optimal length of the carbon chain for the alkyl amidine is
between ethyl and butyl, which is similar to that for the S-alkyl-ITU.
On the other hand cyclic amidines are much more promising inhibitors of iNOS compared
to L-NMA. Some of the synthesized and examined analogues of cyclic amidines are shown in
Figure 1.7.3
R1 R2 name
H H 2-iminopiperidine (12)
CH3 H 4-methyl-2-iminopiperidine (13)
H CH3 6-methyl-2-iminopiperidine (14)
CH3 CH3 4,6-dimethyl-2-iminopiperidine (15)
H CH2C6H11 cyclohexymilmethyl-2-iminopiperidine (16)
Figure 1.7 Structure of cyclic amidines3
It has been reported that substitution of 2-iminopiperidine ring increased the inhibitory potency
of the new derivatives towards iNOS. Recently, a novel cyclic amidine analogue (1S, 5S, 6R, 7R)-
7-chloro-3-imino-5-methyl-2-azabicyclo[4.1.0]heptane hydrochloride has been synthesized
(Scheme 1.2) and examined as a potent iNOS inhibitor. It was found that it revealed 10-fold
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more selectivity for human iNOS over human eNOS. The preliminary pharmacological studies
indicated that it can be considered as a potential therapeutic agent.
Scheme 1.23
N
H
NH
CH3
H
H
H
Cl
HCl
ONO-1714
Indazoles also act as NOS inhibitors. Several nitro derivatives have been synthesized
(Figure 1.8). The biological studies showed that nitration at the 5, 6 or 7-position caused an
increase in inhibitory potency. However, the presence of an amino substituent at the 5- or
6-position made the corresponding compounds less active as seen from the IC50 values.
3, 13
IC50 [µM]Compound
R iNOS nNOS eNOS
H
5-NO2
6-NO2
7-NO2
5-NH2
6-NH2
5.8
177.8
47.3
31.7
0.9
>1000
>1000
0.71
Figure 1.8 Inhibitory activities of indazole derivatives for various NOS subtypes3
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1.5 Nitric oxide donors
Since, NO was identified as the EDRF, the number of compounds which can act as a
potential NO donors has increased dramatically. One of the most well known is glyceryl
trinitrate (GTN), which was used to treat angina pectoris long before its NO donating properties
were discovered.1, 3-5, 8, 16-18 The diversity in the structures of NO donors indicates that their
chemical reactivities and mechanisms of NO production are different. In general, NO is released
by three distinct pathways. The first route involves spontaneous generation of NO through
thermal or photochemical degradation, e.g. S-nitrosothiols, diazeniumdiolates, or oximes.3, 4, 8, 19-22
The second mechanism is based on chemical reactions with acids, alkali metals or thiols. NO is
produced by this route from organic nitrates, nitrites and syndnonimines.3, 6, 16, 23, 24 The last
pathway is an enzymatic oxidation of NO donors such as N-hydroxyguanidines, which require
the presence of NOS or Cyt-P450 to release NO.3, 8, 10, 25-30 Major classes of current NO donors
are summarized in Table 1.2, along with details of the pathway by which NO is generated from
each class, if known. As seen in Table 1.2 some of the compounds are able to produce NO
through more than one mechanism e.g. organic nitrates can also generate NO by enzymatic
catalysis.
Table 1.2 Major classes of NO donors3
Pathway of NO GenerationChemical Class Representativecompounds Non-enzymatic Enzymatic
Organic nitrate
ONO2
ONO2
ONO2
Thiols Cyt-P450, GST,etc.
Organic nitrite
Hydrolysis,
transnitrosation,
thiols, light, heat
Xanthine oxidase,
etc
Metal-NO complex Na2[Fe(CN)5(NO)]·2H2O
Light, thiols
reductants,
nucleophiles
A membrane
bound enzyme
N-Nitrosamine OH-, light Cyt-P450 relatedenzyme
N-Hydroxylnitrosamine Light, heat peroxidases
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Table 1.2 Major classes of NO donors3 (continuation)
Nitrosimine Thiols, light ?
Nitrosothiol
Spontaneous,
enhanced by thiols,
light, metal ions
unknown enzymes
C-Nitroso compound Light, heat ?
Diazetine dioxide
N
N
R1
R2
R3
R4
O
O
Spontaneous, thiols ?
Furoxan & benzofuroxan
NN
O
RR
O
Thiols Unknown enzymes
Oxatriazole-
5-imine Thiols ?
Syndonimine
Spontaneous,
enhanced by light,
oxidants, pH>5
Prodrugs require
enzymatic
hydrolysis
Oxime Spontaneous,O2/FeIII-porphyrine
Cyt-P450
Hydroxylamine
Autoxidation
enhanced by metal
ions
Catalase/H2O2
N-Hydroxyguanidine Oxidants NOS, Cyt-P450
Hydroxyurea
H2O2/CuZn-SOD
or ceruloplasimin,
H2O2/Cu2+, heme-
containing proteins
Peroxidase
Hydroxamic acid ? Guanylate cyclase
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For this project the classes of NO donors which contain a N-hydroxyl functionality are of
major interest. These compounds require enzymatic oxidation to generate NO, either via NOS
or some other oxidizing enzyme.
1.5.1 N-Hydroxyguanidines
Recently, it has been proven that NOS enzymes are able to generate nitric oxide via the
oxidation of many non-α-amino acid monosubstituted N-hydroxyguanidines, including N-alkyl-
and N-aryl-N’-hydroxyguanidines.3, 10, 30-33 Some of these compounds were shown to be as active
as the endogenous substrate, N-hydroxyarginine. On the other hand, some proved to be
selective for only one NOS isoform.10, 30 N-Hydroxyguanidines can be oxidized and generate
nitric oxide, not only by NOS, but also by other oxidizing enzymes such as cytochromes P450,
xanthine oxidase and NADPH oxidoreductase. They also undergo chemical oxidation with the
production of NO or HNO (nitroxyl) depending on the oxidizing agent.3, 10 Due to the
properties of N-hydroxyguanidines there has been a lot of interest in the development of new
guanidine-based NO donor drugs.
Synthesis of N-Hydroxyguanidines
N-Hydroxyguanidines can by synthesized in various ways, depending on the structure of the
final compound. Most techniques involve the reaction of electrophilic nitrogen rich species with
hydroxylamine or its derivatives. The most popular and widely employed procedure involves
cyanamides as key intermediates as shown in Scheme 1.330
Scheme 1.330
This method has been successfully utilized previously and was shown to be a reliable
procedure for the preparation of NHA, homo-NHA and nor-NHA. However, only
monosubstituted N-hydroxyguanidines can be synthesized using the above procedure.10
The second method employs the thioureas as starting materials as presented in Scheme 1.4.
THEORETICAL BACKGROUND
17
Scheme 1.43, 10
There are three methods for the conversion of thioureas to N-hydroxyguanidines. Firstly, the
thiourea can be methylated to yield a reactive intermediate (17). The replacement of the
thiomethyl group is then achieved by reaction with hydroxylamine, most of the time in the
presence of silver nitrate or mercuric chloride.10, 34 Another method employs mercuric oxide
which reacts with the thiourea to give a cyanamide.26, 35 This compound is then treated with
hydroxylamine to give the final product. However, due to the high toxicity of the previously
used reagents, the aminoiminomethanesulfonic acids have gained a lot of interest since their
synthesis is reasonably mild. The key transformation involves activation of the sulfur in the
thiourea through S-oxidation, followed by its displacement by hydroxylamine. A variety of
oxidizing agents have been employed, among them a H2O2/Na2MoO4 mixture, peracetic acid
and quaternary ammonium permanganate.36-39 The methods presented in Scheme 1.4 can be
successfully used in the synthesis of disubstituted derivatives.
Ziman reported the synthesis of tri- and tetrasubstituted N-hydroxyguanidines using
chloroformamidium chlorides, generated from ureas or thioureas, as reactive intermediates.
These were reacted with THP protected hydroxylamine as shown in Scheme 1.5.40
Scheme 1.540
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Kalvins et al. recently developed a convenient reagent, 1-benzyloxy-3-
benzyloxycarbonylthiourea, for N-hydroxyguanylation.41 This reagent can be treated with an
amine to give N- and O-protected hydroxyguanidine derivatives as illustrated in Scheme 1.6.
Catalytic hydrogenation is then used to remove protecting groups and give the final product.
Scheme 1.641
Recently, Marletta et al. reported a concise and general method for the preparation of
N-hydroxyguanidines from primary amines (Scheme 1.7).42 It is a one-pot procedure followed by
the deprotection under non-reducing conditions, which is a big advantage compared to Kalvins’
method, because the N-hydroxyguanylation is possible in the presence of the reduction sensitive
moieties. Both these recent methods can be employed to introduce the hydroxyguanidine
functional group into relatively complex molecules.
Scheme 1.742
Yoshioka et al. published a procedure for the preparation of unsymmetrical
N-hydroxyguanidines, using benzotriazole intermediates as presented in Scheme 1.8.43 A variety
of different N-hydroxyguanidines have been obtained using this approach in good yields.
However, the major disadvantage of this method is the purification step in which basic alumina
is used as a packing for the column chromatography, which is known to be a quite expensive
material.
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Scheme 1.8
Physical properties
Most N-hydroxyguanidines are stable at -20 ºC. Some of them are very hygroscopic.
Therefore, special precautions must be taken in order to avoid their decomposition. They are
also unstable with respect to base. In most cases they are synthesized as salts of a strong acid and
stored under nitrogen. N-Hydroxylation of the guanidine moiety decreases the basicity. Thus for
L-arginine the pKa=13.6 while it is 8.1 for N-hydroxyarginine (NHA).3, 4, 10 The structure of
NHA has been depicted in three different ways, as the oxime tautomer (A), the imine tautomer
(B1 or B2), and the protonated species (C) as shown in Scheme 1.9. According to Fukuto et al.,
the structure (C), is the most likely form of NHA bound to NOS.10, 44
Scheme 1.93
N-Hydroxyguanidines as NO donors
Production of NO from L-arginine is a result of the oxidation of its guanidine fragment by
NOS. Therefore, it was anticipated that molecules which possess the guanidine or
hydroxyguanidine moiety in their structure would act as NO donors via enzymatic action. Very
few guanidine-containing compounds have been found to be substrates for NOS. However,
endogenous NHA, N-hydroxy-L-homoarginine, N-aryl-N’-hydroxyguanidines, and some
N-alkyl-N’-hydroxyguanidines have been shown to be substrates. The way these compounds are
oxidized by NOS is similar to NHA, but the exact mechanism is not clear. There are several
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proposed mechanisms, which involve various intermediates during the oxidation of
N-hydroxyguanidines. However, the major products are ureas and NO, with cyanamides as a
minor secondary metabolite (Scheme 1.10).3, 4, 10, 28, 29, 44-50
Scheme 1.103
This unexpectedly limited number of the exogenous substrates for NOS indicates that this
enzyme needs very specific structural features. Structural studies showed that with attachment of
a suitable hydrophobic group such as n-butyl or propyl to the N-hydroxyguanidine, a substrate
for NOS could be obtained.10 The crystal structure of NHA bound to NOS indicated that the
substrate binds close to the heme using a network of hydrogen bonds, in an almost identical
manner to L-arginine.10, 51 However, an additional hydrogen bond is present between the
NHA-hydroxy oxygen and the amido hydrogen of G365 as shown in Figure 1.9.
Figure 1.9 The crystal structure of NHA bound to NOS.51
The N-hydroxy group is tilted away from iron towards the protein backbone which indicates
that NHA does not ligate Fe(III) heme. The NHA binding mode is almost identical for all three
isoforms of NOS. The subtle variation is that the hydroxyguanidine moiety is planar in eNOS,
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but not in iNOS or nNOS, although it is not clear why.3, 51 Some crystal structures with different
N-hydroxyguanidines bound to NOS have also been obtained and will be discussed later in this
chapter.
However, as mentioned before, not only NOS is able to oxidize the N-hydroxyguanidines,
but also the family of cytochrome P450 enzymes possess the ability to oxidize most of these
compounds.47 The result of this reaction is the formation of nitrogen oxides (NO/NO2
-/NO3
-),
the ureas and also the corresponding cyanamides. The mechanism for this oxidation proposed
by Mansuy et al. is shown in Scheme 1.11.52 It involves a one-electron oxidation of
N-hydroxyguanidines, or amidoximes, with formation of an intermediate iminoxy radical, which
is further oxidized to the nitrosoimine. Elimination of HNO produces RCN and HNO (route
A) while further oxidation of the nitrosoimine produces RCN and NO (route B).
Scheme 1.113, 4, 10
The chemical oxidation of N-hydroxyguanidines and their derivatives was studied by Fukuto
et al.45 Their studies indicated that various oxidants led to different products. It was found that
lead tetraacetate and potassium ferricyanide/hydrogen peroxide generated NO (Scheme 1.12),
while other oxidants (Fe-(III), PbO2, Ag2CO3 and peracids) produced HNO. The organic
product of the oxidation of N-hydroxyguanidines can be either the corresponding urea or the
cyanamide, depending on the oxidants.3, 4, 10, 45
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Scheme 1.123
Biological Activities and Applications
N-Hydroxyguanidines were reported as biologically interesting compounds long before the
biosynthesis of NO was established. In 1973 DeGrazia et al. reported the synthesis of a series of
3,4-dihydro-2(1H)-isoquinolinecarboxamidoximes (18) and their evaluation for antihypertensive
activity in two hypertensive rat models. The results indicated that N-hydroxyguanidines could be
a potent, novel class of antihypertensive agents.25
Scheme 1.1325, 27
Ten years later, Khwaja et al. published the synthesis of a new series of N-hydroxyguanidines
as shown in Scheme 1.13, with an aromatic (19) or heterocyclic ring (20).27 Their anticancer and
antiviral activities were tested using L1210 leukemia cells and chicken embryo fibroblasts
infected with Rous sarcoma virus, respectively. Evaluated compounds exhibited cytotoxicity in
leukemia cells and an anti-tumor activity in vivo.27 In addition, Wikberg et al. studied
N-hydroxyguanidines for their electron acceptor activity in the xanthine oxidase (XO) catalysed
oxidation of xanthine. In their research they found that N-(2-chloro-3,4-
dimethoxybenzylideneamino)-N’-hydroxyguanidine (PR5) was very effective as an alternative
electron acceptor. PR5 possessed a significant protective effect against the induction of
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myocardial necrosis and the arrhythmias in a heart ischemia and reperfusion model. However,
the mechanism of action of PR5 remains elusive and requires further study.53
Scheme 1.1453, 54
Recently, the same group synthesized a series of novel N-amino-N’-hydroxyguanidines (21)
and also evaluated them for the electron acceptor activity in the XO-catalyzed oxidation of
xanthine. It was found that compounds bearing nitro groups possessed the highest acceptor
activity, but also three other derivatives showed reasonably good biological profiles.54 These
novel, XO electron accepting N-hydroxyguanidines can be potent therapeutic agents for the
protection of tissues during conditions related to the ischemia-reperfusion. Additionally,
Guanoxabenz (Scheme 1.14), which is a structurally related to the N-hydroxyguanidines tested
by Wikberg et al., has been used clinically as an antihypertensive agent.54 Recently, NitroMed has
claimed that NHA and other derivatives showed potential to be therapeutics for vasodilatation
dysfunctions, hypoxia, cardiovascular disorders and even loss of memory.10
N-Alkyl-N’-Hydroxyguanidines
As most substrates of NOS are L-arginine or NHA derivatives, simple guanidines and
isothioureas were tested as potential NOS substrates. However, it was found that Nω-methyl-L-
arginine, aminoguanidine and S-ethyl-isothiourea actually act as strong NOS inhibitors.3
Xian et al. synthesized and tested several N-alkyl-N’-hydroxyguanidines in order to examine their
activity with NOS.55 Table 1.3 is a summary of their findings.
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Table 1.3 NO formation [nmol/min/mg protein] from oxidation of various N-alkyl-N’-
hydroxyguanidines in the presence of NOS*55
iNOS nNOS eNOS
R = ethyl 3 (3%) 6(1%) 4 (6%)
R = n-propyl 18 (15%) 418 (70%) 17 (24%)
R = iso-propyl 38 (32%) 450(76%) 27 (38%)
R = n-butyl 50 (42%) 380 (64%) 14 (20%)
R = sec-butyl 14 (12%) 107 (18%) 3 (4%)
R = iso-butyl 6 (5%) 14 (2%) 7 (10%)
R = tert-butyl 0 (0%) 0 (0%) 0 (0%)
R = n-pentyl 38 (32%) 185 (31%) 0 (0%)
R = iso-pentyl 29 (24%) 39 (6%) 0 (0%)
R = n-hexyl 3 (3%) 24(4%) 0 (0%)
R = cyclohexyl 4 (3%) 19 (3%) 0 (0%)
*The initial rate of NO synthesis was determined at 37 ºC using a spectrophotometric oxyhemoglobin
assay for NO. The concentration of substrate was 0.5 mM. The rates were also expressed as a percentage
of those found for NHA.
The parent N-hydroxyguanidine is not a substrate of NOS. However, the introduction of
small alkyl substituents produced new derivatives that are actually substrates for all NOS
subtypes. When an ethyl group was attached to the N-hydroxyguanidine very low activity was
detected. The elongation of the alkyl chain up to the four methylene groups increased the
reactivity of the tested compounds. Further extension, e.g. to n-pentyl, caused the activity to start
to decrease. On the other hand, bulky substituents such as tert-butyl or cyclohexyl destroyed
activity completely. Therefore, the alkyl substituents can not be too small, too large or too bulky
in order to maintain activity. In general, it has been found that simple exogenous compounds
could be oxidized by NOS in a similar fashion to NHA.10, 11, 56
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The structure – activity relationships indicated that potential NOS substrates should possess:
1) a N-hydroxyguanidine functional group, which could anchor the substrate in the NOS
active site;
2) a hydrophobic chain that interacts preferentially with the hydrophobic cavity in the NOS
active site.
Additionally, Li et al. have published the crystal structures of rat nNOS complexed with
N-butyl-N’-hydroxyguanidine (BHG) and N-isopropyl-N’-hydroxyguanidine (IHG), which are
the most potent compounds among the N-alkyl-N’-hydroxyguanidines (Figure 1.10).57
Figure 1.10 Schematic structures of BHG bound to nNOS vs IHG bound to nNOS.57
As presented above, the two compounds have quite different binding modes. BHG binds to
the enzyme active site in a similar manner to the endogenous NHA. The only difference is in the
position of the butyl group, which is tilted toward Gln478 and Val567 away from the binding
site, while the methylene carbons of NHA are directed toward the active site. However, in the
case of IHG, the isopropyl-substituted nitrogen occupied the space which is normally taken by
the hydroxy-substituted terminal nitrogen. This surprising binding mode of IHG gives new
details about the oxidation mechanism of N-hydroxyguanidines.10, 57 Studies done by Mansuy
et al. with Val567 mutants of nNOS indicated that position of the hydrophobic isopropyl group
of Val567 is closely related to the stability of the active site, the substrate recognition and the
biosynthesis of the natural and exogenous substrate to NO.58 Recently, the same group reported
their findings relating to the relationship between the structure of N-hydroxyguanidines and
their binding to iNOS.31, 59 They found that the binding affinity is maximal for the compounds
bearing a butyl or n-pentyl chain, Kd=20 μM and 100 μM respectively.60 However, in the case of
N
N
NH
H3C
H
H
H
O
OH
O
O
Glu592
Trp587 Gln478
Pro565 Val567
Phe584
N-butyl-N'-hydroxyguanidine
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an n-hexyl chain the binding affinity dropped significantly. In general, it was determined that the
binding properties of the N-hydroxyguanidines were mainly dependent on the aromatic or
aliphatic character of the tested compounds and the N-alkyl-N’-hydroxyguanidines showed
significantly higher affinities for iNOS than the aryl derivatives. Mansuy et al. also claimed that
N-(4-chlorophenyl)-N’-hydroxygaunidine was not a specific substrate for iNOS even though
previously it was reported as an iNOS-specific substrate.60
N-Aryl-N’-Hydroxyguanidines
Recently, Renodon-Cornière and co-workers synthesized several new N-aryl-N’-
hydroxyguanidines, and related derivatives, as potential NOS substrates.30, 48 Results showed that
nNOS, eNOS and iNOS possessed different affinities toward N-aryl-N’-hydroxyguanidines
(Table 1.4).
Table 1.4 NO formation [nmol/min/mg protein] from the oxidation of monosubstituted N-aryl-N’-
hydroxyguanidines catalyzed by eNOS, nNOS, iNOS*.30
iNOS nNOS eNOS
R = – C6H5 20 ± 3 1.5 ± 0.5 < 0.2
R = – 4-F-C6H4 41 ± 6 4.5 ± 1 < 0.2
R = – 4-Cl-C6H4 13 ± 3 < 0.2 < 0.2
R = – 4-CH3-C6H4 17.5 ± 4 < 0.2 < 0.2
R = – 4-OH-C6H4 16.5 ± 3 8.5 ± 1 < 0.2
R = – 4-CH3O-C6H4 8 ± 2 3.5 ± 1 < 0.2
R = – 3-NH2-C6H4 3.5 ± 1 2.5 ± 1 6.5 ± 2
R = – 4-NH2-C6H4 8 ± 2 4.5 ± 1 < 0.2
R = – 3-CH2OH-C6H4 6 ± 1 < 0.2 < 0.2
*The initial rate of NO synthesis was determined at 37 ºC using spectrophotometric oxyhemoglobin assay
for NO. The concentration of substrate was 20-30 nM.
In general, it was found that there were more substrates for iNOS compared to eNOS and
nNOS. In addition, the best substrates for each of the NOS isoforms differed significantly.
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The testing of iNOS substrates led to general conclusions that:
1) introduction of a substituent in the para position of the phenyl ring leads to better
activity than the introduction of the same substituent in the ortho or meta position;
2) smaller substituents give larger rates of NO formation;
3) the electron-donating substituents give higher rates of NO formation than electron-
withdrawing groups.
Compound (22) (Scheme 1.15), bearing a para-hydroxy substituent, gave the highest rate of
NO formation in the case of nNOS, whereas compounds (23) and (24) (Scheme 1.15) led to the
highest rates of NO production in the case of iNOS and eNOS, respectively.30
Scheme 1.1530
Since some of the N-aryl-N’-hydroxyguanidines proved to be selective substrates, it was
beneficial to obtain crystallographic data. Poulos et al. solved the crystal structure of bovine
eNOS complexed with N-(4-chlorophenyl)-N’-hydroxygaunidine (CPHG). As expected the
hydroxyguanidine functional group in CPHG adapts essentially the same configuration as
N-hydroxyarginine (NHA).61
1.5.2 Hydroxamic Acids
Hydroxamic acids have been known since 1869, but until the 1980s they did not arouse a lot
of interest. Hydroxamic acids are mainly recognized as a strong metal chelators and they are
known to possess a wide spectrum of biological activities including enzyme-inhibitory
properties.62-68 Recently, Papot et al. reported the synthesis and biological evaluation of the
suberoylanilide hydroxamic acid (SAHA) β-glucuronide and β-galactoside as potential prodrugs
for chemotherapy (Scheme 1.16).69, 70
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Scheme 1.1670
SAHA demonstrated antitumour activity in several in vivo models and is currently progressing
through phase III clinical trials; however it exhibits poor pharmacodynamic properties.
Therefore, the non-toxic prodrug design was employed and SAHA coupled with sugar moieties,
which were demonstrated elsewhere to be easily cleaved off by either β-glucuronidase or
β-galactosidase enzymes once the prodrug reached the site of action. However, only the
β-galactoside prodrug was active under the biological assay. Therefore it is a promising candidate
for further in vivo evaluation.70
In addition, some of the physiological roles of hydroxamic acids, such as their hypotensive
effect (a known nitric oxide property) may be due to their ability to generate nitric oxide.
However, there are still very few publications regarding this matter.
Synthesis of Hydroxamic Acids
Hydroxamic acids may be synthesized by treating esters, acid chlorides or acid anhydrides
with hydroxylamine. The most common methods start from the corresponding carboxylic acids
which are transformed into acid chlorides and then reacted with hydroxylamine hydrochloride
(Scheme 1.17).62-64, 71-74
Scheme 1.1775
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Recently, Devocelle and co-workers have published a useful method for the parallel
synthesis of low molecular-weight hydroxamic acids from carboxylic acids and hydroxylamine
using a solid state catalyst (Figure 1.11), namely a polymer-supported 1-hydroxybenzotriazole.73
N
H
S
N
N
N
OO
OH
+ HO R
O
1. activation or
loading step
2. coupling step
R N
H
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+
N
H
S
N
N
N
OO
OH
Figure 1.11 Parallel synthesis of low molecular-weight hydroxamic acids; reagents and conditions;
1. PS-HOBt (1 equiv.), carboxylic acid (1.5 equiv.), DIC (4.5 equiv.), DMAP (0.6 equiv.), CH2Cl2/DMF
(1:1), 3h; 2. hydroxylamine (0.6 – 0.8 equiv.), THF, 5h.73
The one-pot conversion of carboxylic acids to hydroxamic acids has also been recently
reported by Giacomelli et al. (Scheme 1.18).74
Scheme 1.1874
A suitable carboxylic acid is treated with 2,4,6-trichloro[1,3,5]-triazine (cyanuric chloride,
TCT) (0.3 equiv.) and N-methylmorpholine (NMM) (1 equiv.) in CH2Cl2, and
dimethylaminopyridine (DMAP) as a catalyst (0.1 equiv.), followed by hydroxylamine
hydrochloride (1.1 equiv.) in dichloromethane. The corresponding hydroxamic acids are
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obtained in pure form and in high yields. However, the reaction is not fast and requires from 6
to 12 h for completion.74
Hydroxamic acids as NO donors
Koikov et al. synthesized a series of hydroxamic acids and investigated their ability to
generate NO as a result of chemical oxidation using potassium ferricyanide as the oxidant.19
Among the tested hydroxamic acids, acetohydroxamic acid was shown to be the most effective
NO donor. In general, it could be said that the incorporation of the pyridine ring inhibited the
activity of suitable hydroxamic acids. However, there was no reasonable trend observed in the
aromatic sub-series of hydroxamic acids as shown in Table 1.5. The preliminary biological results
showed that about a two-fold activation of soluble guanylate cyclase from human platelets was
observed for benzohydroxamic acid and 2-hydroxyphenylhydroxamic acid.19
Table 1.5 Yield of NO [%] from hydroxamic acids: oxidation (2 × 10-4 M, 4% EtOH/H2O) by
K3[Fe(CN)6] at pH 12.19
% of NO
R = Me
R = Ph
R = 2-HOC6H4
R = 2-MeOC6H4
R = 4-HOC6H4
R = 4-MeOC6H4
R =4-HOC6H4CH2
R = 2-Pyridine
R = 4-Pyridine
R = 2,6-disubstituted pyridyl
22.9
9.0
14.0
5.1
6.5
16.4
-
0.0
0.8
3.1
On the other hand, Marmion and co-workers have recently shown that hydroxamic acids are
effective NO donors by forming highly stable ruthenium(II)-nitrosyls.67, 68, 76 It has been proven
that the generated complex possesses the ability to cause vascular relaxation of rat aorta. Of the
hydroxamic acids investigated, benzohydroxamic acid was shown to be the most effective. In
general, the NO generated from hydroxamic acids was readily transfered to ruthenium(III).
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Furthermore, hydroxamic acids can cause vascular relaxation in a rat aorta by the NO-mediated
activation of enzyme guanylate cyclase.68, 76 Recently, the same group synthesized a series of
Ru(III)-hydroxymato complexes and carried out a UV-VIS spectroscopic investigation in order
to determine the NO-releasing properties of hydroxamic acids. They found out that NO release
was the fastest from benzohydroxamic acids bearing an amino substituent in the ortho and para
position. Their studies indicated that in the case of substituted aromatic hydroxamic acids the
mesomeric as well as the inductive effect of the substituent on the phenyl ring played a crucial
role in the rate of NO release. However, there is still very little known about the enzymatic
mechanism of NO generation from the hydroxamic acids, although Marmion et al. observed that
in order to cause smooth muscle relaxation, hydroxamic acids had to generate nitric oxide and
activate guanylate cyclase.67, 68, 76
1.6 Nitric oxide in biological systems
As discussed in previous sections both overproduction and deficiency of nitric oxide in the
human body can be harmful. Since our work is focused on the development of novel NO donor
pro-drugs the following chapter will consider mainly those disorders which are related to
insufficient NO production.3, 16, 77
1.6.1 Nitric Oxide Donors in Cardiovascular Disease
Nitric oxide plays a critical and diverse role in the cardiovascular system. Under healthy
conditions, NO synthesized in the endothelium has a protective impact on a number of diseases.
The pharmacological mechanisms of action of NO donors can be grouped into five categories:
vasodilatation, decrease in myocardial oxygen consumption, improvement in hemodynamic
performance, increase in myocardial blood flow and antithrombotic effects.1, 3-6, 18, 77-80
Activation of eNOS in endothelial cells is mainly caused by shear stress (flow-dependent
NO formation). This stimulates the vascular production of NO. Kojda et al. reported that eNOS
is also activated by phosphorylation by serine/threonine protein kinase Akt/PKB.78 In addition,
recent studies indicated that receptor-mediated activation of eNOS by agonists such as
acetycholine is also related to phosphorylation by Akt. 78
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NO activates guanylate cyclase (sGC) which catalyzes the formation of cyclic guanosine
monophosphate (cGMP), an intracellular second messenger, followed by kinase-mediated signal
transduction. Activation of sGC is related to the binding of NO to the heme fragment of the
enzyme to form the nitrosyl – heme adduct of sGC (Figure 1.12).1, 81, 82
Figure 1.12 NO activation of cGC by binding to iron in the heme component.1
The distortion of the heme iron out of the plane of the porphyrin ring causes the activation of
sGC and therefore, formation of cGMP. Cyclic GMP induces two protein kinases (PKG I and
PKG II). One of the protein kinases, (PKG I) is an important mediator in vasodilatation and the
inhibition of platelet aggregation.78, 82, 83
The most well understood activity of NO in the cardiovascular system is vasodilatation.
Within the space of twenty years, studies have proved that endogenous NO synthesis is related
to the regulation of vasomotion and blood pressure. It has been shown that pharmacological
inhibition of NO production causes a rise in blood pressure in man. It is well known that
diseases such as stroke and myocardial infraction are caused by the elevated blood pressure.
Therefore, keeping the blood pressure at the proper level may be considered as part of the
vasoprotective action of NO.78
The mechanism underlying NO-induced vasodilatation has been intensively investigated.
Recent findings indicate a major role for cGMP-dependent activation of PKG I which can
phosphorylate various membrane proteins in the sarcoplasmic reticulum (Figure 1.13).
Subsequently, phosphorylation of these proteins causes a decrease in the intracellular Ca2+
concentration.
Other more recent results show that activation of the PKG I phosphorylates a newly-found
protein, the 1,4,5-inositoltrisphosphate (IP3) receptor associated cGMP kinase substrate (IRAG).
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Schlossmann et al. reported that phosphorylation of IRAG is a result of a strong inhibition of
IP3-induced Ca
2+ release from the sarcoplasmic reticulum.84 However, the mechanism of the
interaction between phosphorylated IRAG and the IP3 receptor is not completely understood.78
Figure 1.13 Mechanism of vasorelaxation induced by NO activation of cGMP78
In addition, NO activates Ca2+- dependent K+ channels which causes a rise in the outward
potassium current. The resulting hyperpolarization of the cell membrane evokes vasodilatation.
Recent reports show that this NO action can be both independent and dependent on activation
of PKG I.78
Nitric oxide also participates in the inhibition of platelet aggregation. It has been reported
that hydrophobic polymer materials that slowly release NO can find a wide application in
medicine. Recent studies indicated that it is possible to design such a polymeric surface, which
would mimic the inner surface of blood vessels by locally releasing NO. Platelets play a crucial
role in haemostasis, whose proper functionality is controlled by nitric oxide. Constitutive or
inducible generation of NO, results in the inhibition of platelet aggregation. This process may be
induced by some aggregating factors or endothelial injury and increase of bleeding time. As
discussed above the inhibition is based on the ability of NO to stimulate activation of soluble
guanylate cyclase by binding to the heme moiety of the enzyme. Therefore, NO is an essential
molecule in these diseases where a reduced vasodilatation is coupled to an impaired platelet
functionality such as e.g. atherosclerosis and coronary artery diseases.1, 3, 18, 77, 78, 81
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1.6.2 Nitric Oxide Donors in Cancer
Nitric oxide’s role in the cancer biology is complex and both, NO decrease and increase,
anticancer strategies appear to be effective in preclinical models. The dual role of NO in
carcinogenesis still remains unclear. NO generated by activated macrophages plays a crucial role
in the defense mechanism against tumor cells thanks to its cytotoxic properties. On the other
hand, some studies have indicated that elevated levels of NO are carcinogenic. Thus, far this
dichotomy has challenged the development of novel and valuable anticancer therapeutics.85-90
Several publications reported the expression of iNOS by infected cells or within the tumor
microenvironment. Studies indicated that iNOS activity depends on various factors such as: type
of cancer and tumor stage. The most investigated are breast and colon cancer, but iNOS activity
was also localized in the case of head and neck, lung, prostate, bladder and other types of
cancer. 88
Several anti-cancer strategies have been reported, most of them are based on the NO-
generating molecules.89, 90
1.6.3 Nitric Oxide in the Central and Peripheral Nervous System
Nitric oxide has been found to be a neurotransmitter and/or neuromodulator in both the central
and peripheral nervous system. Its functionality is also controlled by a cGMP-dependent
mechanism. NO production is catalyzed by the isoform nNOS, which is expressed in most
brain regions. The CNS, which has the ability to synthesize NO, plays an important role in the
activation of neuronal receptors for the major excitatory neurotransmitter glutamate. Ongoing
studies have indicated that NO is involved in regulating feeding and drinking, male and female
sex behavior, learning and memory and several other sensory pathways.1, 3, 6, 13, 15, 79
In the case of the peripheral nervous system, it is commonly accepted that the L-arginine-
NO system is responsible for the non-adrenergic, non-cholinergic transmission in various
anatomic sites. This kind of transmission is known as the nitrergic transmission. In addition, NO
production occurs throughout the entire length of the nerve fibre.
On the other hand an overproduction of NO changes its role from the neuromodulator to a
neurotoxic agent. NO is especially harmful under pathological conditions which involve the
synthesis of reactive oxygen species (ROS) and ONOO- formation. All neurodegenerative
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disorders reveal a slow and gradually evolving death of selective neuronal populations.
Therefore, Parkinson’s disease, Huntington’s disease, Alzheimer disease, amyotrophic lateral
sclerosis, multiple sclerosis and ischemia are classified as neurodegenerative processes.3, 6, 13, 15
1.6.4 Other Biological Roles of Nitric Oxide
Recent findings postulated that a rise in the concentration of NO by human monocyte-derived
macrophages is caused by the presence of the HIV envelope glycoprotein. In general, it was
found that NO production was increased in patients who had AIDS. Most of the generated
nitrogen species were detected as a nitrite and nitrate. Some of the reported results indicated that
increasing formation of NO was related to the type of infection while some of them found that
it was irrelevant. The contrasting effect of exogenous NO seems to be dependent on the type of
NO donors, their releasing kinetics, and the dose used in the study.3
On the other hand, it has been known that NO possesses antiviral activity for several
viruses. This includes murine poxvirus, herpes simplex virus, Epstein-Barr virus, coxsackievirus,
and influenza virus. It has been suggested that many pathological consequences of NO proceed
via its interaction with oxygen radicals, producing peroxynitrite. Based on the mechanism of the
antiviral effects of NO, it has been indicated that NO may be a host response modulator rather
than a simple antiviral agent. In addition, NO has been implicated in bone renewal in both
healthy and diseased states. It mediates bone cell metabolism, where it regulates osteoblast and
osteoclast functionality. Incorporation of NO or NO donors (GTN, 3-morpholonosydonimine
(SIN-1), S-nitrosothiols) into osteoclasts in vitro results in a reduction in bone resorption in
comparison with NO synthase inhibitors which increase bone resorption. Recently, it has been
reported that some of the non-enzymatic NO donors possess the ability to inhibit insulin release
in isolated pancreatic islets. In other studies, L-arginine could stimulate glucose-induced insulin
secretion from the pancreas of diabetic rats. In addition, sodium nitrite, sodium nitroprusside
and S-nitroso-N-acetyl-DL-penicillamine increased insulin sensitivity through simulation of NO
production in the liver.3
In summary, it seems that it is much easier to develop new NO donors than actually
introduce them as commonly used therapeutic agents - mainly, because it is very difficult to
obtain tissue selectivity, controlled release and low toxicity of synthesized compounds. However,
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some classes of the NO donors have found clinical applications as will be discussed in
Section 1.7.
1.7 Nitric oxide – releasing pro-drugs
In general, the NO-releasing pro-drugs can be divided into two major classes. The first one
includes the drug hybrids and the second one contains compounds which require enzymatic
activation to release the active NO donor.3-6, 16, 79
1.7.1 NO Donors/Drug Hybrids
One of the most recent innovations in the development of NO donor drugs is the combination
of an NO donor fragment with another currently available drug. This approach has been
designed to reduce the drug’s toxicity on one hand and introduce NO-dependent biological
activity on the other.
RSNO/Drug Hybrids
S-Nitrosothiols represent an important class of NO donor, which contains a single chemical
bond between a thiol group (R-SH) and the NO fragment. The NO generation from
S-nitrosothiols can be induced by various factors such as light, heat, transition metals and
enzymes. Some of the S-nitrosothiols possessed tissue selectivity (GSNO is selective for arteries
over veins). Additionally, they possess less stringent metabolic requirements which may be a
reason that they do not induce tolerance with long-term use. S-Nitrosothiols are also potent
antiplatelet agents. All these properties make them more potent NO donors compared to other
classes of NO donor. Therefore, some pharmaceutical companies decided to modify currently
available drugs with this functional group, mainly due to the fact that NO releasing drugs have
proved to reduce the severity of mucosal injury.16 This activity may be due to NO and
prostacyclin production. In Figure 1.14 the anti-inflammatory effect of NO-NSAIDs is
presented to emphasize their activity in biological systems.
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Figure 1.14 Anti-inflammatory mechanism of NO-NSAIDs3
NitroMed has combined the S-NO moiety as the NO releasing fragment with ibuprofen
(25), diclofenac (26) and other nonsteroidal anti-inflammatory drugs (NSAIDs–Scheme 1.19).
These compounds constitute a unique class of NO-donating drugs with anti-inflammatory and
analgesic properties but with an enhanced gastric safety profile. The major limitation for the
long-term use of standard NSAIDs is their gastrointestinal toxicity.3, 6, 83, 91
Scheme 1.193
Indeed, the nitrosothiol esters of diclofenac revealed therapeutic potential as nonsteroidal anti-
inflammatory agents with milder gastric effects.
NitroMed also attached an S-NO moiety to other bioactive molecules such as steroid and
dopamine agonists as shown in Scheme 1.20.
THEORETICAL BACKGROUND
38
Scheme 1.203
The steroid hybrid (27) was shown to be a more effective inhibitor of the immediate
response in the ascaris-sensitive sheep assay, which indicated that (27) and its derivatives might
be potent therapeutic agents in the treatment of asthma and other respiratory disorders.
Compound (28) revealed an enhanced ability to relax the phenylephrine-induced contraction of
humane corpus cavernosum tissue biopsy samples compared to dipyramidole.
Nitrosylated α-adrenergic receptor antagonists were also synthesized and examined as
therapeutics for the treatment of impotence. It has been found out that they are more potent
than their parent compounds (nitrosylated yohimibine and moxisylyte).3
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Nitrate/Drug Hybrids
Nicox have designed several novel nitroxylated NSAID prodrugs, most of which are nitrate
ester hybrids. Two aspirin hybrids were made 2-acetoxybenzoate-2-(2-nitroxymethyl)phenyl
ester (NCX-4016) and 2-acetoxybenzoate-2-(2-nitroxy)butyl ester (NCX-4215) as illustrated in
Scheme 1.21.3, 87, 91
Scheme 1.213
NCX-4016 and NCX-4215 were originally made to attempt to inhibit the gastric toxicity of
aspirin. This activity may be due to NO and prostacyclin production.
It has been shown that NCX-4016 possesses higher effectiveness as an anti-inflammatory
and antithrombotic agent than aspirin itself. Recently, Rigas et al. published that NCX-4016 is a
novel drug for cancer prevention.87, 89 Interestingly, the same group reported that biologically
active moiety of NO-aspirin is actually the spacer, which gives a reactive quinone methide.87, 92
As well as NO-aspirin hybrids, NO-mesalamine (NCX-456 – Scheme 1.22) showed
improved anti-inflammatory effects and can protect colonic epithelial cells from cytokine-
induced apoptosis. NCX-1000 and NCX-1015 (Scheme 1.22) are steroid/NO bifunctional
donors.93 The addition of the NO-releasing fragment to NCX-1015 enhanced its anti-
inflammatory activity, whilst NCX-1000 shared effective immunoregulatory and antiapoptotic
activities. 3, 4, 18
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Scheme 1.223
Herrero et al. reported that nitroparacetamol (NCX-701) possessed better analgesic and anti-
inflamatory properties than paracetamol in the case of the acute soft-tissue inflammation,
monoarthritis and neuropathic pain models.94 In addition, NCX-701 was safer to administrate
than its parent compound from the gastric point of view.
Furoxan/Drug Hybrids
In order to obtain new vasodilators capable of showing both NO-dependent effects and the
α1-antagonist activities, furoxan analogues of Prazosin were synthesized. The resulting
bifunctional drugs possess various pharmacological properties. Furoxansulfonyl piperidine
derivatives proved to be active for vasodilation and as α1-antagonists. Hybrids with mixed NO-
dependent vasodilator and β-blocking activities (Scheme 1.23) have also been reported. Some of
them displayed both activities, while others were only effective vasolidators or only β-blocking
agents.16
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Scheme 1.233
De Stilo et al. have developed a series of novel 4-phenyl-1,4-dihydropyridines (Scheme 1.24)
modified with a NO-releasing furoxan functionality.3, 95 These hybrid molecules show
vasodilation by both NO dependent and calcium channel antagonist mechanisms.
Scheme 1.243
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Recently, the synthesis of hybrid molecules was reported which combined the furoxan
functionality with nicorandil (Scheme 1.25).3
THEORETICAL BACKGROUND
42
Scheme 1.253
The effect of these compounds was examined on KCl-induced contraction of rabbit thoracic
aorta without endothelium. Compound (30) exhibited a gradual and sustained hypotensive effect
on the anaesthetized rats at 1.5 mg/kg.3, 16
1.7.2 Enzyme – Activated Nitric Oxide Donors
The main target of the NO-related drug discovery effort is to develop strategies for selective
delivery of NO to target cells. One of the techniques is to attach the spontaneously releasing
NO fragments to stable molecules. The stable part of the pro-drug prevents spontaneous NO
release and helps target the drug to a site of action, where it is selectively removed, usually by an
enzyme. Keefer et al. synthesized a novel NO pro-drug class which was based on the
diazeniumdiolate fragments (Scheme 1.26).3, 20, 96, 97
Scheme 1.263
These compounds are stable in neutral aqueous environment but generate NO upon
metabolism by an esterase. Compound (32) was designed as an organ-selective NO donor to
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protect the liver from apoptotic cell death. It caused a rise in liver cGMP levels and protected
rats from apoptosis and hepatotoxicity.
Most recently, Wang’s group attached diazeniumdiolate functional groups to carbohydrate
units, obtaining compounds as shown in Scheme 1.27. These prodrugs are more stable than their
parent diazeniumdiolate salts and can produce NO upon activation by specific glycosidases.3, 20,
98-100
Scheme 1.273
In addition Wang’s group has also designed PSA (serine protease) substrate-nitric oxide
donor pro-drugs as potential therapeutic agents against metastatic prostate cancer (Scheme
1.28).99
Scheme 1.2899
1.7.3 Other strategies
Recently, several research groups have been working on macromolecular NO donors.
Meyerhoff et al. investigated water-soluble poly(ethylenimine)-based nitric oxide donors as
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anti-thromobosis agents in hemodialysis systems.101 Additionally, Schoenfisch et al. synthesized
S-nitrosothiol-modified dendrimers as a potent NO delivery vehicles. Novel dendrimers were
capable of storing about 2 μmol NO/mg when exposed to factors (light and copper) responsible
for the decomposition of S-nitrosothiol, which makes them a promising tool for the site-
selective delivery of NO.22
Berke et al. developed water soluble iron nitrosyl complexes as NO donor prodrugs. They
reported that depending on the character of the ligand, nitric oxide or nitroxyl donors were
produced.23 A similar approach was employed by Mascharak et al. and a set of ruthenium
nitrosyl-dye conjugates have been synthesized and tested for NO release when exposed to visible
light. Since, the complexes produced are photosensitive NO donors, they were easily tracked in
the cellular environment. In addition, one of the conjugates was used to promote NO-induced
apoptosis in MDA-MB-231 human breast cancer cells, which allowed for controlled delivery of
NO to the site of action.102
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2.1 Introduction
The importance of NO in biological systems is fully discussed in the introduction. Recently,
it has been proven that various N-hydroxyguanidines can act as NO donors and some of the
current studies have investigated the importance of the structural and electronic factors which
determine whether a specific molecule would be a good NO donor.1 In addition, more detailed
studies have been carried out to establish what determines their potency and selectivity as
substrates of the three NOS isoforms.
The initial goal was to synthesize a series of new N-arylalkyl-N’-hydroxyguanidines and test
their ability to release NO and cause smooth muscle relaxation in the isolated rat aorta. The
most potent molecules were then tested in the isolated perfused kidney, since the ultimate goal is
to find a selective drug for an acute renal failure. In addition, they were subjected to toxicological
studies. An investigation of their structural and electronic factors will also be carried out in order
to determine how they affect nitric oxide release. The next step will then focused on designing a
NO donor prodrug based on the best parent molecule which will be than attached to a suitable
carrier molecule to allow selective delivery of NO to the desired sites of action.
From the results of biological testing carried out by our collaborators at the University of
Edinburgh, the most effective N-hydroxyguanidine in terms of NO donation so far was
N-phenylethyl-N’-hydroxyguanidine (QZNO193, Figure 2.1) synthesized in the Botting group.2
Figure 2.1 N-phenylethyl-N’-hydroxyguanidine (QZNO193)
This molecule was tested in the isolated rat aorta and revealed good vasorelaxation
properties (see section 2.2). QZNO193 contained a hydrophobic nitrogen substituent, but was
still water soluble due to the polar nature of the N-hydroxyguanidine functionality. The initial
target was therefore to make similar N-hydroxyguanidines with longer alkyl chains and
investigate the effect of chain extension on the biological activity. Therefore, four new analogues
were required with 4, 3, 1 or 0 methylene groups between the nitrogen and benzene ring, as
shown in Scheme 2.1.
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Scheme 2.1
(33) (34)
(35) (36)
As presented in the introduction a number of methods are available for the synthesis of
N-hydroxyguanidines and the target compounds were synthesized using methods based on the
published procedures which employed a cyanamide intermediate.1 However, some modification
had to be introduced in order to improve the purity of the final products.
The general procedure, which has been successfully used in the Botting group, is shown in
Scheme 2.2. The first series of N-hydroxyguanidines was obtained from commercially available
amines.
Scheme 2.2
H
N NOH
NH2.HCl
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2.1.1 Synthesis of cyanamides
For N-arylalkyl-N’-hydroxyguanidines
As shown in the Scheme 2.2, most of the cyanamides were synthesized from the
commercially available amines. The detailed procedure is described based on the
4-phenylbutylcyanamide. Reaction of the 4-phenylbutylamine with cyanogen bromide (1.05
equivalents) and sodium acetate in methanol gave the corresponding cyanamide (37). Analysis of
the crude product by TLC indicated that there was still some of the unreacted amine. Therefore,
the product was partitioned between CH2Cl2 and an aqueous solution of HCl (0.1 M) in attempt
to remove the starting amine. However, this was not completely successful. Therefore, further
purification was required by column chromatography.
4-Phenylbutylcyanamide (37) was obtained in 50% yield and characterized by 1H and 13C
NMR spectroscopy, mass spectrometry and IR spectroscopy. The most clear-cut indications of
the product structure are the presence of a weak signal at 116 ppm in the 13C NMR spectrum
and a sharp peak at 2215 cm-1 in the IR spectrum, which are both characteristic of a nitrile group
(C≡N). The most indicative data for the synthesized cynamides are presented in Table 2.1.
Table 2.1 Yields and characteristic spectral data for synthesized cyanamides
Cyanamide
IR νmax/cm-1
C≡N
δ 13C NMR [ppm]
C≡N
yield [%]
2227 111.3 73
2214 116.0 79
2215 116.2 65
2215 116.0 50
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As seen in Table 2.1 all the cyanamides were synthesized in good yields. The
phenylcyanamide data differed slightly compared to three other cyanamides. This is due to the
electronic effect of the benzene ring directly attached to the cyanamide functional group. The
electron withdrawing effect shifted the 13C NMR resonance upfield by 5 ppm relative to the
other derivatives. Also the C≡N vibration in the IR spectrum is moved to higher wavenumber
compared to three other analogues.
For derivatives of N-phenylethyl-N’-hydroxyguanidines and heterocyclic N-hydroxyguanidines
As mentioned previously N-phenylethyl-N’-hydroxyguanidine showed the best
pharmacological profile. Therefore, various analogoues with electron-donating and electron-
withdrawing groups, mainly in para position of the benzene ring, were synthesized to probe
further the NO donor activity.
For this series, the starting amines had to be obtained by reduction of commercially available
nitriles. The most common procedures for reduction of nitriles to amines employ strong hydride
donors, such as lithium aluminum hydride or catalytic hydrogenation.3 Recently, a new approach
has been published for the catalytic reduction of nitriles.4, 5 Caddick et al. have synthesized a
number of Boc protected amines via a mild catalytic process.5 This method greatly reduces the
toxicity of the reduction due to its catalytic character. Nickel (II) chloride (NiCl2) and an excess
of sodium borohydride (NaBH4) are used as an indirect reducing agent. However, there are a
few more requirements which have to be met in order for the reaction to work. Namely, the
starting nitrile needs to be present in the reaction mixture before formation of the metal boride.
In addition, the nickel boride has to be prepared freshly before the reaction. The excess of
sodium borohydride and an addition of the trapping agent (diethylenetriamine) are crucial in
order to avoid the formation of dimers.5 The advantage of the method is that Boc protection
reduces the water solubility of the synthesized amines and reduces their ability to complex to
metals. This allows for their easier isolation and purification. In general, the reaction conditions
are very mild and the reaction route is shown in Scheme 2.3.
Scheme 2.35
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Even though the general procedure has been reported for N-Boc-benzylamine, various
nitriles required longer reaction times to give products in reasonable yields. Therefore, an
attempt was made to find the optimum requirements for the reduction of commercially available
4-(trifluoromethyl)phenylacetonitrile to the corresponding protected amine. By trying various
reaction conditions a few main conclusions could be drawn. Firstly, the extension of the reaction
time worsened the yield of the reaction. Secondly, going from 1 g of starting nitrile up to 4 g also
negatively affected the overall yield of the reduction. This may be due to the fact that the sodium
borohydride must be added in small portions because the reaction is exothermic and
effervescent. In order to control the reaction temperature the sodium borohydride had to be
added very slowly. The slower addition of a larger amount of borohydride extended the overall
reaction time, which might affect the composition of the reaction mixture as well as temperature
and result in a lower yield.
The synthesis of the Boc-protected 4-(trifluoromethyl)phenylamine (41) eventually resulted
in a satisfactory 61% yield. The amine was characterized by 1H, 19F and 13C NMR spectroscopy
and elemental analysis. The presence of the tert-butyl protons (9H, 1.51 ppm) in the 1H NMR
spectrum confirmed the chemical structure. In addition, the characteristic peak (155.8 ppm) for
the carbonyl group in the 13C NMR spectrum was observed as well as a single peak (-62.8 ppm)
for the CF3 group in the
19F NMR spectrum. The purity of the synthesized material was
confirmed by elemental analysis, which pointed to nearly 100% purity. However, a major
problem was met while trying to remove the protecting group. The first attempt employed 1M
HCl in diethyl ether and reaction was carried out at 0 ºC. In the second one, the temperature was
increased to room temperature, but still the protected amine was recovered. Finally, the
successful deprotection was achieved using 4M HCl in 1,4-dioxane at room temperature. The
previous trials indicated that the strength of the acid and temperature were essential for
favorable deprotection. The desired amine (42) was obtained in 90% yield and characterized by
1H, 13C NMR spectroscopy, MS and elemental analysis. The disappearance of the peak
corresponding to tert-butyl group in the 1H NMR spectrum confirmed successful deprotection.
In addition, removal of the Boc group was indicated by the absence of the carbonyl carbon in
the 13C NMR spectrum. The 4-(trifluoromethyl)phenylamine (42) was almost 100% pure
according to results of MS and elemental analysis (see experimental). The yields for the catalytic
reduction of nitriles to Boc protected amines and for the deprotection to the amine are given in
Table 2.2 for all the other derivatives.
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Table 2.2 Yields for the catalytic reduction of nitriles together with yields from the deprotection step
Boc-protected amine yield [%] amine yield [%]
61
F3C
NH2.HCl
(42)
90
60 98
61 86
75 75
H3C
H
N O
O
(49)
72 100
55 71
54 87
HN
O
O
(55)
63
NH2.HCl
(56)
94
The Boc protected amines were obtained in very good yields and high purity. The next step
involved removal of the Boc group using 4M HCl in 1,4-dioxane and the final amines were
synthesized in excellent yields.
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Once, the required amines were obtained they were subjected to the reaction with cyanogen
bromide in the presence of base (Scheme 2.2). Since the IR and 13C NMR chemical shift are the
most informative data for the C≡N group they are tabulated for all synthesized cyanamides in
Table 2.3.
Table 2.3 Yields of cyanamide formation together with the characteristic data for synthesized
cyanamides
cyanamide
IR γmax/cm-1
C≡N
δ 13C NMR [ppm]
C≡N
yield [%]
2225 116.2 76
2222 117.2 80
2221 117.2 72
2221 116.1 46
2220 115.3 39
2235 117.7 63
HN
C
N
(63)
2223 116.1 58
2223 N/A 30
N-HYDROXYGUANIDINES
58
Table 2.3 Yields of cyanamide formation together with the characteristic data for
synthesized cyanamides (continuation)
2209 117.5 41
2220 117.0 73
2220 116.2 N/A
N/A 115.6 N/A
2221 116.2 56
2220 116.9 47
2227 115.2 78
2222 115.8 78
2221 N/A 40
2224 115.9 75
As illustrated in Table 2.1, all the cyanamides were synthesized in moderate to good yields.
Due to the presence of C≡N group, they tend to dimerize, therefore it was necessary to react
them further as quickly as possible. Oligomerization was observed for the samples left in the
fridge for long periods and masses corresponding to dimers and trimers were seen in the
electrospray mass spectra. The cyanamides obtained were analyzed using 1H and 13C NMR
spectroscopy, mass spectrometry and IR spectroscopy. They all possessed a very sharp peak at
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about 2220 cm-1 in the IR spectrum, as well as a weak signal in 13C NMR spectrum for
quaternary carbon of C≡N group in the region of 115-117 ppm. In the case of 2-(4’-
hydroxyphenyl)ethylcyanamide (62) the X-ray structure was obtained as shown in Figure 2.2.
Figure 2.2 The X-ray crystal structure of 2-(4’-hydroxyphenyl)ethylcyanamide (62)
The X-ray structure confirmed the structure of 2-(4’-hydroxyphenyl)ethylcyanamide (62).
The bond length between C(9) and N(9) is equal to 1.148 Ǻ, which is a correct value for the 
length of the triple bond for the nitrile. In addition, the bond angle of 178 degree for N(8)-C(9)-
N(9) indicates that the bond has almost linear geometry which is in agreement with the
properties of the triple bond.
2.1.2 Synthesis of N-Arylalkyl-N’-Hydroxyguanidines
The synthesized cyanamides were reacted with hydroxylamine hydrochloride in the presence
of a catalytic amount of potassium carbonate as shown in Scheme 2.2. As previously, the
detailed procedure is described based on the reaction of 4-phenylbutylcyanamide (37) with
hydroxylamine hydrochloride.
Purified 4-phenylbutylcyanamide (37) was mixed with hydroxylamine hydrochloride in dry
methanol in the presence of potassium carbonate as a catalyst and heated under reflux for 4
hours under an argon atmosphere. The elemental analysis of the crude product gave
unsatisfactory results probably due to the presence of traces of hydroxylamine hydrochloride
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(found: C 52.1, H 6.7, N 16.3%; calculated: C 54.2, H 7.4, N 17.2%). The purification included
consecutive crystallizations from CH2Cl2. The third crystallization gave the desired
N-hydroxyguanidine (36) in 55% yield. The results of elemental analysis improved significantly
indicating, that the synthesized compound was nearly 100% pure. In addition, the presence of
the single peak in the mass spectrum at 208.1 (M+H+) confirmed the structure of the
synthesized product. N-(4-Phenylbutyl)-N’-hydroxyguanidine (36) was also characterized using
1H and 13C NMR spectroscopy. The structure of the compound was confirmed by the
appearance of new peaks in the 1H and 13C NMR spectra compared to the starting cyanamide.
For example, there are characteristic broad signals in the low field region of the spectrum, which
indicate the presence of –OH, –NH and –NH2 groups. Based on the integration pattern in the
1H NMR spectrum, the NH2 protons were assigned at 7.66 ppm. In addition, one NH proton
should be split into a triplet by the neighboring CH2 protons, and a triplet at 7.92 ppm (1H) was
identified as this NH. In addition two further peaks were observed at 9.76 and 10.34 ppm. In
order to assign these peaks the 2D 1H-15N HMBC as well as 2D 1H-13C HMBC spectra were
obtained. As shown in the Figure 2.3, the singlet at 9.76 ppm is correlated to the carbon at 158.2
ppm, which is characteristic for the quaternary carbon in the hydroxyguanidine functionality.
However, the second signal at 10.34 is not correlated to any carbon.
ppm
8.08.59.09.510.010.511.0 ppm
157.8
158.0
158.2
158.4
158.6
158.8
159.0
159.2
159.4
159.6
159.8
160.0
Figure 2.3 The expanded 2D 1H-13C HMBC spectrum of N-(4-phenylbutyl)-N’-hydroxyguanidine (36)
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Therefore, a 2D 1H-15N HMBC experiment was performed to assign this final proton.
Unfortunately, the spectrum only showed correlations between protons on NH and NH2 groups
(Figure 2.4), which confirmed the previous results, but did not help with assignment of the
additional singlet in the downfield region of the 1H NMR spectrum.
Figure 2.4 The expanded 2D 1H-15N HMBC spectrum of N-(4-phenylbutyl)-N’-hydroxyguanidine (36)
Therefore, a 2D 1H-15N HMBC experiment was performed to assign this final proton.
Unfortunately, the spectrum only showed correlations between protons on NH and NH2
groups, which confirmed the previous results, but did not help with assignment of the additional
singlet in the downfield region of the 1H NMR spectrum.
Previous studies by Fukoto et al. concluded that structure C is the most likely form of NHA
bound to NOS (Scheme 2.4), and indicated that NHA exists as a protonated form in solution.6, 7
Scheme 2.47
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Our NMR results confirm this hypothesis, as four signals were observed in the 1H NMR
spectrum for NH and OH protons, as shown in Figure 2.5.
Figure 2.5 The expanded 1H NMR spectrum of N-(4-phenylbutyl)-N’-hydroxyguanidine (36)
In general, most of the N-arylalkyl-N’-hydroxyguanidines were obtained in a similar manner
to N-(4-phenylbutyl)-N’-hydroxyguanidine (36). Sometimes, depending on the polarity of the
final compound, different solvents were used for crystallization (see experimental), therefore it is
difficult to define one procedure for all the N-hydroxyguanidines. However, it is worth pointing
out that in the 1H NMR spectra for all of the synthesized N-hydroxyguanidines, a similar pattern
was observed for active protons in the downfield region of the spectra. As illustrated in
Figure 2.6, in all cases one additional signal was seen indicating the protonated form of these
compounds. In the case of N-phenyl-N’-hydroxyguanidine hydrochloride (33), however the
chemical shifts moved even further downfield in the 1H NMR spectrum due to the direct
influence of the benzene ring on the active protons of the hydroxyguanidine functionality.
Namely, the additional signal is observed at about 11 ppm, not as in case of other
hydroxyguanidines at about 10.5 ppm. The NH signal is shifted up to 10.14 ppm (for the other
analogues the chemical shifts are about 8-8.5 ppm) and is no longer a triplet but singlet because
of the absence of CH2 protons. However, for the three other examples in Figure 2.6, the values
of the chemical shifts of active protons do not differ that significantly and they all possess a
similar pattern.
The yields and spectral data for the entire N’-arylalkyl-N-hydroxyguanidines synthesized are
given in Table 2.4.
8.08.59.09.510.010.5 ppm
OH/NH
OH/NH
NH
NH2
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Figure 2.6 The expanded downfield region of the 1H NMR spectra of selected N-hydroxyguanidines
8.08.59.09.510.010.511.0 ppm
8.08.59.09.510.010.5 ppm
8.08.59.09.510.010.5 ppm
8.08.59.09.510.010.5 ppm
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Table 2.4 Yields and characteristic spectral data for synthesized N-arylalkyl-N’-hydroxyguanidines
δ 1H NMR [ppm]N-arylalkyl-
N’-hydroxyguanidine NH2 NH NH/OH
δ 13C NMR
[ppm]CNHOH
yield [%]
7.94 10.14 10.24, 10.95 156.7 47
7.81 8.40 9.88, 10.57 158.3 45
7.71 8.05 9.82, 10.43 158.6 58
7.66 7.92 9.76, 10.34 158.2 55
7.73 7.94 9.82, 10.43 158.1 62
7.69 7.89 9.83, 10.45 158.1 58
7.72 7.92 9.84, 10.29 158.5 53
7.65 7.85 9.79, 10.38 158.2 46
7.69 7.89 9.82, 10.36 158.6 30
7.65 7.81 9.77, 10.38 158.1 40
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HN
NOH
NH2 .HCl
(82)
7.73 8.05 9.85, 10.46 158.1 79
7.68 7.98 9.80, N/A 158.1 32
7.71 7.94 9.81, 10.42 158.1 83
7.69 7.87 9.75, 10.34 158.6 21
7.71 7.94 9.83, 10.47 158.5 N/A
7.72 7.95 9.85, 10.44 158.1 N/A
7.70 7.91 9.81, 10.42 158.1 67
7.44 7.99 9.85, 10.48 158.5 53
7.86 8.29 9.91, 10.65 158.1 20
7.75 8.00 9.89, 10.55 158.1 46
7.74 7.97 9.86, 10.50 158.1 51
7.88 8.41 9.92, 10.68 157.9 34
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Most of the N-arylalkyl-N’-hydroxyguanidines were synthesized in good yields. However, in
some cases the yields are moderate mainly due to the difficulties encountered during purification
of the final compounds. Also, the compounds were to be tested in a biological assay and so
high purity was of prime importance. For example, in the synthesis of N-2-[4’-
(sulfamoyl)phenyl]ethyl-N’-hydroxyguanidine (85), an additional step had to be included in order
to purify the product. Namely, the sulfonamide and hydroxyl groups were Boc protected as
shown in Scheme 2.5.
Scheme 2.5
Protection of the hydrophilic groups allowed purification of the intermediate (94) using
column chromatography. The Boc protected analogue was then easily deprotected using
4M HCl solution in 1,4-dioxane to give the desired N-hydroxyguanidine in a moderate 21% yield
over three steps, but excellent purity.
In the case of some hydroxyguanidines repeated recrystallizations did not give satisfactory
results. This was a problem with compounds with polar or easily oxidizable groups such as -OH,
-COOH, and NO2. The higher polarity made the whole molecule more hygroscopic, therefore
difficult to purify, whilst the propensity for the oxidation resulted in low stability of the final
compounds. Based on the published literature, Mansuy et al. had to face the same issues since in
their experimental data there are no elemental analysis results for N-hydroxyguanidines with
polar substituents.1 In addition, solvent molecules were often included to improve the results of
the elemental analysis. Attempts were made to crystallize these hydroxyguanidines but this only
succeeded for N-2-(4’-hydroxyphenyl)ethyl-N’-hydroxyguanidine hydrochloride (81) and
N-2-(3’-methoxyphenyl)ethyl-N’-hydroxyguanidine hydrochloride (78). The X-ray crystal
structures are presented in Figure 2.7.
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Figure 2.7 The X-ray crystal structures of N-2-(3’-methoxyphenyl)ethyl- (78) and
N-2-(4’-hydroxyphenyl)ethyl-N’-hydroxyguandine hydrochloride (81)
The X-ray crystal structures showed that the additional proton observed by NMR
spectroscopy appears to be attached to the nitrogen of the NOH group, whilst in the solution it
impossible to determine its position. However, the bond lengths for N-2-(3’-
methoxyphenyl)ethyl-N’-hydroxyguanidine hydrochloride (78) are: N(8)-C(9)-1.333 Å, C(9)-
N(9)-1.343 Ǻ and C(9)-N(10)-1.375 Å, which indicate delocalization of the double bond along
the N(8)-C(9)-N(9) fragment. The same is seen for 2-(4’-hydroxyphenyl)ethyl-N’-
hydroxyguanidine hydrochloride (81), namely the bond lengths are N(8)-C(9)-1.321 Å,
C(9)-N(9)-1.338 Ǻ and C(9)-N(10)-1.356 Å, respectively. These findings are in agreement with
results obtained by Fukoto et al. concerning the protonated state of NHA, as described earlier
(Scheme 2.4).6, 7
Twenty two N-arylalkyl-N’-hydroxyguanidines have thus been successfully synthesized;
among them four novel heterocyclic analogues and fifteen new derivatives of N-phenylethyl-N’-
hydroxyguanidine (QZNO193). Most of them were obtained in good yields (45-83%). In a few
cases the yields are lower due to the purification problems. The purity of the synthesized
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molecules was confirmed by the elemental analysis indicating that almost all hydroxyguanidines
were obtained as nearly 100% pure compounds, which was crucial for biological testing.
2.1.3 Synthesis of N–phenyl-N’–methoxyguanidine
As described in the previous chapter, the hydroxyguanidine moiety is essential for NO
generation. Therefore, by substitution on the oxygen of the NOH group one should get inactive
control compound. A suitable compound was prepared by reacting the corresponding
cyanamide with methoxylamine hydrochloride in the presence of base and heating under reflux
for two days according to the Scheme 2.6.
Scheme 2.6
Despite the forcing reaction conditions N-phenyl-N’-methoxyguanidine (95) was obtained in
a poor 7% yield. This might be caused by the fact that methoxylamine is much more volatile
than hydroxylamine and perhaps an excess of this compound would be more effective.
However, the main goal was to obtain a reasonable amount of pure product for biological
testing and the optimisation of the reaction conditions was not necessary. N-Phenyl-N’-
methoxyguanidine (95) was characterized by various analytical techniques. The most significant
indication of the structure was the presence of a singlet at 3.57 ppm for the methyl group in the
1H NMR spectrum as well as a shift of the quaternary carbon from 156 ppm (C=NOH) to 151
ppm (C=NOCH3) in the 13C NMR spectrum. In addition, the correctness of the structure and
purity were confirmed by mass spectrometry and elemental analysis, respectively.
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2.1.4 Synthesis of N-aryalkyl-N’-hydroxyguanidines bearing NH2 groups
It was observed by Mansuy et al. that N-(3-aminophenyl)-N’-hydroxyguanidine was the only
derivative, of those tabulated in Table 1.4, that was oxidized by eNOS with the formation of
NO at a reasonable rate.1 Therefore, it could be beneficial to synthesize the derivative of
QZNO193 bearing the amino group in the meta-position of the phenyl ring, even though e-NOS
may not be the only enzyme in our biological assay that causes the oxidation of N-aryalkyl-N’-
hydroxyguanidines. In order to synthesize N-hydroxyguanidines which possess amino groups in
their structure, either as a substituent of the phenyl ring or as part of the alkyl chain, a more
sophisticated approach had to be employed. The proposed synthetic approach is presented in
Scheme 2.7.
Scheme 2.7
The first route required selective reduction of a nitrile over an aromatic nitro group and then
protection of the resulting amine using 9-fluorenylmethyl chloroformate to give Fmoc
protection, stable under acidic conditions. A suitable procedure to selectively reduce a nitrile in
the presence of a nitro had been already employed to synthesize N-2-(4’-nitrophenyl)ethyl-N’-
hydroxyguanidine hydrochloride (89) and is presented in Scheme 2.8.8
Scheme 2.88
Even though it was possible to successfully reduce the nitrile (96) and leave the nitro group
untouched, the yield of this transformation was very poor 11% (NaBH4 – 1 equiv.; BF3· Et2O –
2 equiv.). Therefore, it was necessary to optimize this method, especially as the published
procedure was very vague. Firstly, the reaction conditions were kept the same (see experimental
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for (96)), except that a new batch of boron trifluoride diethyl etherate (BF3· Et2O) was used,
since the previous BF3· Et2O was quite old. Unfortunately, it did not improve the reaction. TLC
monitoring indicated that, apart from the required product, a whole variety of different
compounds had been formed. Since, the reduction of nitriles occurs in two steps there is a
possibility that the intermediates, or even final amine can react with the starting nitrile. Next, the
number of equivalents of sodium borohydride was increased from one to two. However, no
improvement was observed and again a very complex mixture of products was formed.
It was then found that a similar approach had been employed by Su-Dong Cho et al. to
reduce carboxylic acids, esters, amides and nitriles using NaBH4/BF3·Et2O as an inexpensive and
highly versatile reducing system.9 The major modification compared to the previous procedure
was to use a catalytic amount of boron trifluoride diethyl etherate and 1.5 equivalent of NaBH4
together with heating the reaction mixture under reflux instead of stirring at room temperature.
Unfortunately, this attempt was also not successful.
Itoch et al. reported the use of sodium acyloxyborohydride (NaBH3(OCOR)) as a novel
reducing agent.10 They claimed a 71% yield for the reduction of the 4-nitrophenylacetonitrile
(96) to the corresponding amine (97). Therefore, the same methodology was attempted in our
case as shown in Scheme 2.9.
Scheme 2.9
Several attempts were made in order to repeat the published procedure, but none of them gave
satisfactory results, this time leaving the starting material untouched.
It has been also published that dimethylsulfide borane [(Me)2S·BH3] is a valuable reagent for
the reduction of functional groups. Unfortunately, attempts to reduce 4-nitrophenylacetonitrile
(96) using (Me)2S·BH3 under reflux conditions failed and mainly starting material was
recovered.11, 12 Then, it was decided to employ the nickel boride procedure but decrease the
number of equivalents of NaBH4 from seven to two. However, this time the reaction was not
chemoselective and both groups were reduced at the same time.
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Since for the overall synthetic route it was not essential which group was reduced first, the
selective reduction of nitro group to the amine was examined next. Adger et al. reported the
selective reduction of nitroarylalkylnitriles with hydrazine and a metal catalyst.13 The published
procedure was employed to reduce 4-nitrophenylacetonitrile (96) using hydrazine hydrate
(N2H4·H2O) and 10% Pd/C catalyst. The TLC monitoring indicated that this transformation was
cleaner compared to the previous methods. However, the first attempt gave the corresponding
hydroxylamine instead of the amine according to the 1H NMR data, which suggested incomplete
reduction of the nitro group. Therefore, the same methodology was employed changing the
number of equivalents of N2H4·H2O from 1 to at least 2.5. This led to successful reduction of
4-nitrophenylacetonitrile (96) to 4-aminophenylacetonitrile (98). The resulting amine was then
protected using 9-fluorenylmethyl chloroformate.14 Using our previously developed
methodology, the nitrile was then reduced to the Boc-protected amine.5 This leaves the two
functional groups with orthogonal protecting groups. The model synthetic route was first
performed with 4-nitrophenylacetonitrile (96) as shown in Scheme 2.10, since the commercially
available 3-nitrophenylacetonitrile (99) was expensive.
Scheme 2.10
As shown in Scheme 2.10, the nitro group was selectively reduced to the amine employing
the hydrazine hydrate and a catalytic amount of palladium as a reducing agent.
4-Aminophenylacetonitrile hydrochloride (98) was synthesized in a very good yield (74%) and
characterized by various analytical methods. The most indicative piece of data was the
appearance of a broad singlet at 5.11 ppm in the 1H NMR spectrum integrating for two protons
which corresponded to the amino group. In addition, there was a significant shift of the
aromatic protons from downfield to upfield of the 1H NMR spectrum due to the change in the
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electronic properties of the aromatic substituents from a strongly electron withdrawing to a
strongly electron donating group. The next step involved protection of the amino group using
9-fluorenylmethyl chloroformate in the presence of pyridine to give the Fmoc protected
phenylacetonitrile (100) in a very good yield (77%). The product was analyzed by 1H and 13C
NMR and IR spectroscopy, MS spectrometry and the purity was confirmed by the elemental
analysis (see experimental). All the data proved the correctness of the final compound. The
4-(N-9-fluorenylmethoxycarbonylamino)phenylacetonirile (100) was then subjected to the
reduction reaction using the same methodology as previously described. However, this time a
mixture of anhydrous methanol and tetrahydrofuran had to be employed due to the solubility
issues of the starting nitrile. The nickel hydride reduction of the nitrile group and consecutive
Boc protection of the amine yielded the key intermediate (101), in 58 % yield over 3 steps, which
could be reacted one of two ways.
Scheme 2.11
The first route involved the selective deprotection of the tert-butoxycarbonyl group using
4M HCl solution in 1,4-dioxane as shown in Scheme 2.10. The amine (102) was reacted as
before with cyanogen bromide in the presence of base to give the corresponding cyanamide
(103). The cyanamide (103) bearing the N-9-fluorenylmethoxycarbonyl (Fmoc) group caused
some problems during work-up. Due to the presence of the Fmoc group (hydrophobic) and the
cyanamide functionality (hydrophilic), the molecule possessed an amphiphilic character. It had a
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propensity to form emulsions. Therefore, the extraction time had to be longer than usual, but
this caused the hydrolysis of the cyanamide to the corresponding urea. In order to avoid this
problem, it was found that ethyl acetate was a better solvent for the extraction than
dichloromethane. As in the case of all other cyanamides, this one also had a very sharp peak at
2218 cm-1 in the IR spectrum, as well as a weak signal in the 13C NMR spectrum for the C≡N
group at 117.4 ppm.
2-(4’-N-9)-Fluorenylmethoxycarbonylaminophenyl)ethylcyanamide (103) was then reacted
with hydroxylamine hydrochloride in dry methanol in the presence of a catalytic amount of
potassium carbonate. However, due to the amphiphilic character and solubility problems of the
starting cyanamides, after work-up mainly starting material was recovered. Therefore, the
reaction conditions were slightly modified and 3 equivalents of hydroxylamine hydrochloride
along with sodium acetate instead of potassium carbonate were employed. In addition, methanol
was replaced by acetonitrile, in which the cyanamide was more soluble. The intermediate (104)
was then treated with di-tert-butyl dicarbonate to protect the hydroxyguanidine functionality. The
successful removal of the Fmoc group gave the Boc protected hydroxyguanidine (106) which
was purified using column chromatography and reacted with 4M HCl solution in 1,4-dioxane to
give N-2-(4’-aminophenyl)ethyl-N’-hydroxyguanidine dihydrochloride (107) in a reasonable 23%
yield over 4 steps. The final compound was characterized by various analytical techniques such
as the 1H and 13C NMR spectroscopy, IR spectroscopy and MS spectrometry. The presence of a
single peak in the mass spectrum at 195 (M+H)+ indicated the correct molecular mass.
Additionally, HR-ESI-MS gave the mass as 195.1240 while C9H15N4O required 195.1246.
However, both 1H and 13C NMR spectra of the product in d6-DMSO suggested that the
synthesized molecule was actually a mixture of two species. Two sets of signals were present for
the CH2 protons, while the signals for the aromatic protons and active protons (NH, OH, NH2)
overlapped with each other. Additional experiments were performed to establish the character of
the two species. Firstly, the sample was heated up to 373 K. The 1H spectrum showed that
increasing temperature caused broadening of peaks, but the coalescence was not observed. In
addition, the 1D gs-NOESY spectrum, recorded at room temperature, did not show saturation
transfer (EXSY peak) upon selective irradiation of the CH2 resonance. These results implied that
the two species existing in d6-DMSO were not interconvertible. The elemental analysis also did
not give satisfactory results and consecutive recrystalizations did not improve the data. The
closest result to the theoretical composition (%C 40.46, %H 6.04, %N 20.97) was the following
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percentage: %C 41.92, %H 5.77, %N 20.06. Attempts made to crystallize N-2-(4’-
aminophenyl)ethyl-N’-hydroxyguanidine dihydrochloride (107) were not successful.
The same scheme of reactions was then performed starting from 3-nitrophenylacetonitrile
(99) as shown in Scheme 2.12.
Scheme 2.12
As previously described the nitro group was selectively reduced to the amine, which was
then Fmoc protected to yield 3-(N-9-fluorenylmethoxycarbonylamino)phenylacetonirile (109).
The nitrile (109) was then treated with sodium borohydride in the presence of nickel chloride
and di-tert-butyl dicarbonate to give N-Boc-2-(3’-N-fmocaminophenyl)ethylamine (110) (57%) as
the major product along with the Fmoc deprotected amine (19%) and the unreacted starting
material (24%). The compound (110) was characterized by 1H and 13C NMR and IR
spectroscopy, mass spectrometry and the purity confirmed by elemental analysis. The most
clear-cut indication of the product structure was the presence of the singlet at 1.48 ppm in the
1H NMR spectrum for nine tert-butyl protons. In addition, the elemental analysis indicated that
obtained compound was nearly 100% pure (found: C 73.6, H 6.9, N 6.2%; calculated: C 73.3, H
6.6, N 6.1%). The di-protected amine (110) was then taken through the same reaction pathway,
as for the para analogue, as illustrated in Scheme 2.13.
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Scheme 2.13
Interestingly, N-2-(3’-aminophenyl)ethyl-N’-hydroxyguanidine dihydrochloride (111) showed
the same pattern in the 1H and 13C NMR spectra, suggesting the presence of two species.
However, this time it was possible to crystallize the final compound and the X-ray data
confirmed the absolute structure of the product as shown in Figure 2.8.
Figure 2.8 The X-ray crystal structure of N-2-(3’-aminophenyl)ethyl-N’-hydroxyguanidine
dihydrochloride (111)
The obtained crystal structure indicated that in the solid state the molecule exists as the
dihydrochloride salt. One proton appears to be attached to the amino group on the benzene ring
which is confirmed also by the 1H NMR spectroscopy, as the integration pattern indicated the
presence of NH3
+ in the downfield part of the spectrum. The second proton is located as in the
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case of all hydroxyguanidines on the nitrogen of NOH moiety. The bond lengths equal
N(8)-C(9)-1.310 Å, C(9)-N(9)-1.311 Ǻ and C(9)-N(10)-1.373 Å respectively which suggested that
the double bond is actually delocalized through the N(8)-C(9)-N(9) fragment. Additionally, the
presence of the single peak in the mass spectrum at 195 (M+H)+ indicated the correct molecular
mass. HR-ESI-MS gave the mass of 195.1252 while C9H15N4O required 195.1246. However, the
results of elemental analysis, as in the case of para analogue, were not satisfactory. Therefore,
based on the X-ray data and 1H and 13C NMR spectra one cannot identify two species present in
the solution.
The second route firstly involved removal of the Fmoc group using piperidine in anhydrous
THF as shown in Scheme 2.14.
Scheme 2.14
N-(tert-Butoxycarbonyl)-2-(4’-aminophenyl)ethylamine (112) was then subjected to the
reaction with cyanogen bromide in the presence of sodium acetate to yield the corresponding
cyanamide (113). The desired product was analyzed by various analytical methods. It possessed a
very sharp peak at 2222 cm-1 in the IR spectrum, as well as a weak signal in the 13C NMR
spectrum for the C≡N group at 111.2 ppm. The value of the chemical shift had slightly moved
upfield due to the electronic properties of the benzene ring. The X-ray crystal structure
confirmed the absolute structure of the final product as shown in Figure 2.9.
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Figure 2.9 The X-ray crystal structure of N-(tert-butoxycarbonyl)-2-(4’-aminophenyl)ethylcyanamide
(113)
The bond length between C(15) and N(15) is equal to 1.153 Ǻ, which is a correct value for the 
length of the triple bond for the nitrile. In addition, the bond angle of 179.4 degree for
N(4)-C(15)-N(15) indicates that the bond has a linear geometry which is characteristic for the
triple bond.
N-(tert-Butoxycarbonyl)-2-(4’-aminophenyl)ethylcyanamide (113) was treated with
hydroxylamine hydrochloride in the presence of potassium carbonate, and the product (114) was
taken without the characterization for the next step, which was Boc protection. It yielded the
product (115) which was possible to purify by column chromatography and then subjected to the
global Boc deprotection using 4M HCl in 1,4-dioxane to give N-phenyl-(4-ethylamine)-N’-
hydroxyguanidine dihydrochloride (116) in 44% yield (over 3 steps). The final compound (116)
was characterized by the 1H and 13C NMR spectroscopy, IR spectroscopy, MS spectrometry and
the purity confirmed by elemental analysis. The most indicative data were the characteristic
peaks for the active protons (OH, NH, NH2) in the lowfield region of the
1H NMR spectrum.
As usual an additional signal was seen at 10.86 ppm, confirming the protonated state of the
hydroxyguanidine functionality. The elemental analysis (found: C 40.5, H 6.0, N 20.6%;
calculated: C 40.5, H 6.0, N 20.9%) indicated that synthesized molecule is almost 100% pure.
Surprisingly, just one isomer was present according to the 1H and 13C NMR spectra, which may
suggest as previously speculated that only direct attachment of the amino group to the phenyl
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ring is responsible for the presence of two isomers in previous two analogues. It could be caused
by various protonation states of aniline giving a mixture of di- and monohydrochlorides.
N-Boc-2-(3’-N-Fmocaminophenyl)ethylamine (110) was taken through same steps as in the
case of the para analogue as shown in Scheme 2.15 to yield N-phenyl-(3-ethylamine)-N’-
hydroxyguanidine dihydrochloride (117).
Scheme 2.15
Firstly the Fmoc group was successfully removed by piperidine to give Boc protected
analogue (118) in 81% yield. The product was characterized by various analytical methods. The
most indicative piece of data was appearance of broad singlet integrating for two protons at 4.94
ppm in 1H NMR spectrum confirming the presence of NH2 group. Additionally, the aromatic
protons shifted up-field indicating presence of amino group in their chemical environment.
N-Boc-2-(3’-aminophenyl)ethylamine (118) was reacted with cyanogen bromide to yield the
corresponding cyanamide (119) in 85% yield. As in case of all other cyanamides, this one also
had a very sharp peak at 2226 cm-1 in the IR spectrum, as well as a weak signal in the 13C NMR
spectrum for C≡N group at 112.4 ppm. N-(tert-Butoxycarbonyl)-2-(3’-
aminophenyl)ethylcyanamide (119) was treated with hydroxylamine hydrochloride in the
presence of potassium carbonate and the product was taken without characterization for the
purification steps which included Boc protection and deprotection (Scheme 2.14) to give final
product (117) in 40% yield over 3 steps. The desired N-hydroxyguanidine (117) was analyzed by
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1H and 13C NMR spectroscopy, IR spectroscopy and MS spectrometry. The most indicative data
was appearance of characteristic peaks for the active protons (OH, NH, NH2) in the
1H NMR
spectrum. The values of the chemical shifts were moved slightly down field, relative to the
signals of the alkyl substituted N-hydroxyguanidines, due to the direct presence of the benzene
ring next to the hydroxyguanidine functionality. The additional proton appeared at 10.91 and
10.18 ppm for NH/OH and at 10.07 ppm for NH. As in the case of all other derivatives with
amino group, the NH2 was also protonated and integrated for three protons at 8.27 ppm in the
1H NMR spectrum. As previously, for the para analogue only one isomer was observed,
confirming the theory that two isomers can form when the NH2 group is directly attached to the
benzene ring.
The synthesis of four novel N-arylalkyl-N’-hydroxyguanidines was tedious, but successful.
The final compounds were synthesized in reasonable yields and purities.
2.2 Biological results
2.2.1 Myography studies
Most of the N-hydroxyguanidines were tested in the rat aorta assay using myography to
determine their vasodilatation activity. In general, the rat aorta was cut into small sections and
mounted onto the myograph, and then stretched to 15 mN. Rat aorta rings were then washed
and contracted to 80% of the maximum with phenylephrine. The concentration response curve
was obtained within the range of 1-100 µM. Then, 50 µM ODQ was added to assess the
reversibility of the relaxation. ODQ (1H-[1,2,4]Oxadiazole[4,3-a]quinoxalin-1-one) is a selective
inhibitor of nitric oxide sensitive guanylate cyclase (GC), therefore significant reversibility is an
indication that vasodilatation is mediated through NO. The criteria were set for a good
vasodilator namely it must have an EC50 of 30 μM or less and must show 80% reversibility with
ODQ. The compounds that met above criteria were then examined in the isolated perfused
kidney, to see the effect in the whole organ system.
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The results presented are an average of six consecutive measurements. The log EC50 values
and reversibility percentages for the first class of N-arylalkyl-N’-hydroxyguanidines are
summarized in Table 2.5.
Table 2.5 NO donor activity of N-arylalkyl-N’-hydroxyguanidines in rat aorta
Structure Code No. log EC50[mol/dm3]
ODQ induced
reversibility[%]
AK0 -4.8 ± 0.1 104 ± 13
AK1 -4.9 ± 0.4 37 ± 10
QZNO193 -4.6 ± 0.1 75 ± 16
AK3 -4.8 ± 0.1 68 ± 12
AK4 -3.2 ± 1.6 28 ± 14
AK78 -2.4 ± 0.4 35± 17
The combined relaxation profiles for all the N-arylalkyl-N’-hydroxyguanidines tested at various
concentrations are shown in Figure 2.10.
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Figure 2.10 Vasorelaxation profiles of tested N-arylalkyl-N’-hydroxyguanidines
The biological results indicated that tested compounds act as potent nitric oxide donors. As
seen in Table 2.4, AK0 has a better biological profile than the previous leading compound
(QZNO193). Not only is a smaller concentration required to cause 50% relaxation, but also the
ODQ experiment showed almost complete reversibility indicating that vasodilatation occurs
mainly via generation of NO. However, based on the myography data the extension of the alkyl
chain is beneficial only to three methylene groups. Further elongation of the alkyl chain caused
significant deterioration of the biological activity. On the other hand, N-phenyl-N’-
methoxyguanidine (AK78), which originally was designed as a control compound, caused 48%
relaxation at the highest concentration. However, its mechanism of action is not clear and
requires further investigation.
The vasodilatation by one compound, QZNO193, was examined in the presence of a range
of additives as shown in Figure 2.11. The vasodilatation profile did not change in the presence
of L-NME, a NOS inhibitor, implying the production of NO was not only caused by
NO-synthase, but by other oxidizing enzymes present in the system. The clear inhibition by
ODQ confirmed that the vasodilatation was soluble guanylate cyclase-dependent. In addition,
the biological activity was not affected by haemoglobin, which is a known NO scavenger,
indicating that vasodilatation occurs inside the cells.
-6.5 -6.0 -5.5 -5.0 -4.5 -4.0 -3.5
0
25
50
75
100
AK4
AK0
AK3
QZNO193
AK1
log(concentration) [mol/L]
R
el
ax
at
io
n
(%
)
N-HYDROXYGUANIDINES
82
Figure 2.11 Vasorelaxation profile of QZNO193 in the presence of various additives
Some of the new derivatives of QZNO193 were also examined by myography and their
biological activities are summarized in Table 2.6.
Table 2.6 NO donor activity of modified QZNO193 in a rat aorta
Structure Code No. log EC50[mol/dm3]
ODQ induced
reversibility[%]
AK2F -5.1 ± 0.1 57 ± 9
AW13 -4.2 ± 0.5 11 ± 15
AW21 -4.0 ± 0.1 11 ± 14
AK131 -4.8 ± 0.1 35 ± 14
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AK119 -4.6 ± 0.1 75 ± 10
AK172 -4.9 ± 0.2 35 ± 14
AK120 -4.3 ± 0.1 40.3 ± 3.7
AK164 -4.2 ± 0.4 N/A
HN
NOH
NH2 .HCl
(82)
AK52 -4.3 ± 0.6 0.5 ± 8
AK169 no effect N/A
The dose respond curves are shown in Figure 2.12.
Figure 2.12 Vasorelaxation profiles of modified QZNO193 N-hydroxyguanidines
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The biological data suggested that there is no correlation between the biological activity and
electronic properties of the substituents. However, some data illustrate the relationship between
the size of the substituents and vasodilatation properties. The EC50 values indicated that the
substitution of the phenyl ring with a trifluoromethyl group increased the activity. Almost the
same activity was shown by the methyl substituted derivative, even though the CF3 moiety is an
electron-withdrawing group while CH3 is an electron-donating. The lack of a correlation
between the electronic properties is not a big surprise, because the hydroxyguanidine
functionality is not directly attached to the phenyl ring. On the other hand, the CF3 and CH3 are
almost the same size, which indicates that the size of the substituent is important. However,
N-2-(4’-bromophenyl)ethyl-N’–hydroxyguanidine (AK131) has also a better biological profile
(logEC50= -4.8) compared to the parent phenyl derivative (logEC50= -4.6). The rest of the tested
compounds possessed higher EC50 values, but still remained potent NO donors. Unfortunately,
there is not really a pattern which can allow the most important structural features to be
distinguished. As seen in Table 2.6, most of the new derivatives have poor ODQ reversibility
which may imply that vasorelaxation is not only mediated through NO or that those compounds
may be toxic. In some cases the ODQ errors are quite big. This can be a result of rat aorta
deterioration with time. Interestingly, N–2-[4’-(sulfamoyl)phenyl]ethyl-N’–hydroxyguanidine
(AK169) does not possess any biological activity. Since the detailed mechanism of vasodilatation
is not known one can only speculate that complete loss of activity is due to the secondary
pathway happening on the sulfonamide group such as oxidation, for example.
Additionally, a series of novel heterocyclic N-hydroxyguanidines has been synthesized and
subjected to myography studies. The EC50 values are summarized in Table 2.7.
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Table 2.7 NO donor activity of heterocyclic analogues in rat aorta
Structure Code No. log EC50[mol/dm3]
ODQ induced
reversibility[%]
AK135 -4.4 ± 0.2 86.7 ± 13
AK137 -4.2 ± 0.1 60.1 ± 41
AK151 -4.1 ± 0.6 36.1 ± 22
AK159 -4.8 ± 0.1 27.3 ± 12
Surprisingly, the entire class of heterocyclic compounds acts as nitric oxide donors. Two of
them seemed to be very potent. AK135 and AK137 possessed almost the same NO donation
profile as the lead compound QZNO193. Their vasodilatation profile is shown in Figure 2.13.
Figure 2.13 Vasorelaxation profiles of heterocyclic N-hydroxyguanidines
As in case of QZNO193, the vasodilatation profile of N–furfuryl-N’–hydroxyguanidine
(AK135) was tested in the presence of various additives as illustrated in Figure 2.14. Essentially
the same results were obtained for AK135 and QZNO193.
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Figure 2.14 Vasorelaxation profile of AK135 in the presence of various additives
Since, the starting meta, ortho and para methoxyphenylacetonitriles were commercially
available the corresponding hydroxyguanidines have been synthesized to test the effect of the
substitution position on the vasodilatation. Their EC50’s and ODQ data are gathered in
Table 2.8.
Table 2.8 NO donor activity of methoxyphenylethyl-N’–hydroxyguanidines in rat aorta
Structure Code No. logEC50[mol/dm3]
ODQ induced
reversibility[%]
AK120 -4.3 ± 0.1 40.3 ± 3.7
AK118 -5.4 ± 0.2 8.8 ± 1.7
AK136 -4.7 ± 0.1 13.5 ± 18
All the methoxy derivatives cause vasodilatation under myography conditions. The EC50
values indicate that they are all potent NO donors with the best one being meta > ortho > para
analogue. However, their ODQ reversibility is almost negligible, which may suggest that the
-6 -5 -4
0
25
50
75
100
+ L-NAME
+ L-Arginine
+ Hb
log[AK135]M
R
el
ax
at
io
n
(%
)
N-HYDROXYGUANIDINES
87
biological effect is not NO mediated and there is some secondary biological pathway or that
these compounds are toxic. Their vasorelaxation curves are presented in Figure 2.15.
Figure 2.15 Vasorelaxation profiles of methoxyphenylethyl-N’–hydroxyguanidines
As mentioned at the beginning of this section, the compounds which met the preliminary
criteria were tested in the isolated perfused kidney (IPK) model. The N-hydroxyguanidines
selected for further investigation are presented in Scheme 2.14.
Scheme 2.14
AK0 AK119 AK135
The lead compound AK0 caused ~80% relaxation in the IPK, giving a log EC50 of -4.2
(n=3) as illustrated by the dose response curve in Figure 2.16.
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Figure 2.16 Vasorelaxation profile of AK0 (33) in isolated perfused kidney
The vasodilatation profile of AK0 is slightly worse than in the rat aorta, but still good relaxation
is observed. However, when the AK119 was subjected to the same studies more complex results
were observed. Vasorelaxation was seen initially, but then there was a subsequent
vasoconstriction (Figure 2.17).
Figure 2.17 Vasorelaxation profile of AK119 in isolated perfused kidney
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In this case, the IPK model was not a reflection of the rat aorta model, which can imply that
the nitro analogue undergoes a different biological pathway in the rat aorta compared to the
isolated organ. Therefore, this compound was not taken for further studies. On the other hand,
N-furfuryl-N’–hydroxyguanidine hydrochloride (AK135) possessed a reasonably good biological
profile in the isolated perfused kidney as presented in Figure 2.18.
Figure 2.18 Vasorelaxation profile of AK135 (90) in isolated perfused kidney
The results from the myography as well as from the IPK studies, thus allowed the selection
of two more N-hydroxyguanidines to be parent molecules for the corresponding pro-drugs.
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2.3 Conclusions
Preliminary biological results indicated that almost all of the synthesized
N-hydroxyguanidines (23 compounds) act as NO donors and cause smooth muscle relaxation in
the rat aorta. The exception is N–2-[4’-(sulfamoyl)phenyl]ethyl-N’–hydroxyguanidine (AK169)
which does not cause any vasorelaxant effect. Data for the series of N-arylalkyl-N’-
hydroxyguanidines showed that the extension of the aliphatic chain is beneficial up to three
methylene groups, while further elongation significantly reduced the biological activity. The
compound with the best pharmacological profile turned, in the rat aorta assay, out to be
N-phenyl-N’-hydroxyguanidine hydrochloride (AK0), (EC50 =19.9 μM, ODQ = 104%). AK0
also caused significant vasodilatation in the IPK model. Changes to the benzene ring of
N-phenylethyl-N’-hydroxyguanidine (QZNO193) demonstrated that substitution with
trifluoromethyl group in the para position improved biological activity of the new derivative
(QZNO193, EC50 = 50.1 μM; AK2F, EC50 = 8.0 μM). However, the ODQ test indicated worse
reversibility, which may imply that the vasodilation does not occur mainly through NO mediated
pathway. Additionally, N–2-(4’-nitrophenyl)ethyl-N’–hydroxyguanidine (AK119) had a very
potent biological profile in the rat aorta assay (EC50 = 25.1 μM, ODQ = 75%). However, IPK
model revealed that AK119 caused only initial vasorelaxation, but then a subsequent
vasoconstriction was observed. N–Furfuryl-N’–hydroxyguanidine hydrochloride (AK135) also
possessed a reasonably good biological profile in the rat aorta assay as well as in the isolated
perfused kidney.
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3.1 Introduction
The synthesis of N-hydroxyguanidine pro-drugs in the Botting group has been hampered by
problems occurring due to cyclisation reactions (see Section 6.1). The side reaction was caused
by the presence of free amino group in the hydroxyguanidine functionality which easily reacted
with a neighbouring carbonyl carbon to form an unwanted aromatic five-membered ring.
Therefore, it was proposed that methylation of the free amino group might prevent cyclisation
reactions, assuming that the corresponding N-hydroxyguanidines were still biologically active.
The initial goal was therefore to synthesize the N-hydroxyguanidines shown in the Scheme 3.1
and investigate the role of the free NH2 in the biological formation of NO.
Scheme 3.1
There are only a few publications which report suitable synthetic methodology for
substituted hydroxyguanidines as presented previously in Section 1.5.1.1, 2 Most synthetic routes
involved thioureas as a key intermediate (Scheme 3.2.).
Scheme 3.22
Ziman also reported the alternative employment of C-chloroformamidinium chlorides as
reactive species in the synthesis of tri- and tetra-substituted hydroxyguanidines, which can be
prepared by reaction of the appropriate urea (or thiourea) with phosgene as illustrated in
Scheme 3.3.3
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Scheme 3.33
The synthesis of the dimethyl derivative (122) was investigated first, requiring access to the
corresponding thiourea.4 Reaction of phenylethyl isothiocyante with dimethylamine
hydrochloride in the presence of base gave the N,N-dimethyl-N’-phenylethyl thiourea (123) as
colourless crystals in 80% yield (Scheme 3.3). The product was analyzed by 1H and 13C NMR
spectroscopy, MS and elemental analysis. The presence of the methyl protons (6H, 3.12 ppm) in
the 1H NMR spectrum confirmed the chemical structure of the obtained compound. In addition,
the characteristic peak (181.1 ppm) for the thiocarbonyl group was observed in the 13C NMR
spectrum. The molecular weight was confirmed by the presence of the single peak in the
negative ion mass spectrum at 207 (M-H)-.
Scheme 3.3
Oxidation of the thiocarbonyl group to the sulfonic acid was chosen as a first route to
investigate. According to the literature the reaction of the thiourea with hydrogen peroxide in
the presence of sodium molybdate should lead to the corresponding
aminoiminomethanesulfonic acid.5 Several attempts were made to synthesize N,N-dimethyl-N’-
phenylethylaminoiminomethanesulfonic acid, however each time a yellow oil was isolated. The
results of analysis by MS, 1H and 13C NMR spectroscopy indicated the apparent loss of SO3 due
to the presence of a single peak in the mass spectrum at 177. The appearance of an additional
peak in 1H NMR spectrum at 10.22 ppm (1H, br s) was then identified as the proton between
the two nitrogens in the unexpected product (124). There was also a weak signal in the 13C NMR
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spectrum at 156 ppm which was identified as methine according to the PENDANT spectrum.
This result implied that the transformation of the C=S group to the C–SO3H was achievable,
but than the corresponding aminoiminomethanesulfonic acid was unstable under the reaction
conditions and underwent an elimination reaction with loss of sulfur trioxide to give either the
anion or carbene which was then protonated to give compound (124).6-8
Scheme 3.4
In order to overcome this problem an alternative approach was investigated involving
methylation of the N,N-dimethyl-N’-phenylethylthiourea (123) using methyl iodide, to give the
methylsulfonium iodide (125), and producing a good leaving group for further reaction
(Scheme 3.2).9 When this reaction was carried out the new methyl protons were observed at 2.26
ppm in the 1H NMR spectrum. In addition, a shift of the quaternary carbon in the 13C NMR
spectrum from 181.1 ppm (C=S) to 168.1 (C=S+–CH3) as well as the presence of the single peak
in the mass spectrum at 223 (M+) confirmed the structure of the product. The sulfonium iodide
(125) was then reacted with hydroxylamine hydrochloride in the presence of silver nitrate and
triethylamine. However, spectroscopic analyses indicated that instead of N-phenylethyl-N’-
dimethyl-N”-hydroxyguanidine the corresponding urea (126) was obtained, which was
confirmed by the presence of the single peak in the mass spectrum at 215 (M+Na+).
Additionally, the X-ray crystal structure of the final compound, as shown in Figure 3.1,
confirmed that the urea was the only product. It thus implied that hydrolysis to the urea had
occurred rather then reaction with the hydroxylamine.
Figure 3.1 X-ray crystal structure of N,N-dimethyl-N’-phenethyl urea (126)
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Instead of trying to improve this reaction it was decided to synthesize the N,N-dimethyl-N’-
phenylethyl hydroxyguanidine (122) using the Ziman procedure (Scheme 3.5).3 The required
N,N-dimethyl-N’-phenethyl urea (126) was synthesized from the phenylethylamine and
dimethylcarbamoyl chloride in the presence of triethylamine. Since it is known compound, it was
only analyzed by 1H and 13C NMR spectroscopy and its purity was confirmed by the melting
point (see experimental). In order to avoid the use of phosgene it was first attempted to obtain
the C-chloroformamidinium chloride via the reaction of the urea with phosphorus oxychloride
followed by the reaction with commercially available O-benzylhydroxylamine, as a model
reaction.10 Unfortunately, this did not give satisfactory results. It was suspected that the key
intermediate was not obtained since the O-benzylhydroxylamine was recovered after the work-
up.
Scheme 3.5
The urea (126) was then instead treated with a 1.93 M solution of phosgene (COCl2) in
toluene to give the C-chloroformamidinium chloride (127), which was reacted directly with
O-tetrahydropyranylhydroxylamine in the presence of base to give the THP protected
hydroxyguanidine (128).3, 11 The compound was obtained in 36% yield over the two steps and
characterized by various analytical methods, such as 1H and 13C NMR spectroscopy, IR
spectroscopy and mass spectrometry. The most indicative piece of data was the appearance of a
multiplet (4.97-5.00 ppm) corresponding to the CH proton from THP ring, as well as the
aromatic protons (7.19-7.33 ppm) in the 1H NMR spectrum. It confirmed the successful
nucleophilic addition of the O-tetrahydropyranylhydroxylamine to the electrophilic centre of the
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C-chloroformamidinium chloride. In addition, the correct mass was observed in HR-ESI-MS
spectrum (292.2023 ((M+H)+. C16H26N3O2 requires 292.2025).
N,N-Dimethyl-N’-phenethyl-N”-O-tetrahydropyranylhydroxyguanidine (128) was then easily
deprotected using 4 M HCl in 1,4-dioxane/H2O to give the desired product (122) in 73% yield.
The structure of the compound was confirmed by the loss of peaks corresponding to the THP
ring in the 1H and 13C NMR spectra compared to the starting material. As usual, there were
characteristic signals for the hydroxyguanidine group in the lowfield region of the spectrum. In
addition, the X-ray crystal structure of the final product was obtained and a more detailed
discussion of the structure will be given in the next section of this chapter.
The application of the C-chloroformamidinium chloride in the synthesis of N,N-dimethyl-
N’-phenethyl-N”-hydroxyguanidine (122) resulted in a satisfactory yield and very good purity.
Therefore, the same approach was employed for the synthesis of the monomethylated
derivative. The corresponding urea (129) was a product of the reaction between phenylethyl
isocyanate and methylamine as shown in Scheme 3.6.12
Scheme 3.6
N-Methyl-N’-phenethyl urea (129) was characterized by the 1H and 13C NMR spectroscopy
and its purity confirmed by elemental analysis (see experimental). The next step involved
reaction of the urea with phosgene to form the reactive intermediate. However, several attempts
to perform this reaction failed. Literature studies indicated that the products formed in the
reaction of 1,3-disubstituted ureas with phosgene strongly depend on the substitution pattern of
the starting urea.10, 13 As reported by Ulrich et al., it was found that if the alkyl substituent was
attached to the nitrogen by a primary carbon atom, then the reaction led predominately to attack
on the nitrogen and the corresponding allophanoyl chlorides (130) were formed instead of
C-chloroformamidinium chlorides (Scheme 3.6).13, 14 Since the above approach failed, it was
decided to go back to the aminoiminomethanesulfonic acid as the key intermediate, especially as
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there are few reports describing the application of disubstituted aminoiminomethanesulfonic
acids in the synthesis of disubstituted guanidines.5, 8 However, this time the oxidation was carried
out using freshly prepared peracetic acid as an oxidizing agent, instead of sodium molybdate and
hydrogen peroxide. N-Methyl-N’-phenylethyl thiourea (131) was synthesized in the same way as
in the case of the dimethyl derivative namely from phenylethyl isothiocyante and methylamine
instead of dimethylamine (Scheme 3.3). The desired product was obtained as an off-white solid
in 90% yield. The presence of the methyl protons (3H, 2.89 ppm) in the 1H NMR spectrum
indicated the correct structure of the final compound. In addition, the characteristic peak
(182.4 ppm) for the thicarbonyl group in the 13C NMR spectrum as well as the presence of the
single peak in the mass spectrum at 217 (M+Na)+ confirmed the chemical structure. The results
of elemental analysis confirmed the purity of N-methyl-N’-phenylethyl thiourea (131).
N-Methyl-N’-phenylethyl thiourea (131) was then subjected to oxidation using freshly prepared
peracetic acid to give the corresponding aminoiminomethanesulfonic acid (132) in only 25%
yield, but in very good purity. The product was analyzed by various NMR techniques, MS and
elemental analysis. The presence of the single peak in the mass spectrum at 265 (M+Na)+
indicated the correct molecular mass. The result of elemental analysis pointed out that
synthesized product was nearly 100% pure. Interestingly, both the 1H and 13C NMR spectra of
aminoiminomethanesulfonic acid (132) in d6-DMSO indicated that the synthesized molecule was
actually a mixture of two isomers, which will be discussed in Section 3.2.2.
As the modified oxidation method was successful in the case of N-methyl-N’-phenylethyl
thiourea (131), the same approach was used to synthesize the trisubstituted analogue, which had
failed previously with the NaMoO4/H2O2 oxidazing mixture. A syringe pump was also employed
to control the rate of addition of the thiourea solution to the peracetic acid solution, as an
additional precaution. The final product (133) was obtained as off-white crystals in 58% yield
and was characterized by MS, 1H and 13C NMR spectroscopy. However, the resulting data were
misleading. Some of data indicated the presence of the final product while others the starting
material. The correct molecular weight of N,N-dimethyl-N’-phenylethylaminoiminomethane
sulfonic acid (133) was observed in the mass spectrum (M-H- = 255), but the
aminoiminomethanesulfonic acids generally give a strong signal in negative mode mass
spectrometry. However, the 1H and 13C NMR spectra looked identical to the starting material.
Therefore, the crystal structure was obtained to confirm the identity of the final product, and
indicated the presence of the desired product. Finally, the thin-layer chromatography showed
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that the isolated crystals were actually a mixture of starting thiourea and the product. However,
the sulfonic acid was only a very small percentage of the isolated solid. A few attempts were
made in order to synthesize N,N-dimethyl-N’-phenylethylaminoiminomethane sulfonic acid
(133) using various other oxidizing agents such as H2O2, CF3COOOH and using different
solvents (methanol, acetonitrile, methanol/H2O2), but none of them gave satisfactory results.8, 15-
18 It has been already observed by others that trisubstituted thioureas are resistant to oxidation,
but on the other hand forcing the reaction conditions caused SO3 elimination as described
previously.6, 15
The presence of two isomers of N-phenylethyl-N’-methylaminomethanesulfonic acid (132)
was expected to be a problem in the next step, namely the reaction with hydroxylamine
hydrochloride. Therefore, the approach using methylated thiourea was employed as presented in
Scheme 3.7.
Scheme 3.7
Previously synthesized N-methyl-N’-phenylethyl thiourea (131) was reacted with methyl
iodide to produce N-methyl-N’-phenylethyl-S-methylsulfonium iodide (134) in a good yield
(70%). The structure was confirmed by 1H and 13C NMR spectroscopy and mass spectrometry.
The shift of the quaternary carbon from 182.4 ppm (C=S) to 162.1 ppm (C-SCH3) confirmed
the successful reaction. The next step involved reaction of the methylated thiourea (134) with
THP-protected hydroxylamine in the presence of triethylamine and silver nitrate. The thioether
group is known to react with soft metal ions, particularly Ag(I) and Hg(II).19-21 Therefore,
formation of the insoluble salt should facilitate the nucleophilic substitution. The final product
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(135) gave the correct mass in the HR-ESI-MS spectrum (278.1866 ((M+H)+. C15H23N3O2
requires 278.1869). Interestingly, the 1H and 13C NMR spectra indicated the presence of two
isomers (see experimental), which were not studied in detail, mainly due to the very poor yield of
21% and the small amount of material obtained. Several attempts were made in order to
improve the yield of this reaction, but none of them were very successful. It was suspected that
some side reaction took place involving silver nitrate. Indeed, Steed et al. reported that
1-(3-methylsulfanyl-phenyl)-3-phenyl-1-urea (MPUP) reacted with AgNO3 to form the complex
(136) as shown in Scheme 3.8.22
Scheme 3.822
HN
HN
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HN
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HN
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Based on literature precedent it was expected that a similar reaction could occur with our
substrate since a lot of inorganic solid was filtered off during the work-up. However, for the
biological studies there was enough material to take it through the next step and obtain the final
hydroxyguanidine (121). As shown in Scheme 3.7, the THP-protected hydroxyguanidine (135)
was treated with a 4M HCl solution in 1,4-dioxane/H2O to give N-methyl-N’-
phenethyl-N”-hydroxyguanidine hydrochloride (121) in 71% yield. The product was
characterized by the 1H and 13C NMR spectroscopy, IR spectroscopy and MS. The characteristic
signals for the hydroxyguanidine functional group were observed in the lowfield of the 1H NMR
spectrum indicating the successful deprotection. The novel, substituted hydroxyguanidines were
therefore successfully synthesized and their structures were confirmed by various analytical
techniques. In addition, along with the series of aminoiminomethanesulfonic acids, they were
studied in more detail by X-ray crystallography and 15N NMR spectroscopy, which is described
in the following section.
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3.2 X-Ray crystallography and NMR spectroscopy studies
During the synthetic research it was discovered that aminoiminomethanesulfonic acids, as
well as N-hydroxyguanidines, possessed very interesting structural properties. In addition, there
is a very little known about this class of compounds from the spectroscopic point of view.
Therefore, having these compounds in hand, some additional structural studies were performed
using X-ray crystallography and NMR spectroscopy. A series of aminoiminomethanesulfonic
acids and N-hydroxyguanidines were chosen for more detailed structural studies in order to
determine their characteristics in the solid state as well as in solution and to compare the
obtained data for two classes of compounds. N-phenethylaminoiminomethanesulfonic acid (137)
was synthesized just for the purpose of these studies.
3.2.1 X-Ray Studies
The molecular structures of selected aminoiminomethanesulfonic acids, as determined by X-ray
diffraction are presented in Figures 3.2, 3.3 and 3.4. The most informative X-ray data (selected
bond lengths and torsion angles) are summarized in Table 3.1.
Figure 3.2 The X-ray crystal structure of N-phenethylaminoiminomethanesulfonic acid (137).
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Figure 3.3 The X-ray crystal structure of N-methyl-N’-phenylethylaminoiminomethanesulfonic acid
(132)
Figure 3.4 The X-ray crystal structure of N,N-dimethyl-N’-phenylethylaminoiminomethanesulfonic acid
(133).
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Table 3.1 Torsion angles [°] and bond lengths[Ǻ] for aminoiminomethanesulfonic acids
N
N
H
O3S
CH3
H
(132)
C(8)-N(8)-C(9)-N(9) -1.6(2) 177.79(17) -14.1(7)[22.2(5)]
C(8)-N(8)-C(9)-S(9) -179.73(12) -3.7(2) 166.8(4)[-158.8(2)]
N(9)-C(9) 1.305(2) 1.303(2) 1.309(4)[1.311(4)]
N(8)-C(9) 1.302(2) 1.311(2) 1.320(5)[1.317(4)]
C(9)-SO3- 1.824(15) 1.815(17) 1.839(3)[1.844(3)]
*two rotamers were found in the solid state
The X-ray structures were obtained for the corresponding N-hydroxyguanidines: (120) and (122),
which were synthesized as HCl salts. Several attempts were made to crystallize the
monomethylated derivative (121), but unfortunately none of them were successful. The X-ray
crystal structures of selected N-hydroxyguanidines are shown in Figure 3.5 and 3.6. Selected
bond lengths and torsion angles are given in Table 3.2.
Figure 3.5 The X-ray crystal structure of N-phenylethyl-N’-hydroxyguanidine hydrochloride (120).
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Figure 3.6 The X-ray crystal structure of N,N-dimethyl-N’-phenylethyl-N”-hydroxyguanidine
hydrochloride (122).
Table 3.2 Torsion angles [°] and bond lengths[Ǻ] for N-hydroxyguanidines
C(8)-N(8)-C(9)-N(9) 172.0(3)[7.3(5)] -163.22(17)
C(8)-N(8)-C(9)-N(10) -8.1(6)[-171.9(3)] 19.0(3)
C(9)-N(8)-N(10)-O(10) -19.6(5)[-15.4(5)] -147.6(2)
C(9)-N(9)-N(10)-O(10) 160.5(3)[160.5(3)] 34.7(2)
N(9)-C(9) 1.329(5)[1.326(5)] 1.335(2)
N(8)-C(9) 1.323(5)[1.323(5)] 1.334(2)
N(10)-C(9) 1.466[1.470(5)] 1.466(2)
*two rotamers were found in the solid state
In the case of the aminoiminomethanesulfonic acids, all C(9)-N(8) and C(9)-N(9) bond
lengths stay in a narrow range (1.302-1.320 Ǻ) indicating that all three analogues of
aminoiminomethanesulfonic acids possessed partial double bond character within the
N(9)-C(9)-N(8) fragment and consequently the positive charge should be almost equally
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distributed between two nitrogens. The same is observed in the case of N- hydroxyguanidines.
However, the bond lengths of N-hydroxyguanidines (1.323-1.335 Ǻ) are slightly longer
indicating that both C-N bonds have more single bond character. On the other hand the
N(10)-C(9) bond lengths (1.466-1.470 Ǻ) imply essentially single bond character. Partial double
bond character of C-N bonds is also in accordance with the protonation of N(8) and N(10) in
the case of aminoiminomethanesulfonic acids and N-hydroxyguanidines, respectively. This was
also confirmed by refinement of weakly bonded hydrogens.
The torsion angles imply that the geometry around the sulfonic acid as well as the
hydroxyguanidine functionality is nearly planar. The deviation from planarity is the highest for
(133) and (122) due to the presence of steric hindrance caused by two methyl groups. The
planarity of N-hydroxyguanidines is more distorted which is in agreement with the more single
bond character of the C(9)-N(10) bonds. While N(8), N(9), C(9) and N(10) adopt a nearly
planar arrangement, O(10) diverts significantly from the plane as can be expected due to the
single bond character of C(9)-N(10) bond.
In order to adopt the most energetically favorable configuration, compounds (137) and (133)
exist in the solid state as E-isomers. On the other hand, analogue (132) in order to minimize
steric repulsions adopts a Z-configuration at C(9)-N(8) bond and E-configuration at C(9)-N(9).
According to the X-ray structure, N-phenylethyl-N’-hydroxyguanidine (120) exists in the solid
state as a single E-isomer, similarly as its aminoiminomethanesulfonic acid counterpart (137).
However, (122) adopts opposite configuration and exists in the solid state as a single Z-isomer
likely due to the larger steric hindrance of the N,N-dimethylamino group compared to the
HN-OH group.
In addition, it was found that compounds (133) and (120) exist as two rotamers in the solid
state, which differ only in the orientation of the phenyl ring.
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3.2.2 NMR Spectroscopy Studies
Aminoiminomethanesulfonic Acids
A series of aminoiminomethanesulfonic acids (132) and (137) was analysed by various NMR
techniques such as 1H NMR, 1D gs-NOESY, 1H-1H COSY, 1H-13C HMBC and 1H-15N HMBC.
The values of the 1H and 15N chemical shifts are summarized in Table 3.3. Unfortunately, the
aminoiminomethansulfonic acid (133) could not be studied by NMR spectroscopy since it
contained a large amount of starting thiourea, as described in Section 3.1.
Table 3.3 The values of 1H and 15N chemical shifts for aminoiminomethanesulfonic acids
δ chemical shifts [ppm]*
15N NMR data 1H NMR dataStructure
N(8) N(9) N(8)H N(9)H N(9)CH3
103.4 116.9 9.65
9.24
9.26
-
111.9 108.9 9.09 9.39 2.84
117.9 98.3 9.28 9.12 3.18
*all samples run in the d6-DMSO solutions at room temperature;
In the case of (137), the 1H NMR spectrum showed three NH resonances at 9.24 (s), 9.26 (s)
and 9.65 (t) ppm. The triplet corresponds to the NH which is adjacent to the CH2 fragment and
two singlets correspond to non-equivalent protons of the NH2. Since the singlet resonances at
9.24 and 9.26 coalesced at 300 K it can be concluded that in the d6-DMSO solution (137) has a
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restricted rotation around C(9)-N(9) moiety, which is slow relative to the NMR time scale at
room temperature. This is in agreement with delocalization of the double bond along the
N(8)-C(9)-N(9) moiety found in the solid state. In order to determine the stereochemistry of the
N-C-N fragment, (137) was also studied by 1D gs-NOESY (Scheme 3.9). Irradiation of the
NCH2 signal at 3.47 ppm resulted in NOE effects for NH resonances at 9.24 (s) and
9.65 (t) ppm. Observing NOE enhancement only for one of the two NH2 resonances
corresponded with restricted rotation around C(9)-N(9) fragment and also indicated that (137)
existed in the d6-DMSO solution as the E-isomer, as it also did in the solid state.
Scheme 3.9
N
O3S
N
H
H
H
9.24
9.65
3.479.26
(137)
isomer
Although (132) gave a single peak with the correct mass (209.1112 M+. C11H17N2S requires
209.1115) in the HR-ESI-MS spectrum, 1H and 13C NMR spectra showed two sets of resonances
in a 66:34 ratio. Moreover, 1H-1H COSY and 1H-13C HMBC implied the same connectivity for
both sets of resonances it is likely that there were two geometric isomers of (132) in d6-DMSO
solution. When the sample was heated to 350 K, the 1H NMR spectra showed that the ratio
changed from 66:34 to 61:39. Increasing the temperature also caused broadening of peaks, but
coalescence was not achieved. The 1D gs-NOESY spectrum, recorded at 350 K, indicated
significant saturation transfer (EXSY peak) upon selective irradiation of the NCH2 resonance.
The intensity of the EXSY peak decreased with temperature and became negligible at room
temperature. Therefore it can be concluded that (132a) and (132b) are geometric isomers existing
in the d6-DMSO solution in a dynamic equilibrium with an energy barrier such that the
interconversion is slow relative to the NMR timescale.
Due to the delocalization of double bond, four steroisomers can be formed around the
N-C-N system as illustrated in Scheme 3.10.
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Therefore 1D gs-NOESY was employed to determine the stereochemistry of (132a) and
(132b). NOE was only observed at the neighbouring NH signal at 9.08 ppm for the NCH2
signal of the major isomer (132a, δ=3.88 ppm). However, irradiation of the CH3 resonance
(δ=2.84 ppm) resulted in NOE enhancement for both NH signals (δ=9.08 and 9.38 ppm) which
proves that (132a) exists as the E,Z-isomer. In the case of the minor isomer (132b), the methyl
resonance (δ=3.18 ppm) showed NOE only to the adjacent NH. However, when selective
irradiation was applied to the NCH2 (δ= 3.47 ppm) signal, NOE enhancements were observed
for both NH resonances (δ=9.13 and 9.28 ppm), which identifies the Z,E-isomer.
The aminoiminomethanesulfonic acids were also investigated by 1H-15N HMBC (Figure 3.7
and Figure 3.8). Since the spectra were recorded without using the low-pass filter, both long-
range and single-bond correlations can be observed. Single-bond correlations yield strong
doublets which easily allow 15N resonances to be assigned.
Scheme 3.10
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Figure 3.7 The expanded 2D 1H-15N HMBC spectrum of (137) in d6-DMSO
The values the 15N chemical shifts for (137) and (132) were found to be in a narrow range
(100-120 ppm) which is consistent with the partial double bond character of the C-N bonds.23
The weaker crosspeaks appear due to the long-range 3J correlation. While 1J crosspeaks enable
easily derivation of 1J coupling constants, long-range coupling constants are significantly smaller
and remain unresolved. However, the heteronuclear couplings < 10 Hz generally show a more
or less linear response if the delay Δ for evolution of heteronuclear couplings is kept relatively
short (40-50 ms). Therefore, the intensity of long-range crosspeaks can be used for rough
estimation of small vs. large heteronuclear coupling constants.24 As seen in Figure 3.7, proton
H(9) (δ=9.24 ppm) did not show a 3J crosspeak with nitrogen N(8) whilst protons H(9)
(δ=9.26 ppm) and H(8) have long-range crosspeaks with N(8) and N(9), respectively.
Considering that (137) is the E-isomer, as was established by 1D-gs NOESY and X-ray it is
obvious that the 3J correlation is observed only if proton and nitrogen are in the mutual
trans-position and when the corresponding coupling constant is large.
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Figure 3.8 The expanded 2D 1H-15N HMBC spectrum of (132) in d6-DMSO
The same procedure can be used to confirm the stereochemistry of the (132) isomers. As
seen in Figure 3.8, in the case of major isomer (132a) two long-range crosspeaks are observed.
The crosspeak of proton H(9a) with N(8a) is stronger than the crosspeak of proton H(8a) with
N(9a). This implies that former pair of atoms is in the trans-arrangement while the latter one is in
the cis-arrangement. Minor isomer (132b) shows only one long-range crosspeak for proton H(8b)
and N(9b) showing that these atoms are in a mutual trans-orientation.
H-9a H8b H9b H8a
N8b = 117.9 ppm
N8a = 111.9 ppm
N9a = 108.9 ppm
N9b = 98.3 ppm
3J
3J
3J
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N-Hydroxyguanidines
The N-hydroxyguanidines and their hydrochlorides were also studied by 1H NMR, 1D
gs-NOESY, 1H-1H COSY, 1H-13C HMBC and 1H-15N HMBC. The values of the 1H and 15N
chemical shifts are summarized in Table 3.4.
In the case of (120), there are characteristic broad signals in the low field region of the 1H
NMR spectrum, which indicate the presence of –OH, –NH and –NH2 groups. The singlet at
7.75 ppm with integral intensity of two protons can be assigned to NH2. The triplet at 8.00 ppm
(1H) was identified as NH. In addition two further singlets were observed at 9.84 and 10.53
ppm. Similarly for (122), the triplet corresponding to N(8)H proton was seen at 7.84 ppm as well
as two singlets were observed at 10.19 and 10.69 in the downfield region of the 1H NMR
spectrum. Since the singlets in the downfield region integrated for 1H each, they can be clearly
assigned to OH and N(10)H protons. Neither the 1H NMR nor 2D 1H-13C nor 1H-15N HBMC
spectroscopy allows their discrimination. Unlike the analogous aminoiminomethanesulfonic
acids, the NH2 protons and the N-methyl groups of (120) and (122), respectively, are equivalent
which implies free rotation around the C-N bond.
The values of the 15N chemical shifts for N(8) and N(9) of (120) and (122), obtained
indirectly by 1H-15N HBMC spectroscopy (see Table 3.4), did not differ significantly which
indicated the equal positive charge distribution along the N(8)-C(9)-N(9) fragment. For (122),
N(9) is shifted upfield compared to (120) which can be ascribed to the presence of CH3 groups.
Comparing the values of the 15N chemical shifts with the analogous sulfonic acids reveals
that chemical shifts of both N(8) and N(9) are slightly lower which is in agreement with more
single bond character of the C(9)-N(8) and C(9)-N(9) bonds as already shown by X-ray
crystallography.
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Table 3.4 The values of 1H and 15N chemical shifts for N-hydroxyguanidines
δ chemical shifts [ppm]*
15N NMR data 1H NMR data
Structure
N(9) N(8) N(10) N(8)H NCH2 NCH3 N(9)H NH/OH
64.1 86.6 139.8 7.84 3.47 2.82 - 10.19 10.69
39.0 62.5 264.3 4.98 3.14 2.25 - 8.67 -
73.7 81.3 136.1 8.00 3.40 - 7.75 9.84 10.53
- 59.3 - 4.52 3.09 - 4.77 7.77 -
64.1 77.1 135
71.9 83.0 135
7.84 3.40 2.71 7.98 9.91 10.59
*all samples run in the d6-DMSO solutions at room temperature; 15N values of chemical shifts for (121)
were recorded at 203K in d3-methanol.
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Deprotonation of the nitrogen N(10) of (122) resulted in upfield shifts for N(8)H, NCH2,
NMe and OH resonances in the 1H NMR spectrum. The significant (Δδ=124.5 ppm) downfield 
shift of δN(10) was also seen in the 1H-15N HMBC spectrum. In addition, considerable upfield
shifts were observed for resonances of nitrogens N(8) and N(9). This implied that the double
bond became essentially localized between the C(9) and N(10) fragment. Assuming free rotation
about the N(8)-C(9) axis on the grounds of reduced double bond character, and given the
enhanced C(9)-N(10) double bond character, (122F) might exist as two geometrical isomers, in
principle, but only one set of signals was observed in the 1H NMR spectrum at room
temperature and at 203 K in d4-methanol, which suggests that only one isomer exists in the
solution. However, NOESY experiments did not allow determination of the stereochemistry of
(122F), due to the exchange of weakly bonded hydrogens.
The 2D 1H-15N HBMC experiment for free N-phenylethyl-N’-hydroxyguanidine (120F) did
not provide the values of chemical shifts for all nitrogens. There was only one crosspeak present
which corresponded to the nitrogen N(8). However, the upfield shift by 22 ppm with respect to
the corresponding hydrochloride (120) implied that the N(10) nitrogen was deprotonated and
the double bond was then localized between the C(9)-N(10) fragment, analogously to (120F). In
addition, as seen in Table 3.4, there are significant upfield shifts for the values of δN8H, δN8CH and
δN9R in the 1H NMR spectrum.
Since the 1H NMR spectrum of (120F) in d6-DMSO at room temperature shows a broad
signal for the CH2 group (δ=3.09 ppm), VT studies were performed to explain this
phenomenon. As illustrated in Figure 3.9 the resonance corresponding to the CH2 group gets
narrower at higher temperatures. This can indicate the presence of a dynamic equilibrium
between two possible stereoisomers which is likely the reason for missing crosspeaks in the
1H-15N HMBC NMR spectrum.
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Figure 3.9 The expanded 1H NMR VT spectrum of (120F) in d6-DMSO
Previous experiments indicated that (120) and (122) have a partial bond character along the
N(8)-C(9)-N(9) fragment. However, this is in contradiction to the free rotation of the C-N
bonds deduced from N(9)H and N(9)Me resonances (see above). In order to confirm
delocalization of the double bond VT (variable temperature) NMR studies were performed in
d4-methanol for N,N-dimethyl-N’-phenethyl-N”-hydroxyguanidine (122). As presented in Figure
3.10, the VT NMR spectra illustrate decoalescence of the N(9)Me resonance at about 209 K,
which implies restricted rotation around either the N(8)-C(9) or N(9)-C(9) bond.
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Figure 3.10 The expanded 1H NMR VT spectrum of (122) in d4-methanol
VT studies were also performed for (120) in d3-methanol, which allowed observation of
“weakly bonded” hydrogens. However, at 183 K the downfield region of the 1H NMR spectrum
becomes very complex which likely indicates both the presence of geometric isomers at lower
temperature and the presence of non-equivalent NH2 protons (Figure 3.11). So, these
experiments stay in agreement with the previously stated assumption that the double bond is
delocalized in the N(8)-C(9)-N(9) moiety, but the barrier for the rotation is much lower than that
for the analogous aminoiminomethanesulfonic acids.
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Figure 3.11 The expanded 1H NMR VT spectrum of (120) in d3-methanol
The 1H NMR spectrum of N-methyl-N’-phenethyl-N”-hydroxyguanidine (121) in d6-DMSO
at room temperature showed broad resonances for the NCH2 group (δ=3.40 ppm) and NMe
(δ=2.71 ppm), which get narrower at higher temperatures as illustrated in Figure 3.12. This
suggests a dynamic behavior of the molecule in solution.
The low temperature 1H NMR study of (121) in d3-methanol confirmed this assumption as
the two sets of resonances in a 1:1 ratio became apparent as shown in Figure 3.13.
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Figure 3.12 The expanded 1H NMR VT spectrum of (121) in d6-DMSO
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Figure 3.13 The expanded 1H NMR VT spectrum of (121) in d3-methanol
It was already proven that N-hydroxyguanidine hydrochlorides possessed the double bond
delocalized along the N(8)-C(9)-N(9) fragment whilst the C(9)-N(10) bond had a single bond
character. Therefore, it is likely that N”-methyl-N-phenethyl-N’-hydroxyguanidine (121) exists in
the solution as two of four possible isomers as shown in Scheme 3.11.
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Scheme 3.11
Due to the fast exchange, even at 233 K, it was impossible to identify the stereochemistry of
these compounds by NOESY experiments. As d3-methanol was used for the low temperature
1H NMR studies, the weakly bonded protons were observed at 233K. The resonances became
sharp and the coupling was resolved revealing that multiplets at around 7.6 ppm and 8.1 ppm
were overlapped triplet and quartet of N(8)H and N(9)H as illustrated in Figure 3.14.
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Figure 3.14 The expanded 1H NMR VT spectrum of (121) in d3-methanol (weakly bonded hydrogens)
Both multiplets also showed crosspeaks with the NCH3 and NCH2 resonances in 1H-1H
COSY spectrum which confirms previous assignment. Furthermore, the resonances
corresponding to N(10)H and OH also became sharp and decoalescence was observed at 183K.
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The 2D 1H-15N HMBC spectrum of N”-methyl-N-phenethyl-N’-hydroxyguanidine (121)
recorded at 240K (d3-methanol) showed crosspeaks for four
15N resonances in the aliphatic
region of the spectrum as presented in Figure 3.15.
Figure 3.15 The expanded 2D 1H-15N HMBC spectrum of (121) in d3-methanol at 240K
The two upfield shifted signals (δ=64 and 72 ppm) possessed crosspeaks with methyl
resonances which allowed to assign them as N(9). On the other hand, the downfield crosspeaks
(δ=77 and 82 ppm) can be determined as N(8) as they correlate to CH2 groups.
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H8 H9H8 H9
2 × N10 = 135 ppm
N8b = 83 ppm
N8a = 77 ppm
N9a = 72 ppm
N9b = 64 ppm
3J
3J
3J
Figure 3.16 The expanded 2D 1H-15N HMBC spectrum of (121) in d3-methanol at 203K
In order to see crosspeaks of weakly bonded hydrogens, the 1H-15N HMBC spectrum was
recorded one more time at 203K. This experiment revealed the two additional 15N resonances at
135 ppm, which could be assigned to the nitrogen N(10) (Figure 3.16).
The 15N resonances of N(9) at 64 ppm and N(8) at 77 ppm show 1J crosspeaks with 1H
signals overlapping at around 7.9 ppm and 3J crosspeaks with 1H signals overlapping at around
8.4 ppm. Therefore these nitrogens must come from two different molecules. Consequently, the
same applied to N(9) at 70 ppm and N(8) at 83 ppm, which show only 1J crosspeaks with 1H
signals overlapping at around 8.4 ppm. Both 1J and 3J crosspeaks of N(9) at 72 ppm and N(8) at
77 ppm are slightly shifted upfield in the F2 dimension, which indicated that they both belong to
the same proton (H9). On the other hand, N(9) at 64 ppm and N(8) at 83 ppm correlate with
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H8 shifted downfield in the F2 dimension. This enables assignment of the former 1H and 15N
resonances to isomer (121a) and latter ones to isomer (121b).
In the case of isomer (121a), proton H(8) (δ=7.89 ppm) has a 3J crosspeak with nitrogen
N(10) (δ=135 ppm) whilst proton H(9) (δ=8.39 ppm) has long-range crosspeaks with N(8)
(δ=77 ppm). Considering that the 3J correlation is observed only if proton and nitrogen are in
the mutual trans-position, as was established for aminoiminomethanesulfonic acids, it became
evident that the isomer (121a) possesses E,Z-geometry Analogously, 3J crosspeak of H(8)
(δ=8.40 ppm) with N(9) (δ=64 ppm) and H(9) (δ=7.86 ppm) with N(10) (δ=135 ppm) indicate
that (121b) is Z,E-isomer.
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3.3 Conclusions
The X-ray crystallography and NMR spectroscopy studies have shown that
aminoiminomethanesulfonic acids and hydroxyguanidine hydrochlorides have analogous
electronic structures. Both classes of compounds have the C-N double bond delocalised along
the N(8)-C(9)-N(9) fragment with the positive charge equally distributed between the two
nitrogens. In the case of aminoiminomethanesulfonic acids, the C-N bonds have considerable
double bond character and therefore 137 exists as a single E-isomer in both the solid state and
d6-DMSO solution. However, for the N-methyl analogue (132) only the E,Z-geometry for the
N-C-N fragment was found in the solid state and there is a dynamic equilibrium between the
E,Z-isomer (132a) and the Z,E isomer (132b) in d6-DMSO solution. Since the barrier for
rotation of the N-C-N fragment is rather high, the exchange is slow compared to the NMR
timescale at room temperature. In the solid state, hydroxyguanidine hydrochlorides (120) and
(122) also exist as single E- and Z-isomers, respectively. As the C-N(8) and C-N(9) bonds have
more single bond character, the N(8)-C-N(9) fragment freely rotates in solution. However,
rotamers become apparent at low temperatures which implies that the rotation around C-N(8)
and C-N(9) bonds is still slightly restricted due to double bond delocalisation. In the case of the
N-methyl derivative (121), two rotamers, 121a and 121b, were found in d3-methanol at
temperatures below 240 K, which were identified by 1H-15N HMBC as the E,Z-isomer and
Z,E-isomer, respectively. Observing only two of four possible isomers for both N-methyl
derivatives (121) and (132) underlines the similarity of the electronic structures of
aminoiminomethanesulfonic acids and N-hydroxyguanidine hydrochlorides and suggests that
concerted flipping of C-N(8) and C-N(9) is a preferable pathway over stepwise flipping which
would also yield E,E- and Z,Z-isomers. However, further experiments and computational
studies are required to prove whether it is a kinetic or just thermodynamic effect.
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4.1 Introduction
It has been reported that some of the physiological effects of hydroxamic acids such as
their hypotensive activity may be due to their ability to release nitric oxide as described in
Section 1.5.2.1-7 It was therefore decided to examine a series of hydroxamic acids as NO
donors in our assay system. Preliminary biological results indicated that the commercially
available benzohydroxamic acid was capable of causing smooth muscle relaxation in rat
aorta. The ODQ test implied that the relaxation may be mainly NO mediated since 70%
reversibility was observed. In addition, the EC50 value of 50.1 μM was comparable to the
activity of some N-hydroxyguanidines (see Section 2.2). Therefore, it was decided to prepare
further homologues to explore their activity. Firstly, a series of homologues of
benzohydroxamic acid (Scheme 4.1), with extended alkyl chains between the functional
group and the benzene ring, were synthesized. In addition, a CF3 substituted analogue was
also prepared.
Scheme 4.1
4.1.1 Synthesis of hydroxamic acids
From acid chlorides
The synthesis of 4-phenylbutyrohydroxamic acid (140) was carried out using the
published procedure as in Scheme 4.2.8 Firstly, the acid chloride was prepared via reaction of
4-phenylbutyric acid with oxalyl chloride, in the presence of catalytic DMF. The crude acid
chloride was then reacted with hydroxylamine hydrochloride in the presence of base.
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Scheme 4.28
After purification by flash chromatography, the desired product (140) was obtained,
although in a very poor 11% yield. However, literature data also indicated that there were
difficulties with the isolation and purification steps.1, 8, 9 The final product was analyzed by 1H
and 13C NMR spectroscopy, MS and elemental analysis. The presence of single peaks
corresponding to the NH proton (1H, 8.70 ppm) and the OH proton (1H, 10.37 ppm)
confirmed the structural features of the hydroxamic acid. The presence of the single peak in
the mass spectrum at 202.1 (M+Na)+, as well as results of elemental analysis, supported the
correct structure and purity of the compound.
Recently, an improved one-step procedure has been published for the synthesis of
various hydroxamic acids as shown in Scheme 4.3.10 This also employs formation of the acid
chloride, but in this case in situ using cyanuric chloride, followed by its reaction with
hydroxylamine hydrochloride in the presence of base. The initial goal was to use this method
for the synthesis of the next three analogues. However, the published approach was
employed several times with various modifications, but none of them gave the desired
compounds as the major product.
Scheme 4.310
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From methyl esters
In order to overcome problems with the previous methods, a procedure which utilizes
the corresponding methyl esters instead of the acid chlorides was employed as shown in
Scheme 4.4.11
Scheme 4.411
Methyl phenylacetate (142) was firstly prepared from the corresponding carboxylic acid
by heating it under reflux in methanol with a catalytic amount of concentrated sulfuric acid.
The methyl ester (142) was then reacted with a preformed slurry of hydroxylamine
hydrochloride and potassium hydroxide. After work up, the crude product was obtained as a
pale pink solid which was recrystallized from diethyl ether to give pure
phenylacetohydroxamic acid (138) as pale pink crystals in a more acceptable 58% yield
compared to 11% obtained from the acid chloride. The compound was characterized using
1H and 13C NMR spectroscopy, MS and elemental analysis. The presence of the characteristic
signals for the -NH and -OH groups in the lowfield region of the 1H spectrum indicated the
presence of the hydroxamic acid functionality. The disappearance of the peak corresponding
to methyl group in the 1H NMR spectrum confirmed the successful transformation. In
addition, the single peak at 150 (M-H)- in the mass spectrum as well as the results of
elemental analysis confirmed the structure of the final product and its purity.
3-Phenylpropionohydroxamic acid (139) was obtained as described above, after
recrystallization from petroleum ether. As in the case of other hydroxamic acids, the
presence of two singlets at 8.72 ppm (NH) and 10.38 ppm (OH) showed the presence of the
desired hydroxamic acid group. The results of elemental analysis (see experimental part)
showed that the synthesized compound was nearly 100% pure and this was additionally
confirmed by the presence of the single peak at 166 (M+H)+ in the mass spectrum. The
X-ray crystal structure of the final product (139) is presented in Figure 4.1.
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Figure 4.1 X-ray crystal structure of 3-phenylpropionohydroxamic acid (139)
4-(Trifluoromethyl)phenylacetohydroxamic acid (141) was also prepared as described
above. Firstly, the methyl (4’-trifluoromethylphenyl)acetate (143) was synthesized by the
acidic esterification of the corresponding carboxylic acid. As a known compound, only 1H,
19F and 13C NMR spectroscopy were employed to confirm the structure of the product (see
experimental). In the next step, the methyl ester (143) was treated with a suspension of
hydroxylamine hydrochloride and potassium hydroxide. The final product (141) was
obtained in 47% yield as pale pink crystals. The appearance of the characteristic signals
(8.89 ppm – NH & 10.72 ppm – OH) in the low-field of the 1H NMR spectrum confirmed
the successful transformation. The purity was established by elemental analysis. The X-ray
data proved the structure of the 4-(trifluoromethyl)phenylacetohydroxamic acid (141) as
illustrated in Figure 4.2.
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Figure 4.2 X-ray crystal structure of 4-(trifluoromethyl)phenylacetohydroxamic acid (141)
4.2 Biological Results
The synthesized series of hydroxamic acids was studied by the myography to investigate
their NO donor activity. (Benzohydroxamic acid was commercially available). As in the case
of the unsubstituted N-hydroxyguanidines, the hydroxamic acids were found to be good
nitric oxide donors. The data are shown in Table 4.1.
Table 4.1 Biological activities of tested hydroxamic acids
Structure Code No. logEC50[mol/dm3]
ODQ induced
reversibility[%]
BA -4.3 ± 0.3 70.1 ± 9.8
AK42 -4.5 ± 0.2 96.6 ± 11.1
AK46 -5.3 ± 0.1 95.8 ± 6.5
AKH4 -3.9 ± 0.1 50.0 ± 8.0
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The results indicated that tested hydroxamic acids are very potent NO donors. Their
EC50 values imply that extension of the alkyl chain caused an increase in their biological
activity until the number of methylene groups reached 3. After that point, a higher dose of
compound was required to achieve 50% relaxation. The ODQ test results suggested that the
smooth muscle relaxation is mainly mediated via a NO dependent pathway. The hydroxamic
acids seemed to be a promising class of novel NO donors. Their vasodilatation activity
appeared to be as good as for N-hydroxyguanidines (Figure 4.3).
Figure 4.3 Vasorelaxation profiles of hydroxamic acids
3-Phenylpropionohydroxamic acid (139) possessed the best biological profile with logEC50=
-5.3 [mol/dm3] and 96% ODQ induced reversibility. Therefore it was chosen for further
investigation in the isolated perfused kidney (IPK) model and its vasodilatation activity is
presented in Figure 4.4.
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Figure 4.4 Vasorelaxation profile of AK46 (139) in isolated perfused kidney
The lead compound AK46 caused an initial vasodilatation of 38% at 1 mM, however,
this was short lasting. The perfusion pressure through the kidney rapidly returned to the
preconstricted level. Additionally, a further vasoconstriction was observed at the higher
concentrations of 3-phenylpropionohydroxamic acid. The reason for this unusual behaviour
is unclear. However, this observation implies that AK46 must be producing further
unexpected biological effects in the kidney assay.
-6 -5 -4 -3
-50
-25
0
25
50
75
100
Initial Relaxation
Subsequent vasoconstriction
log[AK46]
R
el
ax
at
io
n
(%
)
HYDROXAMIC ACIDS
134
4.3 Conclusions
Hydroxamic acids are a novel class of NO donors. Interestingly, the hydroxamic acids
that were prepared possess promising pharmacological profiles.
3-Phenylpropionohydroxamic acid (AK46) revealed the most potent NO donation
properties in the rat aorta assay. Data indicated that it met all of the required criteria, namely
a low EC50 value (6.4 μM) and almost 100% reversibility in the ODQ test.
The myography studies proved that hydroxamic acids will give smooth muscle relaxation
in the rat aorta. However, their behavior in the IPK indicated that the whole kidney was
more complex system and that hydroxamic acids did not undergo the same biological
pathway as in the rat aorta. Further mechanistic studies should be performed in order to
investigate this behavior in more detail.
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5.1 Introduction
As described in Chapter 1, nitric oxide has beneficial physiological effects as well as harmful
pathological effects. Due to its instability it is difficult to deliver NO directly to cells. In addition,
global distribution of NO is not beneficial; therefore, it is essential to develop site selective
drugs. There have been several approaches to achieve this goal, as discussed in the introduction.
One of them employs a pro-drug strategy.1, 2 In our case, the idea was based on coupling the
active agent (N-hydroxyguanidine) with a carrier (enzyme recognized structure). The activation
of the pro-drug would occur by hydrolysis (esters, amides, imines), oxidation or reduction.
NO has been found to be an anti-tumoral agent, but its mechanism of action in cancer cells
is still not completely clear.3-5 In addition, glycosidases have been demonstrated to be elevated in
the interstitial fluid of tumors, sera of animals and patients with tumors.6 Therefore, the aim was
to couple the hydroxyguanidine moiety with a glucose molecule to produce the site selective pro-
drug. Two possible retro synthetic approaches are shown in Scheme 5.1. The first route involves
reaction of a cyanamide with a protected O-glycosyl hydroxylamine. In the second route a
glycosyl donor (e.g. acetobromoglucose) is reacted with preformed N-hydroxyguanidine.
Scheme 5.1
NO-DONOR PRO-DRUGS ACTIVATED BY GLYCOSIDASES
138
5.2 Synthesis
5.2.1 Route One
The first route required the synthesis of O-(tetra-O-acetyl-D-glucopyranosyl)hydroxylamine
(144). There are few previously published procedures which describe the synthesis of this
compound.7-13 The first approach employed the reaction of N-hydroxysuccinimide (145) with
acetobromoglucose (146) and deprotection with hydrazine hydrate, as shown in Scheme 5.2.8, 9
Scheme 5.2
However, this synthesis was difficult to repeat. The first step worked well and O-(tetra-O-
acetyl-β-D-glucopyranose)-N-hydroxysuccinimide (147) was obtained in good yield (52%). The
product (147) was analyzed using various analytical techniques such as 1H and 13C NMR
spectroscopy and mass spectrometry. The purity was confirmed by melting point which was
exactly the same as literature value 182-184 °C. Unfortunately the deprotection with hydrazine
hydrate proved very difficult. Since the reaction was performed under reflux conditions for
about 10 minutes, it was very challenging to control the process. The problem was that
hydrolysis of the acetate groups was observed to take place if the reaction was left too long. As a
result a mixture of various glucose derivatives with different numbers of acetate groups was
obtained which was impossible to separate. However, it was possible to completely deprotect
O-(2, 3, 4, 6-tetra-O-acetyl-β-D-glucopyranosyl)-N-hydroxysuccinimide (150) using methodology
which employed ammonium hydroxide at 75oC reported by Wiessler et al. to give
O-β-D-glucopyranosylhydroxylamine (148).9 However, the final product was very difficult to
work with due its high polarity.
In order to synthesize O-(tetra-O-acetyl-D-glucopyranose)hydroxylamine (144), Thomas et al
applied a similar route except that the N-hydroxyphthalimide (149) derivative was used instead
of the N-hydroxysuccinimide (146), as illustrated in Scheme 5.3.14, 15
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Scheme 5.3
Acetobromoglucose (146) was thus reacted with N-hydroxyphthalimide (149) using phase
transfer conditions. O-(Tetra-O-acetyl-β-D-glucopyranose)-N-hydroxyphthalimide (150) was
obtained in moderate 36-55% yield, in agreement with published yields.10, 11 The compound (150)
was characterized using 1H and 13C NMR spectroscopy and mass spectrometry. The HR-ESI-MS
gave the mass of 516.1115, C22H23NO12Na requires 516.1118. Then, it was attempted to achieve
selective deprotection as described in the publication.15 However, as in the case of the
N-hydroxysuccinimide analogue, it was not possible to obtain the pure O-glycosylhydroxylamine.
The very short reaction time and propensity of the acetates to undergo hydrolysis meant that
either the product was a mixture of staring material and the required hydroxylamine, if the time
was short, or a mixture of various partially deprotected O-hydroxylamine derivatives, when the
reaction time was too long. The final successful reaction conditions (Scheme 5.4) employed
methylhydrazine, which was a combination of the literature methodology and a previously
applied procedure by the Botting group.10
Scheme 5.4
O-(Tetra-O-acetyl-D-glucopyranose)hydroxylamine (144) was characterized using 1H and
13C NMR spectroscopy. The most clear-cut indication of the product structure is the singlet at
5.82 ppm with an integration of two, signifying the presence of the NH2 group. In addition, the
absence of signals corresponding to the aromatic protons in the region of 7.75-7.83 ppm of the
1H NMR spectrum as well as the aromatic carbons in the region of 105-135 ppm of the
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13C NMR spectrum showed that no starting material remained. The synthesized hydroxylamine
derivative (144) was then reacted with 2-phenylethylcyanamide (151) as shown in Scheme 5.5.
Scheme 5.5
The above transformation was never successful, either in the presence or absence of
potassium carbonate, which was usually employed in the reaction of cyanamides and
hydroxylamine hydrochloride. Thin-layer chromatography showed no reaction. However,
prolongated heating of the reaction mixture caused hydrolysis of acetate groups. Since, methanol
as a polar, protic solvent can accelerate the loss of acetates; the reaction was performed under
slightly modified conditions, as illustrated in Scheme 5.6.
Scheme 5.6
Benzylcyanamide (39) and O-(tetra-O-acetyl-D-glucopyranose)hydroxylamine (144) were
dissolved in dry dichloromethane and then triethylamine was added. The reaction mixture was
heated under reflux for two days. The thin-layer chromatography indicated that major spots
corresponded to the starting material, even though the reaction conditions were already quite
harsh. In order to check the composition of the reaction mixture the crude product was analyzed
by LC-MS. As shown in Figure 5.1, several peaks were present in the mass spectrum of the
crude product. It illustrated that, except for the signals corresponding to starting materials (386
and 397), there were three other major peaks present which match a product with loss of one
(538), two (496) and three (454) acetate groups, respectively. In addition, no intact product was
observed in the spectrum.
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Figure 5.1 Mass spectrum of the crude product (153) (DCM used as a solvent).
Although, the new set of conditions did not improve the transformation, it helped to
conclude that reaction needs to proceed at higher temperature and that the overall time of the
heating should be shortened in order to avoid the hydrolysis of acetates. Unfortunately, changing
the solvent from dichloromethane (bp 40 °C) to 1,4-dioxane (bp 101 °C) and heating under
reflux for 7h instead of 2 days, did not force the reaction to go. As presented in Figure 5.2, the
mass spectrum shows that mainly starting materials (386) are present in the crude mixture. This
time there were no peaks which indicated the formation of desired product.
Figure 5.2 Mass spectrum of the crude product (153) (1,4-dioxane used as a solvent).
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It was decided to employ alternative synthons for the guanidine moiety such as
phenylethylaminomethanesulfonic acid (137) as already presented in Section 3.1 (Scheme 5.7)
and chloroformamidinium chloride (127) (Scheme 5.8), which had been successfully reacted with
the THP-protected hydroxylamine (see Section 3.1).
Scheme 5.7
The aminoiminomethanesulfonic acids are the products of oxidation of the corresponding
thioureas. They had been reported as guanylating agents and successfully employed in the
synthesis of various guanidines.16, 17 Therefore, they seemed to be suitable intermediates for our
transformation. However, as in the case of previous reactions, thin-layer chromatography
indicated the presence of only starting materials in the reaction mixture.
Scheme 5.8
Reaction of ureas with phosgene leads to very reactive intermediates such as
C-chloroformamidinium chlorides (127), which should rapidly undergo nucleophilic substitution
and had been successfully employed in the synthesis of trisubstituted N-hydroxyguanidines (see
Section 3.1).18 However, treatment of the corresponding C-chloroformamidinium chloride (127)
with the sugar protected hydroxylamine (144), as shown in Scheme 10, did not give reasonable
results. TLC analysis showed only the presence of starting materials. Unfortunately, neither of
the newly employed reactive intermediates reacted with O-(tetra-O-acetyl-D-
glucopyranose)hydroxylamine (144) to give the desired products.
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5.1.2 Route Two
The complete lack of success with the first route led to an investigation of the second
approach. Since both, N-hydroxysuccinimide (145) and N-hydroxyphthalimide (149) reacted with
acetobromoglucose (146) under phase-transfer conditions; the same methodology was utilized to
attempt to combine N-hydroxyguanidines and acetobromoglucose as shown in Scheme 5.9.
Scheme 5.9
However, the above reaction failed. In a number of attempts, a mixture of the starting
materials was obtained according to thin layer chromatography. Since, in these
hydroxyguanidines there are free amino- and hydroxyl- groups, we speculated that they may
compete with each other for the electrophilic bromide. Therefore, we decided to treat
N”,N”-dimethyl-N-phenylethyl-N’-hydroxyguanidine (122) with acetobromoglucose (146) under
the same set of conditions as illustrated in Scheme 5.10.
Scheme 5.10
Elimination of free amino group did not improve the overall transformation. Based on the
TLC analysis, only starting materials were present in the reaction mixture. The reaction time did
not affect the reaction, except that gradual loss of acetates from the acetobromoglucose was
observed.
The Koenigs-Knorr reaction is the most popular set of conditions used for glycosylation of
alcohols. Therefore an attempt was made to glycosylate N-hydroxyguanidines under Koenigs-
Knorr conditions as shown in Scheme 5.11.19
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Scheme 5.11
Thin layer chromatography indicated mainly the presence of acetobromoglucose (146).
Literature data showed that hydroxyguanidines could be easily oxidized using silver carbonate. In
addition, M. Thomas et al. also could not glycosylate hydroxamic acids under Koenigs-Knorr
conditions, probably due to the same reason. However, they successfully O-glycosylated
hydroxamic acids, using glycosyl trichloroacetimidates as glycosyl donors.14
Therefore, the similar approach was employed to O-glycosylate N-hydroxyguanidines. Firstly,
the glycosyl trifluoroacetamidate donor had to be synthesized according to Scheme 5.12.20-24
Scheme 5.12
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Initially, glucose was treated with benzoyl chloride to give fully protected glucose (156)
which was characterized by 1H and 13C NMR spectroscopy. The data were compared with
literature which confirmed the correct structure.20 However, reported values of the melting point
varied from 156 to 191 °C. Therefore, elemental analysis was performed to prove the purity of
the final product (Found: C, 70.4; H, 4.6%. C41H32O11 requires C, 70.3; H, 4.6%) and the melting
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point was found to be 150-151 °C. In the next step, penta-O-benzoyl-β-D-glucopyranoside (156)
was converted to the corresponding bromide using HBr in acetic acid, and it was taken without
any characterization into the next reaction. The hydrolysis of the bromide in the presence of
silver carbonate yielded 2,3,4,6-tetra-O-benzoyl-D-glucopyranose (157) in an excellent yield
(96%). The product was analyzed using 1H and 13C NMR spectroscopy. The spectra confirmed
the structure of the product and were in agreement with literature data.20, 25 The
trifluoroacetimidoyl chloride (158) was synthesized according to the published procedure by
reacting aniline and TFA in the presence of triphenylphosphine and triethylamine.21 This gave
the desired product (158) in 59% yield and the analytical data were in the agreement with
literature.21 The glycosyl trifluoroacetimidate donor (159) was eventually obtained by coupling
2,3,4,6-tetra-O-benzoyl-D-glucopyranose (157) and previously synthesized N-phenyl-2,2,2-
trifluoroacetamidoyl chloride (158) in the presence of potassium carbonate.20 The final product
was synthesized as a mixture of α, β anomers, as reported in the literature.20 The desired
compound was characterized by various methods. The most significant indication of the
structure was the presence of a signal at 6.43 ppm for the ortho- protons (-NPh group) in the 1H
NMR spectrum as well as appearance of a new signal at 171.2 ppm (OC(CF3)NPh) for the
quaternary carbon in the 13C NMR spectrum. In addition, the correct mass was observed in
HR-ESI-MS spectrum. The analytical results were compared with the published data to confirm
the structure.22 2,3,4,6-Tetra-O-benzoyl-D-glucopyranosyl-1-(N-phenyl)-2,2,2-trifluoroacetimidate
(159) was then reacted with 3-phenylpropionohydroxamic acid (139) in the presence of
trimethylsilyl trifluoromethanesulfonate (TMSOTf) as a catalyst (Scheme 5.13).14
Scheme 5.13
Applying the above procedure it was possible to O-glycosylate phenethyl hydroxamic acid
(139) according to the HR-ESI-MS (766.2264, C43H37NO11Na requires 766.2266), even though a
slightly different glycosyl donor was used to that reported by M. Thomas et al.14 The same
methodology was then employed with the N-hydroxyguanidine as illustrated in Scheme 5.14.
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Scheme 5.14
Unfortunately, the above reaction did not give satisfactory results. After flash
chromatography, mainly the starting glycosyl donor (159) was recovered. The N-benzyl-N’-
hydroxyguanidine (34) is a very polar compound and probably stayed on the silica. The
unsuccessful coupling indicated that even though, hydroxamic acids, as well as
N-hydroxyguanidines, possess an N-OH moiety, their reactivity is significantly different. It
indicates that the nucleophilicity of the hydroxyl groups must be different. Hydroxamic acids are
classified as organic acids whilst N-hydroxyguanidines are basic.
A new strategy was then developed as shown in Scheme 5.15.
Scheme 5.15
The idea was to treat O-(tetra-O-acetyl-D-glucopyranose)hydroxylamine (144) with cyanogen
bromide in the presence of sodium acetate to obtain the corresponding cyanamide (162) which
could be further reacted with a suitable amine. Unfortunately, the above reaction did not yield
the desired cyanamide, but the starting material was recovered instead making the second step
impossible to perform.
Based on the results obtained, a final attempt was designed. The most promising reaction
thus far had been treatment of benzyl cyanamide (39) with O-(tetra-O-acetyl-D-
glucopyranose)hydroxylamine (144) in the presence of triethylamine. However, the long reaction
time caused the hydrolysis of acetate groups. Therefore, it was thought that replacement of the
acetate groups with benzoyl groups would make the compound less susceptible towards
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hydrolysis. Firstly, O-(tetra-O-benzoyl-D-glucopyranose)hydroxylamine (163) had to be
synthesized. Two approaches were chosen as shown in Scheme 5.16.
Scheme 5.16
Unfortunately, the reactivity of bromosugar (164) and N-hydroxyphthalimide (149) was
extremely low and therefore neither of the above reactions led to the desired product.
Additionally, literature indicated that the O-(tetra-O-benzoyl-D-glucopyranose)hydroxylamine
(165) had never been obtained before, which could suggest that the synthesis of this compound
was difficult to perform.
5.3 Conclusions
In conclusion, it can be seen that a large number of attempts were made to synthesize a
glycosylated N-hydroxyguanidine, using a variety of strategies. Unfortunately none of these were
successful. Future work could involve designing a suitable linker between the sugar and
hydroxyguanidine moiety to simplify the synthesis.
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6.1 Introduction
The first aim of previous studies was to design a renal selective pro-drug to treat acute renal
failure (ARF), which affects up to 5% of all hospitalized patients and 10-30% of patients in
critical care units.1 This pathological condition is a result of a blood deficiency in the kidney
caused by a constriction, or obstruction, of its blood vessels. So far, several therapies have been
proposed to treat ARF condition, such as a renal-dose dopamine or mannitol, but their potential
benefits still have to be confirmed. Ischemia is the most common cause of ARF. However, the
pathology of ischemic conditions is very complex. It is known that reduced nitric oxide
bioavailability is a major reason for this illness.2 Recently, It has been suggested that ischemic
ARF is the condition in which NO supplementation is probably the most beneficial approach.3-6
Therefore it would be highly useful to deliver NO which can cause vasorelaxation and maintain
the proper blood flow in the kidney. However, due to its instability it is very difficult to
introduce NO into biological systems. Therefore, one strategy is to combine a NO releasing
molecule with an enzyme recognizable fragment to generate a pro-drug which can selectively
deliver NO to the kidney. N-Hydroxyguanidines (NHG) have been shown to cause NO-
mediated vasodilatation; therefore they were chosen to be a NO releasing part of the pro-drug.
On the other hand, γ-glutamyl moiety was selected to protect the free hydroxyl group of NHG,
since hopefully this can be reversibly cleaved off in vivo by the γ-glutamyl transpeptidase (γ-GT);
an enzyme expressed almost exclusively in the kidney, liver and pancreas of most mammals,
including man. In addition, γ-GT activity is considerably higher (5-10-fold) in the kidney than in
liver and pancreas.1, 2 The graphic representation of the pro-drug idea is presented in Scheme 6.1.
Scheme 6.1
Zhang began work on the γ-GT derivatives for selective release in the kidney aiming to obtain
simple glutamyl adducts as shown in Scheme 6.2.7
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Scheme 6.2
Unfortunately, these targets were not synthetically achievable due to problems with
intramolecular cyclization reactions. The side reaction was caused by the presence of a free
amino group in the hydroxyguanidine functionality which easily reacted with a neighbouring
carbonyl carbon to form an unwanted aromatic five-membered ring as shown in Scheme 6.3.
Scheme 6.3
Therefore, the next design involved the incorporation of an aliphatic linker which should
prevent unwanted cyclizations. The new generation of pro-drugs was successfully synthesized;
however the molecules were not active as substrates of γ-GT.
The final design was based on the incorporation of an aromatic linker as illustrated in
Scheme 6.4. The corresponding molecule was synthetically achievable and γ-GT active, and also
caused smooth muscle relaxation in the IPK model.
Scheme 6.4
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6.2 Improved Linker
6.2.1 Improved linker design
Smith et al. investigated the metabolism of glutathione (GSH) as well as the activity of
γ-glutamyl transpeptidase (γ-GT) by inhibition studies using various inhibitors.8, 9 γ-GT is an
enzyme consisting of two nonidentical subunits, light and heavy, and is responsible for the
cleavage of the γ-glutamyl bond of GSH and related compounds.9 In addition, Smith et al.
mapped the active site of γ-GT with L-γ-glutamyl-p-nitroanilide and compared its binding with
that of glutathione. They found out that there was a quite big pocket in the active site of γ-GT in
the position of –SH group as shown in Scheme 6.5. In addition, the carboxylic acid functionality
seemed to be crucial for binding to the active site of the enzyme. In the L-γ-glutamyl-p-
nitroanilide, the nitro group was shown to bind in the place of the carboxyl group of
glutathione.9 Based on these findings, the pro-drug QZNO382 can be modified to fit better into
the active site of γ-GT. The new pro-drug has been proposed and a synthetic route designed. As
presented in the Scheme 6.5, the current pro-drug, even though it is the substrate for γ-GT, does
not take a full advantage of structural features within the active site of an enzyme. Therefore, the
novel pro-drug will incorporate the hydroxyguanidine functionality in the position of –SH group
of glutathione to fit better into the active site of γ-GT. In addition, the carboxylic acid moiety
will be added to the structure to improve binding properties of the pro-drug.
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Scheme 6.5
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6.2.2 Improved linker synthesis
Since Zhang previously established an efficient synthetic methodology for the original pro-
drug (QZNO382), a modified approach was firstly envisaged for the new target molecule as
shown in Scheme 6.6.
Scheme 6.6
O
O
OH
NH2
O
NHAlloc
HO
CO2Allyl THF, EEDQ
O
O
N
H
OH
O
NHAlloc
CO2Allyl+
The key amino acid fragment, N-alloc L-glutamic acid α-allyl ester (166) was previously
synthesized by Zhang and the same reaction pathway, shown in Scheme 6.7, was employed.
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Scheme 6.7
The first reaction involved a conversion of the carboxylic acid into the cesium salt, which
was then treated with allyl bromide to give L-α-allyl-γ-tert-butyl-N-9-
fluorenylmethoxycarbonylglutamate (167) in 75% yield. The compound (167) was characterized
by 1H and 13C NMR spectroscopy and the purity was confirmed by melting point. Treatment of
the product (167) with diethylamine in the presence of a catalytic amount of DBU allowed for
removal of the Fmoc protecting group. The resulting crude product was then treated with allyl
chloroformate to give L-α-allyl-γ-tert-butyl-N-allyloxycarbonylglutamate (168) in 56% yield. Its
structure was confirmed by the 1H and 13C NMR spectroscopy. The selective deprotection of the
tert-butyl ester group was then achieved using trifluoroacetic acid to yield the final product (166),
which was analyzed by the 1H and 13C NMR spectroscopy (see experimental).
Once the glutamyl part of the new pro-drug had been successfully obtained, the next part of
this project was focused on the synthesis of the new linker fragment derived from allyl 4-amino-
3-(hydroxymethyl)benzoate (169). A commercially available starting material with suitable
substituents in the required arrangement was methyl 3-formyl-4-nitrobenzoate. The initial
approach is shown in Scheme 6.8. Methyl 3-formyl-4-nitrobenzoate was firstly reduced using in
situ formed nickel boride to give methyl 4-amino-3-(hydroxymethyl)benzoate (170) in 55%
yield.10
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Scheme 6.8
The structure of the product (170) was confirmed by the 1H and 13C NMR spectroscopy and
mass spectrometry. The presence of the CH2 protons (2H, 4.37 ppm) and NH2 protons (2H,
5.74 ppm) in the 1H NMR spectrum confirmed the successful reduction of the aldehyde and
nitro group to the alcohol and amine, respectively. In the next step, the ethyl ester was
hydrolysed using lithium hydroxide and the resulting carboxylate (171) was reacted with allyl
bromide. However, the desired allyl ester (169) was obtained in a poor 11% yield, which was not
acceptable as it was just a starting material for more complex transformations as shown in
Scheme 6.6. Therefore, a new synthetic route was derived as illustrated in Scheme 6.9.
Scheme 6.9
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Baumhof et al. reported the application of dibutyltin oxide (Bu2SnO) as a catalyst for a
transesterification of methyl esters with various alcohols including the allyl alcohol.11 Therefore,
the published procedure was used with methyl 3-formyl-4-nitrobenzoate which was heated for
five hours under reflux in allyl alcohol with a catalytic amount of Bu2SnO. The allyl 3-formyl-4-
nitrobenzoate (172) was obtained in an acceptable 61% yield. The disappearance of the singlet
corresponding to the methyl group and appearance of the new characteristic peaks for the allyl
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group in the 1H NMR spectrum confirmed successful transesterification (see experimental). The
purity was established by the elemental analysis which indicated that the final product was
obtained as nearly 100% pure (Found: C, 56.1; H, 3.6; N, 5.8%. C11H9NO5 requires C, 56.2; H,
3.9; N, 6.0%). The allyl derivative (172) was then subjected to the reduction using the nickel
chloride and sodium borohydride procedure.10 However, the isolated compound was not the
expected product. According to the results of 1H NMR spectroscopy, the double bond of the
allyl functionality had also been reduced giving the propyl ester (173). In order to overcome this
problem, alternative reduction conditions were derived, which reduced the nitro and aldehyde
groups in a stepwise fashion as shown in Scheme 6.10.
Scheme 6.10
Zhang et al. recently reported a procedure for the selective reduction of nitro groups in the
presence of aldehyde and ester groups using iron, acetic acid and a catalytic amount of
concentrated hydrochloric acid.12 Allyl 4-amino-3-formyl benzoate (174) was synthesized using
this procedure in an excellent 94% yield. The appearance of the new singlet corresponding to
the NH2 protons (2H, 6.59 ppm) in the 1H NMR spectrum confirmed the successful
transformation. In addition, the characteristic peaks for the allyl group remained unchanged as
well as the aldehyde singlet (see experimental). The product of reduction (174) was then treated
with sodium borohydride in order to convert the aldehyde into the corresponding alcohol. The
desired compound (169) was isolated in 53% yield. The most clear-cut indication of the product
structure was the presence of new CH2 protons (2H, 4.57 ppm) and the disappearance of the
singlet (CHO) in the low-field of the 1H NMR spectrum. However, this method failed to work
on a larger scale. Therefore, the reaction pathway was further modified as presented in Scheme
6.11.
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Scheme 6.11
This time the methyl 3-formyl-4-nitrobenzoate was firstly treated with sodium borohydride
to reduce the aldehyde and the desired product (175) was obtained in 71% yield, which was
better than the reduction of allyl 4-amino-3-formyl benzoate (53%). In addition, the purification
step was easier because it involved just simple recrystallization instead of column
chromatography. The methyl 3-(hydroxymethyl)-4-nitrobenzoate (175) was analyzed by various
methods. The structure was confirmed by the presence of CH2 protons (2H, 5.02 ppm) and OH
proton (1H, 2.34) in the 1H NMR spectrum. Additionally, the HR-ESI-MS gave the mass of
234.0376 (M+Na+) and C9H9NO5Na required 234.0378. The product was then transesterified to
the allyl ester using the previously described Bu2SnO catalyzed procedure.
11 Allyl
3-(hydroxymethyl)-4-nitrobenzoate (176) was synthesized in a very good yield (84%) and
characterized by the 1H and 13C NMR spectroscopy, IR spectroscopy and mass spectrometry.
The successful transesterification was confirmed by the disappearance of the singlet
corresponding to the methyl group and appearance of the new characteristic peaks for the allyl
group in the 1H NMR spectrum. In addition, this time also the yield was significantly better and
the purification was simplified to recrystallization and the column chromatography was
excluded. The last step involved the reduction of the nitro group using the iron and acetic acid.
Allyl 3-(hydroxymethyl)-4-aminobenzoate (169) was obtained in an excellent 99% yield. The
most indicative piece of data was an upfield shift of aromatic protons in the 1H NMR spectrum,
which was characteristic for the presence of the amino substituent. Based on the obtained
results, the route illustrated in Scheme 6.11 was chosen for the synthesis of allyl
3-(hydroxymethyl)-4-aminobenzoate (169). Having both starting materials in hand, the coupling
reaction was then examined as shown in Scheme 6.12.
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Scheme 6.12
For the coupling EEDQ (N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline) was employed
rather than a carbodiimide to avoid racemisation of the amino acid. Thus, N-alloc L,α-
allylglutamate (166) and allyl 3-(hydroxymethyl)-4-aminobenzoate (169) were dissolved in
anhydrous DCM and EEDQ added. Unfortunately the reaction was quite complex, mainly from
the purification point of view. Four different chromatography columns with various eluting
systems from non-polar to pure ethyl acetate had to be performed in order to obtain the pure
product. This significantly affected the yield of the reaction giving only 6% of isolated product.
The next step involved bromination of the alcohol using phosphorus tribromide (Scheme
6.13).13
Scheme 6.1313
A number of attempts were made in order to successfully convert the alcohol (177) into the
bromide (178). Firstly using PBr3, the reaction was monitored by thin-layer chromatography and
run at 0 ° and then at room temperature for about 48 hours. The TLC analysis indicated that
only starting material was present in the reaction mixture. The next approach employed carbon
tetrabromide (CBr4) and triphenylphosphine (PPh3)
14, 15, but as previously only the starting
material was recovered. Therefore, we once more decided to change the strategy as shown in
Scheme 6.14.
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Scheme 6.14
However, there was one difficult to predict step in the reaction pathway, namely the
reduction of the nitro group under acidic conditions in the presence of the Boc protected
hydroxylamine moiety. Therefore, in order to determine the feasibility of this reaction a model
compound was used and taken trough the same set of transformations as presented in Scheme
6.15.
Scheme 6.15
Commercially available 2-nitrobenzyl bromide was treated with Boc protected
hydroxylamine, deprotonated using sodium hydride, to yield tert-butyl
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2-nitrobenzyloxycarbamate (179). The structure was confirmed by 1H NMR spectroscopy, by the
appearance of a 9H singlet for the tert-butyl functionality. The product was then heated under
reflux in the presence of iron, a catalytic amount of HCl and acetic acid to give tert-butyl
2-aminobenzyloxycarbamate (180) in a good yield.12 The model reaction indicted that the
hydroxylamine moiety remained untouched under the reduction conditions. Therefore, the next
step involved the bromination of the allyl 3-(hydroxymethyl)-4-nitrobenzoate as shown in
Scheme 6.16.
Scheme 6.16
Unfortunately, the bromination of the corresponding alcohol using either PBr3 or
CBr4/PPh3 did not give satisfactory results. The problem may be caused by the high reactivity of
the bromide product and close proximity of the nitro group, which can react with each other to
give a five membered ring. In addition, Austin et al. studied oxidation-reduction reactions which
involved nitro groups.16 They discovered that when 2-nitrobenzyl alcohol was placed in
trifluoromethanesulfonic acid at room temperature it was rapidly converted into the
C-protonated conjugate acid of anthranil N-oxide (181) as shown in Scheme 6.17.
Scheme 6.1716
The same product was observed from 2-nitrobenzyl chloride at elevated temperature. It was
suspected that the same transformation could occur during bromination reaction. In addition,
the literature procedures for the synthesis of 2-nitrobenzyl bromide only involve bromination of
2-nitrotoluene.
RENAL SELECTIVE NO-DONOR PRO-DRUG
163
6.3 Conclusions
The synthesis of the improved linker was not successful even though several approaches
were employed to achieve the target molecule. The limiting step was coupling the
hydroxyguanidine moiety with glutamyl fragment using EEDQ, which yielded the required
product in a poor yield. Therefore, future work can focus on the optimization of this reaction.
However, the preliminary results when EDC was employed as a coupling agent did not improve
the overall transformation.
Additionally, the new synthetic route may be designed in which the bromination could be
preformed using toluene derivative. This should help to avoid the difficulties encounter during
bromination of 2-nitrobenzyl alcohol.
Even though the target compound has not been obtained, the synthetic studies allowed the
exploration of a whole variety of novel chemical reactions.
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Summary and future work
In summary, thirty new N-hydroxyguanidines have been synthesized, but only twenty two
were tested as nitric oxide donors. Preliminary biological results indicated that almost all of the
synthesized N-hydroxyguanidines act as NO donors and cause smooth muscle relaxation in the
rat aorta. Data for the series of N-phenylalkyl-N’-hydroxyguanidines showed that extension of
the aliphatic chain was beneficial up to three methylene groups, while further elongation
significantly reduced the biological activity. The compound with the best pharmacological profile
turned out to be N-phenyl-N’-hydroxyguanidine hydrochloride (AK0), (EC50 =19.9 μM, ODQ
reversibility = 100%). Changes to the benzene ring of N-phenylethyl-N’-hydroxyguanidine
(QZNO193) demonstrated that substitution with a trifluoromethyl group in the para position
improved the biological activity of the new derivative (QZNO193, EC50 = 50.1 μM whereas
AK2F, EC50 = 8.0 μM). However, the ODQ test indicated worse reversibility, which may imply
that the vasodilation does not occur mainly through NO mediated pathway. N–Furfuryl-N’–
hydroxyguanidine (AK135) and N–2-(4’-nitrophenyl)ethyl-N’–hydroxyguanidine (AK119)
appeared to be as good as the unsubstituted analogue based on the EC50 values as well as ODQ
reversibility. Interestingly, N–2-[4’-(sulfamoyl)phenyl]ethyl-N’–hydroxyguanidine (AK169) did
not possess any biological activity, which is probably due to the secondary biological pathway
occurring on the sulfonamide group such as oxidation, for example. Unfortunately, there does
not seem to be a logical structure activity relationship amongst this series of compounds which
would allow the most important structural features for NO donor activity to be distinguished.
Therefore, it would be beneficial to investigate the rat aorta assay in more detail and try to
determine which enzyme is responsible for oxidation of N-hydroxyguanidines and eventually
perform QSAR studies to be able to optimize the structure to produce the optimum NO donor
molecule.
Methylated analogues of N-phenylethyl-N’-hydroxyguanidine were also synthesized, to
investigate the effect of N-methylation on NO donor activity. However, these analogues have
not yet been tested in the myography assay and so further biological studies need to be carried
out in order to determine the vasorelaxation properties of compounds (121) and (122). During
these synthetic studies it was discovered that these N-hydroxyguanidines along with their
counterpart aminoiminomethanesulfonic acids revealed very interesting behaviour in the solid
state as well as in solution. Therefore, detailed structural studies were performed using X-ray
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crystallography and NMR spectroscopy, which showed that N-hydroxyguanidines and
aminoiminomethanesulfonic acids possess analogous electronic structures. It would be
interesting to carry out computational analysis on this set of compounds in order to calculate the
rotational energy barriers for these molecules and compare the theory with the experimental
data.
Interestingly, the hydroxamic acids that were prepared also possessed promising
pharmacological profiles. 3-Phenylpropionohydroxamic acid (AK46) revealed the most potent
biological profile with a low EC50 value (6.4 μM) and almost 100% reversibility in the ODQ test.
Unfortunately, preliminary biological studies in the isolated perfused kidney (IPK) model only
showed initial vasorelaxation and then there was a subsequent unexpected vasoconstriction. This
obviously excluded hydroxamic acids from further research towards renal selective NO donor
pro-drugs. However, since there are very few publications related to the mechanism of NO
donation by hydroxamic acids, more studies should be carried out to understand their behaviour.
These studies should include chemical and enzymatic oxidation, using isolated NOS enzymes, to
confirm that NO is indeed formed and elucidate the chemical mechanism of the process.
Two different types of enzyme-activated pro-drugs were designed using
N-hydroxyguanidines as the NO donating molecule. The first was a glycoside derivative, where a
glucose moiety was attached to the N-hydroxyguanidine and its release by a suitable glycosidase
would be required before NO could be formed. Unfortunately, the synthesis of this compound
proved to be very problematic and although a number of approaches were investigated, the
target molecule was not successfully synthesised. Future work should focus on the design and
synthesis of a suitable linker between the hydroxyguanidine and the sugar moiety, which based
on the results of current studies, should be significantly easier to synthesise (Scheme 7.1). Once
the target compound is synthetically achievable, biological studies should be performed to
determine its affinity for glycosidases.
Scheme 7.1
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The second pro-drug design consisted of an N-hydroxyguanidine attached via a linker molecule
to a γ-glutamyl functionality and was based on earlier studies in the group. This pro-drug should
require the enzyme γ-GT for release of the active moiety, which would target its activity to the
kidney. The new design described in the thesis was a modification of the first generation pro-
drug, which was aimed at improving the binding of the pro-drug to the active site of γ-GT and,
therefore, its substrate activity. Synthetic studies towards this target were carried out using
various approaches. However, the target molecule was not achieved in this work as a number of
problems were experienced, in particular in the final stages where cyclisation reactions appeared
to be the major problem. In the light of these studies new approaches have been devised that
could be attempted. For example, using a different starting material, methyl 3-methyl-4-
nitrobenzoate as shown in Scheme 7.2, would allow an alternative radical bromination to be
employed and avoid the intermediacy of the alcohol, the bromination of which appeared to be
the main problem.  In this new synthetic approach the coupling of the γ-glutamyl fragment
could also be improved as removal of the hydroxyl group means that the amine cannot
hydrogen bond to the adjacent hydroxyl, and so may be more reactive.
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Scheme 7.2
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7.1 General
1H NMR spectra were recorded on a Bruker Avance 300 (300.1 MHz) instrument, Bruker
Avance 400 (400.1 Hz) instrument, Bruker Avance 500 (499.9 MHz) instrument or a Varian
Gemini 2000 (300.0 MHz) instrument, using deuterated solvents such as CDCl3, d6-DMSO,
d4-methanol and D2O as reference and internal deuterium lock. The chemical shift data for each
signal are given as δ in units of parts per million (ppm) relative to tetramethylsilane (TMS). The
multiplicity of each signal is indicated by: s (singlet); br s (broad singlet); d (doublet); t (triplet);
td (triplet of doublets); dd (doublet of doublets); ddd (doublet of doublet of doublets);
q (quartet); or m (multiplet). The number of protons (n) for a given resonance is indicated by
nH. Coupling constants (J) are quoted in Hz and are recorded to the nearest 0.1 Hz.
13C NMR spectra were recorded on a Bruker Avance 300 (75.46 MHz) instrument and Bruker
Avance 400 (100.10 Hz) instrument using the PENDANT and DEPTH sequence and internal
deuterium lock or on a Varian Gemini 2000 (75.46 MHz) instrument using proton decoupling
and internal deuterium lock. The chemical shift data for each signal are given as δ in units of
ppm relative to TMS. Where appropriate, coupling constants (J) are quoted in Hz and are
recorded to the nearest 0.1 Hz.
19F NMR spectra were recorded on a Bruker Avance 400 (376.5 MHz) instrument using proton
decoupling and internal deuterium lock. The chemical shift data for each signal are given as δ in
units of ppm.
IR spectra were recorded on a Perkin-Elmer Paragon series 1000 FTIR spectrometer as thin
films or nujol mulls between sodium chloride discs or as potassium bromide disks as indicated.
Absorption maxima are reported in wavenumbers (cm-1).
Melting points were determined in open capillary tubes using an Electrothermal Melting Point
Apparatus and are uncorrected.
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Analytical thin layer chromatography (TLC) was carried out on pre-coated plastic Flex 60A
Macherey-Nagel silica gel plates. Visualisation was achieved by absorption of UV light, or
thermal development after dipping in either a methanolic solution of 10% sulfuric acid or an
aqueous solution of potassium permanganate, potassium carbonate and sodium hydroxide.
Flash Column chromatography was carried out on silica gel (Apollo Scientific Ltd 40-63
micron) under a positive pressure of compressed air.
Kugelrohr bulb-to-bulb distillations were carried out using a Büchi B580 instrument.
Solvents and Chemicals
Dichloromethane and methanol were distilled from calcium hydride in a recycling still. Diethyl
ether was distilled from sodium in a recycling still using benzophenone ketyl as an indicator.1
THF and toluene were purified using MBRAUN solvent purification systems (MB SPS-800).
Chemicals were purchased from Acros UK, Aldrich UK, Avocado UK, Fisher UK or Fluka UK.
All solvents and reagents were purified and dried, where necessary, by standard techniques.1
Where appropriate and if not stated otherwise, all non aqueous reactions were performed under
an inert atmosphere of nitrogen or argon. Brine refers to a saturated aqueous solution of sodium
chloride. Hexane refers to n-hexane and petroleum ether to the fraction boiling between
40-60 oC. Room temperature (RT) refers to the temperature of 25 °C.
Hydroxamic Acid Test2
The drop, or a few small crystals of the test compound were dissolved in 1 ml of ethanol and
1 ml of 1M HCl was added. Then the prepared mixture was treated with one drop of 5% iron
(III) chloride solution. The appearance of the deep wine color indicated the presence of the
hydroxamic acid.
Biological Assays (performed by Dr Philip Milliken University of Edinburgh)
The biological testing was a staged screening process. Initially the compounds were examined in
the rat aorta using myography, to determine their vasodilation activity. The compounds that
meet the criteria below in these experiments were then examined in the isolated perfused kidney,
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to see the effect in the whole organ system. Presented results are an average of six consecutive
experiments.
The criteria set for the compounds in the myography study were:
 compounds must have an EC50 of 30 [µM] or less (this is the concentration that causes
50% of the maximum relaxation);
 80% reversibility with ODQ (selective inhibitor of NO sensitive guanylate cyclase).
This allows selecting compounds with a good vasodilator profile, mediated through NO. If the
relaxation is not reversed by ODQ, then the effect of the compound is not via NO, and the
compound may be acting through other pathways, or could be toxic.
Myography
The rat aorta was cut into 2 mm sections and mounted onto the myograph, and stretched to
15 mN. Vessels were contracted with KCl to determine the maximal constriction. Vessels were
washed and contracted to 80% of the maximum with phenylephrine. A concentration response
curve was obtained for the compound (1-100 μM). Then, 50 μM ODQ was added to assess the
reversibility of the relaxation.
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Synthesis of 4-phenylbutylcyanamide (37)
To a suspension of 4-phenylbutylamine (1.83 g, 12.3 mmol) and sodium acetate (1.60 g,
19.5 mmol) in dry methanol (30 ml) was added dropwise a methanolic solution of BrCN
(1.44 ml, 13.0 mmol). The mixture was stirred in an ice bath for 3 h, then the ice bath was
removed and the reaction mixture was allowed to stir at room temperature overnight. The
solvent was removed at reduced pressure and the crude product was extracted from water with
CH2Cl2 (3 x 15 ml). The organic layer was washed with water (30 ml), 1M HCl (30 ml) and brine
(30 ml), dried over MgSO4 and evaporated at reduced pressure. The pure
4-phenylbutylcyanamide (37) was obtained by column chromatography on silica using petroleum
ether/diethyl ether (1:2) as the eluting solvent. This gave the desired product as a pale yellow oil
(1.10 g, 50%). νmax(PTFE card)/cm-1 3400 (NH), 2987 (CH aromatic), 2215 (C≡N), 1599 (C=C);
δH (300 MHz, CDCl3) 1.55-1.72 (4H, m, CH2-2,3), 2.62 (2H, t, J 7 Hz, CH2-4) 3.04 (2H, dt, J 7
Hz, J 6 Hz, CH2-1) 3.57 (1H, br s, NH) 7.12-7.19 (3H, m, H-2’, 4’, 6’) 7.23-7.29 (2H, m, H-3’,5’);
δC (75.46 MHz, CDCl3) 28.4 (C-3), 29.7 (C-2), 35.7 (C-4), 46.6 (C-1), 116 (C≡N), 126.4 (C-4’),
128.8 (Ar-CH), 142.0 (C-1’); m/z (ES+) 197.1056 ((M+Na)+. C11H14N2Na requires 197.1055);
m/z (ES-) 173 (M-H-, 100%).
Synthesis of N–(4-phenylbutyl)-N’–hydroxyguanidine hydrochloride (36)
4-Phenylbutylcyanamide (37) (1.64 g, 9.4 mmol) was mixed with hydroxylamine hydrochloride
(0.65 g, 9.4 mmol) in methanol (30 ml) and potassium carbonate (0.1 equiv) as a catalyst and
heated under reflux for 4 h under an argon atmosphere. After cooling, the solvent was removed
at reduced pressure and the desired product was recrystallized from CH2Cl2. Then the product
was redissolved in minimum amount of methanol and precipitated out using CH2Cl2. A final
crystallization from CH2Cl2 gave the pure product (36) as colourless crystals (1.27 g, 55%).
mp 122-123 ºC; (Found: C, 53.8; H, 7.8; N, 17.2%. C11H18ClNO3 requires C, 54.2; H, 7.5; N,
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17.2%); νmax(nujol)/cm-1 3428 (NH), 1625 (C=C); δH (300 MHz, d6-DMSO) 1.42-1.64 (4H, m,
CH2-2,3), 2.58 (2H, t, J 7 Hz, CH2-4) 3.16 (2H, dt J 7 Hz, J 6 Hz, CH2-1), 7.14-7.21 (3H, m, H-2’,
4’, 6’), 7.24-7.29 (2H, m, 3’, 5’), 7.66 (2H, br s, NH2), 7.92 (1H, t, J 7 Hz, NH), 9.76 (1H, br. s,
NH/OH), 10.34 (1H, br. s, NH/OH); δC (75.46 MHz, d6-DMSO) 27.9 (C-3), 28.1 (C-2), 34.6
(C-4), 38.6 (C-1), 125.7 (C-4’), 128.3 (Ar-CH), 141.9 (C-1’), 158.2 (C=NOH); m/z (ES+) 208
((M+H)+, 100%).
Synthesis of 3-phenylpropylcyanamide (40)
To a suspension of 3-phenyl-1-propylamine hydrochloride (5.00 g, 29.1 mmol) and sodium
acetate (4.77 g, 58.2 mmol) in dry methanol (50 ml) was added dropwise a 3M solution of BrCN
in CH2Cl2 (9.70 ml, 29.12 mmol). The mixture was stirred in an ice bath for 3 h, than the ice
bath was removed and reaction mixture was allowed to stir at room temperature overnight. The
solvent was removed at reduced pressure and the crude product was extracted with CH2Cl2 (3 x
30 ml). The organic layer was washed with brine (40 ml), dried over MgSO4 and evaporated at
reduced pressure. The pure cyanamide (40) was obtained by column chromatography on silica
using petroleum ether/diethyl ether (1:2) as the eluting solvents. This gave the desired product
(40) as a pale yellow oil (3.05 g, 65%). νmax(PTFE card)/cm-1 3163, 2923 (NH), 2215 (C≡N),
1653 (C=C); δH (300 MHz, CDCl3), 1.95 (2H, q, J 7 Hz, CH2-2), 2.71 (2H, t, J 7 Hz, CH2-3), 3.09
(2H, dt, J 7 Hz, J 6 Hz, CH2-1), 3.63 (1H, br s, NH), 7.17-7.24 (3H, m, H-2’, 4’, 6’), 7.27-7.33
(2H, m, H-3’,5’); δC (75.46 MHz, CDCl3) 31.1 (C-3), 32.4 (C-2), 45.5 (C-1), 116.2 (C≡N), 126.3
(C-4’), 128.4 (C-3’, 5’), 128.6 (C-2’, 6’), 140.6 (C-1’); m/z (ES+) 183.0904 ((M+Na)+. C10H12N2Na
requires 183.0898); m/z (ES-) 159 (M-H+, 100%).
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Synthesis of N–(3-phenylpropyl)-N’–hydroxyguanidine hydrochloride (35)
3-Phenylpropylcyanamide (40) (3.05 g, 19.1 mmol) was mixed with hydroxylamine hydrochloride
(1.19 g, 17.2 mmol) in methanol (40 ml) and potassium carbonate (0.1 equiv) was added as a
catalyst. The reaction mixture was heated under reflux for 5 h under an argon atmosphere. After
cooling, the solvent was removed at reduced pressure and the desired product was crystallized
from CH2Cl2 and diethyl ether. Further purification was carried out by recrystallization from
CH2Cl2 to give the pure product (35) as colourless crystals (2.28 g, 58%). mp 120-122 ºC;
(Found: C, 52.0; H, 6.9; N, 18.4%. C10H16ClN3O requires C, 52.3; H, 7.0; N, 18.3%);
νmax(nujol)/cm-1 3267, 3133 (NH, OH), 1578 (C=C); δH (300 MHz, d6-DMSO) 1.77 (2H, q, J 7
Hz, CH2-2), 2.59 (2H, t, J 7 Hz, CH2-3), 3.15 (2H, q, J 7 Hz, CH2-1), 7.14-7.23 (3H, m, H-2’, 4’,
6’), 7.25-7.31 (2H, m, H-3’, 5’), 7.71 (2H, br s, NH2), 8.05 (1H, t, J 7 Hz, NH), 9.82 (1H, br s,
NH/OH), 10.43 (1H, br s, NH/OH); δC (75.46 MHz, D2O) 29.4 (C-3), 31.9 (C-2), 40.4 (C-1),
126.2 (C-4’), 128.5 (C-2’, 6’), 128.7 (C-3’, 5’), 141.5 (C-1’), 158.6 (C=NOH); m/z (ES+), 194
(M+H+, 100%).
Synthesis of phenylcyanamide (38)3
To a suspension of aniline hydrochloride (10 g, 77.2 mmol) and dry sodium acetate (18.9 g,
231.5 mmol) in dry methanol (100 ml) was added dropwise 3 M solution of BrCN in CH2Cl2
(25.7 ml, 77.2 mmol). The mixture was stirred in an ice bath for 3 h, then the ice bath was
removed and the reaction mixture was allowed to stir at room temperature overnight. The
solvent was removed at reduced pressure and the crude product was extracted with CH2Cl2 (3 x
40 ml). The organic layer was washed with brine (50 ml), dried over MgSO4 and evaporated at
reduced pressure. The pure phenylcyanamide (38) was obtained by column chromatography on
silica using petroleum ether/diethyl ether (1:2) as the eluting solvent. This gave the desired
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product (38) as a colourless oil (6.65 g, 73%). νmax(neat)/cm-1 3174, 3100 (NH), 2227 (C≡N),
1600 (C=C); δH (300 MHz, CDCl3) 6.67 (1H, br s, NH), 6.92-7.17 (3H, m, H-2’, 4’, 6’), 7.27-7.41
(2H, m, H-3’,5’); δC (75.46 MHz, CDCl3) 111.3 (C≡N), 115.4 (C-2’, 6’), 123.7 (C-4’), 129.8 (C-3’,
5’), 137.2 (C-1’); m/z (ES-) 117 ((M-H)-, 100%).
Synthesis of N–phenyl-N’–hydroxyguanidine hydrochloride (33)3
Phenylcyanamide (38) (4.30 g, 36.4 mmol) was combined with hydroxylamine hydrochloride
(2.28 g, 32.8 mmol) in absolute methanol (50 ml) with dry potassium carbonate (0.1 equiv) as a
catalyst and heated under reflux for 6 h under an argon atmosphere. After cooling, the inorganic
salt was filtered off and solvent was removed at reduced pressure. The desired product was
crystallized from CH2Cl2 and diethyl ether. The pure product (33) was obtained by further
recrystallization from CH2Cl2 to give the final product as an off-white solid (2.95 g, 47%).
mp 126-128 ºC (lit.,3 128-129 ºC); νmax(nujol)/cm-1 3289 (NH), 1618, 1599 (C=C); δH (300 MHz,
d6-DMSO) 7.15-7.26 (3H, m, H-2’, 4’, 6’), 7.39 (2H, m, H-3’, 5’), 7.94 (2H, br s, NH2), 10.14
(1H, br s, NH), 10.24 (1H, br. s, NH/OH), 10.95 (1H, br. s, NH/OH); δC (75.46 MHz,
d6-DMSO) 123.6 (C-2’, 6’), 126.0 (C-4’), 129.5 (C-3’, 5’), 135.3 (C-1’), 156.7 (C=NOH);
m/z (ES+) 152 ((M+H), 100%), 153 (10).
Synthesis of N–phenyl-N’–methoxyguanidine (95)
Phenylcyanamide (38) (3.8 g, 32.3 mmol) was combined with methoxylamine hydrochloride (1.8
g, 21.5 mmol) and dry potassium carbonate (4.45 g, 32.3 mmol) in dry 1,4-dioxane (50 ml) and
heated under reflux for two days under an argon atmosphere. After cooling, the inorganic salt
was filtered off and solvent was removed at reduced pressure. The desired product was purified
by column chromatography on silica using ethyl acetate/diethyl ether (3:1) as the eluting solvent.
The pure product (95) was obtained by crystallization from diethyl ether to give the final product
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as a colourless solid (198 mg, 7%). mp 126-128 ºC; (Found: C, 58.5; H, 6.7; N, 25.4%. C8H11N3O
requires C, 58.2; H, 6.7; N, 25.4%); νmax(nujol)/cm-1 3469 3255, 3154, (NH), 1641, 1588 (C=C);
δH (300 MHz, d6-DMSO) 3.57 (3H, s, CH3), 5.21 (2H, br s, NH2), 6.73-6.80 (1H, m, H-4’), 7.12-
7.20 (2H, m, H-2’, 6’), 7.29 (2H, d, J 8 Hz, H-3’, 5’), 7.65 (1H, br s, NH); δC (75.46 MHz,
d6-DMSO) 60.8 (CH3), 117.1 (C-2’, 6’), 119.8 (C-4’), 128.8 (C-3’, 5’), 141.9 (C-1’), 151.6
(C=NOCH3); m/z (ES
+) 188 ((M+Na)+, 100%), 166 (20).
Synthesis of benzylcyanamide (39)3
To a suspension of benzylamine (10.00 g, 93.4 mmol) and sodium acetate (7.60 g, 93.4 mmol) in
dry methanol (100 ml) was added dropwise a 3 M solution of BrCN in CH2Cl2 (31.0 ml, 93.4
mmol). The mixture was stirred in an ice bath for 5 h, and then the reaction mixture was allowed
to stir at room temperature overnight. The solvent was removed at reduced pressure and the
crude product was extracted with CH2Cl2 (3 x 40 ml). The organic layer was washed with brine
(50 ml), dried over MgSO4 and evaporated at reduced pressure. The pure benzylcyanamide was
obtained by column chromatography on silica using petroleum ether/diethyl ether (1:2) as the
eluent. This gave the desired product (39) as an off-white solid (9.70 g, 79%). mp 39-40 ºC;
(Found: C, 72.2; H, 6.1; N, 21.2%. C8H8N2 requires C, 72.7; H, 6.1; N, 20.9%); νmax(nujol)/cm-1
3252 (NH), 2214 (C≡N); δH (300 MHz, CDCl3) 3.92 (1H, br s, NH), 4.13 (2H, d, J 6 Hz, CH2-1),
7.21-7.33 (5H, m, Ar-H); δC (75.46 MHz, CDCl3) 50.3 (C-1), 116.0 (C≡N), 127.8 (C-4’), 128.6
(C-2’, 6’), 129.0 (C-3’, 5’), 136.2 (C-1’) ; m/z (ES-) 131 ((M-H)-, 100%).
Synthesis of N–benzyl-N’–hydroxyguanidine hydrochloride (34)3
Benzylcyanamide (39) (9.55 g, 72.3 mmol) was heated under reflux with hydroxylamine
hydrochloride (4.52 g, 65.1 mmol) and dry potassium carbonate (0.1 equiv) as a catalyst in
absolute methanol (100 ml) for 6 h under an argon atmosphere. After cooling, the inorganic salt
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was filtered off and the solvent was removed at reduced pressure. The desired product was
crystallized from CH2Cl2 and diethyl ether. The pure product (34) was obtained by further
recrystallization from CH2Cl2 to give the final product as a colourless solid (5.92 g, 45%).
mp 159-160 ºC (lit.3, 158-159 ºC); (Found: C, 47.5; H, 5.9; N, 21.0%. C8H12ClN3O requires
C, 47.6; H, 6.0; N, 20.9%); νmax(nujol)/cm-1 3244, 3089 (NH, OH), 1635, 1579 (C=C); δH (300
MHz, d6-DMSO) 4.42 (2H, d, J 6 Hz, CH2-1), 7.25-7.41 (5H, m, Ar-H), 7.81 (2H, br s, NH2),
8.40 (1H, t, J 7Hz, NH), 9.88 (1H, br. s, NH/OH), 10.57 (1H, br. s, NH/OH); δC (75.46 MHz,
d6-DMSO) 43.5 (C-1), 127.1 (C-2’, 6’), 127.4 (C-4’), 128.4 (C-3’, 5’), 137.3 (C-1’), 158.3
(C=NOH); m/z (ES+) 166 (M+H+, 100%).
Synthesis of phenylethylcyanamide (151)3
To a suspension of phenylethylamine (2.01 g, 16.5 mmol) and sodium acetate (2.71 g,
33.0 mmol) in dry methanol (100 ml) was added dropwise a 3 M solution of BrCN in CH2Cl2
(5.5 ml, 16.5 mmol). The mixture was stirred in an ice bath for 5 h, and then the reaction
mixture was allowed to stir at room temperature overnight. The solvent was removed at reduced
pressure and the crude product was extracted with CH2Cl2 (3 x 40 ml). The organic layer was
washed with brine (50 ml), dried over MgSO4 and evaporated at reduced pressure. The pure
phenylethylcyanamide was obtained by column chromatography on silica using petroleum
ether/diethyl ether (1:2) as the eluant. This gave the desired product (151) as an a pale yellow oil
(1.46 g, 41%). δH (300 MHz, CDCl3) 2.85 (2H, t, J 7 Hz, CH2-2), 3.24-3.35 (3H, m, CH2-1, NH),
7.11-7.31 (5H, m, Ar-H); δC (75.46 MHz, CDCl3) 36.3 (C-2), 47.9 (C-1), 116.2 (C≡N), 127.5
(C-4’), 129.3 (C-2’, 6’), 129.5 (C-3’, 5’), 136.7 (C-1’).
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Synthesis of N–phenylethyl-N’–hydroxyguanidine hydrochloride (120)3
Phenylethylcynamide (151) (4.31 g, 0.02 mol) was heated under reflux with hydroxylamine
hydrochloride (1.39 g, 0.02 mol) and dry potassium carbonate (0.1 equiv) as a catalyst in absolute
methanol (150 ml) for 6 h under an argon atmosphere. After cooling, the inorganic salt was
filtered off and the solvent was removed at reduced pressure. The desired product was
crystallized from CH2Cl2 and diethyl ether. The pure product (120) was obtained by further
recrystallization from CH2Cl2 to give the final product as a colourless solid (3.10 g, 70%).
mp 109-111 ºC; (Found: C, 50.1; H, 6.4; N, 19.7%. C9H14ClN3O requires C, 50.1; H, 6.5; N, 19.5
%); νmax(KBr)/cm-1 3327, 3176, 3075 (NH, OH), 1635, 1579 (C=C); δH (300 MHz, d6-DMSO)
2.79 (2H, t, J 7 Hz, CH2-2), 3.43-3.67 (2H, m, CH2-1) 7.18-7.24 (3H, m, H-2’, 4’, 6’), 7.27-7.32
(2H, m, H-3’, 5’), 7.75 (2H, br s, NH2), 8.00 (1H, t, J 6Hz, NH), 9.88 (1H, br. s, NH/OH), 10.53
(1H, br. s, NH/OH); δC (75.46 MHz, d6-DMSO) 34.5 (C-2), 42.5 (C-1), 127.2 (C-2’, 6’), 129.1
(C-4’), 129.3 (C-3’, 5’), 138.6 (C-1’), 159.0 (C=NOH); m/z (ES+) 180 (M+H+, 100%).
Synthesis of N-(tert-butoxycarbonyl)-2-(4’-methoxyphenyl)ethylamine (49)
To a stirred solution of (4-methoxyphenyl)acetonitrile (2.00 g, 13.6 mmol) in dry methanol (80
ml), cooled to 0 ºC, were added di-tert-butyl dicarbonate (Boc2O) (5.93 g, 27.2 mmol) and
NiCl2· 6H2O (0.32 g, 1.36 mmol). NaBH4 (3.59 g, 95.1 mmol) was then added in small portions
over 3 h. The resulting reaction mixture, containing a finely divided black precipitate, was
allowed to warm to room temperature and stirred for further 16 h, at which point
diethylenetriamine (1.47 ml, 13.6 mmol) was added. The mixture was allowed to stir for 1.5 h
before solvent evaporation. The purple residue was then dissolved in ethyl acetate (250 ml) and
extracted with saturated aq. NaHCO3 (3 x 80 ml). The organic layer was dried over MgSO4 and
the solvent was removed at reduced pressure to yield a yellow oil. The crude product was
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purified by column chromatography on silica with petroleum ether/diethyl ether (2:3) as eluting
solvent. This gave the desired product (49) as a colourless solid (2.04 g, 60%). mp 56 ºC; (Found:
C, 66.9; H, 8.9; N, 5.5%. C14H21NO3 requires C, 66.9; H, 8.4; N, 5.6%); νmax(nujol)/cm-1 3360
(NH), 1725 (C=O); δH (300 MHz, CDCl3) 1.43 (9H, s, t-butyl), 2.73 (2H, t, J 7 Hz, CH2-2), 3.33
(2H, dt, J 7, J 6 Hz, CH2-1), 3.78 (3H, s, OCH3), 4.55 (1H, br s, NH), 6.82-6.87 (2H, m, H-3’, 5’),
7.07-7.13 (2H, m, H-2’, 6’); δC (75.46 MHz, CDCl3) 28.4 (CH3), 35.3 (C-2), 42.0 (C-1), 55.3
(OCH3), 79.2 (C-t-butyl), 114.0 (C-3’, 5’), 129.7 (C-2’, 6’), 131.0 (C-1’), 155.9 (C-4’), 158.2
(C=O); m/z (ES+) 290 ((M+K)+, 100%), 274 ((M+Na)+, 65%).
Synthesis of 2-(4’-methoxyphenyl)ethylamine hydrochloride (50)4
A solution of N-(tert-butoxycarbonyl)-2-(4’-methoxyphenyl)ethylamine (49) (1.94 g, 7.73 mmol)
in dry diethyl ether (3 ml) was treated with anhydrous HCl in 1,4-dioxane (4 M, 10 ml) at room
temperature for 12 h. The excess solvent was decanted off and a colourless solid was filtered off
and washed with petroleum ether. This gave the pure product (50) (1.45 g, 98%).
mp 210-212 ºC, (lit.,4 211-213 ºC); (Found: C, 57.6; H, 7.9; N, 7.8%. C9H14ClNO requires:
C, 57.6 ; H, 7.5; N, 7.5%; νmax(nujol)/cm-1 3651 (NH), 1601 (C=C aromatic); δH (300 MHz,
d6-DMSO) 2.82 (2H, t, J 7 Hz, H-2), 2.88-3.03 (2H, m, H-1), 3.73 (3H, s, OCH3), 6.86-6.92 (2H,
m, H-3’, 5’), 7.15-7.20 (2H, m, H-2’,6’), 8.10 (3H, br s, NH3
+); δC (75.46 MHz, d6-DMSO) 32.1
(C-2), 40.1 (C-1), 55.0 (OCH3), 114.0 (C-3’, 5’), 129.1 (C-1’), 129.6 (C-2’, 6’), 158.0 (C-4’);
m/z (ES+) 152 ((M+H)+, 80%), 135 (100), 122 (100).
Synthesis of 2-(4’-methoxyphenyl)ethylcyanamide (58)
To a suspension of 2-(4’-methoxyphenyl)ethylamine hydrochloride (50) (1.32 g, 7.03 mmol) and
sodium acetate (1.16 g, 14.2 mmol) in dry methanol (30 ml) was added dropwise a 3M solution
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of BrCN in CH2Cl2 (2.34 ml, 7.03 mmol). The mixture was stirred in an ice bath for 3 h, then the
ice bath was removed and the reaction mixture was allowed to stir at room temperature
overnight. The solvent was removed at reduced pressure and the residue was dissolved in water
(30 ml). The crude product was extracted with CH2Cl2 (3 x 20 ml). The organic layer was washed
with brine (20 ml), dried over MgSO4 and evaporated at reduced pressure. The pure product was
obtained by chromatography on silica using petroleum ether/diethyl ether (1:2) as the eluting
solvent. This gave the desired product (58) as a pale yellow oil (0.99 g, 80%). νmax(neat)/cm-1
3219, 3004 (NH), 2936 (CH aromatic), 2222 (C≡N), 1612 (C=C aromatic); δH (300 MHz,
d6-DMSO) 2.70 (2H, t, J 7 Hz, CH2-2), 3.07-3.15 (2H, m, CH2-1), 3.72 (3H, s, OCH3), 6.77 (1H,
t, J 6 Hz, NH), 6.84-6.89 (2H, m, H-3’, 5’), 7.12-7.19 (2H, m, H-2’, 6’); δC (75.46 MHz,
d6-DMSO) 34.5 (C-2), 46.1 (C-1), 54.9 (OCH3), 113.8 (C-3’, 5’), 117.2 (C≡N), 129.7 (C-2’, 6’),
130.1 (C-1’), 157.8 (C-4’); m/z (ES+) 199.0848 ((M+Na)+. C10H12N2ONa requires 199.0847);
m/z (ES-) 175 ((M-H)-, 100%).
Synthesis of N–2-(4’-methoxyphenyl)ethyl-N’–hydroxyguanidine hydrochloride (77)
2-(4’-Methoxyphenyl)ethylcyanamide (58) (0.76 g, 4.28 mmol) was mixed with hydroxylamine
hydrochloride (0.30 g, 4.28 mmol) in dry methanol (25 ml) and potassium carbonate (0.1 equiv)
was added as a catalyst. The reaction mixture was heated under reflux for 6 h under an argon
atmosphere. After cooling, the solvent was removed at reduced pressure and the desired product
was crystallized from CH2Cl2 and diethyl ether. Further purification was achieved by redissolving
the crude product in minimum amount of methanol and the insoluble solid was filtered off. The
addition of CH2Cl2 and diethyl ether gave the pure product (77) as colourless crystals (0.61 g,
58%). mp 90-92 ºC; (Found: C, 49.2; H, 6.3; N, 16.9%. C10H16ClN3O2 requires C, 48.9; H, 6.6;
N, 17.1%); νmax(nujol)/cm-1 3414, 3308, 3140 (NH, OH), 1581 (C=C aromatic); δH (300 MHz,
d6-DMSO) 2.72 (2H, t, J 7 Hz, CH2-2), 3.30-3.38 (2H, m, CH2-1), 3.72 (3H, s, OCH3), 6.83-6.89
(2H, m, H-3’, 5’), 7.16-7.22 (2H, m, H-2’,6’), 7.69 (2H, br s, NH2), 7.89 (1H, t, J 6 Hz, NH), 9.83
(1H, br s, NH/OH), 10.45 (1H, br s, NH/OH); δC (75.46 MHz, d6-DMSO) 34.1 (C-2), 42.6
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(C-1), 55.4 (OCH3), 114.1 (C-3’, 5’), 130.2 (C-2’, 6’), 130.7 (C-1’), 157.8 (C-4’), 158.1 (C=NOH);
m/z (ES+), 210 ((M+H)+, 100%).
Synthesis of N-(tert-butoxycarbonyl)-2-(3’-methoxyphenyl)ethylamine (45)
To a stirred solution of 3-methoxyphenylacetonitrile (2.00 g, 13.6 mmol) in dry methanol
(80 ml), cooled to 0 ºC, were added di-tert-butyl dicarbonate (Boc2O) (5.93 g, 27.2 mmol) and
NiCl2 · 6H2O (0.32 g, 1.36 mmol). NaBH4 (3.59 g, 95.1 mmol) was then added in small portions
over 3 h. The resulting reaction mixture, containing a finely divided black precipitate, was
allowed to warm to room temperature and stirred for further 4 h, at which point
diethylenetriamine (1.47 ml, 13.6 mmol) was added. The mixture was allowed to stir for 1.5 h
before solvent evaporation. The purple residue was then dissolved in ethyl acetate (250 ml) and
extracted with saturated aq. NaHCO3 (3 x 80 ml). The organic layer was dried over MgSO4 and
the solvent was removed at reduced pressure to yield yellow oil. The crude product was purified
by column chromatography on silica with petroleum ether/diethyl ether (1:2) as eluting solvent.
This gave the desired product (45) as a colourless solid (2.07g, 61%). mp 36 ºC; (Found: C, 67.1;
H, 8.8; N, 5.7%. C14H21NO3 requires C, 66.9; H, 8.4; N, 5.6%); νmax(nujol)/cm-1 3343 (NH), 1725
(C=O), 1603 (C=C aromatic); δH (300 MHz, CDCl3) 1.45 (9H, s, t-butyl), 2.79 (2H, t, J 7 Hz,
CH2-2), 3.39 (2H, t, J 7Hz, CH2-1), 3.82 (3H, s, OCH3), 4.56 (1H, br s, NH), 6.73-6.83 (3H, m,
H-2’, 4’, 6’), 7.21-7.28 (1H, m, H-5’); δC (75.46 MHz, CDCl3) 28.3 (CH3), 36.3 (C-2), 41.7 (C-1),
55.2 (OCH3), 79.3 (C-t-butyl), 111.8 (C-4’), 114.5 (C-2’), 121.2 (C-6’), 129.6 (C-5’), 140.6 (C-1’),
155.9 (C=O), 159.8 (C-3’); m/z (ES+) 290 ((M+K)+, 100%), 261 (70).
Synthesis of 2-(3’-methoxyphenyl)ethylamine hydrochloride (46)5
A solution of N-(tert-butoxycarbonyl)-2-(3’-methoxyphenyl)ethylamine (45) (2.03 g, 8.07 mmol)
in dry diethyl ether (3 ml) was treated with anhydrous HCl in 1,4-dioxane (4 M, 10 ml) at room
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temperature for 12 h. The excess of solvent was decanted off and the colourless solid was
filtered off and washed with petroleum ether. This gave the pure product (46) (1.51 g, 86%).
mp 132 ºC, (lit.,5 132 ºC); (Found: C, 57.4; H, 7.9; N, 7.5%. C9H14ClNO requires: C, 57.6 ; H,
7.5; N, 7.5%); νmax(nujol)/cm-1 3651 (NH), 1602 (C=C aromatic); δH (300 MHz, d6-DMSO)
2.84-2.91 (2H, m, CH2-2), 2.95-3.05 (2H, m, CH2-1), 3.74 (3H, s, OCH3), 6.79-6.85 (3H, m, H-2’,
4’, 6’), 7.20-7.27 (1H, m, H-5’), 8.19 (3H, br s, NH3
+); δC (75.46 MHz, d6-DMSO) 32.9 (C-2),
39.9 (C-1), 54.9 (OCH3), 112.2 (C-4’), 114.2 (C-2’), 120.8 (C-6’), 129.6 (C-5’), 138.9 (C-1’), 159.4
(C-3’); m/z (ES+) 152 ((M+H)+, 100%).
Synthesis of 2-(3’-methoxyphenyl)ethylcyanamide (59)
To a suspension of 2-(3’-methoxyphenyl)ethylamine hydrochloride (46) (1.20 g, 6.39 mmol) and
sodium acetate (1.05 g, 12.8 mmol) in dry methanol (30 ml) was added dropwise a 3M solution
of BrCN in CH2Cl2 (2.13 ml, 6.39 mmol). The mixture was stirred in an ice bath for 2 h, then the
ice bath was removed and reaction mixture was allowed to stir at room temperature overnight.
The solvent was removed at reduced pressure and the residue was dissolved in water (30 ml).
The crude product was extracted with CH2Cl2 (3 x 20 ml). The organic layer was washed with
brine (20 ml), dried over MgSO4 and evaporated. The pure product was obtained by column
chromatography on silica using petroleum ether/diethyl ether (1:2) as the eluting solvents. This
gave the desired product (59) as a colourless oil (0.81 g, 72%). νmax(neat)/cm-1 3221, 3003 (NH),
2940 (CH aromatic), 2221 (C≡N), 1602 (C=C aromatic); δH (300 MHz, d6-DMSO) 2.74 (2H, t, J
7 Hz, CH2-2), 3.11-3.20 (2H, m, CH2-1), 3.74 (3H, s, OCH3), 6.76-6.84 (4H, m, C-2’, 4’, 6’, NH),
7.18-7.24 (1H, m, H-5’); δC (75.46 MHz, d6-DMSO) 35.4 (C-2), 45.8 (C-1), 54.9 (OCH3), 111.8
(C-4’), 114.4 (C-2’), 117.2 (C≡N), 121.0 (C-6’), 129.3 (C-5’), 139.8 (C-1’), 159.3 (C-3’); m/z (ES+)
199.0850 ((M+Na)+. C10H12N2ONa requires 199.0847); m/z (ES
-) 175 ((M-H)-, 100%).
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Synthesis of N–2-(3’-methoxyphenyl)ethyl-N’–hydroxyguanidine hydrochloride (78)
2-(3’-Methoxyphenyl)ethylcyanamide (59) (0.81 g, 4.57 mmol) was mixed with hydroxylamine
hydrochloride (0.32 g, 4.57 mmol) in dry methanol (30 ml) and potassium carbonate (0.1 equiv)
was added as a catalyst. The reaction mixture was heated under reflux for 6 h under an argon
atmosphere. After cooling, the solvent was removed and the desired product was crystallized
from CH2Cl2 and diethyl ether. Further purification was achieved by redissolving the crude
product in the minimum amount of methanol and the insoluble solid was filtered off. Addition
of CH2Cl2 and diethyl ether gave the pure product (78) as colourless solid (0.60 g, 53%).
mp 88-90 ºC; (Found: C, 48.2; H, 6.7; N, 17.6%. C10H16ClN3O2 requires C, 48.9; H, 6.6; N,
17.1%); νmax(nujol)/cm-1 3318 (NH), 1639, 1586 (C=C aromatic); δH (300 MHz, d6-DMSO) 2.76
(2H, t, J 7 Hz, H-2), 3.38-3.43 (2H, m, H-1), 3.74 (3H, s, OCH3), 6.75-6.89 (3H, m, H-2’, 4’, 6’),
7.21 (1H, t, J 8 Hz, H-5’), 7.72 (2H, br s, NH2), 7.92 (1H, t, J 6 Hz, NH), 9.84 (1H, br s,
NH/OH), 10.29 (1H, br s, NH/OH); δC (75.46 MHz, d6-DMSO) 34.9 (C-2), 42.2 (C-1), 55.3
(OCH3), 112.3 (C-4’), 114.8 (C-2’), 121.4 (C-6’), 129.7 (C-5’), 140.21 (C-1’), 158.5 (C=NOH),
159.6 (C-3’); m/z (ES+) 210 ((M+H)+, 100%).
Synthesis of N-(tert-butoxycarbonyl)-2-(2’-methoxyphenyl)ethylamine (47)
To a stirred solution of 2-methoxyphenylacetonitrile (2.50 g, 17.0 mmol) in dry methanol
(100 ml), cooled to 0 ºC, were added di-tert-butyl dicarbonate (Boc2O) (7.42 g, 34.0 mmol) and
NiCl2 · 6H2O (0.40 g, 1.70 mmol). NaBH4 (4.50 g, 119 mmol) was then added in small portions
over 4 h. The resulting reaction mixture, containing a finely divided black precipitate was
allowed to warm to room temperature and stirred for a further 16 h, at which point
diethylenetriamine (1.75 ml, 17.0 mmol) was added. The mixture was allowed to stir for 1.5 h
before solvent evaporation. The purple residue was then dissolved in ethyl acetate (250 ml) and
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extracted with saturated aq. NaHCO3 (3 x 100 ml). The organic layer was dried over MgSO4 and
the solvent was removed at reduced pressure to yield a yellow oil. The crude product was
purified by column chromatography on silica with dichloromethane/ethyl acetate (1:1) as eluting
solvent. This gave the desired product (47) as a colourless solid (3.18 g, 75%). mp 52-54 ºC;
(Found: C, 67.2; H, 8.6; N, 5.3%. C14H21NO3 requires C, 66.9; H, 8.4; N, 5.6%); νmax(nujol)/cm-1
3324 (NH), 1687 (C=O), 1602, 1588 (C=C aromatic); δH (300 MHz, CDCl3) 1.35 (9H, s, t-butyl),
2.73 (2H, t, J 7 Hz, CH2-2), 3.27 (2H, t, J 7 Hz, CH2-1), 3.75 (3H, s, OCH3), 4.55 (1H, br s, NH),
6.73-6.85 (2H, m, H-3’, 5’), 7.01-7.19 (2H, m, H-4’, 6’); δC (75.46 MHz, CDCl3) 28.4 (CH3), 30.8
(C-2), 40.8 (C-1), 55.2 (OCH3), 79.1 (C-t-butyl), 110.3 (C-3’), 120.5 (C-5’), 127.4 (C-1’), 127.7
(C-4’), 130.6 (C-6’), 157.6 (C-2’), 156.1 (C=O); m/z (ES+) 274 ((M+Na)+, 100%).
Synthesis of 2-(2’-methoxyphenyl)ethylamine hydrochloride (48)6
A solution of N-(tert-butoxycarbonyl)-2-(2’-methoxyphenyl)ethylamine (47) (2.74 g, 10.9 mmol)
in dry dioxane (3 ml) was treated with anhydrous HCl in 1,4-dioxane (4 M, 14 ml) at room
temperature for 12 h. The excess of solvent was decanted off and the colourless solid was
filtered off and washed with petroleum ether. This gave the pure product (48) (1.36 g, 68%).
mp 139-140 ºC, (lit.,6 141-142ºC); δH (300 MHz, D2O) 2.89 (2H, t, J 7 Hz, CH2-2), 3.13 (2H, t, J
7 Hz, CH2-1), 3.76 (3H, s, OCH3), 6.87-7.00 (2H, m, H-3’, 5’), 7.14-7.19 (1H, m, H-4’), 7.22-7.30
(1H, m, H-6’); δC (75.46 MHz, D2O) 27.8 (C-2), 39.6 (C-1), 55.3 (OCH3), 111.4 (C-3’), 121.1
(C-5’), 124.7 (C-1’), 129.0 (C-4’), 130.8 (C-6’), 157.4 (C-2’).
Synthesis of 2-(2’-methoxyphenyl)ethylcyanamide (60)
To a suspension of 2-(2’-methoxyphenyl)ethylamine hydrochloride (48) (1.30 g, 6.93 mmol) and
sodium acetate (1.13 g, 13.8 mmol) in dry methanol (25 ml) was added dropwise a 3M solution
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of BrCN in CH2Cl2 (2.31 ml, 6.93 mmol). The mixture was stirred in an ice bath for 3 h, then the
ice bath was removed and the reaction mixture was allowed to stir at room temperature
overnight. The solvent was removed at reduced pressure and the residue was dissolved in water
(30 ml). The crude product was extracted with CH2Cl2 (3 x 20 ml). The organic layer was washed
with brine (20 ml), dried over MgSO4 and evaporated at reduced pressure. The pure product was
obtained by chromatography on silica using petroleum ether/diethyl ether (1:2) as the eluting
solvent. This gave the desired product (60) as a pale yellow oil (0.56 g, 46%). νmax(neat)/cm-1
3214 (NH), 2939, 2838 (CH aromatic), 2221 (C≡N), 1602, 1589 (C=C aromatic); δH (300 MHz,
CDCl3) 2.84 (2H, t, J 7 Hz, CH2-2), 3.22-3.29 (2H, m, CH2-1), 3.55 (1H, br s, NH), 3.76 (3H, s,
OCH3), 6.78-6.89 (2H, m, H-3’, 5’), 7.06-7.11 (1H, m, H-4’), 7.14-7.22 (1H, m, H-6’); δC (75.46
MHz, CDCl3) 31.0 (C-2), 46.4 (C-1), 55.3 (OCH3), 110.5 (C-3’), 116.1 (C≡N), 120.8 (C-5’), 125.6
(C-1’), 128.5 (C-4’), 130.9 (C-6’), 157.5 (C-2’); m/z (ES+) 199.0854 ((M+Na)+. C10H12N2ONa
requires 199.0847).
Synthesis of N–2-(2’-methoxyphenyl)ethyl-N’–hydroxyguanidine hydrochloride (79)
2-(2’-Methoxyphenyl)ethylcyanamide (60) (0.52 g, 2.95 mmol) was mixed with hydroxylamine
hydrochloride (0.18 g, 2.65 mmol) in dry methanol (20 ml) and potassium carbonate (0.1 equiv)
was added as a catalyst. The reaction mixture was heated under reflux for 5 h under an argon
atmosphere. After cooling, the solvent was removed and the desired product was crystallized
from CH2Cl2 and diethyl ether. Further purification was achieved by redissolving the crude
product in the minimum amount of methanol and the insoluble solid was filtered off. Addition
of CH2Cl2 and diethyl ether gave the pure product (79) as colourless crystals (0.65 g, 46%).
mp 90-92 ºC; (Found: C, 49.0; H, 6.6; N, 17.1%. C10H16ClN3O2 requires C, 48.9; H, 6.6; N,
17.1%); νmax(nujol)/cm-1 3746, 3353 (NH), 1586 (C=C aromatic); δH (300 MHz, d6-DMSO) 2.78
(2H, t, J 7 Hz, CH2-2), 3.28-3.36 (2H, m, CH2-1), 3.78 (3H, s, OCH3), 6.84-6.99 (2H, m, H-3’,
5’), 7.17-7.25 (2H, m, H-4’,6’), 7.65 (2H, br s, NH2), 7.85 (1H, t, J 6 Hz, NH), 9.79 (1H, br s,
NH/OH), 10.38 (1H, br s, NH/OH); δC (75.46 MHz, d6-DMSO) 28.9 (C-2), 40.7 (C-1), 55.3
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(OCH3), 110.6 (C-3’), 120.2 (C-5’), 126.0 (C-1’), 127.9 (C-4’), 130.1 (C-6’), 157.1 (C-2’), 158.2
(C=NOH); m/z (ES+), 210 ((M+H)+, 100%).
Synthesis of 2-(4’-nitrophenyl)ethylamine hydrochloride (97)7
4-Nitrophenylacetonitrile (5.00 g, 30.8 ml) was dissolved in dry THF (60 ml) and BF3
. Et2O
complex (11.6 ml, 92.4 mmol) was added. The solution was cooled to 0 ºC in an ice bath and
treated with small portions of NaBH4 (1.16 g, 30.8 mmol). Then, the ice bath was removed and
the mixture left to stir at room temperature for 16 h. The solvent was evaporated at reduced
pressure and the residue extracted between water (50 ml) and CH2Cl2 (3 × 60 ml). The organic
layer was washed with a saturated solution of sodium bicarbonate (70 ml) and dried over
MgSO4. A red oil was obtained after solvent evaporation and dissolved in few drops of MeOH.
Addition of CH2Cl2 and diethyl ether caused precipitation. The crude product was filtered off
and recrystallized from CH2Cl2 to give the final product (97) as a yellow solid (0.54g, 11%).
mp 199-200 ºC, (lit.,7 200 ºC); δH (300 MHz, D2O) 3.08 (2H, t, J 7 Hz, CH2-2), 3.29 (2H, t, J 7
Hz, CH2-1), 7.47 (2H, d, J 8 Hz, H-2’, 6’), 8.16 (2H, d, J 8 Hz, H-3’,5’); δC (75.46 MHz,
d6-DMSO) 33.0 (C-2), 40.3 (C-1), 124.4 (C-3’, 5’), 130.3 (C-2’, 6’), 145.1 (C-4’), 147.2 (C-1’);
m/z (ES+) 237 (100%),167 ((M+H)+, 20%).
Synthesis of 2-(4’-nitrophenyl)ethylcyanamide (70)
O2N
H
N
C
N
To a suspension of 2-(4’-nitrophenyl)ethylamine hydrochloride (101) (0.49 g, 2.40 mmol) and
sodium acetate (0.40 g, 4.80 mmol) in dry methanol (25 ml) was added dropwise a 3M solution
of BrCN in CH2Cl2 (0.80 ml, 2.40 mmol). The mixture was stirred in an ice bath for 2 h, then the
ice bath was removed and the reaction mixture was allowed to stir at room temperature
overnight. The solvent was removed at reduced pressure and the residue was dissolved in water
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(30 ml). The crude product was extracted with ethyl acetate (3 x 20 ml). The organic layer was
washed with brine (20 ml), dried over MgSO4 and evaporated. The pure product was obtained
by column chromatography on silica using ethyl acetate/diethyl ether (2:1) as the eluting solvent.
This gave the desired product (70) as a yellow solid (0.21 g, 47%). mp 88 ºC; νmax(neat)/cm-1
3200 (NH), 2220 (C≡N), 1597 (C=C aromatic), 1517, 1346; δH (300 MHz, d6-DMSO) 2.92 (2H,
t, J 7 Hz, CH2-2), 3.21-3.28 (2H, m, CH2-1), 6.85 (1H, t, J 6Hz, NH), 7.53-7.58 (2H, m, H-2’, 6’),
8.16-8.21 (2H, m, H-3’, 5’); δC (75.46 MHz, CDCl3) 35.1 (C-2), 45.2 (C-1), 116.9 (C≡N), 123.4
(C-3’, 5’), 130.2 (C-2’, 6’), 146.2 (C-4’), 146.8 (C-1’); m/z (ES+) 214.0594 ((M+Na)+.
C9H9N3O2Na requires 214.0592); m/z (ES-) 190 ((M-H)-, 100%).
Synthesis of N–2-(4’-nitrophenyl)ethyl-N’–hydroxyguanidine hydrochloride (89)
2-(4’-Nitrophenyl)ethylcyanamide (70) (0.21 g, 1.08 mmol) was mixed with hydroxylamine
hydrochloride (0.08 g, 1.08 mmol) in dry methanol (15 ml) and potassium carbonate (0.1 equiv)
was added as a catalyst. The reaction mixture was heated under reflux for 8 h under an argon
atmosphere. After cooling, the solvent was removed at reduced pressure and the desired product
was crystallized from CH2Cl2 and diethyl ether. Further purification was achieved by redissolving
the crude product in minimum amount of methanol and the insoluble solid was filtered off.
Addition of CH2Cl2 gave the pure product (89) as a pale yellow solid (0.28 g, 53%). mp 92-94 ºC;
νmax(nujol)/cm-1 3428, 3316 (NH), 1653, 1597 (C=C aromatic), 1511; δH (300 MHz, d6-DMSO)
2.95 (2H, t, J 7 Hz, CH2-2), 3.42-3.50 (2H, m, CH2-1), 7.44 (2H, br s, NH2), 7.55-7.60 (2H, m,
H-2’, 6’), 7.99 (1H, t, J 6 Hz, NH), 8.15-8.20 (2H, m, H-3’,5’), 9.85 (1H, br s, NH/OH), 10.48
(1H, br s, NH/OH); δC (75.46 MHz, d6-DMSO) 34.7 (C-2), 41.6 (C-1), 123.8 (C-3’, 5’), 130.6 (C-
2’, 6’), 146.6 (C-4’), 147.1 (C-1’), 158.5 (C=NOH); m/z (ES+) 225.0986 ((M+H)+. C9H13N4O3
requires 225.0988) (ES+), 225 ((M+H)+, 100%).
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Synthesis of 2-(4’-bromophenyl)ethylcyanamide (69)
To a suspension of 2-(4’-bromophenyl)ethylamine hydrochloride (1.34 g, 5.69 mmol) and
sodium acetate (0.93 g, 11.4 mmol) in dry methanol (30 ml) was added dropwise a 3M solution
of BrCN in CH2Cl2 (1.90 ml, 5.69 mmol). The mixture was stirred in an ice bath for 2 h, then the
ice bath was removed and the reaction mixture was allowed to stir at room temperature
overnight. The solvent was removed at reduced pressure and the residue was dissolved in water
(30 ml). The crude product was extracted with CH2Cl2 (3 x 20 ml). The organic layer was washed
with brine (20 ml), dried over MgSO4 and evaporated. The pure product was obtained by
chromatography on silica using petroleum ether/ethyl acetate (1:1) as the eluting solvent. This
gave the desired product (69) as a colourless oil (0.71 g, 56%). νmax(neat)/cm-1 3215 (NH), 2928
(CH aromatic), 2221 (C≡N), 1637 (C=C aromatic); δH (300 MHz, CDCl3) 2.83 (2H, t, J 7 Hz,
CH2-2), 3.25 (2H, dt, J 6 Hz, J 7 Hz, CH2-1), 4.26 (1H, t, J 6 Hz, NH), 7.05-7.11 (2H, m, H-2’,
6’), 7.40-7.46 (2H, m, H-3’, 5’); δC (75.46 MHz, CDCl3) 35.3 (C-2), 46.9 (C-1), 116.2 (C≡N),
120.8 (C-4’), 127.0 (C-2’, 6’), 128.8 (C-2’, 6’), 130.6 (C-3’, 5’), 131.8 (C-3’, 5’), 136.4 (C-1’);
m/z (ES+) 246.9846 ((M+Na)+. C9H9N2Na
79Br requires 246.9847), 248.9829 ((M+Na)+.
C9H9N2Na81Br requires 248.9826); m/z (ES-) 223 ((M-H)-, 100%), 225 ((M-H)-, 92%).
Synthesis of N–2-(4’-bromophenyl)ethyl-N’–hydroxyguanidine hydrochloride (88)
2-(4’-Bromophenyl)ethylcyanamide (69) (0.47 g, 2.09 mmol) was mixed with hydroxylamine
hydrochloride (0.13 g, 1.88 mmol) in dry methanol (20 ml) and potassium carbonate (0.1 equiv)
was added as a catalyst. The reaction mixture was heated under reflux for 6 h under an argon
atmosphere. After cooling, the solvent was removed at reduced pressure and the desired product
was crystallized from CH2Cl2 and diethyl ether. Further purification was achieved by redissolving
the crude product in the minimum amount of methanol and the insoluble solid was filtered off.
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Addition of CH2Cl2 gave the pure product (88) as a colourless solid (0.37 g, 67%).
mp 132-134 ºC; (Found: C, 36.8; H, 4.2; N, 14.3%. C9H13BrClN3O requires C, 36.7; H, 4.4; N,
14.3%); νmax(nujol)/cm-1 3125 (NH), 1590 (C=C aromatic); δH (300 MHz, d6-DMSO) 2.77 (2H, t,
J 7 Hz, CH2-2), 3.35-3.43 (2H, m, CH2-1), 7.22-7.27 (2H, m, H-2’, 6’), 7.47-7.52 (2H, m, H-
3’,5’), 7.70 (2H, br s, NH2), 7.91 (1H, t, J 6 Hz, NH), 9.81 (1H, br s, NH/OH), 10.42 (1H, br s,
NH/OH); δC (75.46 MHz, d6-DMSO) 33.8 (C-2), 41.6 (C-1), 119.5 (C-4’), 131.1 (C-2’, 3’, 5’, 6’),
137.7 (C-1’), 158.1 (C=NOH); m/z (ES+) 260 ((M+H)+, 100%).
Synthesis of furfurylcyanamide (71)
To a suspension of furfurylamine (3.00 g, 30.9 mmol) and sodium acetate (2.53 g, 30.9 mmol) in
dry methanol (70 ml) was added dropwise a 3M solution of BrCN in CH2Cl2 (10.30 ml, 30.9
mmol). The mixture was stirred in an ice bath for 2 h, then the ice bath was removed and the
reaction mixture was allowed to stir at room temperature overnight. The solvent was removed at
reduced pressure and the residue was dissolved in water (80 ml). The crude product was
extracted with ethyl acetate (3 x 50 ml). The organic layer was dried over MgSO4. Evaporation of
the solvent at reduced pressure gave the desired product (71) as a yellow oil (2.95 g, 78%).
νmax(neat)/cm-1 3205 (NH), 2925 (CH aromatic), 2227 (C≡N), 1601 (C=C aromatic); δH (300
MHz, CDCl3) 1.70 (1H, br s, NH), 4.20 (2H, d, J 6 Hz, CH2-1), 6.32-6.37 (2H, m, H-3’, 4’), 7.41
(1H, t, J 1.4 Hz, H-5’); δC (75.46 MHz, CDCl3) 42.9 (C-1), 115.2 (C≡N), 109.2 (C-3’), 110.6
(C-4’), 143.3 (C-5’), 149.4 (C-2’); m/z (ES+) 145.0375 ((M+Na)+. C6H6N2ONa requires
145.0378); m/z (ES-) 121 ((M-H)-, 100%).
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Synthesis of N–furfuryl-N’–hydroxyguanidine hydrochloride (90)
Furfurylcyanamide (71) (1.63 g, 13.3 mmol) was mixed with hydroxylamine hydrochloride
(0.83 g, 12.0 mmol) in dry methanol (40 ml) and potassium carbonate (0.1 equiv) was added as a
catalyst. The reaction mixture was heated under reflux for 6 h under an argon atmosphere. After
cooling, the solvent was removed and the desired product was crystallized from ethyl acetate and
diethyl ether. Further purification was achieved by redissolving the crude product in the
minimum amount of methanol and the insoluble solid was filtered off. Addition of ethyl acetate
gave the pure product (90) as a pale brown solid (0.43 g, 20%). mp 108-110 ºC; (Found: C, 37.7;
H, 4.9; N, 21.6%. C6H10ClN3O2 requires C, 37.6; H, 5.2; N, 21.9%); νmax(nujol)/cm-1 3333 (NH),
1579 (C=C); δH (300 MHz, d6-DMSO) 4.43 (2H, d, J 6 Hz, CH2-1), 6.38-6.44 (2H, m, H-3’, 4’),
7.62-7.64 (1H, m, H-5’) 7.86 (2H, br s, NH2), 8.29 (1H, t, J 6 Hz, NH), 9.91 (1H, br s, NH/OH),
10.65 (1H, br s, NH/OH); δC (75.46 MHz, d6-DMSO) 37.3 (C-1), 108.0 (C-3’), 110.5 (C-4’),
142.8 (C-5’), 150.1 (C-2’), 158.1 (C=NOH); m/z (ES+) 156 ((M+H)+, 100%).
Synthesis of thiophene-2-ethylcyanamide (72)
To a suspension of thiophene-2-ethylamine (2.50 g, 19.6 mmol) and sodium acetate (2.42 g,
29.5 mmol) in dry methanol (50 ml) was added dropwise a 3M solution of BrCN in CH2Cl2
(6.55 ml, 19.6 mmol). The mixture was stirred in an ice bath for 2 h, then the ice bath was
removed and the reaction mixture was allowed to stir at room temperature overnight. The
solvent was removed at reduced pressure and the residue was dissolved in water (80 ml). The
crude product was extracted with CH2Cl2 (3 x 40 ml). The organic layer was dried over MgSO4
and the solvent evaporated under reduced pressure. The pure product was obtained by
chromatography on silica using petroleum ether/ethyl acetate (1:1) as the eluting solvent. This
gave the desired product (72) as a pale yellow oil (2.32 g, 78%). νmax(neat)/cm-1 3212 (NH), 2934
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(CH aromatic), 2222 (C≡N), 1610 (C=C aromatic); δH (300 MHz, CDCl3) 3.13 (2H, t, J 7 Hz,
CH2-2), 3.33 (2H, quartet, J 7 Hz, CH2-1), 3.91 (1H, br s, NH), 6.86-7.00 (2H, m, H-3’, 5’),
7.16-7.22 (1H, m, H-4’); δC (75.46 MHz, CDCl3) 30.2 (C-2), 42.9 (C-1), 115.8 (C≡N), 124.6
(C-5’), 126.1 (C-3’), 127.3 (C-4’), 139.3 (C-2’); m/z (ES+) 175.0307 ((M+Na)+. C7H8N2NaS
requires 175.0306); m/z (ES-) 151 ((M-H)-, 100%).
Synthesis of N–(thiophene-2-ethyl)-N’–hydroxyguanidine hydrochloride (91)
Thiophene-2-ethylcyanamide (72) (2.09 g, 13.7 mmol) was mixed with hydroxylamine
hydrochloride (0.86 g, 12.3 mmol) in dry methanol (40 ml) and potassium carbonate (0.1 equiv)
was added as a catalyst. The reaction mixture was heated under reflux for 7 h under an argon
atmosphere. After cooling, the solvent was removed and the desired product was crystallized
from CH2Cl2 and diethyl ether. Further purification was achieved by redissolving the crude
product in the minimum amount of methanol and the insoluble solid was filtered off. Addition
of CH2Cl2 gave the pure product (91) as a pale yellow solid (1.25 g, 46%). mp 100-102 ºC;
νmax(nujol)/cm-1 3393 (NH), 1578 (C=C); (Found: C, 37.5; H, 5.1; N, 18.8%. C7H12ClN3OS
requires C, 37.9; H, 5.5; N, 18.9%; δH (300 MHz, d6-DMSO) 3.01 (2H, t, J 7 Hz, CH2-2), 3.38-
3.47 (2H, m, CH2-1), 6.94-6.98 (2H, m, H-3’, 4’), 7.36 (1H, br t, J 3 Hz, H-5’), 7.75 (2H, br s,
NH2), 8.00 (1H, t, J 6 Hz, NH), 9.89 (1H, br s, NH/OH), 10.55 (1H, br s, NH/OH); δC (75.46
MHz, d6-DMSO) 28.7 (C-2), 42.0 (C-1), 124.3 (C-5’), 125.7 (C-3’), 127.0 (C-4’), 140.2 (C-2’),
158.1 (C=NOH); m/z (ES+) 186 ((M+H)+, 100%).
Synthesis of N-(tert-butoxycarbonyl)-thiophene-3-ethylamine (53)
To a stirred solution of thiophene-3-acetonitrile (2.00 g, 16.2 mmol) in dry methanol (100 ml),
cooled to 0 ºC, were added di-tert-butyl dicarbonate (Boc2O) (7.09 g, 32.5 mmol) and
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NiCl2 · 6H2O (0.39 g, 1.62 mmol). NaBH4 (4.30 g, 114 mmol) was then added in small portions
over 4 h. The resulting reaction mixture, containing a finely divided black precipitate, was
allowed to warm to room temperature and stirred for a further 16 h, at which point
diethylenetriamine (1.68 ml, 16.2 mmol) was added. The mixture was allowed to stir for 1.5 h
before solvent evaporation. The purple residue was then dissolved in ethyl acetate (250 ml) and
extracted with saturated aq. NaHCO3 (3 x 80 ml). The organic layer was dried over MgSO4 and
the solvent was removed at reduced pressure to yield a yellow oil. The crude product was
purified by column chromatography on silica with petroleum ether/diethyl ether (1:2) as eluting
solvent. This gave the desired product (53) as a colourless oil (1.99 g, 54%). νmax(neat)/cm-1 3382
(NH), 1726 (C=O); δH (300 MHz, CDCl3) 1.45 (9H, s, t-butyl), 2.84 (2H, t, J 7 Hz, CH2-2), 3.40
(2H, quartet, J 7 Hz, CH2-1), 4.59 (1H, br s, NH), 6.95-7.04 (2H, m, H-2’, 4’), 7.27-7.32 (1H, m,
H-5’); δC (75.46 MHz, CDCl3) 28.4 (CH3), 30.7 (C-2), 41.1 (C-1), 79.3 (C-t-butyl), 121.3 (C-2’),
125.8 (C-5’), 128.1 (C-4’), 139.3 (C-3’), 156.0 (C=O); m/z (ES+) 250.0873 ((M+Na)+.
C11H17NO2NaS requires 250.0878).
Synthesis of thiophene-3-ethylamine hydrochloride (54)8
A solution of N-(tert-butoxycarbonyl)-thiophene-3-ethylamine (53) (1.90 g, 8.34 mmol) in dry
diethyl ether (3 ml) was treated with anhydrous HCl in 1,4-dioxane (4 M, 10 ml) at room
temperature for 10 h. The excess solvent was decanted off and the colourless solid was filtered
off and washed with diethyl ether. This gave the pure product (54) (1.18 g, 87%).
mp 198-200 ºC; δH (300 MHz, D2O) 2.96 (2H, t, J 7 Hz, CH2-2), 3.20 (2H, t, J 7 Hz, CH2-1), 7.02
(1H, dd, J 2, J 3 Hz, H-4’), 7.18-7.21 (1H, m, H-2’), 7.40 (1H, quartet, J 2.5 Hz, H-5’); δC (75.46
MHz, D2O) 27.3 (C-2), 40.0 (C-1), 123.0 (C-2’), 127.0 (C-5’), 127.9 (C-4’), 136.7 (C-3’);
m/z (ES+) 128.0531 ((M+H)+. C6H10NS requires 128.0534).
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Synthesis of thiophene-3-ethylcyanamide (73)
To a suspension of thiophene-3-ethylamine hydrochloride (54) (1.13 g, 6.90 mmol) and sodium
acetate (1.13 g, 13.8 mmol) in dry methanol (30 ml) was added dropwise a 3M solution of BrCN
in CH2Cl2 (2.30 ml, 6.90 mmol). The mixture was stirred in an ice bath for 2 h, then the ice bath
was removed and the reaction mixture was allowed to stir at room temperature overnight. The
solvent was removed at reduced pressure and the residue was dissolved in water (50 ml). The
crude product was extracted with CH2Cl2 (3 x 25 ml). The organic layer was dried over MgSO4
and the solvent removed under reduced pressure. The pure product was obtained by
chromatography on silica using petroleum ether/diethyl ether (1:2) as the eluting solvent. This
gave the desired product (73) as a yellow oil (1.05 g, 40%). νmax(neat)/cm-1 3375 (NH), 3099 (CH
aromatic), 2221vs (C≡N), 1606 (C=C aromatic); δH (300 MHz, CDCl3) 2.96 (2H, t, J 7 Hz,
CH2-2), 3.33 (2H, dt, J 7, J 6 Hz, CH2-1), 3.48 (1H, br s, NH), 6.93-6.98 (1H, m, H-4’), 7.05-7.10
(1H, m, H-2’), 7.30-7.35 (1H, m, H-5’); δC (75.46 MHz, CDCl3) 30.4 (C-2), 46.8 (C-1), 122.3
(C-2’), 126.6 (C-5’), 127.8 (C-4’), 137.3 (C-3’); m/z (ES+) 153.0489 ((M+H)+. C7H9N2S requires
153.0486); m/z (ES-) 151 ((M-H)-, 100%).
Synthesis of N–thiophene-3-ethyl-N’–hydroxyguanidine hydrochloride (92)
Thiophene-3-ethylcyanamide (73) (0.38 g, 2.50 mmol) was mixed with hydroxylamine
hydrochloride (0.16 g, 2.25 mmol) in dry methanol (20 ml) and potassium carbonate (0.1 equiv)
was added as a catalyst. The reaction mixture was heated under reflux for 6 h under an argon
atmosphere. After cooling, the solvent was removed and the desired product was crystallized
from CH2Cl2 and diethyl ether. Further purification was achieved by redissolving the crude
product in the minimum amount of methanol and the insoluble solid was filtered off. Addition
of CH2Cl2 gave the pure product (92) as an off-white solid (0.55 g, 51%). mp 114-116 ºC;
(Found: C, 37.9; H, 5.3; N, 18.8%. C7H12ClN3OS requires C, 37.9; H, 5.5; N, 18.9%);
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νmax(nujol)/cm-1 3395 (NH), 1582 (C=C); δH (300 MHz, d6-DMSO) 2.81 (2H, t, J 7 Hz, CH2-2),
3.36-3.45 (2H, m, CH2-1), 7.08 (1H, dd, J 2, J 3 Hz, H-4’), 7.27-7.30 (1H, m, H-2’), 7.47 (1H, dd,
J 2, J 3 Hz, H-5’) 7.74 (2H, br s, NH2), 7.97 (1H, t, J 6 Hz, NH), 9.86 (1H, br s, NH/OH), 10.50
(1H, br s, NH/OH); δC (75.46 MHz, d6-DMSO) 29.1 (C-2), 41.3 (C-1), 121.8 (C-2’), 125.9 (C-5’),
128.5 (C-4’), 138.5 (C-3’), 158.1 (C=NOH); m/z (ES+) 186 ((M+H)+, 100%).
Synthesis of thiophene-2-methylcyanamide (75)
To a suspension of thiophene-2-methylamine (1.50 g, 13.2 mmol) and sodium acetate (2.17 g,
26.4 mmol) in dry methanol (40 ml) was added dropwise a 3M solution of BrCN in CH2Cl2 (4.42
ml, 13.2 mmol). The mixture was stirred in an ice bath for 2 h, than the ice bath was removed
and reaction mixture was allowed to stir at room temperature overnight. The solvent was
removed at reduced pressure and the residue was dissolved in water (50 ml). The crude product
was extracted with CH2Cl2 (3 x 25 ml). The organic layer was dried over MgSO4. The pure
product was obtained by chromatography on silica using diethyl ether/ethyl acetate (2:1) as the
eluting solvents. This gave the desired product (75) as a pale yellow, low melting solid (1.37 g,
75%). (Found: C, 51.8; H, 4.4; N, 19.9%. C6H6N2S requires C, 52.2; H, 4.4; N, 20.3%);
νmax(neat)/cm-1 3931, 3815 (NH), 2224 (C≡N); δH (300 MHz, CDCl3) 4.30 (1H, br s, NH), 4.38
(2H, d, J 7 Hz, CH2-1), 6.96-7.00 (1H, m, H-3’), 7.03-7.07 (1H, m, H-4’), 7.29-7.32 (1H, m,
H-5’); δC (75.46 MHz, CDCl3) 45.2 (C-1), 115.9 (C≡N), 126.9 (C-5’), 126.7 (C-3’), 127.6 (C-4’),
138.9 (C-2’); m/z (ES+) 139.0325 ((M+H)+. C7H6N2S requires 139.0330); m/z (ES+) 97 (100%).
Synthesis of N–thiophene-2-methyl-N’–hydroxyguanidine hydrochloride (93)
Thiophene-2-methylcyanamide (75) (1.28 g, 9.25 mmol) was mixed with hydroxylamine
hydrochloride (0.58 g, 8.32 mmol) in dry methanol (40 ml) and potassium carbonate (0.1 equiv)
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was added as a catalyst. The reaction mixture was heated under reflux for 6 h under an argon
atmosphere. After cooling, the solvent was removed and the desired product was crystallized
from CH2Cl2 and diethyl ether. Further purification was achieved by redissolving the crude
product in the minimum amount of methanol and the insoluble solid was filtrated off. Addition
of CH2Cl2 gave the pure product (93) as a dark yellow solid (0.65 g, 34%). mp 108-110 ºC;
(Found: C, 35.0; H, 4.8; N, 20.0%. C6H10ClN3OS requires C, 34.7; H, 4.8; N, 20.2%);
νmax(nujol)/cm-1 3367 (NH), 1576 (C=C); δH (300 MHz, d6-DMSO) 4.62 (2H, d, J 7 Hz, CH2-1),
6.97-7.01 (1H, m, H-3’), 7.08-7.12 (1H, m, H-4’), 7.47 (1H, dd, J 2, J 3 Hz H-5’), 7.88 (2H, br s,
NH2), 8.41 (1H, t, J 6 Hz, NH), 9.92 (1H, br s, NH/OH), 10.68 (1H, br s, NH/OH); δC (75.46
MHz, d6-DMSO) 125.8 (C-5’), 126.4 (C-3’), 126.8 (C-4’), 139.8 (C-2’), 157.9 (C=NOH);
m/z (ES+) 172 ((M+H)+, 100%).
Synthesis of N-(tert-butoxycarbonyl)-2-(4’-methylphenyl)ethylamine (49)
To a stirred solution of 4-methylphenylacetonitrile (1.00 g, 7.62 mmol) in dry methanol (50 ml),
cooled to 0 ºC, were added di-tert-butyl dicarbonate (Boc2O) (3.33 g, 15.2 mmol) and
NiCl2 · 6H2O (0.18 g, 0.76 mmol). NaBH4 (2.02 g, 53.4 mmol) was then added in small portions
over 1.5 h. The resulting reaction mixture, containing a finely divided black precipitate, was
allowed to warm to room temperature and stirred for further 16 h, at which point
diethylenetriamine (0.82 ml, 7.62 mmol) was added. The mixture was allowed to stir for 1.5 h
before solvent evaporation. The purple residue was then dissolved in ethyl acetate (150 ml) and
extracted with saturated aq. NaHCO3 (3 x 50 ml). The organic layer was dried over MgSO4 and
the solvent was removed at reduced pressure to yield yellow oil. The crude product was purified
by column chromatography on silica with petroleum ether/diethyl ether (1:1) as eluting solvent.
This gave the desired product (49) as colourless crystals (1.79 g, 72%). mp 38-40 ºC; (Found:
C, 71.5; H, 9.3; N, 5.9%. C14H21NO2 requires C, 71.5; H, 9.0; N, 5.9%); νmax(nujol)/cm-1 3372
(NH), 1899 (C=O), 1604 (C=C aromatic); δH (300 MHz, CDCl3) 1.43 (9H, s, t-butyl), 2.33 (3H,
s, CH3), 2.75 (2H, t, J 7 Hz, CH2-2), 3.29-3.41 (2H, m, CH2-1), 4.54 (1H, br s, NH), 7.05-7.14
(4H, m, Ar-H); δC (75.46 MHz, CDCl3) 21.0 (CH3), 28.4 (CH3), 35.8 (C-2), 41.9 (C-1), 79.1
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(t-butyl), 128.7 (C-2’, 6’), 129.3 (C-3’, 5’), 135.8 (C-4’), 135.9 (C-1’), 155.9 (C=O); m/z (ES+) 258
((M+Na)+, 100%).
Synthesis of 2-(4’-methylphenyl)ethylamine hydrochloride (50)5
A solution of N-(tert-butoxycarbonyl)-2-(4’-methylphenyl)ethylamine (49) (1.08, 3.11 ml) in dry
diethyl ether (2 ml) was treated with anhydrous HCl in 1,4-dioxane (4 M, 4.0 ml) at room
temperature for 12 h. The excess of solvent was decanted off and the colourless solid was
filtered off and washed with petroleum ether. This gave the pure product (50) (0.53 g, 100%).
mp 216-217 ºC, (lit.,5 217-218 ºC); δH (300 MHz, d4-methanol) 2.31 (3H, s, CH3), 2.92 (2H, t, J 7
Hz, CH2-2), 3.12-3.18 (2H, m, CH2-1), 7.14-7.16 (4H, br s, Ar-H); δC (75.46 MHz, d4-methanol)
21.1 (CH3), 34.2 (C-2), 42.1 (C-1), 129.7 (C-2’, 6’), 130.6 (C-3’, 5’), 134.8 (C-4’), 138.0 (C-1’).
Synthesis of 2-(4’-methylphenyl)ethylcyanamide (61)
To a suspension of 2-(4’-methoxyphenyl)ethylamine hydrochloride (50) (0.48 g, 2.78 mmol) and
sodium acetate (0.46 g, 5.56 mmol) in dry methanol (20 ml) was added dropwise a 3M solution
of BrCN in CH2Cl2 (0.93 ml, 2.78 mmol). The mixture was stirred in an ice bath for 3 h, then the
ice bath was removed and reaction mixture was allowed to stir at room temperature overnight.
The solvent was removed at reduced pressure and the residue was dissolved in water (30 ml).
The crude product was extracted with CH2Cl2 (3 x 20 ml). The organic layer was washed with
brine (20 ml), dried over MgSO4 and evaporated. The pure product was obtained by
chromatography on silica using petroleum ether/diethyl ether (1:2) as the eluting solvent. This
gave the desired product (61) as a colourless oil (0.18 g, 39%). νmax(neat)/cm-1 3228, 3021 (NH),
2220 (C≡N), 1616, 1576 (C=C); δH (400 MHz, CDCl3) 2.33 (3H, s, CH3), 2.87 (2H, t, J 7 Hz,
CH2-2), 3.32 (2H, t, J 7 Hz, CH2-1), 3.44 (1H, br s, NH), 7.08-7.16 (4H, m, Ar-H); δC (100 MHz,
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CDCl3) 21.1 (CH3), 35.4 (C-2), 47.6 (C-1), 115.3 (C≡N), 128.7 (C-2’, 6’), 129.6 (C-3’, 5’), 134.0
(C-4’), 136.7 (C-1’); m/z (ES+) 183.0901 ((M+Na)+. C10H12N2Na requires 183.0898); m/z (ES
-)
159 ((M-H)-, 100%).
Synthesis of N–2-(4’-methylphenyl)ethyl-N’–hydroxyguanidine hydrochloride (80)
2-(4’-Methylphenyl)ethylcyanamide (61) (0.15 g, 0.92 mmol) was mixed with hydroxylamine
hydrochloride (0.06 g, 0.83 mmol) in dry methanol (15 ml) and potassium carbonate (0.1 equiv)
was added as a catalyst. The reaction mixture was heated under reflux for 7 h under an argon
atmosphere. After cooling, the solvent was removed at reduced pressure and the desired product
was crystallized from CH2Cl2 and diethyl ether. Further purification was achieved by redissolving
the crude product in the minimum amount of methanol and the insoluble solid was filtered off.
Addition of CH2Cl2 gave the pure product (80) as a colourless solid (63 mg, 30%).
mp 118-120 ºC; (Found: C, 52.5; H, 6.9; N, 18.4%. C10H16ClN3O requires C, 52.3; H, 7.0; N,
18.3%); νmax(nujol)/cm-1 3306, 3110 (NH), 1590 (C=C), 1517; δH (400 MHz, d6-DMSO) 2.26
(3H, s, CH3), 2.74 (2H, t, J 7 Hz, CH2-2), 7.13 (4H, 2 x d, J 8, Ar-H), 7.69 (2H, br s, NH2), 7.89
(1H, t, J 6 Hz, NH), 9.82 (1H, br s, NH/OH), 10.36 (1H, br s, NH/OH); δC (100 MHz,
d6-DMSO) 21.1 (CH3), 34.5 (C-2), 42.5 (C-1), 129.2 (C-2’, 6’), 129.4 (C-3’, 5’), 135.6 (C-4’), 135.8
(C-1’), 158.6 (C=NOH); m/z (ES+) 194 ((M+H)+, 100%).
Synthesis of N-(tert-butoxycarbonyl)-2-(4’-hydroxyphenyl)ethylamine (51)
To a stirred solution of 4-hydroxyphenylacetonitrile (1.52 g, 11.4 mmol) in dry methanol (50 ml),
cooled to 0 ºC, were added di-tert-butyl dicarbonate (Boc2O) (4.99 g, 22.8 mmol) and
NiCl2 · 6H2O (0.27 g, 1.14 mmol). NaBH4 (3.03 g, 80.0 mmol) was then added in small portions
over 2 h. The resulting reaction mixture, containing a finely divided black precipitate, was
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allowed to warm to room temperature and stirred for further 16 h, at which point
diethylenetriamine (1.18 ml, 11.4 mmol) was added. The mixture was allowed to stir for 1.5 h
before solvent evaporation. The purple residue was then dissolved in ethyl acetate (250 ml) and
extracted with saturated aq. NaHCO3 (3 x 80 ml). The organic layer was dried over MgSO4 and
the solvent was removed at reduced pressure to yield a yellow oil. The crude product was
purified by column chromatography on silica with petroleum ether/diethyl ether (2:3) as eluting
solvent. This gave the desired product (51) as a colourless solid (2.11 g, 55%). mp 68 ºC; (Found:
C, 64.2; H, 8.2; N, 4.0%. C18H27NO5 requires C, 64.1; H, 8.1; N, 4.1%); νmax(nujol)/cm-1 3408
(NH), 1752 (C=O), 1595 (C=C, aromatic); δH (300 MHz, CDCl3) 1.43 (9H, s, carbonate, t-butyl),
1.55 (9H, s, carbamate, t-butyl), 2.78 (2H, t, J 7 Hz, CH2-2), 3.30-3.40 (2H, m, CH2-1), 4.54 (1H,
br s, NH), 7.06-7.13 (2H, m, H-3’, 5’), 7.15-7.22 (2H, m, H-2’, 6’); δC (75.46 MHz, CDCl3) 27.7
(CH3), 28.4 (CH3), 35.6 (C-2), 41.7 (C-1), 65.9 (C-(CH3)3), 83.5 (C-(CH3)3), 121.4 (C-3’, 5’), 129.7
(C-2’, 6’), 136.5 (C-1’), 149.6 (O-C=O), 152.1 (C-4’), 155.8 (N-C=O); m/z (ES+) 360 ((M+H)+,
100%).
Synthesis of 2-(4’-hydroxyphenyl)ethylamine hydrochloride (52)9
A solution of N-(tert-butoxycarbonyl)-2-(4’-hydroxyphenyl)ethylamine (51) (2.11 g, 6.24 mmol)
in dry diethyl ether (3 ml) was treated with anhydrous HCl in dioxane (4 M, 8.0 ml) at room
temperature for 12 h. The excess solvent was decanted off and the colourless solid was filtered
off and washed with petroleum ether. The solid was then dissolved in dry 1,4-dioxane (3 ml) and
treated again with anhydrous HCl in 1,4-dioxane (4 M, 4.0 ml) at room temperature for 12 h.
This gave the pure product (52) as a colourless solid (0.77 g, 71%). mp 270-272 ºC (dec.),
(lit.9, 270-272 ºC); δH (300 MHz, d6-DMSO) 2.72-2.80 (2H, m, CH2-2), 2.89-2.96 (2H, m, CH2-1),
6.68-6.75 (2H, m, H-3’, 5’), 7.00-7.06 (2H, m, H-2’,6’), 8.05 (3H, br s, NH3+), 9.37 (1H, s, OH);
δC (75.46 MHz, d6-DMSO) 32.1 (C-2), 38.6 (C-1), 115.3 (C-3’, 5’), 127.2 (C-1’), 129.5 (C-2’, 6’),
156.1 (C-4’).
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Synthesis of 2-(4’-hydroxyphenyl)ethylcyanamide (62)
To a suspension of 2-(4’-hydroxyphenyl)ethylamine hydrochloride (52) (0.77 g, 4.42 mmol) and
sodium acetate (0.72 g, 8.84 mmol) in dry methanol (20 ml) was added dropwise a 3M solution
of BrCN in CH2Cl2 (1.47 ml, 4.42 mmol). The mixture was stirred in an ice bath for 3 h, then the
ice bath was removed and the reaction mixture was allowed to stir at room temperature
overnight. The solvent was removed at reduced pressure and the residue was dissolved in water
(30 ml). The crude product was extracted with CH2Cl2 (3 x 20 ml). The organic layer was washed
with brine (20 ml), dried over MgSO4 and the solvent was removed at reduced pressure. This
gave the desired product (62) as an off-white solid (0.45 g, 63%). mp 102-103 ºC;
νmax(nujol)/cm-1 3173 (NH), 2235 (C≡N), 1889, 1615, 1598 (C=C); δH (300 MHz, d6-DMSO)
2.64 (2H, t, J 7 Hz, CH2-2), 3.04-3.11 (2H, m, CH2-1), 6.64-6.71 (2H, m, H-3’, 5’), 6.75 (1H, t, J 6
Hz, NH), 6.98-7.05 (2H, m, H-2’, 6’), 9.22 (1H, s, OH); δC (75.46 MHz, d6-DMSO) 35.1 (C-2),
46.8 (C-1), 115.6 (C-3’, 5’), 117.7 (C≡N), 128.7 (C-1’), 130.1 (C-2’, 6’), 156.3 (C-4’); m/z (ES+)
185.0695 ((M+Na)+. C9H10N2ONa requires 185.0691); m/z (ES-) 161 ((M-H)-, 100%).
Synthesis of N–2-(4’-hydroxyphenyl)ethyl-N’–hydroxyguanidine hydrochloride (81)
2-(4’-Hydroxyphenyl)ethylcyanamide (62) (0.14 g, 0.88 mmol) was mixed with hydroxylamine
hydrochloride (0.06 g, 0.78 mmol) in dry methanol (15 ml) and potassium carbonate (0.1 equiv)
was added as a catalyst. The reaction mixture was heated under reflux for 6 h under an argon
atmosphere. After cooling, the solvent was removed at reduced pressure and the desired product
was crystallized from ethyl acetate and CH2Cl2. Further purification was achieved by redissolving
the crude product in the minimum amount of methanol and the insoluble solid was filtered off.
Addition of ethyl acetate gave the pure product (81) as a colourless solid (81 mg, 40%).
mp 120-122 ºC; δH (300 MHz, d6-DMSO) 2.67 (2H, t, J 7 Hz, CH2-2), 3.26-3.73 (2H, m, CH2-1),
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6.66-6.73 (2H, m, H-3’, 5’), 7.01-7.08 (2H, m, H-2’,6’), 7.65 (2H, br s, NH2), 7.81 (1H, t, J 6 Hz,
NH), 9.29 (1H, s, phenyl-OH), 9.77 (1H, br s, NH/ OH), 10.38 (1H, br s, NH/OH); δC (75.46
MHz, d6-DMSO) 33.6 (C-2), 42.3 (C-1), 115.1 (C-3’, 5’), 128.2 (C-1’), 129.6 (C-2’, 6’), 155.9 (C-
4’), 158.1 (C=NOH); m/z (ES+) 196.1083 ((M+H)+. C9H14N3O2 requires 196.1086); m/z (ES
+)
196 ((M+H)+, 100%).
Synthesis of 2-(4’-(sulfamoyl)phenyl]ethylcyanamide (66)
To a suspension of 2-[4’-(sulfamoyl)phenyl]ethylamine (2.00 g, 9.99 mmol) and sodium acetate
(1.64 g, 20.0 mmol) in dry methanol (50 ml) was added dropwise a 3M solution of BrCN in
CH2Cl2 (3.33 ml, 9.99 mmol). The mixture was stirred in an ice bath for 3 h, then the ice bath
was removed and the reaction mixture was allowed to stir at room temperature overnight. The
solvent was removed at reduced pressure and the residue was dissolved in water (50 ml). The
crude product was extracted with CH2Cl2 (3 x 30 ml). The organic layer was washed with brine
(30 ml), dried over MgSO4 and the solvent was removed at reduced pressure. This gave the
desired product (66) as a colourless oil (1.63 g, 73%). νmax(neat)/cm-1 3340 (NH), 2220 (C≡N),
1598 (C=C), 1332, 1157 (SO2NH2); δH (400 MHz, d6-DMSO) 2.85 (2H, t, J 7 Hz, CH2-2), 3.17-
3.25 (2H, m, CH2-1), 6.83 (1H, t, J 6 Hz, NH), 7.31 (2H, br s, NH2), 7.41-7.49 (2H, m, H-2’, 6’),
7.73-7.78 (2H, m, H-3’, 5’); δC (100 MHz, d6-DMSO) 35.1 (C-2), 45.5 (C-1), 117.0 (C≡N), 129.1
(C-3’, 5’), 129.3 (C-2’, 6’), 142.3 (C-4’), 142.5 (C-1’); m/z (ES+) 248.0473 ((M+Na)+.
C9H11N3O2NaS requires 248.0470).
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Synthesis of N–2-[4’-(sulfamoyl)phenyl]ethyl-
N’–hydroxyguanidine hydrochloride (85)
H2NO2S
H
N NH2
.HCl
NOH
2-[4’-(Sulfamoyl)phenyl]ethylcyanamide (66) (1.50 g, 6.66 mmol) was mixed with hydroxylamine
hydrochloride (0.42 g, 5.99 mmol) in dry methanol (40 ml) and potassium carbonate (0.1 equiv)
was added as a catalyst. The reaction mixture was heated under reflux for 7 h under an argon
atmosphere. After the completion, the mixture was cooled in an ice bath and di-tert-butyl
dicarbonate (1.45 g, 6.66 mmol) and potassium carbonate (0.92 g, 6.66 mmol) were added. The
solution was left to stir for an hour. The solvent was then removed at reduced pressure and the
residue was partitioned between water (20 ml) and ethyl acetate (40 ml). The organic layer was
dried over MgSO4 and the solvent was removed at reduced pressure to give a yellow oil. Further
purification was achieved by column chromatography of the protected hydroxyguanidine
(petroleum: diethyl ether: ethyl acetate-gradient). The product was then dissolved in dry THF
(10 ml) and treated with anhydrous HCl in 1,4-dioxane (4 M, 10.0 ml) at room temperature for
12 h. The solid was filtered off and washed with diethyl ether to give the pure product (85) as a
colourless solid (0.361 g, 21%); mp 136-138 ºC; (Found: C, 37.0; H, 5.3; N, 18.7%.
C9H15ClN4O3S requires C, 36.7; H, 5.1; N, 19.0%); νmax(nujol)/cm-1 3478, 3311, 3275, 3156 (NH,
OH), 1646, 1597 (C=C); δH (300 MHz, d6-DMSO) 2.87 (2H, t, J 7 Hz, CH2-2), 3.36-3.47 (2H, m,
CH2-1), 7.32 (2H, br s, NH2), 7.42-7.48 (2H, m, H-2’, 6’), 7.69 (2H, br s, NH2), 7.73-7.79 (2H, m,
H-3’, 5’), 7.87 (1H, br s, NH), 9.75 (1H, br s, NH/OH), 10.34 (1H, br s, NH/OH); δC (75.46
MHz, d6-DMSO) 34.6 (C-2), 42.0 (C-1), 126.1 (C-3’, 5’), 129.7 (C-2’, 6’), 142.8 (C-4’), 142.9
(C-1’), 158.6 (C=NOH); m/z (ES+) 259 ((M+H)+, 100%).
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Synthesis of 2-(4’-carboxyphenyl)ethylcyanamide (65)
To a suspension of 4-(2-aminoethyl)benzoic acid (2.00 g, 9.92 mmol) and sodium acetate (1.63 g,
19.94 mmol) in dry methanol (50 ml) was added dropwise a 3M solution of BrCN in CH2Cl2
(3.31 ml, 9.92 mmol). The mixture was stirred in an ice bath for 2 h, then the ice bath was
removed and the reaction mixture was allowed to stir at room temperature overnight. The
solvent was removed at reduced pressure and the residue was dissolved in water (50 ml). The
crude product was extracted with CH2Cl2 (3 x 30 ml). The organic layer was washed with brine
(30 ml), dried over MgSO4 and the solvent was removed at reduced pressure. The crude product
was purified by column chromatography on silica with petroleum ether/diethyl ether (1:2) as
eluting solvent. This gave the desired product (65) as a pale yellow solid (0.77 g, 41%).
mp 114-116 ºC; (Found: C, 62.7; H, 5.2; N, 14.6%. C10H10N2O2 requires C, 63.1; H, 5.3; N,
14.7%); νmax(nujol)/cm-1 3325 (NH), 2676 (CH aromatic), 2209 (C≡N), 1700, 1684 (C=O), 1611,
1576 (C=); δH (400 MHz, d6-DMSO) 2.84 (2H, t, J 7 Hz, CH2-2), 3.20 (2H, t, J 7 Hz, CH2-1),
6.85 (1H, br s, NH), 7.34-7.38 (2H, m, H-2’, 6’), 7.84-7.90 (2H, m, H-3’, 5’); δC (100 MHz,
d6-DMSO) 35.8 (C-2), 46.0 (C-1), 117.5 (C≡N), 129.3 (C-2’, 6’), 129.8 (C-3’, 5’), 129.3 (C-4’),
143.8 (C-1’), 167.8 (C=O); m/z (ES+) 191.0824 ((M+H)+. C10H11N2O2 requires 191.0821).
Synthesis of N–2-(4’-carboxyphenyl)ethyl-N’–hydroxyguanidine hydrochloride (84)
2-(4’-Carboxyphenyl)ethylcyanamide (65) (0.21 g, 1.11 mmol) was mixed with hydroxylamine
hydrochloride (0.07 g, 1.00 mmol) in dry methanol (20 ml) and potassium carbonate (0.1 equiv)
was added as a catalyst. The reaction mixture was heated under reflux for 7 h under an argon
atmosphere. After cooling, the solvent was removed at reduced pressure and the desired product
was crystallized from CH2Cl2 and diethyl ether. Further purification was achieved by redissolving
the crude product in the minimum amount of methanol and the insoluble solid was filtered off.
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Addition of CH2Cl2 gave the pure product (84) as a colourless solid (0.21 mg, 83%).
mp 168-170 ºC; νmax(nujol)/cm-1 3379 (NH), 1693 (C=O), 1660, 1613 (C=C); δH (300 MHz, d6-
DMSO) 2.87 (2H, t, J 7 Hz, CH2-2), 3.42 (2H, quartet, J 7 Hz, CH2-1), 7.37-7.42 (2H, m, H-2’,
6’), 7.71 (2H, br s, NH2), 7.85-7.91 (2H, m, H-3’, 5’), 7.94 (1H, br t, J 6 Hz, NH), 9.81 (1H, br s,
NH/OH), 10.42 (1H, br s, NH/OH); δC (75.46 MHz, d6-DMSO) 34.4 (C-2), 41.5 (C-1), 129.0
(C-3’, 5’), 129.1 (C-4’), 129.3 (C-2’, 6’), 143.5 (C-1’), 158.1 (C=NOH), 167.2 (C=O); m/z (ES+)
224.1032 ((M+H)+. C10H14N3O3 requires 224.1035); m/z (ES+) 224 ((M+H)+, 100%).
Synthesis of N-(tert-butoxycarbonyl)-2-(4’-trifluoromethylphenyl)ethylamine (41)
To a stirred solution of 4-(trifluoromethyl)phenylacetonitrile (1.05 g, 5.7 mmol) in dry methanol
(40.5 ml), cooled to 0 ºC, were added di-tert-butyl dicarbonate (Boc2O) (2.40 g, 11.0 mmol) and
NiCl2 · 6H2O (0.13 g, 0.6 mmol). NaBH4 (1.46 g, 38.6 mmol) was then added in small portions
over 1.5 h. The resulting reaction mixture, containing a finely divided black precipitate, was
allowed to warm to room temperature and stirred for further 2 h, at which point
diethylenetriamine (0.58 ml, 5.4 mmol) was added. The mixture was allowed to stir for 1.5 h
before solvent evaporation. The purple residue was then dissolved in ethyl acetate (150 ml) and
washed with saturated aq. NaHCO3 (2 x 40 ml). The organic layer was dried over MgSO4 and
the solvent was removed at reduced pressure to yield a colourless precipitate. The crude product
was purified by column chromatography on silica with petroleum ether/diethyl ether (1:1) as
eluting solvent. This gave the desired product (41) as a colourless solid (1.00g, 61%).
mp 78-79 ºC; (Found: C, 58.2; H, 6.1; N, 4.6%. C14H18F3NO2 requires C, 58.1; H, 6.2; N, 4.8%);
νmax(nujol)/cm-1 3361 (NH), 1672 (C=O), 1525; δH (300 MHz, CDCl3) 1.58 (9H, s, t-butyl), 2.86
(2H, t, J 7 Hz, CH2-2), 3.39 (2H, q, J 7 Hz, CH2-1) 4.54 (1H, br s, NH), 7.31 (2H, d, J 8 Hz,
H-2’, 6’), 7.56 (2H, d, J 8 Hz, H-3’,5’); δC (75.46 MHz, CDCl3) 28.4 (CH3), 36.1 (C-2), 41.5 (C-1),
79.4 (C-t-butyl), 125.3 (q, J 271 Hz [13C-19F], CF3), 125.4 (q, J 4 Hz [13C-19F], C-3’, 5’), 128.6 (q, J
32 Hz [13C-19F], C-4’), 129.2 (C-2’, 6’), 143.2 (C-1’), 155.8 (C=O); δF (376.5 MHz, CDCl3), -62.8
(CF3); m/z (ES+) 312 ((M+Na)+, 100%).
EXPERIMENTAL
206
Synthesis of 2-(4’-trifluoromethylphenyl)ethylamine hydrochloride (42)
A solution of N-(tert-butoxycarbonyl)-2-(4’-trifluoromethylphenyl)ethylamine (41) (0.70 g, 2.4
mmol) in dry 1,4-dioxane (2 ml) was treated with anhydrous HCl in 1,4-dioxane (4 M, 10 ml) at
room temperature for 6 h. At that point a few drops of petroleum ether were added to aid
precipitation. The solution was left overnight. The excess of solvent was decanted off and
yellowish solid was filtered off and washed with petroleum ether. This gave the pure product
(42) as a colourless solid (0.5 g, 90%). mp 178-179 ºC; (Found: C, 48.0; H, 4.7; N, 6.0%.
C9H11ClF3N requires: C, 47.9; H, 4.9; N, 6.2%); νmax(nujol)/cm-1 3424 (NH), 1638, 1602 (C=C);
δH (300 MHz, D2O) 2.95 (2H, t, J 7 Hz, CH2-2), 3.18 (2H, t, J 7 Hz, CH2-1) 7.35 (2H, d, J 8 Hz,
H-2’, 6’) 7.58 (2H, d, J 8 Hz, H-3’,5’); δC (75.46 MHz, D2O) 32.9 (C-2), 40.5 (C-1), 125.7 (C-3’,
5’), 128.9 (C-4’), 129.3 (C-2’, 6’), 140.9 (C-1’) δC (125.7 MHz, CDCl3) 32.5 (C-2), 40.3 (C-1),
124.1 (q, J 271 Hz [13C-19F], CF3), 125.7 (q, J 4 Hz [
13C-19F], C-3’, 5’), 128.7 (q, J 32 Hz [13C-19F],
C-4’), 129.3 (C-2’, 6’), 140.9 (C-1’); δF (376.5 MHz, D2O), -62.8 (CF3); m/z (ES+) 190 ((M+H)+,
100%), 173 (15), 155 (4).
Synthesis of 2-(4’-trifluoromethylphenyl)ethylcyanamide (57)
To a suspension of 2-(4’-trifluoromethylphenyl)ethylamine hydrochloride (42) (1.07 g, 4.7 mmol)
and sodium acetate (1.16 g, 14.2 mmol) in dry methanol (25 ml) was added dropwise a 3M
solution of BrCN in CH2Cl2 (1.60 ml, 4.7 mmol). The mixture was stirred in an ice bath for 3 h,
than the ice bath was removed and reaction mixture was allowed to stir at room temperature
overnight. The solvent was removed at reduced pressure and the crude product was extracted
with CH2Cl2 (3 x 15 ml). The organic layer was washed with brine (20 ml), dried over MgSO4
and evaporated. The pure product was obtained by column chromatography on silica using
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petroleum ether/diethyl ether (1:2) as the eluent. This gave the desired product (57) as a yellow
oil (0.68 g, 76%). νmax(neat)/cm-1 3211 (NH), 2937 (CH aromatics), 2225 (C≡N), 1725, 1619
(C=C); δH (300 MHz, CDCl3) 2.93 (2H, t, J 7 Hz, CH2-2), 3.30 (2H, q, J 7 Hz, CH2-1), 3.63 (1H,
br s, NH), 7.27 (2H, d, J 8 Hz, H-2’, 6’), 7.53 (2H, d, J 8 Hz, H-3’,5’); δC (75.46 MHz, CDCl3)
35.6 (C-2), 47.1 (C-1), 125.8 (C-3’, 5’), 129.2 (C-2’, 6’); δC (125.7 MHz, CDCl3) 35.5 (C-2), 46.5
(C-1), 116.2 (C≡N), 124.0 (q, J 272 Hz [13C-19F], CF3), 125.4 (q, J 4 Hz [13C-19F], C-3’, 5’), 128.9
(q, J 32 Hz [13C-19F], C-4’), 129.1 (C-2’, 6’), 141.5 (C-1’); δF (376.5 MHz, CDCl3), -63.0 (CF3);
m/z (ES+) 215.0791 ((M+H)+. C10H10N2F3 requires 215.0796).
Synthesis of N–2-(4’-trifluoromethylpheny)lethyl-
N’–hydroxyguanidine hydrochloride (76)
2-(4’-Trifluoromethylphenyl)ethylcyanamide (57) (0.62 g, 3.3 mmol) was mixed with
hydroxylamine hydrochloride (0.21 g, 3.0 mmol) in dry methanol (25 ml) and potassium
carbonate (0.1 equiv) was added as a catalyst. The reaction mixture was heated under reflux for
4 h under an argon atmosphere. After cooling down, the solvent was removed at reduced
pressure and the desired product was crystallized from CH2Cl2 and diethyl ether. Further
purification was done by redissolving the crude product in minimum amount of methanol and
precipitated out from CH2Cl2 and diethyl ether. A final crystallization from CH2Cl2 gave the pure
product (76) as colourless crystals (0.52 g, 62%); mp 118-120 ºC; (Found: C, 41.8; H, 4.4;
N, 14.8%. C10H13ClF3N3O requires C, 42.3; H, 4.6; N, 14.8%); νmax(nujol)/cm-1 3353, 3309, 3108
(NH), 1649, 1589 (C=C); δH (300 MHz, d6-DMSO) 2.90 (2H, t, J 7 Hz, CH2-2), 3.43 (2H, q, J 7
Hz, CH2-1), 7.50 (2H, d, J 8 Hz, H-3’, 5’), 7.68 (2H, d, J 8 Hz, H-2’,6’), 7.73 (2H, br s, NH2),
7.94 (1H, t, J 7 Hz, NH), 9.82 (1H, br s, NH/OH), 10.43 (1H, br s, NH/OH); δC (125.7 MHz,
d6-DMSO) 34.1 (C-2), 41.7 (C-1), 124.3 (q, J 269 Hz [13C-19F], CF3), 125.4 (q, J 4 Hz [13C-19F],
C-3’, 5’), 128.4 (q, J 32 Hz [13C-19F], C-4’), 129.7 (C-2’, 6’), 143.3 (C-1’), 158.1 (C=NOH);
δF (376.5 MHz, CDCl3), -61.2 (CF3); m/z (ES+) 248 ((M+H)+, 100%).
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Synthesis of N-(tert-butoxycarbonyl)-2-(1’-naphthyl)ethylamine (55)
To a stirred solution of 1-naphthylacetonitrile (3.00 g, 17.9 mmol) in dry methanol (60 ml),
cooled to 0 ºC, were added di-tert-butyl dicarbonate (Boc2O) (7.83 g, 35.9 mmol) and
NiCl2·6H2O (0.43 g, 1.8 mmol). NaBH4 (4.75 g, 125.6 mmol) was than added in small portions
over 3 h. The resulting reaction mixture, containing a finely divided black precipitate, was
allowed to warm to room temperature and stirred for further 2 h, at which point
diethylenetriamine (1.94 ml, 17.9 mmol) was added. The mixture was allowed to stir for 3 h
before solvent evaporation. The purple residue was then dissolved in ethyl acetate (250 ml) and
extracted with saturated aq. NaHCO3 (2 x 60 ml). The organic layer was dried over MgSO4 and
the solvent was removed at reduced pressure to yield a colourless precipitate. The crude product
was purified by column chromatography on silica with petroleum ether/diethyl ether (1:2) as
eluting solvent. This gave the desired product, which was recrystallized from diethyl ether. The
final product (55) was obtained as a colourless solid (3.05 g, 63%); mp 84-86 ºC; (Found: C, 75.3;
H, 7.8; N, 5.1%. C17H21NO2 requires C, 75.3; H, 7.8; N, 5.2%); νmax(nujol)/cm-1 3337 (NH), 1681
(C=O); δH (500 MHz, CDCl3) 1.47 (9H, s, t-butyl), 3.29 (2H, t, J 7 Hz, CH2-2), 3.51 (2H, br s,
CH2-1), 4.69 (1H, br s, NH), 7.34 (1H, d, J 8 Hz, H-2’), 7.42 (1H, t, J 8 Hz, H-3’), 7.50 (1H, t, J
8 Hz, H-6’), 7.55 (1H, t, J 8 Hz, H-7’), 7.76 (1H, d, J 8 Hz, H-4’), 7.87 (1H, d, J 8 Hz, H-5’),
8.10 (1H, d, J 8 Hz, H-8’); δC (125.70 MHz, CDCl3) 28.4 (CH3), 33.4 (C-2), 41.4 (C-1), 79.2 (C-t-
butyl), 123.8 (C-9’), 125.7 (C-7’, 8’), 126.8 (C-2’, 3’), 127.2 (C-4’), 128.8 (C-6’), 132.0 (C-10’),
133.9 (C-5’), 135.2 (C-1’), 156.0 (C=O); m/z (ES+) 294 ((M+Na)+, 100%), 310 ((M+K)+, 100%).
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Synthesis of 2-(1’-naphthyl)ethylamine hydrochloride (56)
A solution of N-(tert-butoxycarbonyl)-2-(1’-naphthyl)ethylamine (55) (2.83 g, 10.4 mmol) in dry
1,4-dioxane (10 ml) was treated with anhydrous HCl in 1,4-dioxane (4 M, 15 ml) at room
temperature and left to stir overnight. The excess of solvent was decanted off and the off-white
solid was filtered off and washed with diethyl ether. This gave the pure product (56) as a
colourless solid (2.04 g, 94%). mp 250 ºC (dec.); (Found: C, 68.9; H, 6.5; N, 6.8%. C12H14ClN
requires: C, 69.3; H, 6.7; N, 6.8%); νmax(nujol)/cm-1 3424 (NH), 1638, 1594 (C=C); δH (500 MHz,
D2O) 3.28 (2H, t, J 7 Hz, CH2-1), 3.38 (2H, t, J 7 Hz, CH2-2), 7.36-7.44 (2H, m, H-6’, 7’), 7.48-
7.58 (2H, m, H-2’, 3’), 7.81 (1H, d, J 8 Hz, H-4’), 7.90 (1H, d, J 8 Hz, H-5’), 7.99 (1H, d, J 8 Hz,
H-8’); δC (125.7 MHz, D2O) 29.9 (C-2), 39.7 (C-1), 123.0 (C-9’), 125.7 (C-7’), 126.3 (C-8’), 127.4
(C-2’, 3’), 128.0 (C-4’), 128.9 (C-6’), 131.0 (C-10’), 132.4 (C-5’), 133.6 (C-1’); m/z (ES+) 172
((M+H)+, 100%).
Synthesis of 2-(1’-naphthyl)ethylcyanamide (63)
To a suspension of 2-(1’-naphthyl)ethylamine hydrochloride (56) (1.90 g, 9.2 mmol) and sodium
acetate (2.25 g, 27.4 mmol) in dry methanol (25 ml) was added dropwise a 3M solution of BrCN
in CH2Cl2 (3.05 ml, 9.2 mmol). The mixture was stirred in an ice bath for 3 h, then the ice bath
was removed and reaction mixture was allowed to stir at room temperature overnight. The
solvent was removed at reduced pressure and the crude product was extracted with CH2Cl2 (3 x
20 ml). The organic layer was washed with brine (30 ml), dried over MgSO4 and evaporated at
the solvent was removed at reduced pressure. The pure cyanamide was obtained by column
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chromatography on silica using petroleum ether/diethyl ether (1:1) as the eluting solvent. This
gave the desired product (63) as a yellow oil (1.05 g, 58%). νmax(neat)/cm-1 3211, 3062, (NH),
2937 (CH), 2223 (C≡N), 1719, 1597 (C=C); δH (300 MHz, CDCl3) 3.36-3.52 (5H, m, CH2-1, 2,
NH), 7.36-7.46 (2H, m, H-2’, 3’), 7.49-7.59 (2H, m, H-7’, 8’), 7.79 (1H, d, J 8 Hz, H-4’), 7.88
(1H, d, J 8 Hz, H-5’), 7.97 (1H, d, J 8 Hz, H-8’); δC (75.46 MHz, CDCl3) 33.5 (C-2), 47.1 (C-1),
116.1 (C≡N), 123.4 (C-9’), 125.9 (C-7’), 126.3 (C-8’), 126.9 (C-2’), 127.7 (C-3’), 128.4 (C-4’),
129.5 (C-6’), 131.9 (C-10’), 133.4 (C-5’), 134.4 (C-1’); m/z (ES+) 219.0906 ((M+Na)+.
C13H12N2Na requires 219.0898); m/z (ES
-) 195 ((M+H)-, 100%)
Synthesis of N–2-(1’-naphthyl)ethyl-N’–hydroxyguanidine hydrochloride (82)
2-(1’-Naphthyl)ethylcyanamide (63) (0.92 g, 4.7 mmol) was mixed with hydroxylamine
hydrochloride (0.29 g, 4.2 mmol) in dry methanol (25 ml) and potassium carbonate was added
(0.1 equiv) as a catalyst. The reaction mixture was heated under reflux for 5 h under an argon
atmosphere. After cooling down, the solvent was removed at reduced pressure and the desired
product was crystallized from CH2Cl2 and diethyl ether. Crystallization from CH2Cl2 gave the
pure product (82) as an off-white solid (0.88 g, 79%); mp 94-96 ºC; (Found: C, 58.5; H, 6.1; N,
15.9%. C13H16ClN3O requires C, 58.8; H, 6.1; N, 15.8%); νmax(nujol)/cm-1 3436, 3323 (NH),
1617, 1577 (C=C); δH (300 MHz, d6-DMSO) 3.24-3.32 (2H, m, CH2-1), 3.45-3.55 (2H, m,
CH2-2), 7.36-7.46 (2H, m, H-6’, 7’), 7.43-7.56 (2H, m, H-2’, 3’), 7.73 (2H, br s, NH2), 7.82 (1H,
dt, J 5 Hz, J 3 Hz, H-5’), 7.94 (1H, d, J 8 Hz, H-8’), 8.05 (1H, br t, J 7 Hz, NH), 9.85 (1H, br s,
NH/OH), 10.46 (1H, br. s, NH/OH); δH (300 MHz, D2O) 3.24 (2H, t, J 7 Hz, H-1), 3.47 (2H, t,
J 7 Hz, H-2), 7.27-7.42 (2H, m, H-6’, 7’), 7.43-7.55 (2H, m, H-2’, 3’), 7.76 (1H, d, J 8 Hz, H-4’),
7.86 (1H, d, J 8 Hz, H-5’), 7.98 (1H, d, J 8 Hz, H-8’);δC (75.46 MHz, d6-DMSO) 31.5 (C-2), 41.3
(C-1), 123.6 (C-9’), 125.5 (C-7’), 125.7 (C-8’), 126.2 (C-2’), 126.9 (C-3’), 127.1 (C-4’), 128.6 (C-6’),
131.4 (C-10’), 133.4 (C-5’), 134.2 (C-1’); 158.1 (C=NOH); m/z (ES+) 230 ((M+H)+, 100%).
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Synthesis of 4-aminophenylacetonitrile hydrochloride (98)10
To a magnetically stirred solution of 4-nitrophenylacetonitrile (3.00 g, 18.5 mmol) in ethanol
(30 ml) was added 10% Pd-Charcoal catalyst (480 mg). Hydrazine hydrate (2.25 ml, 46.3 mmol)
was added dropwise maintaining the temperature in the range 20-25 ºC. When effervescence had
ceased the catalyst was removed by filtration through celite. Evaporation of the filtrate at
reduced pressure afforded 4-aminophenylacetontirile as a yellow oil, which was converted to the
hydrochloride salt by the addition of 4M HCl (5 ml) in 1,4-dioxane. The final product (98) was
obtained as a pale yellow solid (2.31 g, 74%). mp 218 ºC (dec.), (lit.10, 220 ºC); νmax(nujol)/cm-1
2565, 2594 (NH), 2248 (C≡N); (Found: C, 56.8; H, 5.3; N, 16.3%. C8H9ClN2 requires C, 57.0; H,
5.4; N, 16.6%); δH (400 MHz, d6-DMSO, free amine) 3.76 (2H, s, H-1), 5.11 (2H, s, NH2), 6.54
(2H, d, J 8Hz, H-3’,5’), 6.96 (2H, d, J 8 Hz, H-2’, 6’); δC (75.46 MHz, d6-DMSO, HCl salt) 21.9
(C-1), 119.0 (C≡N), 123.5 (C-3’, 5’), 129.4 (C- 2’, 5’), 130.8 (C-4’), 131.8 (C-1’).
Synthesis of 4-(N-9-fluorenylmethoxycarbonylamino)phenylacetonirile (100)
To a solution of 4-amiophenylacetonitrile hydrochloride (98) (1.26 g, 7.5 mmol) and pyridine
(1.44 ml, 18.0 mmol) in CH2Cl2 (20 ml) at 0 ºC was added 9-fluorenylmethoxycarbonyl chloride
(2.13 g, 8.2 mmol). The solution was stirred at 0 ºC for further 15 minutes, before the ice bath
was removed and stirring continued at room temperature for 1 h. CH2Cl2 (30 ml) was added and
the solution washed with H2O (2×20 ml). The organic layer was dried (MgSO4) and
concentrated under reduced pressure to give a yellow solid which was recrystallized from
CH2Cl2/petroleum ether to give the final compound (100) as an off-white solid (2.03g, 77%).
mp 156 ºC; νmax(nujol)/cm-1 3278 (NH), 2248 (C≡N), 1700 (C=O), 1597 (C=C); (Found: C,
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77.5; H, 5.0; N, 7.6%. C23H18N2O2 requires C, 77.9; H, 5.1; N, 7.9%); δH (300 MHz, CDCl3) 3.71
(2H, s, CH2CN), 4.28 (1H, t, J 7 Hz, H-9), 4.57 (2H, d, J 7 Hz, CH2O), 6.67 (1H, br s, NH),
7.22-7.46 (8H, m, H-1, 2, 3, 6, 7, 8, H-2’, 6’), 7.62 (2H, d, J 8 Hz, H-3’, 5’), 7.79 (2H, d, J 8 Hz,
H-4, 5); δC (75.46 MHz, CDCl3) 23.0 (CH2), 44.1 (C-9), 66.9 (CH2O), 120.1 (C- 3’, 5’), 124.9
(C-3, 6), 127.2 (C-2, 3, 6, 7), 127.9 (C-1, 8), 128.7 (C-2’, 6’), 137.6 (C-1’), 141.4 (C-4a, 5a), 143.3
(C-1a, 8a), 143.6 (C-4’); m/z (ES+) 377 ((M+Na)+, 100%).
Synthesis of N-(tert-butoxycarbonyl)-
-2-(4’-N-9-fluorenylmethoxycarbonylaminophenyl)ethylamine (101)
N
H
O
O
1
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To a stirred solution of 4-(N-9-fluorenylmethoxycarbonyl)phenylacetonirile (100) (4.27 g,
12.1 mmol) in a mixture of dry THF (125 ml) and dry methanol (125 ml), cooled to 0 ºC, were
added di-tert-butyl dicarbonate (Boc2O) (5.28 g, 24.2 mmol) and NiCl2·6H2O (0.29 g,
1.21 mmol). NaBH4 (3.19 g, 84.4 mmol) was then added in small portions over 2 h. The
resulting reaction mixture, containing a finely divided black precipitate, was allowed to warm to
room temperature and stirred for further 24 h, at which point diethylenetriamine (1.30 ml,
12.1 mmol) was added. The mixture was allowed to stir for 1.5 h before solvent evaporation.
The purple residue was then dissolved in ethyl acetate (250 ml) and extracted with saturated
aq. NaHCO3 (3 x 80 ml). The organic layer was dried over MgSO4 and the solvent was removed
at reduced pressure to yield a pale yellow solid. The crude product was washed with diethyl ether
to remove unreacted starting material. This gave the desired product (101) as an off-white solid
(3.23 g, 58%). mp 166-168 ºC; νmax(nujol)/cm-1 3332 (NH), 1700, 1697 (C=O), 1653 (C=C);
(Found: C, 73.6; H, 6.3; N, 6.1%. C28H30N2O4 requires C, 73.3; H, 6.6; N, 6.1%); δH (400 MHz,
CDCl3) 1.43 (9H, s, t-butyl), 2.75 (2H, t, J 7 Hz, CH2-2), 3.31-3.39 (2H, m, CH2-1), 4.28 (1H, t, J
7 Hz, H-9), 4.54-4.59 (3H, m, CH2O, NH), 6.55 (1H, br s, NH), 7.12 (2H, d, J 8 Hz, H-2’, 6’),
7.28-7.33 (4H, m, H-2, 3, 6, 7), 7.42 (2H, t, J 8 Hz, H-1, 8), 7.62 (2H, d, J 8 Hz, H-3’, 5’), 7.79
(2H, d, J 8 Hz, H-4, 5); δC (75.46 MHz, CDCl3) 28.4 (CH3), 35.5 (C-2), 41.8 (C-1), 47.2 (C-9),
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66.8 (CH2O), 79.3 (C-t-butyl), 119.3 (C-3’, 6’), 120.1 (C-3, 6), 125.0 (C-2, 4, 5, 7), 127.2 (C-2’, 6’),
127.8 (C-2, 6’), 129.4 (C-1, 8), 134.8 (C-4’), 136.1 (C-1’), 141.4 (C-4a, 5a), 143.8 (C-1a, 8a), 155.9
(C=O); m/z (ES+) 480 ((M+Na)+, 100%), 481 (48).
Synthesis of 2-(4’-N-9-fluorenylmethoxycarbonylaminophenyl)ethylamine
hydrochloride (102)
A solution of N-(tert-butoxycarbonyl)-2-(4’-N-9-fluorenylmethoxycarbonylphenyl)ethylamine (101) (1.63
g, 3.5 mmol) in dry THF (5 ml) was treated with anhydrous HCl in 1,4-dioxane (4 M, 9.0 ml) at
room temperature for 16 h. The solid was filtered off and washed with diethyl ether to give the
pure product (102) as a colourless solid (1.02 g, 73%). mp 220 ºC (dec); νmax(nujol)/cm-1 3336,
2067 (NH), 1697 (C=O), 1606 (C=C); (Found: C, 69.6; H, 5.8; N, 6.9%. C23H23ClN2O2 requires:
C, 69.9; H, 5.9; N, 7.1%); δH (300 MHz, d4-methanol) 2.82 (2H, t, J 7 Hz, CH2-2), 3.06 (2H, t, J 7
Hz, CH2-1), 4.19 (1H, t, J 7 Hz, H-9), 4.40 (2H, t, J 7 Hz, CH2O), 7.11 (2H, d, J 8 Hz, H-2’, 6’),
7.21-7.27 (2H, m, H-2, 7), 7.29-7.38 (4H, m, H-1, 3, 6, 8), 7.62 (2H, d, J 8 Hz, H-3’, 5), 7.73 (2H,
d, J 8 Hz, H-4, 5); δC (75.46 MHz, d4-methanol) 32.4 (C-2), 40.4 (C-1), 46.9 (C-9), 66.2 (CH2O),
119.4 (C- 3’, 5’), 124.6 (C-3, 6), 126.7 (C-2, 4), 127.3 (C-5, 7), 128.7 (C-2’, 6’), 130.8 (C-1, 8),
137.8 (C-1’, 4’), 141.1 (C-4a, 5a), 143.8 (C-1a, 8a), 154.4 (C=O); m/z (ES+) 380 ((M+Na)+ 50%),
358 ((M+H)+, 100%).
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Synthesis of 2-(4’-N-9-fluorenylmethoxycarbonylaminophenyl)ethylcyanamide (103)
To a suspension of 2-[4’-(N-9-fluorenylmethoxycarbonyl)phenyl]ethylamine hydrochloride (102)
(1.02 g, 2.6 mmol) and sodium acetate (0.42 g, 5.16 mmol) in dry methanol (25 ml) was added
dropwise a 3M solution of BrCN in CH2Cl2 (0.86 ml, 2.6 mmol). The mixture was stirred in an
ice bath for 3 h, then the ice bath was removed and the reaction mixture was allowed to stir at
room temperature for 48 h. The solvent was removed at reduced pressure and the crude product
was extracted with CH2Cl2 (6 x 100 ml). The organic layer was washed with 2M HCl (100 ml)
and then with H2O (2 x 100 ml) and finally with brine (100 ml), dried over MgSO4 and the
solvent was removed at reduced pressure. The pure product was obtained by recrystallization
from CH2Cl2/petroleum ether. This gave the desired product (103) as an off-white solid (0.56 g,
56%). mp 170 ºC; νmax(nujol)/cm-1 3318 (NH), 2218 (C≡N), 1696 (C=O); δH (400 MHz,
d6-DMSO) 2.70 (2H, t, J 7 Hz, CH2-2), 3.08-3.14 (2H, m, CH2-1), 4.30 (1H, t, J 7 Hz, H-9), 4.47
(2H, t, J 7 Hz, CH2O), 6.77 (1H, br t, J 6 Hz, NH), 7.14 (2H, d, J 8 Hz, H-2’, 6’), 7.33-7.43 (6H,
m, H-1, 2, 3, 6, 7, 8), 7.75 (2H, d, J 8 Hz, H-3’, 5’), 7.91 (2H, d, J 8 Hz, H-4, 5), 9.61 (1H, br s,
NH); δC (100.6 MHz, d6-DMSO) 34.5 (C-2), 45.9 (C-1), 46.5 (C-9), 65.5 (CH2O), 117.4 (C≡N),
118.5 (C-3’, 5’), 120.1 (C-3, 6), 125.0 (C-2, 4, 5, 7), 127.2 (C-2’, 6’), 127.7 (C-2’, 6’), 129.1 (C-1, 8),
132.5 (C-1’, 4’), 140.7 (C-4a, 5a), 143.6 (C-1a, 8a), 153.6 (C=O); m/z (ES+) 406.1524 ((M+Na+).
C24H21N3O2Na requires 406.1532); m/z (ES+) 406 ((M+Na+), 100%).
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Synthesis of N–2-(4’-aminophenyl)ethyl-N’–hydroxyguanidine dihydrochloride (107)
2-(4’-N-9-Fluorenylmethoxycarbonylaminophenyl)ethylcyanamide (103) (1.07 g, 2.8 mmol) was
mixed with hydroxylamine hydrochloride (0.58 g, 8.3 mmol) in dry methanol (100 ml) and
acetonitrile (30 ml) and sodium acetate (0.2 equiv) was added as a catalyst. The reaction mixture
was heated under reflux for 8 h under an argon atmosphere. Then, the reaction mixture was
cooled to 0 °C in an ice bath and di-tert-butyl dicarbonate (0.61 g, 2.8 mmol) and potassium
carbonate (0.40 g, 2.8 mmol) were added. The solution was left to stir for an hour. The solvent
was then removed at reduced pressure and the residue was partitioned between water (20 ml)
and ethyl acetate (40 ml). The organic layer was dried over MgSO4 and the solvent was removed
at reduced pressure to give a yellow oil. The residue was dissolved in dry THF (20 ml) and
piperidine (20% w/w solution) was added. The reaction was left to stir for another hour. The
solvent was removed at reduced pressure and the crude product was purified by column
chromatography (petroleum: diethyl ether: ethyl acetate-gradient). The product was then
dissolved in dry THF (5 ml) and treated with anhydrous HCl in 1,4-dioxane (4 M, 10.0 ml) at
room temperature for 16 h. The solid was filtered off and washed with diethyl ether to give the
pure product (107) as an-off white solid. (175 mg, 23%). mp 210-212 ºC (dec.); νmax(nujol)/cm-1
3160, 2590 (NH), 1643 (C=C); δH (300 MHz, d6-DMSO) major isomer: 2.91 (2H, t, J 7 Hz,
CH2-2), 3.75 (2H, t, J 7 Hz, CH2-1), 6.74 (1H, br s), 7.31-7.74 (4H, m, Ar-H), 7.74 (2H, s, NH2),
7.97 (1H, br t, J 5 Hz, NH), 9.84 (1H, br s, NH/OH), 10.47 (3H, br s, NH3+), 10.91 (1H, s,
NH/OH); minor isomer: 2.82 (2H, t, J 7 Hz, CH2-2), 3.40 (2H, t, J 7 Hz, CH2-1), 6.74 (1H, br
s), 7.31-7.74 (4H, m, Ar-H), 7.74 (2H, s, NH2), 7.97 (1H, br t, J 5 Hz, NH), 9.84 (1H, br s,
NH/OH), 10.47 (3H, br s, NH3+), 10.91 (1H, s, NH/OH); δC (75.46 MHz, d6-DMSO) major
isomer: 34.2 (C-1), 42.0 (C-2), 123.5 (C-3’, 5’), 124.5 (C-1’), 130.4 (C-2’, 6’), 130.7 (C-4’), 158.6
(C=NOH); minor isomer: 32.9 (C-1), 39.9 (C-2), 122.4 (C-3’, 5’), 124.5 (C-1’), 129.2 (C-2’, 6’),
130.7 (C-4’), 157.9 (C=NOH); m/z (ES+) 195.1240 ((M+H)+. C9H15N4O requires 196.1246);
m/z (ES+) 195 ((M+H)+, 100%).
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Synthesis of N-(tert-butoxycarbonyl)-2-(4’-aminophenyl)ethylamine (112)
N-(tert-Butoxycarbonyl)-2-(4’-N-9-fluorenylmethoxycarbonylphenyl)ethylamine (101) (1.54 g,
3.36 mmol) was dissolved in THF (20 ml) and piperidine (5 ml) was added. The reaction mixture
was left to stir over night. After removal of solvent under reduced pressure and the residue was
purified by column chromatography using gradient elution with diethyl ether and ethyl acetate.
The pure product (112) was obtained as a pale yellow solid (0.33 g, 79%). mp 68 ºC; (Found:
C, 66.5; H, 8.9; N, 11.5%. C13H20N2O2 requires C, 66.1; H, 8.5; N, 11.8%); νmax(nujol)/cm-1 3378,
3182 (NH), 1684 (C=O), 1528; δH (400 MHz, CDCl3) 1.43 (9H, s, CH3), 2.68 (2H, t, J 7 Hz,
H-2), 3.31 (2H, dt, J 7 Hz, H-1), 3.60 (2H, br s, NH2), 4.52 (1H, br s, NH), 6.64 (2H, d, J 8 Hz,
H-3’, 5’), 6.97 (2H, t, J 8 Hz, H-2’, 6’); δC (75.46 MHz, CDCl3) 28.4 (CH3), 35.5 (C-2), 41.8 (C-1),
115.4 (C-3’, 5’), 129.6 (C-2’, 6’), 137.8 (C-1’), 144.8 (C-4’), 155.9 (C=O); m/z (ES+) 259
((M+Na)+, 100%).
Synthesis of N-(tert-butoxycarbonyl)-2-(4’-aminophenylethyl)cyanamide (113)
To a suspension of N-(tert-butoxycarbonyl)-2-(4’-aminophenyl)ethylamine (112) (0.99 g,
4.2 mmol) and sodium acetate (0.69 g, 8.4 mmol) in dry methanol (20 ml) was added dropwise a
3M solution of BrCN in CH2Cl2 (1.40 ml, 4.2 mmol). The mixture was stirred in an ice bath for
3 h, then the ice bath was removed and reaction mixture was allowed to stir at room temperature
overnight. The solvent was removed at reduced pressure and the crude product was extracted
with CH2Cl2 (3 x 20 ml). The organic layer was washed with brine (20 ml), dried over MgSO4
and the solvent was removed at reduced pressure. The pure cyanamide was obtained by column
chromatography on silica using gradient of petroleum ether/diethyl ether (1:1) to ethyl acetate as
the eluting solvents. This gave the desired product (113) as colourless crystals (0.46 g, 42%).
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mp 104-106 ºC; (Found: C, 64.3; H, 7.7; N, 16.2%. C14H19N3O2 requires C, 64.3; H, 7.3;
N, 16.1%); νmax(nujol)/cm-1 3344, 3147, 3079 (NH), 2222 (C≡N), 1680 (C=O); δH (400 MHz,
CDCl3) 1.43 (9H, s, CH3), 2.75 (2H, t, J 7 Hz, CH2-2), 3.33 (2H, dt, J 7 Hz, CH2-1), 4.60 (1H, br
s, NH), 6.50 (1H, br s, NH), 6.94 (2H, d, J 8 Hz, H-3’, 5’), 7.13 (2H, d, J 8 Hz, H-2’, 6’);
δC (75.46 MHz, CDCl3) 28.4 (CH3), 35.5 (C-2), 41.9 (C-1), 79.8 (C-t-butyl), 111.2 (C≡N), 115.6
(C-3’, 5’), 130.1 (C-2’, 6’), 134.2 (C-1’), 136.0 (C-4’), 156.2 (C=O); m/z (ES+) 284.1382
((M+Na+). C14H19N3O2Na requires 284.1375); m/z (ES+) 284 ((M+Na+), 100%), m/z (ES-) 260
((M-H)-, 100%).
Synthesis of N–phenyl-(4-ethylamine)-N’–hydroxyguanidine hydrochloride (116)
N-(tert-Butoxycarbonyl)-2-(4’-aminophenyl)cyanamide (115) (0.72 g, 2.7 mmol) was mixed with
hydroxylamine hydrochloride (0.20 g, 2.7 mmol) in dry methanol (50 ml) and potassium
carbonate (0.1 equiv) was added as a catalyst. The reaction mixture was heated under reflux for
7 h under an argon atmosphere. After the completion, the mixture was cooled in an ice bath and
di-tert-butyl dicarbonate (0.60 g, 2.7 mmol) and potassium carbonate (0.38 g, 2.7 mmol) were
added. The solution was left to stir for an hour. The solvent was then removed at reduced
pressure and the residue was partitioned between water (10 ml) and ethyl acetate (20 ml). The
organic layer was dried over MgSO4 and the solvent was removed at reduced pressure to give a
yellow oil. Further purification was achieved by column chromatography of the protected
hydroxyguanidine (petroleum: diethyl ether: ethyl acetate-gradient). The product was then
dissolved in dry THF (5 ml) and treated with anhydrous HCl in 1,4-dioxane (4 M, 10.0 ml) at
room temperature for 16 h. The solid was filtered off and washed with diethyl ether to give the
pure product (116) as a pale yellow solid (478 mg, 44%). mp 142-144 ºC (dec.); (Found: C, 40.5;
H, 6.0; N, 20.6%. C9H16Cl2N4O requires C, 40.5; H, 6.0; N, 20.9%); νmax(nujol)/cm-1 3382, 2448
(NH), 1609 (C=C), 1511; δH (300 MHz, d6-DMSO) 2.87-3.05 (4H, m, CH2-1, 2), 7.17 (2H, d, J 8
Hz, H-2’, 6’), 7.31 (2H, d, J 8 Hz, H-3’, 5’), 7.88 (2H, br s, NH2), 8.26 (3H, br s, NH3+), 10.00
(1H, br s, NH), 10.13 (1H, br s, NH/OH), 10.86 (1H, s, NH/OH); δC (75.46 MHz, d6-DMSO)
32.6 (C-1), 66.7 (C-2), 125.0 (C-2’, 6’), 130.2 (C-3’,5’), 134.2 (C-4’), 135.9 (C-1’), 157.3
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(C=NOH); m/z (ES+) 195.1235 ((M+H)+. C9H15N4O requires 195.1246); m/z (ES+) 195
((M+H)+, 100%).
Synthesis of methyl 4-(2-aminoethyl)benzoate (178)11
4-(2-Aminoethyl)benzoic acid hydrochloride (2.05 g, 10.1 mmol) was dissolved in distilled water
(40 ml) and basified with 2 M NaOH to pH 8-9. The aqueous layer was extracted with ethyl
acetate (3 x 30 ml), dried (MgSO4) and the solvent was removed at reduced pressure to give the
free amine, which was then dissolved in MeOH (10 ml) and one drop of concentrated H2SO4
was added. The reaction mixture was heated under reflux for 5 h. After cooling, the solvent was
removed under reduced pressure and the residue was partitioned between CH2Cl2 (30 ml) and
H2O (30 ml). The organic layer was washed with saturated sodium bicarbonate solution (2 x
20 ml) and dried over MgSO4. The solvent was evaporated under reduced pressure to give the
pure product (178) as a colourless solid (1.04 g, 57%). mp 54-56 ºC; δH (400 MHz, d4-methanol)
2.90 (2H, t, J 7 Hz, CH2-1), 3.05 (2H, t, J 7 Hz, CH2-2), 3.81 (3H, s, CH3), 7.31 (2H, d, J 8 Hz,
H-3’, 5’), 7.91 (2H, d, J 8 Hz, H-2’, 6’); δC (75.46 MHz, d4-methanol) 35.1 (C-1), 41.7 (C-2), 52.7
(CH3), 130.1 (C-2’, 6’), 130.7 (C-2’, 6’), 131.1 (C-3’, 5’), 144.3 (C-1’), 168.4 (C-4’), 180.4 (C=O);
m/z (ES+) 180 ((M+H)-, 70%), 163 (100).
Synthesis of methyl 4-(2-cyanamidoethyl)benzoate (64)
To a suspension of methyl 4-(2-aminoethyl)benzoate (178) (1.00 g, 5.59 mmol) and sodium
acetate (0.92 g, 11.2 mmol) in dry methanol (30 ml) was added dropwise a 3M solution of BrCN
in CH2Cl2 (1.86 ml, 5.59 mmol). The mixture was stirred in an ice bath for 2 h, then the ice bath
was removed and reaction mixture was allowed to stir at room temperature overnight. The
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solvent was removed at reduced pressure and the residue was dissolved in water (30 ml). The
crude product was extracted with CH2Cl2 (3 x 30 ml). The organic layer was washed with brine
(30 ml), dried over MgSO4 and evaporated. The pure product was obtained by chromatography
on silica using petroleum ether/diethyl ether (1:2) as the eluting solvent. This gave the desired
product (64) as a colourless oil (0.32 g, 30%). νmax(neat)/cm-1 3336 (NH), 2223 (C≡N), 1700
(C=O), 1576 (C=C); δH (400 MHz, CDCl3) 2.94 (2H, t, J 7 Hz, CH2-2), 3.32 (2H, dt, J 6 Hz, J 7
Hz, CH2-1), 3.86 (3H, s, CH3), 4.64 (1H, br s, NH), 7.22-7.28 (2H, m, C-2’, 6’), 7.95 (2H, d, J 8
Hz, C-3’, 5’); δC (75.46 MHz, CDCl3) 36.3 (C-2), 47.6 (C-1), 60.8 (CH3), 129.3 (C-2’, 6’), 130.5
(C-3’, 5’), 143.0 (C-4’), 151.1 (C-1’), 167.4 (C=O); m/z (ES-) 203.0819 ((M-H)-. C11H11N2O2
requires 203.0821); m/z (ES+) 227 ((M+Na)+, 100%).
Synthesis of methyl 4-(2-(2-hydroxyguanidino)ethyl)benzoate hydrochloride (87)
Methyl 4-(2-cyanamidoethyl)benzoate (66) (0.30 g, 1.45 mmol) was mixed with hydroxylamine
hydrochloride (0.10 g, 1.45 mmol) in dry methanol (20 ml) and potassium carbonate (0.1 equiv)
was added as a catalyst. The reaction mixture was heated under reflux for 3 h under an argon
atmosphere and then stirred for further 12 h at room temperature. The solvent was removed at
reduced pressure, and the product was crystallized from CH2Cl2 and diethyl ether. Further
purification was achieved by redissolving the crude product in the minimum amount of
methanol and the insoluble solid was filtrated off. Addition of CH2Cl2 gave the pure product
(87) as a colourless solid (128 mg, 32%). mp 148-150 ºC; (Found: C, 46.8; H, 5.9; N, 14.9%.
C10H16ClN3O; 0.4 H2O requires C, 47.0; H, 6.0; N, 14.9%); νmax(nujol)/cm-1 3345, 3139 (NH),
1714 (C=O), 1653 (C=C), 1284 (C–O); δH (400 MHz, d6-DMSO) 2.88 (2H, t, J 7 Hz, CH2-1),
3.36-3.40 (2H, m, CH2-2), 3.84 (3H, s, CH3), 7.43 (2H, d, J 8 Hz, H-3’, 5’), 7.68 (2H, br s, NH2),
7.88-7.95 (3H, m, H-2’, 6’ and NH), 9.80 (1H, br s, OH); δC (100 MHz, d6-DMSO) 34.4 (C-1),
41.2 (C-2), 52.0 (CH3), 127.8 (C-1’), 129.2 (C-3’, 5’), 129.3 (C-2’, 6’), 144.1 (C-4’), 158.1
(C=NOH), 166.1 (C=O); m/z (ES+) 238 ((M+H)+, 100%).
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Synthesis of 3-aminophenylacetonitrile hydrochloride (108)12
To a stirred solution of 3-nitrophenylacetonitrile (2.50 g, 15.4 mmol) in ethanol (25 ml) was
added 10% Pd-charcoal catalyst (400 mg). Hydrazine hydrate (1.88 ml, 38.5 mmol) was then
added dropwise maintaining the temperature in the range 20-25 ºC. When effervescence had
ceased the catalyst was removed by filtration through celite. Removal of the solvent at reduced
pressure afforded 3-aminophenylacetontirile as a yellow oil, which was converted to the
hydrochloride salt by the addition of 4M HCl in 1,4-dioxane (5 ml). The final product (108) was
obtained as a pale yellow solid (2.25 g, 87%). mp 210 ºC (dec.), (lit.12, 209-210 ºC);
νmax(nujol)/cm-1 2628, 2591 (NH), 2251 (C≡N), 1603 (C=C); δH (300 MHz, d4-methanol) 3.92
(2H, s, CH2), 7.26-7.31 (1H, m, H-2’), 7.34-7.50 (3H, m, H-4’, 5’, 6’); δC (75.46 MHz,
d4-methanol) 23.7 (CH2), 119.3 (C≡N), 124.1 (C-4’), 124.3 (C-6’), 130.5 (C-2’), 132.4 (C-3’),
133.1 (C-1’), 136.0 (C-5’).
Synthesis of 3-(N-9-fluorenylmethoxycarbonylamino)phenylacetonirile (109)
To a solution of 3-amiophenylacetonitrile hydrochloride (108) (4.27 g, 25.3 mmol) and pyridine
(4.89 ml, 60.8 mmol) in CH2Cl2 (80 ml) at 0 ºC was added 9-fluorenylmethoxycarbonyl chloride
(7.21 g, 27.9 mmol). The solution was stirred at 0 ºC for 15 minutes, before the ice bath was
removed and stirring continued at room temperature for 1 h. CH2Cl2 (60 ml) was added and the
solution washed with H2O (2 × 50 ml). The organic layer was dried (MgSO4) and the solvent
was removed at reduced pressure to give a yellow solid which was purified by column
chromatography using petroleum ether/diethyl ether (1:2) as an eluting solvent giving the final
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compound (109) as an off-white solid (5.87g, 65%). mp 108-109 ºC; νmax(nujol)/cm-1 3312 (NH),
2361 (C≡N), 1737, 1699 (C=O), 1612 (C=C); (Found: C, 78.1; H, 5.1; N, 7.2%. C23H18N2O2
requires C, 77.9; H, 5.1; N, 7.9%); δH (400 MHz, CDCl3) 3.70 (2H, s, CH2CN), 4.27 (1H, t, J 7
Hz, H-9), 4.56 (2H, d, J 7 Hz, CH2O), 6.77 (1H, br s, NH), 7.01-7.06 (1H, m, H-6’), 7.27-7.47
(8H, m, H-1, 2, 3, 6, 7, 8, H-4’, 5’), 7.62-7.64 (1H, m, H-2’), 7.79 (2H, d, J 8 Hz, H-4, 5);
δC (75.46 MHz, CDCl3) 23.6 (CH2), 47.1 (C-9), 66.9 (CH2O), 117.7 (C≡N), 118.1 (C-1, 8), 120.1
(C-4’), 122.9 (C-2’), 125.1 (C-6’), 127.2 (C-2, 7), 127.9 (C-3, 4, 5, 6), 129.9 (C-5’), 131.0 (C-1’),
138.5 (C-3’), 141.4 (C-4a, 5a), 143.7 (C-1a, 8a), 152.8 (C=O); m/z (ES+) 377.1257 ((M+Na)+.
C23H18N2O2Na requires 377.1266); m/z (ES+) 377 ((M+Na)+, 100%).
Synthesis of N-(tert-butoxycarbonyl)-
-2-(3’-N-9-fluorenylmethoxycarbonylaminophenyl)ethylamine (110)
To a stirred solution of 3-(N-9-fluorenylmethoxycarbonyl)phenylacetonirile (109) (5.58 g, 15.7
mmol) in a mixture of dry THF (150 ml) and dry methanol (150 ml), cooled to 0 ºC, were added
di-tert-butyl dicarbonate (Boc2O) (6.87 g, 31.5 mmol) and NiCl2·6H2O (0.37 g, 1.57 mmol).
NaBH4 (4.17 g, 110 mmol) was then added in small portions over 3 h. The resulting reaction
mixture, containing a finely divided black precipitate, was allowed to warm to room temperature
and stirred for further 24 h, at which point diethylenetriamine (1.70 ml, 15.7 mmol) was added.
The mixture was allowed to stir for 1.5 h before solvent evaporation. The purple residue was
then dissolved in ethyl acetate (250 ml) and extracted with saturated aq. NaHCO3 (3 x 80 ml).
The organic layer was dried over MgSO4 and the solvent was removed at reduced pressure to
yield a pale yellow solid. The crude product was purified by the column chromatography using
diethyl ether/petroleum ether (2:1) as an eluting solvent. This gave the starting material (0.80 g),
Fmoc-deprotected amine (0.64 g) and the desired product (110) as an off-white solid (1.93 g,
EXPERIMENTAL
222
28%). mp 60-61 ºC; νmax(nujol)/cm-1 3303 (NH), 1699, 1686 (C=O), 1612, 1596 (C=C); (Found:
C, 73.6; H, 6.9; N, 6.2%. C28H30N2O4 requires C, 73.3; H, 6.6; N, 6.1%); δH (300 MHz, CDCl3)
1.48 (9H, s, t-butyl), 2.79 (2H, t, J 7 Hz, CH2-2), 3.42 (2H, t, J 7 Hz, CH2-1), 4.28 (1H, t, J 7 Hz,
H-9), 4.54 (2H, d, J 7 Hz, CH2O), 6.65 (1H, br s, NH), 6.92-6.97 (1H, m, 6’), 7.12 (2H, d, J 8 Hz,
H-2, 7), 7.28-7.33 (4H, m, H-3, 6, 4’, 5’), 7.42 (2H, t, J 8 Hz, H-1, 8), 7.62-7.65 (1H, m, H-2’),
7.79 (2H, d, J 8 Hz, H-4, 5); δC (75.46 MHz, CDCl3) 28.4 (CH3), 36.2 (C-2), 41.9 (C-1), 47.2
(C-9), 68.9 (CH2O), 120.1 (C-3’, 6’), 124.1 (C-3, 6), 125.0 (C-2, 4, 5, 7), 127.2 (C-2’, 6’), 127.8
(C-2, 6’), 129.3 (C-1, 8), 138.0 (C-4’), 140.1 (C-1’), 141.4 (C-4a, 5a), 143.8 (C-1a, 8a), 152.6
(C=O); m/z (ES+) 481 ((M+Na)+, 100).
Synthesis of 2-(3’-N-9-fluorenylmethoxycarbonylaminophenyl)ethylamine
hydrochloride (179)
A solution of N-(tert-butoxycarbonyl)-2-(3’-N-9-fluorenylmethoxycarbonylphenyl)ethylamine
(114) (1.92 g, 4.2 mmol) in dry THF (5 ml) was treated with anhydrous HCl in 1,4-dioxane (4 M,
10.5 ml) at room temperature for 16 h. The precipitate was filtered off and washed with diethyl
ether to give the pure product (179) as a colourless solid (1.13 g, 69%). mp 198-200 ºC (dec);
(Found: C, 69.5; H, 5.8; N, 6.8%. C23H23ClN2O2 requires: C, 69.9; H, 5.9; N, 7.1%);
νmax(nujol)/cm-1 3163, 3079, 2692, 2596 (NH), 1709 (C=O), 1597 (C=C); δH (300 MHz,
d4-methanol) 2.92 (2H, t, J 7 Hz, CH2-2), 3.16 (2H, t, J 7 Hz, CH2-1), 4.28 (1H, t, J 7 Hz, H-9),
4.49 (2H, d, J 7 Hz, CH2O), 6.62-6.98 (1H, m, H-6’), 7.23-7.44 (6H, m, H-2, 3, 6, 7, 4’, 5’), 7.47
(1H, br s, NH), 7.70 (2H, d, J 8 Hz, H-1, 8), 7.81-7.90 (3H, m, H-4, 5, 2’); δC (75.46 MHz,
d4-methanol) 35.0 (C-2), 42.3 (C-1), 48.8 (C-9), 68.1 (CH2O), 119.4 (C-5’), 120.6 (C-3, 6), 121.4
(C-2, 4), 124.8 (C-5, 7), 126.5, 128.6 (C-2’, 6’), 129.3, 130.9 (C-1, 8), 139.0 (C-1’, 4’), 141.1 (C-4a,
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5a), 143.1 (C-1a, 8a), 145.6 (C-3’), 155.0 (C=O); m/z (ES+) 359.1750 ((M+H+). C23H23N2O2
requires 359.1760); m/z (ES+) 359 ((M+H+), 100%).
Synthesis of 2-(3’-N-9-fluorenylmethoxycarbonylaminophenyl)ethylcyanamide (180)
To a suspension of 2-[3’-(N-9-fluorenylmethoxycarbonyl)phenyl]ethylamine hydrochloride (179)
(2.30 g, 5.8 mmol) and sodium acetate (1.43 g, 17.5 mmol) in dry methanol (75 ml) was added
dropwise a 3M solution of BrCN in CH2Cl2 (1.94 ml, 5.8 mmol). The mixture was stirred in an
ice bath for 3 h, then the ice bath was removed and the reaction mixture was allowed to stir at
room temperature for 10 h. The solvent was removed at reduced pressure and the crude product
was extracted with ethyl acetate (3 x 100 ml). The organic layer was washed with 2M HCl
(100 ml) and then with H2O (2 x 100 ml) and finally with brine (100 ml), dried over MgSO4 and
the solvent was removed at reduced pressure. The pure product was obtained by recrystallization
from CH2Cl2/petroleum ether. This gave the desired product (180) as an off-white solid (1.58 g,
71%). mp 84-85 ºC; νmax(nujol)/cm-1 3308, 2727 (NH), 2218 (C≡N), 1695 (C=O), 1611 (C=C);
δH (400 MHz, CDCl3) 2.88 (2H, t, J 7 Hz, CH2-2), 3.29-3.36 (2H, m, CH2-1), 3.56 (1H, br s, NH),
4.27 (1H, t, J 7 Hz, H-9), 4.54 (2H, d, J 7 Hz, CH2O), 6.76 (1H, br t, J 6 Hz, NH), 6.91 (1H, d, J
8 Hz, H-6’), 7.18-7.45 (6H, m, H-4’, 5’, 2, 3, 6, 7), 7.62 (2H, d, J 8 Hz, H-1, 8), 7.78-7.85 (3H, m,
H-4, 5, 2’); δC (100.6 MHz, CDCl3) 36.2 (C-2), 47.5 (C-1), 47.7 (C-9), 67.3 (CH2O), 119.5 (C-2’,
4’), 120.5 (C-1, 8), 124.5 (C-6’), 125.3, 125.5 (C-2, 7), 127.6 (C-4, 5), 128.3 (C-3, 6), 130.0 (C-5’),
138.8 (C-1’), 141.8 (C-4a, 5a), 144.1 (C-1a, 8a); m/z (ES+) 406.1535((M+Na+). C24H21N3O2Na
requires 406.1532); m/z (ES+) 406 ((M+Na+), 100%).
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Synthesis of N–2-(3’-aminophenyl)ethyl-N’–hydroxyguanidine dihydrochloride (111)
ClH.H2N
H
N NH2.HCl
NOH
2-(3’-N-9-Fluorenylmethoxycarbonylaminophenyl)ethylcyanamide (180) (637 mg, 1.7 mmol) was
mixed with hydroxylamine hydrochloride (127 mg, 1.8 mmol) in dry methanol (20 ml) and
sodium acetate (13.6 mg, 0.17 mmol) was added as a catalyst. The reaction mixture was heated
under reflux for 8 h under an argon atmosphere. Then, the reaction mixture was cooled to 0 °C
in an ice bath and di-tert-butyl dicarbonate (0.29 g, 1.34 mmol) and potassium carbonate (0.17 g,
1.21 mmol) were added. The solution was left to stir for an hour. Then, the solvent was removed
at reduced pressure and the residue was partitioned between water (10 ml) and ethyl acetate
(20 ml). The organic layer was dried over MgSO4 and the solvent was removed at reduced
pressure to give a yellow oil. The residue was dissolved in dry THF (10 ml) and piperidine
(20% w/w solution) was added. The reaction was left to stir for another hour. The solvent was
removed at reduced pressure and the residue was dissolve in dry methanol (10 ml). Then, the
reaction mixture was cooled to 0 °C in an ice bath and di-tert-butyl dicarbonate (0.29 g,
1.34 mmol) and potassium carbonate (0.17 g, 1.21 mmol) were added. The solution was left to
stir for an hour. Then, the solvent was removed at reduced pressure and the residue was
partitioned between water (10 ml) and ethyl acetate (20 ml). The organic layer was dried over
MgSO4 and the solvent was removed at reduced pressure to give a yellow oil. The crude
product was purified by column chromatography (petroleum: diethyl ether: ethyl acetate-
gradient). The pure product was then dissolved in dry THF (1 ml) and treated with anhydrous
HCl in 1,4-dioxane (4 M, 5 ml) at room temperature for 16 h. The solid was filtered off and
washed with diethyl ether to give the pure product (111) as an off-white solid. (121 mg, 37%).
mp 169-170 ºC (dec.); νmax(nujol)/cm-1 3118, 2613 (NH), 1639 (C=C); δH (300 MHz, d6-DMSO)
major isomer: 2.90 (2H, t, J 7 Hz, CH2-2), 3.73 (2H, t, J 7 Hz, CH2-1), 6.69 (2H, br s),
7.11-7.24 (3H, m, H-2’, 4’, 6’), 7.37 (1H, t, J 8 Hz, H-5’), 7.72 (2H, s, NH2), 7.92 (1H, br t, NH),
9.79 (3H, br s, NH3
+), 10.41 (1H, s, NH/OH); minor isomer: 2.82 (2H, t, J 7 Hz, CH2-2),
3.34-3.42 (2H, m, CH2-1), 6.69 (2H, br s), 7.11-7.24 (3H, m, H-2’, 4’, 6’), 7.37 (1H, t, J 8 Hz,
H-5’), 7.72 (2H, s, NH2), 7.92 (1H, br t, NH), 9.79 (3H, br s, NH3
+), 10.41 (1H, s, NH/OH);
δC (75.46 MHz, d6-DMSO) major isomer: 33.2 (C-1), 41.9 (C-2), 120.5 (C-4’), 122.5 (C-2’),
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127.0 (C-6’), 130.1 (C-5’), 157.2 (C=NOH); minor isomer: 34.2 (C-1), 42.1 (C-2), 120.5 (C-4’),
122.5 (C-2’), 127.0 (C-6’), 130.1 (C-5’), 157.2 (C=NOH); m/z (ES+) 195.1252((M+H)+.
C9H15N4O requires 195.1246); m/z (ES+) 195 ((M+H)+, 100%).
Synthesis of N-(tert-butoxycarbonyl)-2-(3’-aminophenyl)ethylamine (118)
N-(tert-Butoxycarbonyl)-2-(3’-N-9-fluorenylmethoxycarbonylphenyl)ethylamine (110) (0.92 g,
2.01 mmol) was dissolved in THF (15 ml) and piperidine (2.5 ml) was added. The reaction
mixture was left to stir over night. After removal of the solvent under reduced pressure, the
residue was purified by column chromatography using gradient elution with diethyl ether and
ethyl acetate. The pure product (118) was obtained as a pale yellow solid (0.38 g, 81%).
mp 100-101 ºC; (Found: C, 66.4; H, 8.8; N, 11.7%. C13H20N2O2 requires C, 66.1; H, 8.5; N,
11.8%); νmax(nujol)/cm-1 3430, 3376, 3350 (NH), 1674 (C=O), 1604, 1589 (C=C); δH (400 MHz,
d6-DMSO) 1.37 (9H, s, CH3), 2.48-2.52 (2H, m, H-2), 3.01-3.09 (2H, m, H-1), 4.94 (2H, br s,
NH2), 6.31 (1H, d, J 8 Hz, H-4’), 6.35-6.40 (2H, m, H-2’, 6’), 6.83 (1H, br t, J 6 Hz, NH),
6.87-6.92 (1H, m, H-5’); δC (75.46 MHz, d6-DMSO) 28.2 (CH3), 35.9 (C-2), 41.7 (C-1), 77.4 (C-t-
butyl), 111.8 (C-4’), 114.1 (C-2’), 116.0 (C-6’), 128.8 (C-5’), 139.8 (C-1’), 148.6 (C-3’), 155.4
(C=O); m/z (ES+) 259.1416 ((M+Na+). C13H20N2O2Na requires 259.1422); m/z (ES
+) 259
((M+Na+), 100%).
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Synthesis of N-(tert-butoxycarbonyl)-2-(3’-aminophenyl)cyanamide (119)
To a suspension of N-(tert-butoxycarbonyl)-2-(3’-aminophenyl)ethylamine (118) (0.95 g,
4.0 mmol) and sodium acetate (0.66 g, 8.0 mmol) in dry methanol (40 ml) was added dropwise a
3M solution of BrCN in CH2Cl2 (1.4 ml, 4.0 mmol). The mixture was stirred in an ice bath for
3 h, then the ice bath was removed and reaction mixture was allowed to stir at room temperature
overnight. The solvent was removed at reduced pressure and the crude product was extracted
with ethyl acetate (3 x 50 ml). The organic layer was washed with brine (50 ml), dried over
MgSO4 and the solvent was removed at reduced pressure. The pure cyanamide was obtained by
column chromatography on silica using dichloromethane/ethyl acetate (1:1) as the eluting
solvents. This gave the desired product (119) as a yellow oil (0.88 g, 85%). νmax(nujol)/cm-1 3321,
3065, 2977 (NH), 2226 (C≡N), 1710 (C=O), 1609 (C=C); δH (400 MHz, CDCl3) 1.42 (9H, s,
CH3), 2.74 (2H, t, J 7 Hz, CH2-2), 3.26-3.39 (2H, m, CH2-1), 4.75 (1H, br s, NH), 6.82-6.91 (3H,
m, H-2’, 4’, 6’), 7.22 (1H, t, J 8 Hz, H-5’), 8.06 (1H, br s, NH); δC (75.46 MHz, CDCl3) 28.8
(CH3), 36.5 (C-2), 42.0 (C-1), 66.3 (C-t-butyl), 112.4 (C≡N), 113.9 (C-6’), 116.1 (C-2’), 124.1
(C-4’), 130.3 (C-5’), 138.5 (C-1’), 141.1 (C-3’), 156.7 (C=O); m/z (ES+) 284.1375 ((M+Na+).
C14H19N3O2Na requires 284.1373); m/z (ES+) 284 ((M+Na+), 100%), m/z (ES-) 260 ((M-H)-,
100%).
Synthesis of N–phenyl-(3-ethylamine)-N’–hydroxyguanidine hydrochloride (117)
N
H
ClHH2N
NOH
NH2
.HCl
N-(tert-Butoxycarbonyl)-2-(3’-aminophenyl)cyanamide (119) (0.79 g, 3.0 mmol) was mixed with
hydroxylamine hydrochloride (0.21 g, 3.0 mmol) in dry methanol (30 ml) and potassium
carbonate (0.1 equiv) was added as a catalyst. The reaction mixture was heated under reflux for
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7 h under an argon atmosphere. After the completion, the mixture was cooled in an ice bath and
di-tert-butyl dicarbonate (1.62 g, 3.73 mmol) and potassium carbonate (0.54 g, 3.73 mmol) were
added. The solution was left to stir for an hour. The solvent was then removed at reduced
pressure and the residue was partitioned between water (10 ml) and ethyl acetate (20 ml). The
organic layer was dried over MgSO4 and the solvent was removed at reduced pressure to give
a yellow oil. Further purification was achieved by column chromatography of the protected
hydroxyguanidine (petroleum: diethyl ether: ethyl acetate-gradient). The pure product was then
dissolved in dry THF (2 ml) and treated with anhydrous HCl in 1,4-dioxane (4 M, 5 ml) at room
temperature for 14 h. The solid was filtered off and washed with diethyl ether to give the pure
product (117) as a yellow solid (150 mg, 22%). mp 159-160 ºC (dec.); νmax(nujol)/cm-1 3322, 2458
(NH), 1600, 1598 (C=C); δH (300 MHz, d6-DMSO) 2.92 (2H, t, J 7 Hz, CH2-1), 2.98-3.06 (2H,
m, CH2-2), 7.07 (1H, d, J 8 Hz, H-6’), 7.13-7.19 (2H, m, H-2’, 4’), 7.35 (1H, t, J 8 Hz, H-5’), 7.93
(2H, br s, NH2), 8.27 (3H, br s, NH3+), 10.07 (1H, br s, NH), 10.18 (1H, br s, NH/OH), 10.91
(1H, s, NH/OH); δC (75.46 MHz, d6-DMSO) 33.0 (C-1), 40.1 (C-2), 120.7 (C-6’), 123.2 (C-2’),
125.0 (C-4’), 127.2 (C-5’), 130.2 (C-1’), 138.9 (C-3’), 156.7 (C=NHOH); m/z (ES+) 195.1246
((M+H)+. C9H15N4O requires 195.1246); m/z (ES
+) 195 ((M+H)+, 100%).
Synthesis of N,N-dimethyl-N’-phenethyl thiourea (123)13, 14
Phenylethyl isothiocyanate (5.0 g, 30.6 mmol) was dissolved in methanol (45 ml) and water
(5 ml), and then potassium carbonate (4.23 g, 30.6 mmol) was added. Dimethylamine
hydrochloride (2.5 g, 30.6 mmol) was dissolved in methanol (10 ml) and added dropwise to the
reaction mixture. The solution was allowed to stir overnight at room temperature. The inorganic
salt was filtered off and product (123) was crystallized from methanol as colourless crystals (5.08
g, 80%). mp 110-112 ºC (lit.14, 112 ºC); (Found: C, 63.4; H, 7.9; N, 13.5%. C11H16N2S requires C,
63.4; H, 7.7; N, 13.4%); νmax(nujol)/cm-1 3424 (NH), 1638 (C=C), 1535; δH (300 MHz,
d6-DMSO) 2.83 (2H, t, J 7, CH2-2), 3.12 (6H, s, 2×CH3), 3.60-3.67 (2H, m, CH2-1), 7.15-7.23
(3H, m, H-2’, 4’, 6’), 7.25-7.32 (2H, m, H-3’, 5’), 7.46 (1H, t, J 5 Hz, NH); δC (75.46 MHz,
d6-DMSO) 35.0 (C-2), 40.1 (CH3), 46.8 (C-1), 126.0 (C-4’), 128.3 (C-2’, 6’), 128.6 (C-3’, 5’), 139.6
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(C-1’), 181.1 (C=S); m/z (ES+) 209 ((M+H)+, 100%), 231 (7), 247 (40); m/z (ES-) 207 ((M-H)-,
100%);
Synthesis of N,N-dimethyl-N’-phenethyl-S-methylsulfonium iodide (125)
N,N-Dimethyl-N’-phenethylthiourea (123) (1.53 g, 7.4 mmol) was dissolved in acetonitrile
(30 ml) and then iodomethane (2.09 g, 14.7 mmol) was added dropwise. The reaction mixture
was stirred under an argon atmosphere overnight. The solvent was removed at reduced pressure
and trapped solvent was treated with bleach. The residue was partitioned between water (20 ml)
and CH2Cl2 (2 × 20 ml), the organic layer was washed with aq. NaHCO3 (30 ml) and dried over
MgSO4. Removal of solvent at reduced pressure gave the final product (125) as pale yellow
crystals (1.56 g, 61%). mp 66-67 ºC; δH (500 MHz, CDCl3) 2.26 (3H, s, CH3), 3.17 (2H, t, J 7 Hz,
CH2-2), 3.41 (6H, s, 2×CH3), 3.99 (2H, dt, J 6 Hz, J 7 Hz, CH2-1), 7.18-7.31 (5H, m, Ar-H ),
10.00 (1H, br t, J 6 Hz, NH); δC (125.7 MHz, CDCl3) 17.0 (S–CH3), 36.3 (C-2), 43.8 (CH3), 49.1
(C-1), 53.5 (CH3), 126.9 (C-4’), 128.7 (C-2’, 6’), 129.3 (C-3’, 5’), 137.5 (C-1’), 168.1 (C=S–CH3);
m/z (ES+) 223.1268 ((M)+. C12H19N2S requires 223.1269).
Attempted synthesis of N,N-dimethyl-N’-phenethyl-N”-hydroxyguanidine (122)
N,N-Dimethyl-N’-phenethyl-S-methylsulfonium iodide (125) (2.13 g, 6.1 mmol), hydroxylamine
hydrochloride (0.42 g, 6.1 mmol) and triethylamine (2.53 g, 18.24 mmol) were dissolved in
CH3CN (40 ml) and cooled to 0 ºC. Then AgNO3 (1.14 g, 6.7 mmol) was dissolved in CH3CN
(5ml) and added dropwise to the reaction mixture which was stirred at 0 ºC for 3 hours. Then
the suspension was filtered through celite to remove the grey-black silver salts. The filtrate was
concentrated and residue dissolved in ethyl acetate (30 ml). The organic layer was washed with
1M H3PO4 (2 × 30 ml) and brine (30 ml), then dried over MgSO4 and concentrated at reduced
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pressure to give a brown oil. The addition of diethyl ether caused precipitation and the
colourless solid was filtered off and recrystallized from diethyl ether. However, the synthesized
product according to results of 1H, 13C NMR, mass spectrometry, elemental analysis and X-ray
was N,N-dimethyl-N’-phenethyl urea (126) (453 mg, 21%). mp 95-96 ºC, (lit.15, 98 ºC); The rest
of data are the same as below.
Synthesis of N,N-dimethyl-N’-phenethyl urea (126)15
To a solution of phenylethylamine (11.17 g, 70.9 mmol) and triethylamine (19.75 ml,
141.7 mmol) in CH2Cl2 (100 ml) was added dropwise dimethylcarbamoyl chloride (6.51 ml,
70.9 mmol). The reaction mixture was stirred for about 6 h and then it was washed with water
(3 × 40 ml). The organic layer was dried over Na2SO4 and the solvent was removed under
reduced pressure to give a desired product (126) as pale yellow crystals (11.45 g, 84%).
mp 98-99 ºC, (lit.15, 98 ºC); δH (300 MHz, d6-DMSO) 2.70 (2H, t, J 7 Hz, CH2-2), 2.76 (6H, s,
2×CH3), 3.16-3.25 (2H, m, CH2-1), 6.36 (1H, br t, J 6 Hz, NH), 7.15-7.21 (3H, m, H-2’, 4’, 5’),
7.24-7.32 (2H, m, 3’, 6’); δC (75.46 MHz, d6-DMSO) 35.8 (CH3), 36.2 (C-2), 42.0 (C-1), 125.9
(C-4’), 128.2 (C-2’, 6’), 128.6 (C-3’, 5’), 139.9 (C-1’), 158.1 (C=O).
Synthesis of N-methyl-N’-phenethyl urea (129)16
To a solution of phenylethyl isocyanate (4.7 g, 32 mmol) in dry THF (60 ml) was added
dropwise a 2M solution of methylamine in methanol (16 ml, 32 mmol). The reaction mixture
was stirred for about 12 h and the solvents were removed under reduced pressure. The residue
was recrystallized from petroleum ether and CH2Cl2 to give a final product (129) as pale yellow
solid (4.45 g, 78%). mp 70-72 ºC; (Found: C, 67.6; H, 7.9; N, 15.8%. C10H14N2O requires C, 67.4;
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H, 7.9; N, 15.7%); δH (300 MHz, CDCl3) 2.61 (3H, br s, CH3), 2.70 (2H, t, J 7 Hz, CH2-2), 3.32
(2H, t, J 7Hz, CH2-1), 4.78 (2H, br s, 2×NH), 7.06-7.16 (3H, m, H-2’, 4’, 5’), 7.17-7.25 (2H, m,
3’, 6’); δC (75.46 MHz, CDCl3) 27.0 (CH3), 36.5 (C-2), 41.7 (C-1), 126.4 (C-4’), 128.6 (C-2’, 6’),
128.8 (C-3’, 5’), 139.2 (C-1’), 159.4 (C=O).
Synthesis of O-Tetrahydropyranyl-N-hydroxyphtalimide (181)17
N
O
O
O
O
1
2
3
4 5
6
N-Hydroxyphthalimide (6.24 g, 38.2 mmol) was dissolved in dry CH2Cl2 (100 ml). Then,
3,4-dihydropyran (5.23 ml, 57.4 mmol) and pyridinium-p-toluenosulfonate (0.46 g, 3.82 mmol)
were added. The reaction was left to stir for 17 h under an argon atmosphere. The reaction
mixture was then diluted with diethyl ether (500 ml) and washed with brine (3 × 200 ml). The
organic layer was dried over MgSO4. Removal of the solvent at reduced pressure yielded a
colourless solid which was recrystallized from ethyl acetate to give a final product (181) as a
colourless solid (5.37 g, 60%). mp 122-124 ºC (lit.17, 123 ºC); δH (300 MHz, CDCl3) 1.58-2.18
(6H, m, CH2-3,4,5), 3.61-3.70 (1H, m, H-6a), 4.45-4.57 (1H, m, H-6b), 5.39-5.43 (1H, m, CH2-2),
7.69-7.76 (2H, m, H-3’, 4’), 7.78-7.86 (2H, m, H-2’, 5’); δC (75.46 MHz, CDCl3) 17.6 (C-4), 24.8
(C-5), 27.7 (C-3), 62.3 (C-6), 103.1 (C-2), 123.4 (C-2’, 5’), 129.1 (C-3’, 4’), 134.3 (C-1’, 6’), 163.8
(C=O); m/z (ES+) 270 ((M+Na)+, 100%).
Synthesis of O-Tetrahydropyranylhydroxylamine (182)
O-Tetrahydropyranyl-N-hydroxyphthalimide (181) (5.37 g, 21.7 mmol) was dissolved in ethanol
(300 ml) and hydrazine hydrate (1.06 ml, 21.7 mmol) was added. The reaction mixture was
heated under reflux for 5 h and then cooled to room temperature. The by-product was removed
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by filtration and the filtrate concentrated under reduced pressure to give off-white solid to which
another portion of ethanol (50 ml) was added. The by-product was filtrated off and the removal
of solvent gave a yellow residue, which was then distilled under reduced pressure using
Kugelrohr apparatus to give the final product (182) as colourless oil (1.71 g, 50 %). δH (300 MHz,
d6-DMSO) 1.53-1.71 (2H, m, CH2-3), 1.36-1.53 (4H, m, CH2-4,5), 3.38-3.45 (1H, m, H-6a),
3.71-3.81 (1H, m, H-6b), 4.54-4.58 (1H, m, H-2), 5.98 (2H, br s, NH2); δC (75.46 MHz,
d6-DMSO) 19.4 (C-4), 24.8 (C-5), 28.5 (C-3), 61.6 (C-6), 101.5 (C-2); m/z (ES+), 140.0687
((M+Na)+. C5H11NO2Na requires 140.0686); m/z (ES
+) 140 (100%).
Synthesis of N,N-dimethyl-N’-phenethyl-
N”-O-tetrahydropyranylhydroxyguanidine (128)
N,N-Dimethyl-N’-phenethyl urea (126) (5.67 g, 29.5 mmol) was dissolved in dry toluene
(150 ml) and cooled to -22 ºC. Then, a 1.93 M solution of COCl2 in toluene (15.29 ml,
29.5 mmol) was added at such rate to maintain the temperature at -22 ºC. The reaction mixture
was stirred at -22 ºC for 6 h and then left so as to stir at room temperature for another 14 h. The
intermediate C-chloroformamidinium chloride (127) was formed as a white, moisture-sensitive
solid and was used for next step without characterization. The toluene was decanted off and the
solid was redissolved in dry CH2Cl2 (35 ml). The solution was then added dropwise to a cool
(-22 ºC) solution of O-tetrahydropyranylhydroxylamine (3.51 g, 29.5 mmol) and triethylamine
(8.23 ml, 59.0 mmol) in dry CH2Cl2 (10 ml). The reaction mixture was warmed to the room
temperature and stirred for another 4 h. Then, more CH2Cl2 (40 ml) was added and the organic
layer was washed with water (6 × 40 ml) and dried over MgSO4. After removal of the solvent at
reduced pressure, the residue was purified by column chromatography on silica using ethyl
acetate/diethyl ether (3:1) as the eluting solvent. This gave the desired product (128) as a
colourless oil (3.09 g, 36%). δH (400 MHz, CDCl3) 1.42-1.61 (4H, m, CH2-4”, 5”), 1.65-1.80 (2H,
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m, CH2-3”), 2.68 (6H, s, 2 × CH3), 2.81 (2H, t, J 7 Hz, CH2-1), 3.25-3.99 (2H, m, CH2-2),
3.51-3.58 (1H, m, H-6”a), 3.77-3.84 (1H, m, H-6”b), 4.76 (1H, br s, NH), 4.97-5.00 (1H, m,
H-2”), 7.19-7.33 (5H, m, Ar-H); δC (100 MHz, CDCl3) 20.4 (C-4”), 25.3 (C-5”), 29.4 (C-3”), 37.0
(C-1), 39.7 (CH3), 45.2 (C-2), 63.3 (C-6”), 100.8 (C-2”), 126.5 (C-4’), 128.6 (C-2’, 6’), 128.9 (C-3’,
5’), 138.9 (C-1’), 160.8 (C=N); m/z (ES+) 292.2023 ((M+H)+. C16H26N3O2 requires 292.2025);
m/z (ES-) 207 (100%).
Synthesis of N,N-dimethyl-N’-phenethyl-N”-hydroxyguanidine hydrochloride (122)
N,N-Dimethyl-N’-phenethyl-N”-O-tetrahydropyranylhydroxyguanidine (128) (1.00 g, 3.4 mmol)
was dissolved in 1,4-dioxane (5 ml) and water (1 ml) and then a 4M HCl solution in 1,4-dioxane
(8.6 ml, 34.3 mmol) was added. The reaction mixture was heated under reflux for 4 h. After
cooling, the solvent was removed at reduced pressure and the residue was extracted between
CH2Cl2 (25 ml) and H2O (25 ml). Removal of water at reduced pressure yielded a brown oil,
which was dissolved in the minimum amount of CH3CN and crystallized from EtOAc/Et2O to
give the final product (122) as pale pink crystals (71 mg, 73%). mp 122-123 ºC; νmax(KBr)/cm-1
3198, 3089, 2853 (NH), 1869, 1641, 1571 (C=C); (Found: C, 54.3; H, 7.6; N, 17.0%.
C11H18ClN3O requires C, 54.2; H, 7.4; N, 17.2%); δH (300 MHz, d6-DMSO) 2.82 (6H, s, 2 ×
CH3), 2.85 (2H, t, J 7 Hz, CH2-2), 3.47 (2H, dt, J 7 Hz, CH2-1), 7.17-7.33 (5H, m, Ar-H), 7.76
(1H, t, J 6 Hz, NH), 10.19 (1H, s, NH/OH), 10.69 (1H, br s, NH/OH); δC (75.46 MHz,
d6-DMSO) 35.6 (C-2), 39.2 (CH3), 45.3 (C-1), 126.8 (C-4’), 128.8 (C-3’, 5’), 129.3 (C-2’, 6’), 138.9
(C-1’), 158.9 (C=NOH); m/z (ES+) 207 (100%).
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Synthesis of N-methyl-N’-phenethylthiourea (131)18
Phenylethyl isothiocyante (2.5 g, 15.3 mmol) was dissolved in methanol (25 ml), and then an
aqueous solution of methylamine (11.95 ml, 15.3 mmol, 40%) was added. The solution was
allowed to stir overnight at room temperature. The solvent was removed at reduced pressure.
Addition of cold water caused precipitation and the crude product was filtered off. Pure
N-methyl-N’-phenethyl thiourea (131) was obtained by crystallization from cold water/methanol
(9:1) as a colourless solid (2.67 g, 90%). mp 62-64 ºC, (lit.18, 66-67 ºC); (Found: C, 61.7; H, 7.8;
N, 14.5%. C10H14N2S requires C, 61.8; H, 7.3; N, 14.4%); νmax(nujol)/cm-1 3400, 3214 (NH),
1638, 1560; δH (300 MHz, CDCl3) 2.89 (3H, s, CH3), 2.95 (2H, t, J 7 Hz, CH2-2), 3.78 (2H, t, J 7
Hz, CH2-1), 7.20-7.30 (3H, m, H-2’, 4’, 6’), 7.30-7.38 (2H, m, H-3’, 5’); δC (75.46 MHz, CDCl3)
30.4 (CH3), 35.2 (C-2), 45.7 (C-1), 126.8 (C-4’), 128.8 (C-2’, 6’), 128.9 (C-3’, 5’), 138.3 (C-1’),
182.4 (C=S); m/z (ES+) 217 ((M+Na)+, 100%).
Synthesis of N-methyl-N’-phenethyl-S-methylsulfonium iodide (134)
N-Methyl-N’-phenethylthiourea (131) (5.04 g, 26.0 mmol) was dissolved in dry acetonitrile
(150 ml) and then iodomethane (7.37 g, 51.9 mmol) was added drop wise. The reaction mixture
was stirred under an argon atmosphere overnight. The solvent was removed at reduced pressure
and trapped solvent was treated with bleach. The residue was partitioned between water (80 ml)
and CH2Cl2 (2 × 60 ml), the organic layer was washed with aq. NaHCO3 (60 ml) and dried over
MgSO4. Removal of solvent at reduced pressure led to the final product (134) as pale yellow low
melting crystals (6.05 g, 70%). δH (300 MHz, CDCl3) 2.52 (3H, s, CH3), 2.97 (2H, t, J 7 Hz,
CH2-2), 3.04 (3H, br s, CH3), 3.67 (2H, t, J 7 Hz, CH2-1), 6.28 (1H, br s, NH), 7.16-7.31 (5H, m,
Ar-H ); δC (75.46 MHz, CDCl3) 15.6 (SCH3), 33.1 (CH3), 36.3 (C-2), 47.4 (C-1), 127.1 (C-4’),
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129.0 (C-2’, 6’), 129.4 (C-3’, 5’), 138.8 (C-1’), 162.1 (C=S); m/z (ES+) 209.1112 ((M)+. C11H17N2S
requires 209.1115).
Synthesis of N-methyl-N’-phenylethylaminomethane sulfonic acid (132)
Peracetic acid was prepared by slowly adding acetic anhydride (25 ml, 266 mmol) to 30% H2O2
(22.5 ml, 625 mmol) cooled in an ice bath. The addition of two drops of concentrated H2SO4
caused a violent reaction. After the reaction was completed, acetic anhydride (55 ml, 582 mmol)
was slowly added to the cooled mixture. The mixture was left to stand for one day. A cooled
solution of N-methyl-N’-phenethyl thiourea (131) (1.10 g, 5.7 mmol) in CH2Cl2 (50 ml) was
added to the freshly prepared peracetic acid (3 equiv.) at such a rate so as to maintain the
temperature of the reaction at 2-5 ºC. The mixture was then warmed to room temperature and
left overnight. The yellow solid was filtered off and recrystallized from EtOH to give the final
product (132) as colourless crystals (342 mg, 25%). mp 203-204 ºC; (Found: C, 49.3; H, 5.6;
N, 11.5%. C10H14N2O3S requires C, 49.6; H, 5.8; N, 11.6%); νmax(PTFE card)/cm-1 1273s (SO3H),
m/z (ES+) 265 ((M+Na)+, 100%).
The NMR data showed the presence of two geometric isomers:
δH (300 MHz, d6-DMSO)*
Protons δH 132a (66%) δH 132b (34%)
-CH3 2.82 (3H, d, J 6 Hz) 3.17 (3H, d, J 6 Hz)
H-1 3.84-3.90 (2H, m) 3.43-3.50 (2H, m)
H-2 2.86-2.95 (2H, m) 2.86-2.95 (2H, m)
-NH+ 9.07 (1H, t, J 6 Hz) 9.26 (1H, t, J 6 Hz)
-NHCH3 9.36-9.41 (1H, m) 9.10-9.14 (1H, m)
Aromatic 7.19-7.35 (5H, m) 7.19-7.35 (5H, m)
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δC (75.46 MHz, d6-DMSO)*
Carbons δC 132a (66%) δC 132b (34%)
-CH3 31.4 29.3
C-1 46.1 43.2
C-2 36.1 33.2
C-1’ 138.5 138.3
C-2’, 6’ 128.9 128.7
C-3’, 5’ 129.1 129.0
C-4’ 126.8 126.8
C–SO3- 164.5 163.8
* The data are supported by 1H-1H COSY, 1H-13C HMBC and 1D gs-NOESY experiments, which also
established the configuration and ratio of two isomers.
Synthesis of N-phenylethylaminomethane sulfonic acid (137)
Peracetic acid was prepared by slowly adding acetic anhydride (25 ml, 266 mmol) to 30% H2O2
(22.5 ml, 625 mmol) cooled in an ice bath. The addition of two drops of concentrated H2SO4
caused a violent reaction. After the reaction was completed, acetic anhydride (55 ml, 582 mmol)
was slowly added to the cooled mixture. The mixture was left to stand for one day. A cooled
solution of N-phenethyl thiourea (1.02 g, 5.7 mmol) in MeOH (51 ml) was added to the freshly
prepared peracetic acid (3 equiv.) at such a rate so as to maintain the temperature of the reaction
at 2-5 ºC. The mixture was then warmed to room temperature and left overnight. The yellow
solid was filtered off and recrystallized from EtOH to give the final product (137) as colourless
crystals (0.98, 76%). mp 135-137 ºC ; (Found: C, 47.7; H, 5.40; N, 12.1%. C9H12N2O3S requires
C, 47.4; H, 5.30; N, 12.3 %); νmax(nujol)/cm-1 3100 (NH), 1250 (R-SO3-); δH (300 MHz,
d6-DMSO) 2.82 (2H, d, J 7 Hz, CH2-2), 3.41-3.50 (2H, m, CH2-1), 7.18-7.33 (5H, m, Ar-H), 9.24
(1H, s, NH), 9.26 (1H, s, NH), 9.64 (1H, br t, J 6 Hz, NH); δC (75.46 MHz, d6-DMSO) 33.0
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(C-2), 43.3 (C-1), 126.4(C-4’), 128.3 (C-2’, 6’), 128.8 (C-3’, 5’), 137.9 (C-1’), 165.3 (C-SO3-);
m/z (ES-) 227 (M-H+, 100%).
Synthesis of N-methyl-N’-phenethyl-N”-O-tetrahydropyranylhydroxyguanidine (135)
A solution of N-methyl-N’-phenethyl-S-methylsulfonium iodide (134) (2.00 g, 5.9 mmol),
triethylamine (0.99 ml, 7.1 mmol) and O-tetrahydropyranylhydroxylamine (1.04 g, 8.9 mmol) in
dry acetonitrile (40 ml) was added to a solution of AgNO3 (2.53 g, 14.9 mmol) in dry acetonitrile
(5 ml) at such a rate so as to keep the temperature at 0 ºC. A yellow precipitate was formed. The
reaction mixture was left to stir for 2h in the ice bath. Then, the inorganic solid was filtered
through celite and the filtrate was concentrated under reduced pressure to give a yellow oil. The
residue was purified by flash chromatography on silica gel using a gradient of diethyl ether and
ethyl acetate to afford the final product (135) as a pale yellow oil (343 mg, 21%). δH (400 MHz,
CDCl3) 1.40-1.56 (4H, m, H-4”, 5”, CH2), 1.62-1.75 (2H, m, H-3”, CH2), 2.57 (3H, br d, J 6 Hz,
CH3), 2.77 (2H, t, J 7 Hz, H-1, CH2), 3.20-3.28 (2H, m, H-2, CH2), 3.43-3.51 (1H, m, H-6”, CH),
3.75-3.86 (1H, m, NH), 4.61-4.65 (1H, m, H-2”, CH-minor isomer), 4.67-4.86 (1H, m, H-2”,
CH-major isomer), 7.17-7.30 (5H, m, Ar-H); δC (100 MHz, CDCl3) 19.6, 20.8 (two isomers,
C-4”), 25.3, 25.4 (two isomers, C-5”), 28.5 (CH3), 28.8, 29.7 (C-3”, two isomers), 37.0 (C-1), 42.3
(C-2), 62.5, 63.7 (two isomers, C-6”), 101.0, 102.5 (two isomers, C-2”), 126.5 (C-4’), 128.6 (C-3’,
5’), 128.9 (C-4’, 6’), 138.0 (C-1’), 156.7 (C=N); m/z (ES+), 278.1866 ((M+H)+. C15H23N3O2
requires 278.1869); m/z (ES+) 300 (100%), 278 (53%).
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Synthesis of N-methyl-N’-phenethyl-N”-hydroxyguanidine hydrochloride (121)
N-Methyl-N’-phenethyl-N”-O-tetrahydropyranylhydroxyguanidine (135) (139 mg, 0.5 mmol) was
dissolved in 1,4-dioxane (1 ml) and water ( 0.1 ml) and then a 4M HCl solution in 1,4-dioxane
(1.3 ml, 5.0 mmol) were added. The reaction mixture was heated under reflux for 4 h. After
cooling, the solvent was removed at reduced pressure and residue extracted between CH2Cl2
(10 ml) and H2O (10 ml). The removal of water yielded a brown oil, which was dissolved in the
minimum amount of CH3CN and crystallized from EtOAc/Et2O to give the final product (121)
as an off-white solid (81 mg, 71%). mp 170-171 ºC; δH (400 MHz, d6- DMSO) 2.71 (3H, br,
CH3), 2.83 (2H, t, J 7 Hz, CH2-2), 7.15-7.42 (5H, m, Ar-H), 7.88 (1H, br s, NH), 7.98 (1H, br d, J
6 Hz, NH), 9.91 (1H, s, NH/OH), 10.59 (1H, br s, NH/OH), [CH2-1 overlapped with solvent];
δH (400 MHz, d4-methanol) 2.76 (3H, br, CH3), 2.90 (2H, t, J 7 Hz, CH2-2), 3.43 (2H, br t, J 7
Hz, CH2-1), 7.20-7.27 (3H, m, H-2’, 4’, 6’), 7.29-7.34 (2H, m, H-3’, 5’); δC (75.46 MHz,
d6-DMSO) 27.6 (CH3), 34.4 (C-2), 41.9 (C-1), 126.3 (C-4’), 128.3 (C-3’, 5’), 128.8 (C-2’, 6’), 138.4
(C-1’), 156.9 (C=NOH); m/z (ES+), 194.1300 ((M+H)+. C10H16N3O requires 194.1293); m/z
(ES+) 194 (100%).
Synthesis of 4-phenylbutyrohydroxamic acid (140)19
4-Phenylbutyric acid (2.38 g, 14.5 mmol) and DMF (few drops) were dissolved in CH2Cl2
(100 ml) and cooled to 0 ºC. Oxalyl chloride (4.4 g, 33.6 mmol) was added slowly to the reaction
mixture. After being stirred for 40 minutes, the mixture was added to a solution of
hydroxylamine hydrochloride (3.75 g, 58 mmol) and triethylamine (8.8 g, 87 mmol) in
THF (50 ml)/H2O (10 ml). After being stirred for an additional 30 minutes, the mixture was
poured into 2 M HCl (20 ml) and extracted with CH2Cl2 (2 x 20 ml). The organic phase was dried
over MgSO4 and the solvent was removed at reduced pressure. The residue was washed with
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aq. saturated NaHCO3 (30 ml) and extracted with ethyl acetate (2 x 30 ml). The solvent was
removed at reduced pressure and crude product was purified by flash chromatography on silica,
using diethyl ether/petroleum ether (2:1) as the eluting solvent. The final product (140) was
recrystallized from diethyl ether to give tan yellow crystals (0.28 g, 11%). mp 72-74 ºC
(lit.19, 77.5-79 ºC); (Found: C, 66.6; H, 7.3; N, 7.7%. C10H13NO2 requires C, 67.0; H, 7.1; N,
7.8%); δH (300 MHz, d6-DMSO) 1.73-1.83 (2H, m, CH2-3), 1.97 (2H, t, J 7 Hz, CH2-4) 2.55 (2H,
t, J 7 Hz, CH2-2) 7.15-7.20 (3H, m, H-2’, 4’, 6’) 7.25-7.31 (2H, m, H-3’, 5’) 8.70 (1H, s, NH),
10.37 (1H, s, OH); δC (75.46 MHz, d6-DMSO) 26.9 (C-2), 31.7 (C-1), 34.5 (C-3), 125.7 (C-4’),
128.3 (C-3’, 5’), 129.4 (C-2’, 6’), 141.6 (C-1’), 168.8 (C=O); m/z (ES+) 202 ((M+Na)+, 100%).
Synthesis of methyl phenylacetate (142)20
OCH3
O
Phenylacetic acid (2.67 g, 19.9 mmol) was heated under reflux for 8 h in methanol (10 ml) with a
catalytic amount of concentrated sulfuric acid. After cooling, the solvent was removed at
reduced pressure and the residue was partitioned between CH2Cl2 (30 ml) and H2O (30 ml). The
organic layer was washed with aq. saturated NaHCO3 (2 × 30 ml) and dried over MgSO4. Then
the solvent was removed at reduced pressure to give the pure product (142) as a colourless oil
(2.73 g, 91%). δH (300 MHz, CDCl3) 3.63 (2H, s, CH2-2), 3.70 (3H, s, OCH3), 7.26-7.37 (5H, m,
Ar-H); δC (75.46 MHz, CDCl3) 41.2 (C-2), 52.0 (OCH3), 127.1 (C-4’), 128.6 (C-3’, 5’), 129.3
(C-2’, 6’), 134.0 (C-1’), 172.0 (C=O).
Synthesis of phenylacetohydroxamic acid (138)19
Methyl phenylacetate (142) (1.68 g, 11.2 mmol) in dry methanol (25 ml) was cooled in an ice bath
and a preformed slurry of hydroxylamine hydrochloride (1.56 g, 22.4 mmol) and potassium
hydroxide (2.51 g, 44.8 mmol) in dry methanol (15 ml) was added. The reaction mixture was
stirred under an argon atmosphere overnight and was then acidified to pH 4 with HCl. The
EXPERIMENTAL
239
solvent was removed at reduced pressure to give a colourless solid, which was repeatedly boiled
in ethyl acetate and filtered until the ferrous chloride test was negative confirming that the entire
product had been extracted. The combined filtrate was concentrated under reduced pressure to
give phenylacetohydroxamic acid as a pale pink solid. The crude product was recrystallized from
diethyl ether to give the pure hydroxamic acid (138) as pale pink crystals (0.97 g, 58%).
mp 120-121 ºC (lit.19, 122-123 ºC); (Found: C, 63.7; H, 6.1; N, 9.3%. C8H9NO2 requires C, 63.6;
H, 6.0; N, 9.3%); δH (300 MHz, d6-DMSO) 3.35 (2H, br s, CH2-1), 7.18-7.35 (5H, m, Ar-H), 8.83
(1H, s, NH), 10.65 (1H, s, OH); δC (75.46 MHz, d6-DMSO) 40.3 (C-2), 126.4 (C-4’), 128.1 (C- 3’,
5’), 128.9 (C-2’, 6’), 136.0 (C-1’), 167.0 (C=O), m/z (ES+) 174 ((M+Na)+, 100%); m/z (ES-) 150
((M-H)-, 100%).
Synthesis of methyl 3-phenylpropionate (183)21
Hydrocinnamic acid (5.0 g, 33.3 mmol) was heated under reflux for 8 h in methanol (15 ml) with
a catalytic amount of concentrated sulfuric acid. After cooling, the solvent was removed at
reduced pressure and the residue was partioned between CH2Cl2 (40 ml) and H2O (40 ml). The
organic layer was washed with saturated sodium bicarbonate solution (2 × 40 ml) and dried over
MgSO4. Then the solvent was removed at reduced pressure to give the pure product (183) as a
colourless oil (4.08 g, 74%). δH (300 MHz, CDCl3) 2.67 (2H, t, J 7 Hz, CH2-1), 2.99 (2H, t, J 7
Hz, CH2-2), 3.70 (3H, s, CH3), 7.20-7.36 (5H, m, Ar-H); δC (75.46 MHz, CDCl3) 31.0 (C-2), 35.7
(C-3), 51.6 (CH3), 126.3 (C-4’), 128.3 (C-3’, 5’), 128.5 (C-2’, 6’), 140.5 (C-1’), 173.3 (C=O).
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Synthesis of 3-phenylpropionohydroxamic acid (139)19
A solution of methyl 3-phenylpropionate (183) (3.96 g, 24.1 mmol) in dry methanol (40 ml) was
cooled in an ice bath and a preformed slurry of hydroxylamine hydrochloride (3.35 g,
48.3 mmol) and potassium hydroxide (5.41 g, 96.6 mmol) in dry methanol (30 ml) was added.
The reaction mixture was stirred under an argon atmosphere overnight and was than acidified to
pH 4 with HCl. The solvent was removed at reduced pressure to give a colourless solid, which
was repeatedly boiled in ethyl acetate and filtered until the ferrous chloride test was negative.
The combined filtrates were concentrated under reduced pressure to give a pale pink solid. The
crude product was recrystallized from petroleum ether to give the pure hydroxamic acid (139) as
colourless crystals (2.67 g, 67%). mp 78-79 ºC (lit.19, 79-80 ºC); (Found: C, 65.0; H, 6.7; N, 8.6%.
C9H11NO2 requires C, 65.4; H, 6.7; N, 8.5%); δH (300 MHz, d6-DMSO) 2.25 (2H, t, J 7 Hz,
CH2-1), 2.80 (2H, t, J 7 Hz, CH2-2), 7.12-7.21 (3H, m, H-2’, 4’, 6’), 7.22-7.30 (2H, m, H-3’, 5’),
8.72 (1H, br s, NH), 10.38 (1H, s, OH); δC (75.46 MHz, d6-DMSO) 30.8 (C-2), 33.8 (C-3), 125.9
(C-4’), 128.2 (C-3’, 5’), 128.3 (C-2’, 6’), 141.0 (C-1’), 168.2 (C=O); m/z (ES+), 166 ((M+H)+,
100%), 188 (20).
Synthesis of methyl (4’-trifluoromethylphenyl)acetate (143)
4-(Trifluoromethyl)phenylacetic acid (2.50 g, 12.2 mmol) was heated under reflux for 8 h in
methanol (20 ml) with a catalytic amount of concentrated sulfuric acid. After cooling, the solvent
was removed at reduced pressure and the residue was partitioned between CH2Cl2 (30 ml) and
H2O (30 ml). The organic layer was washed with saturated sodium bicarbonate solution
(2 × 30 ml) and dried over MgSO4. Then the solvent was removed under reduced pressure to
give the pure product (143) as a colourless oil (2.08 g, 78%). δH (300 MHz, CDCl3) 3.69 (2H, s,
CH2), 3.71 (3H, s, CH3), 7.40 (2H, d, J 8 Hz, H-2’, 6’), 7.59 (2H, d, J 8 Hz, H-3’, 5’); δC (75.46
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MHz, CDCl3) 40.9 (C-2), 52.3 (CH3), 125 (C-4’), 128.6 (C-3’, 5’), 129.3 (C-2’, 6’), 137.9 (C-1’),
171.2 (C=O); δF (376.5 MHz, CDCl3), -63.0 (CF3).
Synthesis of 4-(trifluoromethyl)phenylacetohydroxamic acid (141)
Methyl (4’-trifluoromethyl)phenylacetate (143) (2.00 g, 9.20 mmol) in dry methanol (25 ml) was
cooled in an ice bath, and charged with preformed slurry of hydroxylamine hydrochloride (1.27
g, 18.3 mmol) and potassium hydroxide (2.06 g, 36.8 mmol) in dry methanol (15 ml). The
reaction mixture was stirred under an argon atmosphere overnight and then was acidified to pH
4 with HCl. The solvent was removed at reduced pressure to give a colourless solid, which was
repeatedly boiled in ethyl acetate and filtered until the ferrous chloride test was negative
confirming that the entire product had been extracted. The combined filtrate was concentrated
under reduced pressure to give 4-(trifluoromethyl)phenylacetohydroxamic acid as a pale pink
solid. The crude product was recrystallized from diethyl ether to give the pure hydroxamic acid
(141) as pale pink crystals (0.95 g, 47%). mp 138-139 ºC; (Found: C, 49.4; H, 3.4; N, 6.2%.
C9H8F3NO2 requires C, 49.3; H, 3.7; N, 6.4%); νmax(nujol)/cm-1 3201 (NH, OH), 1636 (C=O),
1585 (C=C); δH (400 MHz, d6-DMSO) 3.40 (2H, br s, CH2), 7.48 (2H, d, J Hz, H-2’, 6’), 7.67
(2H, d, J Hz, H-3’, 5’), 8.89 (1H, s, NH), 10.72 (1H, s, OH); δC (75.46 MHz, d6-DMSO) 40.3
(C-2), 125.2 (q, J 4 Hz [13C-19F], C-3’, 5’), 126.5 (q, J 271 Hz [13C-19F], CF3), 127.3 (q, J 32 Hz
[13C-19F], C-4’), 129.7 (C-2’, 6’), 130.5 (C-1’), 166.2 (C=O); δF (376.5 MHz, CDCl3), -61.3 (CF3);
m/z (ES+) 174 ((M+Na)+, 100%); m/z (ES-) 150 ((M-H)-, 100%).
Synthesis of 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide (146)22
45% w/v Hydrogen bromide in acetic acid (60 ml) was added dropwise to D-glucose (39.0 g,
216 mmol) in acetic anhydride (150 ml) at 0 °C under an argon atmosphere. After 4 hours
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further 45% w/v hydrogen bromide in acetic acid (180 ml) was added and the solution stirred at
room temperature overnight. The reaction mixture was taken up in DCM (300 ml) and poured
into ice/water (500 ml). The organic layer was then added carefully to an ice/saturated NaHCO3
solution (600 ml) with stirring. Once the gas evolution became less vigorous the organic phase
was separated and dried over MgSO4. The solvent was removed at reduced pressure to give
a golden oil which solidified upon cooling to 0 °C. The product was recrystallized from diethyl
ether to give 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide (146) as a colourless solid (84.9 g,
96%). mp 87-88 ºC (lit.22, 88-89 ºC); δH (400 MHz, CDCl3) 2.02 (3H, s, CH3), 2.04 (3H, s, CH3),
2.08 (3H, s, CH3), 2.09 (3H, s, CH3), 4.09-4.15 (1H, m, H-5), 4.25-4.35 (2H, m, H6a, 6b), 4.82 (1H,
dd, J 5 Hz, J 10 Hz, H-2), 5.15 (1H, t, J 10 Hz, H-4), 5.54 (1H, t, J 10 Hz, H-3), 6.59 (1H, t, J 5
Hz, H-1); δC (100.6 MHz, CDCl3) 20.54 (CH3), 20.61 (CH3), 20.64 (CH3), 20.65 (CH3), 60.9
(C-6), 67.2 (C-4), 70.2 (C-2), 70.6 (C-3), 72.3 (C-5), 86.6 (C-1), 169.5 (C=O), 169.7 (C=O), 169.8
(C=O), 170.5 (C=O).
Synthesis of O-(tetra-O-acetyl-β-D-glucopyranose)-N-hydroxysuccinimide (147)23
Acetobromoglucose (146) (5.00 g, 12.2 mmol) was dissolved in CH2Cl2 (100 ml) while
N-hydroxysuccinimide (4.90 g, 42.6 mmol) and tetrabutylammonium hydrogen sulfate (4.54 g,
13.4 mmol) were dissolved in 1M Na2CO3 (100 ml). The two solutions were added together and
vigorously stirred at room temperature for 12 h. To the solution more CH2Cl2 (50 ml) was added
and organic phase was washed with distilled water (2 × 70 ml) and brine (50 ml). The organic
extracts were dried over Na2SO4 and evaporated under reduced pressure to give an off-white
solid (147) (2.84 g, 52%). mp 182-184 ºC (lit.23, 182-184 ºC); δH (400 MHz, CDCl3) 2.01 (6H, s,
2×CH3), 2.06 (3H, s, CH3), 2.11 (3H, s, CH3), 2.72 (4H, s, succinimide-CH2), 3.71-3.78 (1H, m,
H-5), 4.14 (1H, dd, J5,6b 3 Hz, J6a,6b 12 Hz, H-6b,), 4.28 (1H, dd, J5,6a 3 Hz, J6a,6b 12 Hz, H-6a), 5.05
(1H, d, J 7 Hz, H-1,), 5.17-5.5.30 (3H, m, H-2, 3, 4); δC (100.6 MHz, CDCl3) 20.57 (CH3), 20.60
(CH3), 20.65 (CH3), 20.73 (CH3), 25.4 (CH2), 61.7 (C-4), 68.1 (C-2), 69.6 (C-3), 72.2 (C-6), 72.4
(C-5), 103.8 (C-1), 169.3 (NC=O), 169.4 (C=O), 170.0 (C=O), 170.1 (C=O), 170.6 (C=O);
m/z (ES+) 468.1127 (M+Na+). C18H23NO12Na requires 468.1118).
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Synthesis of O-(tetra-O-acetyl-β-D-glucopyranose)-N-hydroxyphthalimide (150)24
Acetobromoglucose (146) (10.00 g, 24.3 mmol) was dissolved in CH2Cl2 (200 ml) while
N-hydroxyphthalimide (11.90 g, 73.0 mmol) and tetrabutylammonium hydrogen sulfate (9.08 g,
26.8 mmol) were dissolved in 1M Na2CO3 (200 ml). The two solutions were added together and
vigorously stirred at room temperature for 12 h. To the solution more CH2Cl2 (100 ml) was
added and organic phase was washed with distilled water (2×100 ml) and brine (50 ml). The
organic extracts were dried over Mg2SO4 and concentrated under reduced pressure to give
a colorless oil, which was further purified by the column chromatography (ethyl acetate:
petroleum ether – 2:1) to yield the pure product (150) as a colorless solid (2.72 g, 23%).
mp 160-161 ºC; δH (400 MHz, CDCl3) 2.02 (3H, s, CH3), 2.04 (3H, s, CH3), 2.05 (3H, s, CH3),
2.19 (3H, s, CH3), 3.74-3.80 (1H, m, H-5), 4.13 (1H, dd, J5,6b 3 Hz, J6a,6b 12 Hz, H-6b), 4.34 (1H,
dd, J5,6a 3 Hz, J6a,6b 12 Hz, H-6a), 5.09-5.12 (1H, m, H-1,), 5.20-5.28 (1H, m, H-2), 5.28-5.32 (2H,
m, H-3, 4), 7.75-7.80 (2H, m, H-2’, 5’), 7.83-7.88 (2H, m, H-3’, 4’); δC (100.6 MHz, CDCl3) 20.58
(CH3), 20.62 (CH3), 20.70 (CH3), 61.8 (C-4), 68.1 (C-2), 69.0 (C-3), 72.4 (C-6), 72.5 (C-5), 105.2
(C-1), 123.8 (C-2’, 5’), 128.7 (C-3’, 4’), 134.8 (C-1’, 6’), 162.6 (NC=O), 169.3 (C=O), 169.5
(C=O), 170.2 (C=O), 170.6 (C=O); m/z (ES+) 516.1115 (M+Na+). C22H23NO12Na requires
516.1118).
Synthesis of O-(tetra-O-acetyl-β-D-glucopyranose)hydroxylamine (144)22
Method 1:
O-(Tetra-O-acetyl-β-D-glucopyranose)-N-hydroxysuccinimide (0.76 g, 1.72 mmol) (147) was
stirred in dry THF (10 ml) and dry methanol (5 ml) and hydrazine hydrate (0.17 ml, 3.42 mmol)
was added. The reaction mixture was heated under reflux for 10 minutes and then cooled to
room temperature. The suspension was diluted with aqueous sodium bicarbonate solution
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(5%, 10 ml) and washed with diethyl ether (2 × 15 ml), dried over MgSO4 and concentrated
under reduced pressure to yield a colourless solid (144) (170 mg, 48%). mp 120-121 ºC; δH (400
MHz, CDCl3) 2.00 (3H, s, CH3), 2.03 (3H, s, CH3), 2.07 (3H, s, CH3), 2.10 (3H, s, CH3),
3.72-3.77 (1H, m, H-5), 4.17 (1H, dd, H-6b, J5,6b 3 Hz, J6a,6b 12 Hz), 4.30 (1H, dd, H-6a, J5,6a 3 Hz,
J6a,6b 12 Hz), 4.72 (1H, d, J 8 Hz, H-1), 5.10-5.22 (3H, m, H-2, 3, 4), 5.82 (2H, s, NH2); δC (100.6
MHz, CDCl3) 20.6 (CH3), 20.7 (CH3), 20.8 (CH3), 61.8 (C-4), 68.2 (C-2), 69.6 (C-3), 71.8 (C-6),
72.9 (C-5), 103.4 (C-1), 169.5 (C=O), 170.2 (C=O), 170.7 (C=O); m/z (ES+) 386.1062
((M+Na+). C14H21NO10Na requires 386.1063).
Method 2:
O-(Tetra-O-acetyl-β-D-glucopyranose)-N-hydroxyphthalimide (150) (1.03 g, 2.03 mmol) was
stirred in dry THF (10 ml) and methylhydrazine was added (0.22 ml, 4.05 mmol). The reaction
mixture was heated under reflux for 15 minutes (the progress of the reaction was controlled by
TLC) and then cooled to room temperature. The suspension was diluted with aqueous sodium
bicarbonate solution (5%, 10 ml) and washed with diethyl ether (2 × 15 ml), dried over MgSO4
and concentrated under reduced pressure to yield a colourless solid (144) (0.44 g, 59%).
Analytical data are the same as above.
Synthesis of N-phenyl-2, 2, 2-trifluoroacetimidoyl chloride (158)25
Triphenylphosphine (18.6 g, 71 mmol), triethylamine (4.0 ml, 28 mmol) and trifluoroacetic acid
(1.8 ml, 24 mmol) were dissolved in carbon tetrachloride (12 ml). The solution was stirred for
about 10 minutes in an ice bath. Aniline (2.65 g, 28 mmol) was dissolved in carbon tetrachloride
(12 ml) and added to the reaction mixture. The solution was then heated under reflux for 3 h.
The solvents were removed at reduced pressure and the residue was diluted with hexane (20 ml)
and filtered. The residual solid comprising of Ph3PO, Ph3P and Et3N.HCl, was washed with
hexane several times. The filtrate was concentrated under reduced pressure and the residue was
distilled under reduced pressure using the Kugelrohr apparatus to give the final product (158) as
a pale yellow oil (2.90 g, 59%). δH (400 MHz, CD3Cl) 7.09-7.13 (2H, m, H-2’, 6’), 7.29-7.34 (1H,
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m, H-4’), 7.42-7.47 (2H, m, H-3’, 5’); δC (75.46 MHz, CD3Cl) 115.4 (CF3), 121.0 (C-2’,6’), 127.8
(C-4’), 129.6 (C-3’, 5’), 143.3 (C-1'); δF (400 MHz, CD3Cl) -71.62 (CF3).
Synthesis of 1, 2, 3, 4, 6-penta-O-benzoyl-D-glucopyranoside (156)26
To glucose (20.0 g, 110 mmol) stirring in pyridine (240 ml) for 20 minutes was added benzoyl
chloride (0.67 mol, 80 ml). The dark yellow solution was stirred in an oil bath at 60-65 ºC for an
hour. The resulting suspension was quenched with water (10 ml) and allowed to stir at room
temperature for 10 minutes after which more water (100 ml) was added. The mixture was then
poured into 2 litres of iced water and allowed to stir for an hour. The white precipitate was
filtered and recrystallized repeatedly from acetone/methanol to give the final product (156) as
a colourless solid (48.0 g, 62%). mp 150-151 ºC (lit.26, 172-174 ºC); (Found: C, 70.4; H, 4.6%.
C41H32O11 requires C, 70.3; H, 4.6%); δH (400 MHz, CDCl3) 4.39-4.45 (1H, m, H-5), 4.52 (1H,
dd, J5,6b 4.7 Hz, J6a,6b 12 Hz, H-6b), 4.67 (1H, dd, J5,6a 3 Hz, J6a,6b 12 Hz, H-6a), 5.80-5.88 (2H, m,
H-2, 4), 6.05 (1H, t, J 9.5 Hz, H-3), 6.31 (1H, d, J 8.0 Hz, H-1), 7.27-7.58 (15H, m, Ar-H), 7.80-
8.10 (10H, m, Ar-ortho-H); δC (75.46 MHz, CDCl3) 62.7 (C-6), 69.1 (C-4), 70.9 (C-2), 72.8 (C-3),
73.2 (C-5), 92.7 (C-1), 128.4, 128.5, 128.6 (Ar-ortho), 128.8, 128.7, 129.6 (Ar-quaternary), 129.9,
130.3 (Ar-meta), 133.1, 133.4, 133.5, 133.6, 133.9 (Ar-para), 164.6 (C=O), 165.2 (C=O), 165.7
(C=O), 166.1 (C=O); m/z (ES+) 723 ((M+Na)+, 100%).
Synthesis of 2, 3, 4, 6-tetra-O-benzoyl-D-glucopyranose (157)27
1, 2, 3, 4, 6-Penta-O-benzoyl-D-glucopyranoside (156) (46.0 g, 65.6 mmol), was stirred in DCM
(150 ml) and HBr/HOAc (30%, 30 ml) at room temperature, forming a clear orange solution.
After 3h, the solution was washed with saturated NaHCO3 (2 × 40 ml) and brine (40 ml) and
finally with water (40 ml). The organic layer was dried over MgSO4 and then concentrated under
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reduced pressure to give a yellow oil. The residue solidified to an off-white solid under high
vacuum and was dissolved in acetone (40 ml) and water (2 ml). The solution was treated with
AgCO3 (9.05 g, 32.8 mmol) for 2 h and filtered over celite to give the final product (157) as a
pale-pink solid (37.7 g, 96%). δH (400 MHz, CDCl3) 4.41-4.54 (2H, m, H-3, 4), 4.60-4.74 (2H, m,
H-5, 6b), 5.33 (1H, dd, J5,6a 3 Hz, J6a,6b 12 Hz, H-6a), 5.74-5.80 (1H, m, H-2), 6.24-6.30 (1H, m,
H-1), 7.26-8.20 (20H, m, Ar-H); δC (75.46 MHz, CDCl3) 63.4 (C-6), 68.1 (C-4), 69.9 (C-2), 70.9
(C-3), 72.9 (C-5), 90.9 (C-1), 128.9, 129.3, 129.6 (Ar-ortho, meta), 130.2, 130.3, 130.5
(Ar-quaternary), 133.6, 134.0, 134.0, 134.4 (Ar-para), 165.6 (C=O), 165.8 (C=O), 166.3 (C=O),
166.8 (C=O); m/z (ES+) 619.1569 (M+Na+). C34H28O10Na requires 619.1580).
Synthesis of 2, 3, 4, 6-tetra-O-benzoyl-β-D-glucopyranosyl
1-(N-phenyl)-2, 2, 2-trifluoroacetimidate (159)28
Tetra-O-benzoyl-D-glucopyranose (157) (4.21 g, 7.0 mmol), N-phenyl-2,2,2-trifluoroacetimidoyl
chloride (158) (2.90 g, 14.0 mmol) and potassium carbonate (1.93 g, 14.0 mmol) were suspended
in acetone (100 ml) and stirred for 3 hours. The inorganic salt was filtered off, and the filtrate
was concentrated under reduced pressure. The residue was purified by flash chromatography
using ethyl acetate and petroleum ether (3:1) as an eluting solvent to give final product (159) as
an-off white solid (2.14 g, 40%). mp 78-80 ºC; δH (400 MHz, CDCl3) 4.51 (1H, dd, J5,6b 4.7 Hz,
J6a,6b 12.2 Hz H-6b), 4.60 (1H, br m, H-5), 4.67 (1H, d, J6a,6b 12.2 Hz, H-6a), 5.61 (1H, br d, J 9.7
Hz, H-2), 5.82 (1H, t, J 9.7 Hz, H-4), 6.25 (1H, t, J 9.7 Hz, H-3), 6.43 (2H, br m, Ar-H), 6.83
(1H, br m, H-1), 6.99-8.12 (23H, m, Ar-H); δC (75.46 MHz, CDCl3) 62.4 (C-6), 68.6 (C-4), 70.0
(C-2), 70.5 (C-3), 70.8 (C-5), 119.1 (C-1), 120. 2 (phenyl-ortho), 124.4 (phenyl-para), 128.4, 128.5,
128.6 (Bz-meta), 129.4 (quaternary), 129.5, 129.8, 129.9 (Bz-ortho), 131.9 (phenyl-meta), 133.2,
133.4, 133.6, 133.7 (Bz-para), 142.8 (quaternary), 165.2 (C=O), 165.3 (C=O), 165.7 (C=O), 166.0
(C=O), 171.2 (C=NHPh); m/z (ES+) 790.1876 (M+Na+). C42H32F3NO10Na requires 790.1876).
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Synthesis of methyl 4-amino-3-(hydroxymethyl)benzoate (170)
To a stirred solution of methyl 3-formyl-4-nitrobenzoate (1.05 g, 5.0 mmol) in dry methanol
(40.5 ml), cooled to 0 ºC, was added NiCl2·6H2O (0.12 g, 0.5 mmol). NaBH4 (1.34 g, 35.4 mmol)
was then added in small portions over 1.5 h. The resulting reaction mixture, containing a finely
divided black precipitate, was allowed to warm to room temperature and stirred for further 10 h,
at which point diethylenetriamine (0.6 ml, 5.0 mmol) was added. The mixture was allowed to stir
for 1 h before solvent evaporation. The purple residue was then dissolved in ethyl acetate
(150 ml) and washed with saturated aq. NaHCO3 (2 x 40 ml). The organic layer was dried over
MgSO4 and the solvent was removed at reduced pressure to yield a pale yellow solid (170) (0.51g,
55%). δH (400 MHz, d6-DMSO) 3.73 (3H, s, OCH3), 4.37 (2H, d, J 6 Hz, CH2), 5.11 (1H, t, J 6
Hz, OH), 5.74 (2H, s, NH2), 6.61 (1H, d, J 8 Hz, H-5), 7.57 (1H, dd, J 2 Hz, J 8 Hz, H-6), 7.73
(1H, d, J 2 Hz, H-2); δC (75.46 MHz, d6-DMSO) 56.4 (CH2), 65.5 (CH3), 118.6 (C-5), 121.0 (C-1),
129.5 (C-3), 134.2 (C-2)), 134.7 (C-6), 156.0 (C-4), 171.8 (C=O); m/z (CI) 182 ((M+H)+, 100%);
182.0823 (M+H)+ C9H11NO3 requires 182.0817).
Synthesis of allyl 3-formyl-4-nitrobenzoate (172)
Methyl 3-formyl-4-nitrobenzoate (2.0 g, 9.6 mmol) was dissolved in allyl alcohol (80 ml). After
the addition of dibutyltin oxide (0.24 g, 0.96 mmol) the mixture was heated under reflux for 5 h.
After completion of the reaction, the solution was poured into a saturated sodium bicarbonate
solution (100 ml) and extracted with ethyl acetate (3 × 100 ml). The combined organic layers,
which contained Bu2SnO as a fine white precipitate, where filtered through celite and dried over
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Na2SO4. After removal of solvent at reduced pressure, the product was purified by column
chromatography using diethyl ether and petroleum ether (1:2) as an eluting solvent to give final
product (172) as a pale green solid (1.37 g, 61%). mp 46-47 ºC; (Found: C, 56.1; H, 3.6; N, 5.8%.
C11H9NO5 requires C, 56.2; H, 3.9; N, 6.0%); νmax(nujol)/cm-1 3101, 1722 (C=O), 1690 (C=O),
1650 (NO2), 1586 (C=C); δH (400 MHz, CDCl3) 4.89 (2H, dt, J 1.3 Hz, J 5.8 Hz, allyl CH2), 5.36
(1H, dd, J 1.3 Hz, J 10 Hz, H1), 5.44 (1H, dd, J 1.3 Hz, J 17 Hz, H2), 5.98-6.11 (1H, m, H3), 8.16
(1H, d, J 8 Hz, H-5), 8.41 (1H, dd, J 2 Hz, J 8 Hz, H-6), 8.60 (1H, d, J 2 Hz, H-2), 10.41 (1H, s,
CHO); δC (CDCl3) 66.9 (CH2), 119.7 (CH2=), 124.8 (C-5), 131.1 (CH=), 131.3 (C-6), 134.7 (C-2),
155.7 (C-4), 164.2 (C=O), 187.0 (HC=O); m/z (CI) 236 ((M+H)+, 100%); 236.0557 (M+H)+
C11H9NO5 requires 236.0559).
Synthesis of allyl 4-amino-3-formyl benzoate (174)
Allyl 3-formyl-4-nitrobenzoate (172) (0.56 g, 2.4 mmol), iron powder (1.02 g, 18.4 mmol) and
conc. HCl (2 drops), were added to a mixture of ethanol, acetic acid and water (2:2:1, 25 ml).
The resulting suspension was heated under reflux for 15 minutes and then stirred at 25 °C for 30
minutes. Subsequently, it was filtered, diluted with water (100 ml) and extracted with ethyl
acetate (3 × 100 ml). The organic layer was washed with saturated NaHCO3 (2 × 100 ml) and
water (2 × 100 ml), dried over MgSO4, and concentrated under reduced pressure to give the final
compound (174) as a yellow solid (0.46 g, 94%). mp 78-80 ºC; νmax(nujol)/cm-1 3443, 3336 (NH),
1686, 1655 (C=O), 1618 (C=C); δH (300 MHz, CDCl3) 4.80 (2H, dd, J 1.3 Hz, J 5.8 Hz, allyl
CH2), 5.28 (1H, dd, J 1.3 Hz, J 10 Hz, H1), 5.40 (1H, dd, J 1.3 Hz, J 17 Hz, H2), 5.96-6.11 (1H,
m, H3), 6.59 (2H, s, NH2), 6.65 (1H, d, J 8 Hz, H-5), 7.92-8.00 (1H, m, H-6’), 8.22-8.28 (1H, m,
H-2’), 9.90 (1H, s, CHO); δC (75.46 MHz, d4-methanol) 66.3 (CH2), 116.9 (C-5), 118.3 (C-3),
118.7 (CH2=), 134.0 (C-2), 136.5 (CH=), 140.0 (C-6), 155.6 (C-4), 167.1 (C=O), 195.2 (HC=O);
m/z (ES+) 228 ((M+H)+, 100%), 441 (78); 228.0632 (M+Na)+ C11H11NO3Na requires 228.0637).
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Synthesis of methyl 3-(hydroxymethyl)-4-nitrobenzoate (175)
Methyl 3-formyl-4-nitrobenzoate (3.0 g, 14.3 mmol) was dissolved in dry methanol (100 ml). The
reaction mixture was cooled to 0 °C and NaBH4 (0.81 g, 21.5 mmol) was slowly added over a
period of 20 minutes. The resulting reaction mixture was allowed to warm to room temperature
and then diluted with water (100 ml). The suspension was extracted with DCM (3 x 100 ml). The
combined organic layers were washed with water (2 x 100 ml) and brine (50 ml) and finally dried
over MgSO4. Removal of the solvent at reduced pressure gave a red oil, which solidified under
high vacuum. The crude product was recrystallized from diethyl ether to give the desired
compound (175) as ivory needle crystals (2.15 g, 71%). mp 58-59 ºC; (Found: C, 51.6; H, 4.0;
N, 6.7%. C9H9NO5 requires C, 51.2; H, 4.3; N, 6.6%); νmax(nujol)/cm-1 3259 (OH), 1725 (C=O),
1612, 1589 (C=C); δH (300 MHz, CDCl3) 2.34 (1H, br s, OH), 3.97 (3H, s, CH3), 5.02 (2H, br s,
CH2), 8.10-8.11 (2H, m, H-2,6), 8.42-8.43(1H, m, H-5); δC (75.46 MHz, CDCl3) 53.0 (CH3), 62.2
(CH2), 125.2 (C-5), 129.7 (C-2), 131.2 (C-6), 135.0 (C-3), 137.3 (C-1), 165.4 (C=O); m/z (ES+)
234.0376 (M+Na+). C9H9NO5Na requires 234.0378).
Synthesis of allyl 3-(hydroxymethyl)-4-nitrobenzoate (176)
Methyl 3-(hydroxymethyl)-4-nitrobenzoate (175) (1.65 g, 7.9 mmol) was dissolved in allyl alcohol
(65 ml). After the addition of dibutyltin oxide (0.20 g, 0.79 mmol) the mixture was heated under
reflux for 5 h. After the completion of the reaction the solution was poured into a saturated
sodium bicarbonate solution and extracted with ethyl acetate (3 × 100 ml). The combined
organic layers, which contained Bu2SnO as a fine white precipitate, were filtered through celite
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and dried over Na2SO4. The removal of solvent gave a brown oil, which solidified under high
vacuum. The crude product was recrystallized from diethyl ether to yield the final compound
(176) as pale yellow crystals (1.56 g, 84%). mp 68-70 ºC; (Found: C, 55.5; H, 4.6; N, 6.0%.
C11H11NO5 requires C, 55.7; H, 4.7; N, 5.9%); νmax(nujol)/cm-1 3320 (OH), 1716 (C=O), 1650,
1611, 1588 (C=C); δH (300 MHz, CDCl3) 2.62 (1H, br s, OH), 4.86 (2H, dt, J 1.3 Hz, J 5.8 Hz,
allyl CH2), 5.02 (2H, br s, CH2), 5.33 (1H, dd, J 1.3 Hz, J 10 Hz, H1), 5.43 (1H, dd, J 1.3 Hz, J 17
Hz, H2), 5.95-6.11 (1H, m, H3), 8.09-8.13 (2H, m, H-2, 6), 8.43 (1H, d, J 8 Hz, H-5); δC (75.46
Hz, CDCl3) 62.0 (CH2), 66.5 (CH2), 119.2 (CH2=), 125.0 (C-5), 129.0 (C-2), 129.5 (C-6), 131.0
(CH=), 134.8 (C-3), 137.1 (C-1), 150.0 (C-4), 164.4 (C=O); m/z (ES+) 260.0535 (M+Na+).
C11H11NO5Na requires 260.0535).
Synthesis of allyl 4-amino-3-(hydroxymethyl)benzoate (169)
Method 1:
Allyl 4-amino-3-formylbenzoate (174) (0.20 g, 0.96 mmol) was dissolved in dry methanol (20 ml).
The reaction mixture was cooled to 0 °C and NaBH4 (0.25 g, 6.7 mmol) was slowly added. The
resulting reaction mixture was allowed to warm to room temperature and stirred for further 2 h.
After removal of the solvent, the residue was dissolved in ethyl acetate (50 ml) and extracted
with water (2 x 20 ml). The organic layer was dried over MgSO4 and the solvent was removed at
reduced pressure to yield a yellow oil, which was purified by column chromatography using ethyl
acetate and diethyl ether as an eluting solvent (1:2). The pure product (169) was obtained as a
pale yellow oil (0.10g, 53%). νmax(neat)/cm-1 3371, 3085, 2923 (NH, OH), 2680, 1911, 1694
(C=O), 1505; δH (400 MHz, d4-methanol) 4.57 (2H, s, CH2), 4.73 ( 2H, dt, J 6 Hz, J 1.6 Hz, H1),
5.24 (1H, dd, J 10 Hz, J 1.6 Hz, H2), 5.37 (1H, dd, J 17 Hz, J 1.6 Hz, H3), 5.97-6.09 (1H, m, allyl
CH), 6.70 (1H, d, J 8 Hz, H-5), 7.73 (1H, dd, J 2 Hz, J 8 Hz, H-6), 7.80 (1H, d, J 2 Hz, H-2);
δC (75.46 MHz, d4-methanol) 52.0 (CH), 63.2 (CH2), 65.9, 66.1 (O-CH2), 115.3 (C-5), 117.9 (allyl
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CH2), 118.6 (C-1), 125.1 (C-2), 131.7 (C-6), 131.8 (allyl CH), 134.2 (C-3), 153.1 (C-4), 168.4
(C=O); m/z (CI) 190 ((M-H2O+H)
+, 100%); 208.0976 (M+H)+ C11H14NO3 requires 208.0974).
Method 2:
Allyl 3-(hydroxymethyl)-4-nitrobenzoate (176) (1.04 g, 4.4 mmol), iron powder (1.94 g, 34.0
mmol) and conc. HCl (3 drops), were added to a mixture of ethanol, acetic acid and water
(2:2:1, 50 ml). The resulting suspension was heated under reflux for 15 minutes and then stirred
at 25 °C for 30 minutes. Subsequently, it was filtered, diluted with water (100 ml) and extracted
with ethyl acetate (3 × 100 ml). The organic layer was washed with aq. saturated NaHCO3
(3 × 100 ml) and water (3 × 100 ml), dried over MgSO4, and concentrated under reduced
pressure to give the final compound (169) as a yellow oil (0.91 g, 99%). Analytical data are the
same as above.
Synthesis of L-α-allyl-γ-tert-butyl-N-9-fluorenylmethoxycarbonylglutamate (167)
Fmoc-Glu(OtBu)-OH (12.75 g, 30 mmol) in aqueous methanol (90%, 100 ml) was titrated with a
solution of CsCO3 (5.17 g, 15.7 mmol, 25% in water) to pH 7. The solvents were evaporated at
reduced pressure and coevaporated with toluene (2 × 100 ml). The residue was dried under
vacuum overnight. The cesium salt was suspended in anhydrous DMF (100 ml), cooled to 0 °C,
and treated with allyl bromide (5.2 ml, 60 mmol) by dropwise addition over 20 minutes. After 1
h stirring the reaction mixture was allowed to warm to room temperature and stirring was
continued for a further 10 h. The solvent was removed at reduced pressure and the residue was
partitioned between water (100 ml) and ethyl acetate (3 × 100 ml). The combined organic layers
were dried over MgSO4 and the solvent removed at reduced pressure. The residue was purified
by column chromatography using petroleum ether: diethyl ether (2:1) as a eluting solvent giving
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a pure product as a colourless solid which was recrystallized from diethyl ether to give a final
compound (167) as needle crystals (9.76 g, 75%). mp 79-80 ºC; δH (400 MHz, CDCl3) 1.45
(9H, s, CH3), 1.93-2.03 (1H, m, Glu-β, CH), 2.14-2.25 (1H, m, Glu-β, CH), 2.29-2.37 (2H, m,
Glu-γ, 2×CH), 4.22 (1H, t, J 7 Hz, Fmoc, CH), 4.33-4.55 (3H, m, Glu-α, CH and Fmoc, CH2),
4.65 (2H, d, J 6 Hz, allyl, CH2), 5.26 (1H, dd, J 1.1 Hz, J 10 Hz, allyl, CH), 5.34 (1H, dd, J 1.1 Hz,
J 17 Hz, allyl, CH), 5.48 (1H, d, J 8 Hz, NH), 5.84-5.98 (1H, m, allyl CH), 7.32 (2H, t, J 8 Hz),
7.40 (2H, t, J 8 Hz), 7.57-7.63 (2H, m), 7.76 (2H, d, J 8 Hz); δC (75.46 MHz, CDCl3) 27.6 (CH2),
28.1 (CH3), 31.5 (CH2), 47.2 (Fmoc CH), 53.6 (CH), 66.2 (O-CH2), 67.1 (O-CH2), 80.9 (t-butyl),
119.0 (allyl CH2), 120.0 (C-3), 125.2 (C-4), 127.1 (C-6), 127.7 (C-5), 131.5 (allyl CH), 141.3 (C-7),
143.7 (C-2), 143.9 (C-2), 156.0 (C=O), 171.8 (C=O), 172.1 (C=O).
Synthesis of L-α-allyl-γ-tert-butyl-N-allyloxycarbonylglutamate (168)
To a solution of L-α-allyl-γ-tert-butyl-N-9-fluorenylmethoxycarbonylglutamate (167) (6.22 g,
13.4 mmol) in dry THF (100 ml) was added freshly distilled diethylamine (28 ml, 267 mmol) and
DBU (0.41 ml, 2.7 mmol). The mixture was stirred under an argon atmosphere in darkness for
12 h at room temperature. The solvents were removed under reduced pressure and residue was
taken up in 1,4-dioxane (100 ml) and aqueous Na2CO3 (20%). The reaction mixture was cooled
to 0 °C and allyl chloroformate (2.12 ml, 20.0 mmol) was added dropwise. Then, the resulting
solution was allowed to stir for 2 h at 0 °C before it was diluted with water (100 ml) and
extracted with ethyl acetate (3 × 100 ml). The combined organic layers were washed with water
(2 × 50 ml), brine (50 ml) and dried over MgSO4. The solvent was removed under reduced
pressure to give the crude product as a yellow oil, which was purified using column
chromatography (petroleum ether : diethyl ether-2:1) to yield the final compound (168) as a
colourless oil (2.55 g, 58%). νmax(neat)/cm-1 3346, 3086, 2979, 2936 (NH), 1729 (C=O), 1529
(C=C), 1257, 1154 (COO); δH (400 MHz, CDCl3) 1.43 (9H, s, CH3), 1.89-2.01 (1H, m, Glu-β,
CH), 2.10-2.21 (1H, m, Glu-β, CH), 2.24-2.41 (2H, m, Glu-γ, 2×CH), 4.35-4.43 (1H, m, Glu-α),
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4.56 (2H, d, J 6 Hz, allyl, CH2), 4.64 (2H, dt, J 6 Hz, J 1.1 Hz, allyl, CH), 5.19-5.39 (5H, m, allyl,
2×CH and NH), 5.85-5.96 (2H, m, allyl CH); δC (75.46 MHz, CDCl3) 27.6 (CH2), 28.1 (CH3),
31.5 (CH2), 53.6 (CH), 65.9 (O-CH2), 66.1(O-CH2), 80.9(t-butyl), 117.8 (allyl CH2), 119.0 (allyl
CH2), 131.5 (allyl CH), 132.6 (allyl CH), 167.3 (C=O), 171.7 (C=O), 172.0 (C=O); m/z (ES
+)
350.1580 (M+Na+). C16H25NO6Na requires 350.1577).
Synthesis of allyl N-alloc L-glutamate (166)
L-α-Allyl-γ-tert-butyl-N-allyloxycarbonylglutamate (168) (2.50 g, 7.6 mmol) was treated with TFA
in dry DCM (50:50, 20 ml) at room temperature for 12 h. The solvents were removed at reduced
pressure and the residue was co-evaporated, several times, with toluene to give the product (166)
as a pale yellow oil (2.00 g, 97%). δH (300 MHz, CDCl3) 1.91-2.07 (1H, m, Glu-β, CH), 2.16-2.31
(1H, m, Glu-β, CH), 2.38-2.57 (2H, m, Glu-γ, 2×CH), 4.37-4.49 (1H, m, Glu-α), 4.57 (2H, d, J 6
Hz, allyl, CH2), 4.64 (2H, dt, J 1.3 Hz, J 6 Hz, allyl, CH), 5.18-5.38 (4H, m, allyl, 2×CH), 5.44
(1H, d, J 8 Hz, NH), 5.83-5.99 (2H, m, allyl CH); δC (75.46 MHz, CDCl3) 27.5 (CH2), 29.9 (CH2),
53.6 (CH), 66.0 (O-CH2), 66.3 (O-CH2), 118.0 (allyl CH2), 119.2 (allyl CH2), 131.3 (allyl CH),
132.5 (allyl CH), 155.9 (C=O), 171.9 (C=O), 177.7 (C=O); m/z (ES+) 294.0954 (M+Na+).
C12H17NO6Na requires 294.0950).
EXPERIMENTAL
254
Synthesis of (S)-vinyl 4-(5-(allyloxy)-4-(allyloxycarbonylamino)-5-oxopentanamido)-3-
(hydroxymethyl)benzoate (177)
To a solution of allyl N-alloc L-glutamate (166) (1.28 g, 4.73 mmol) and allyl 4-amino-3-
(hydroxymethyl)benzoate (169) (1.11 g, 5.36 mmol)) in dry DCM (100 ml) was added EEDQ
(1.32 g, 5.36 g). The mixture was stirred under an argon atmosphere at room temperature for 16
h and poured into 1N HCl solution (100 ml). The layers were separated and the aqueous layer
was extracted with DCM (2 × 100 ml). The combined organic layers were washed with water
(2 × 100 ml), brine (50 ml) and dried over MgSO4. After removal of solvent, the crude product
was purified four times by column chromatography with various eluting systems. The first
column was performed using petroleum ether:diethyl ether (1:2) in order to separate the major
product. This was analyzed by 1H NMR spectroscopy and it was still a mixture of more than two
compounds. Therefore, another eluting system (DCM:ethyl acetate, 2:1) was chosen and the
purification was performed again, but still the product was not pure. In order to obtain
reasonably pure material two more chromatography columns were done, finally using pure ethyl
acetate as an eluting solvent. This gave a desired product (177) as a yellow oil (131 mg, 6%).
δH (300 MHz, CDCl3) 1.88-2.05 (1H, m, Glu-β, CH), 2.18-2.29 (1H, m, Glu-β, CH), 2.43-2.53
(2H, m, Glu-γ, 2×CH), 4.36-4.46 (1H, m, Glu-α), 4.51-4.63 (4H, m, allyl, CH2), 4.79 (1H, dt, J
1.3 Hz, J 6 Hz, allyl, CH), 5.17-5.39 (7H, m, allyl, 2×CH), 5.46 (1H, br d, J 8 Hz, NH), 5.82-5.95
(2H, m, allyl CH), 5.96-6.08 (1H, m, allyl CH), 7.04 (1H, br d, J 8 Hz, H-5), 7.90-8.00 (2H, m,
H-2,6); δC (75.46 MHz, CDCl3) 27.5 (CH2), 29.9 (CH2), 58.7 (CH), 60.4 (aromatic O-CH2), 64.1
(O-CH2), 65.4 (O-CH2), 66.9 (O-CH2), 115.2 (C-5), 117.9 (allyl CH2), 118.3 (allyl CH2), 119.3
(allyl CH2), 131.1 (C-2), 131.2 (C-6), 131.3 (allyl CH), 132.5 (allyl CH), 133.7 (allyl CH), 150.3
(C-1), 150.4 (C-4), 155.9 (C=O), 166.4 (C-3), 171.9 (C=O), 173.0 (C=O), 175.8 (C=O); m/z
(ES+) 483 (M+Na+).
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2-(4’-hydroxyphenyl)ethylcyanamide (62)
Crystal data and structure refinement for (62)
Empirical formula C9 H10 N2 O Index ranges
-7<=h<=5, -9<=k<=7,
-7<=l<=11
Formula weight 162.19 Reflections collected 2380
Temperature 93(2) K Independentreflections 796 [R(int) = 0.0437]
Wavelength 0.71073 Å Completeness to theta= 25.00° 94.9 %
Crystal system Monoclinic Absorption correction Multiscan
Space group P2(1) Max. and min.transmission 1.0000 and 0.9445
Unit cell dimensions
a = 5.835(2) Å,
α= 90°
b = 7.606(3) Å,
β=101.066(15)°
c = 9.857(4) Å,
= 90°
Refinement method Full-matrix least-squareson F2
Volume 429.3(3) Å3 Data / restraints /parameters 796 / 3 / 119
Z 2 Goodness-of-fit on F2 1.128
Density (calculated) 1.255 Mg/m3 Final R indices[I>2sigma(I)] R1 = 0.0441, wR2 = 0.1001
Absorption coefficient 0.085 mm-1 R indices (all data) R1 = 0.0571, wR2 = 0.1067
F(000) 172 Absolute structureparameter 0(10)
Crystal size 0.100 x 0.100 x 0.010 mm3 Extinction coefficient 0.024(16)
Theta range for data
collection 3.41 to 25.33°
Largest diff. peak and
hole 0.183 and -0.146 e.Å
-3
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Bond lengths [Å] and angles [°] for (62)
_____________________________________________________
C(1)-C(6) 1.393(5)
C(1)-C(2) 1.395(5)
C(1)-C(7) 1.507(5)
C(2)-C(3) 1.381(5)
C(3)-C(4) 1.386(5)
C(4)-O(4) 1.376(4)
C(4)-C(5) 1.385(5)
C(5)-C(6) 1.382(5)
C(7)-C(8) 1.513(6)
C(8)-N(8) 1.468(5)
N(8)-C(9) 1.315(5)
C(9)-N(9) 1.148(5)
C(6)-C(1)-C(2) 117.7(3)
C(6)-C(1)-C(7) 121.9(3)
C(2)-C(1)-C(7) 120.4(3)
C(3)-C(2)-C(1) 121.3(3)
C(2)-C(3)-C(4) 119.9(3)
O(4)-C(4)-C(5) 117.8(3)
O(4)-C(4)-C(3) 122.3(3)
C(5)-C(4)-C(3) 119.9(3)
C(6)-C(5)-C(4) 119.7(3)
C(5)-C(6)-C(1) 121.5(3)
C(1)-C(7)-C(8) 114.3(3)
N(8)-C(8)-C(7) 113.1(3)
C(9)-N(8)-C(8) 120.3(3)
N(9)-C(9)-N(8) 178.0(4)
_____________________________________________________________
Torsion angles [°] for (62)
________________________________________________________________
C(6)-C(1)-C(2)-C(3) -0.4(5)
C(7)-C(1)-C(2)-C(3) 179.8(3)
C(1)-C(2)-C(3)-C(4) 0.7(5)
C(2)-C(3)-C(4)-O(4) 179.5(3)
C(2)-C(3)-C(4)-C(5) -0.7(5)
O(4)-C(4)-C(5)-C(6) -179.9(3)
C(3)-C(4)-C(5)-C(6) 0.3(6)
C(4)-C(5)-C(6)-C(1) 0.0(5)
C(2)-C(1)-C(6)-C(5) 0.0(5)
C(7)-C(1)-C(6)-C(5) 179.7(3)
C(6)-C(1)-C(7)-C(8) -106.7(4)
C(2)-C(1)-C(7)-C(8) 73.1(4)
C(1)-C(7)-C(8)-N(8) 60.5(4)
C(7)-C(8)-N(8)-C(9) 62.7(4)
C(8)-N(8)-C(9)-N(9) 90(11)
________________________________________________________________
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N-2-(3’-methoxyphenyl)ethyl-N’-hydroxyguanidine hydrochloride (78)
Crystal data and structure refinement for (78)
Empirical formula C10H16ClN3O2 Index ranges
-8<=h<=8, -14<=k<=9, -
32<=l<=35
Formula weight 245.71 Reflections collected 15862
Temperature 93(2) K Independentreflections 7649 [R(int) = 0.0572]
Wavelength 0.71073 Å Completeness to theta= 25.00° 99.8 %
Crystal system Monoclinic Absorption correction Multiscan
Space group Pc Max. and min.transmission 1.0000 and 0.8204
Unit cell dimensions
a = 6.8502(16) Å,
α= 90°
b = 12.383(3) Å,
β= 95.292(7)°
c = 29.607(7) Å,
γ= 90°
Refinement method Full-matrix least-squareson F2
Volume 2500.7(10) Å3 Data / restraints /parameters 7649 / 22 / 618
Z 8 Goodness-of-fit on F2 1.054
Density (calculated) 1.305 Mg/m3 Final R indices[I>2sigma(I)] R1 = 0.0722, wR2 = 0.1574
Absorption coefficient 0.296 mm-1 R indices (all data) R1 = 0.1039, wR2 = 0.1890
F(000) 1040 Absolute structureparameter 0.01(12)
Crystal size 0.1000 x 0.0300 x 0.0100mm3 Extinction coefficient N/A
Theta range for data
collection 1.64 to 25.35°
Largest diff. peak and
hole 0.943 and -0.445 e.Å
-3
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Bond lengths [Å] and angles [°] for (78)
_____________________________________________________
C(1)-C(6) 1.405(4)
C(1)-C(2) 1.407(4)
C(1)-C(7) 1.548(4)
C(2)-C(3) 1.370(4)
C(2)-H(2A) 0.9500
C(3)-O(3) 1.348(3)
C(3)-C(4) 1.424(4)
O(3)-C(10) 1.432(4)
C(4)-C(5) 1.408(5)
C(4)-H(4A) 0.9500
C(5)-C(6) 1.323(4)
C(5)-H(5A) 0.9500
C(6)-H(6A) 0.9500
C(7)-C(8) 1.547(4)
C(7)-H(7A) 0.9900
C(7)-H(7B) 0.9900
C(8)-N(8) 1.458(3)
C(8)-H(8A) 0.9900
C(8)-H(8B) 0.9900
N(8)-C(9) 1.333(3)
N(8)-H(8N) 0.9800(8)
C(9)-N(9) 1.343(3)
C(9)-N(10) 1.375(3)
N(9)-H(9A) 0.9800
N(9)-H(9B) 0.9800
N(10)-O(10) 1.4031(12)
N(10)-H(10N) 0.9800(8)
O(10)-H(10O) 0.9800(8)
C(10)-H(10A) 0.9800
C(10)-H(10B) 0.9800
C(10)-H(10C) 0.9800
C(11)-C(12) 1.358(4)
C(11)-C(16) 1.392(4)
C(11)-C(17) 1.474(4)
C(12)-C(13) 1.393(4)
C(12)-H(12A) 0.9500
C(13)-C(14) 1.379(4)
C(13)-O(13) 1.383(4)
O(13)-C(20) 1.418(4)
C(14)-C(15) 1.338(5)
C(14)-H(14A) 0.9500
C(15)-C(16) 1.444(4)
C(15)-H(15A) 0.9500
C(16)-H(16A) 0.9500
C(17)-C(18) 1.518(4)
C(17)-H(17A) 0.9900
C(17)-H(17B) 0.9900
C(18)-N(18) 1.463(3)
C(18)-H(18A) 0.9900
C(18)-H(18B) 0.9900
N(18)-C(19) 1.345(3)
N(18)-H(18N) 0.9800(8)
C(19)-N(19) 1.319(3)
C(19)-N(20) 1.321(3)
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N(19)-H(19A) 0.9800
N(19)-H(19B) 0.9800
N(20)-O(20) 1.4345(11)
N(20)-H(20N) 0.9799(8)
O(20)-H(20O) 0.9800(8)
C(20)-H(20A) 0.9800
C(20)-H(20B) 0.9800
C(20)-H(20C) 0.9800
C(21)-C(22) 1.357(4)
C(21)-C(26) 1.364(4)
C(21)-C(27) 1.491(4)
C(22)-C(23) 1.408(4)
C(22)-H(22A) 0.9500
C(23)-C(24) 1.356(4)
C(23)-O(23) 1.388(3)
O(23)-C(30) 1.432(4)
C(24)-C(25) 1.358(4)
C(24)-H(24A) 0.9500
C(25)-C(26) 1.450(4)
C(25)-H(25A) 0.9500
C(26)-H(26A) 0.9500
C(27)-C(28) 1.534(4)
C(27)-H(27A) 0.9900
C(27)-H(27B) 0.9900
C(28)-N(28) 1.477(3)
C(28)-H(28A) 0.9900
C(28)-H(28B) 0.9900
N(28)-C(29) 1.325(3)
N(28)-H(28N) 0.9800(8)
C(29)-N(29) 1.343(3)
C(29)-N(30) 1.349(3)
N(29)-H(29A) 0.9800
N(29)-H(29B) 0.9800
N(30)-O(30) 1.4467(13)
N(30)-H(30N) 0.9800(8)
O(30)-H(30O) 0.9800(8)
C(30)-H(30A) 0.9800
C(30)-H(30B) 0.9800
C(30)-H(30C) 0.9800
C(31)-C(36) 1.412(4)
C(31)-C(32) 1.413(4)
C(31)-C(37) 1.540(4)
C(32)-C(33) 1.383(3)
C(32)-H(32A) 0.9500
C(33)-O(33) 1.354(3)
C(33)-C(34) 1.426(3)
O(33)-C(40) 1.427(3)
C(34)-C(35) 1.387(4)
C(34)-H(34A) 0.9500
C(35)-C(36) 1.344(4)
C(35)-H(35A) 0.9500
C(36)-H(36A) 0.9500
C(37)-C(38) 1.498(4)
C(37)-H(37A) 0.9900
C(37)-H(37B) 0.9900
C(38)-N(38) 1.478(3)
C(38)-H(38A) 0.9900
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C(38)-H(38B) 0.9900
N(38)-C(39) 1.312(3)
N(38)-H(38N) 0.9800(8)
C(39)-N(39) 1.327(3)
C(39)-N(40) 1.371(2)
N(39)-H(39A) 0.9800
N(39)-H(39B) 0.9800
N(40)-O(40) 1.3961(14)
N(40)-H(40N) 0.9799(8)
O(40)-H(40O) 0.9800(8)
C(40)-H(40A) 0.9800
C(40)-H(40B) 0.9800
C(40)-H(40C) 0.9800
C(6)-C(1)-C(2) 119.5(3)
C(6)-C(1)-C(7) 121.5(3)
C(2)-C(1)-C(7) 118.9(2)
C(3)-C(2)-C(1) 119.6(2)
C(3)-C(2)-H(2A) 120.2
C(1)-C(2)-H(2A) 120.2
O(3)-C(3)-C(2) 124.5(2)
O(3)-C(3)-C(4) 114.3(2)
C(2)-C(3)-C(4) 121.0(3)
C(3)-O(3)-C(10) 116.9(2)
C(5)-C(4)-C(3) 116.5(3)
C(5)-C(4)-H(4A) 121.8
C(3)-C(4)-H(4A) 121.8
C(6)-C(5)-C(4) 123.2(3)
C(6)-C(5)-H(5A) 118.4
C(4)-C(5)-H(5A) 118.4
C(5)-C(6)-C(1) 120.0(3)
C(5)-C(6)-H(6A) 120.0
C(1)-C(6)-H(6A) 120.0
C(8)-C(7)-C(1) 109.7(2)
C(8)-C(7)-H(7A) 109.7
C(1)-C(7)-H(7A) 109.7
C(8)-C(7)-H(7B) 109.7
C(1)-C(7)-H(7B) 109.7
H(7A)-C(7)-H(7B) 108.2
N(8)-C(8)-C(7) 109.1(2)
N(8)-C(8)-H(8A) 109.9
C(7)-C(8)-H(8A) 109.9
N(8)-C(8)-H(8B) 109.9
C(7)-C(8)-H(8B) 109.9
H(8A)-C(8)-H(8B) 108.3
C(9)-N(8)-C(8) 123.12(17)
C(9)-N(8)-H(8N) 118.1(8)
C(8)-N(8)-H(8N) 118.7(7)
N(8)-C(9)-N(9) 123.4(2)
N(8)-C(9)-N(10) 117.90(19)
N(9)-C(9)-N(10) 118.7(2)
C(9)-N(9)-H(9A) 120.0
C(9)-N(9)-H(9B) 120.0
H(9A)-N(9)-H(9B) 120.0
C(9)-N(10)-O(10) 114.29(15)
C(9)-N(10)-H(10N) 104.0(7)
O(10)-N(10)-H(10N) 116.7(6)
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N(10)-O(10)-H(10O) 100.55(11)
O(3)-C(10)-H(10A) 109.5
O(3)-C(10)-H(10B) 109.5
H(10A)-C(10)-H(10B) 109.5
O(3)-C(10)-H(10C) 109.5
H(10A)-C(10)-H(10C) 109.5
H(10B)-C(10)-H(10C) 109.5
C(12)-C(11)-C(16) 118.1(2)
C(12)-C(11)-C(17) 119.7(2)
C(16)-C(11)-C(17) 121.8(3)
C(11)-C(12)-C(13) 122.6(3)
C(11)-C(12)-H(12A) 118.7
C(13)-C(12)-H(12A) 118.7
C(14)-C(13)-O(13) 116.0(3)
C(14)-C(13)-C(12) 118.0(3)
O(13)-C(13)-C(12) 126.0(3)
C(13)-O(13)-C(20) 116.4(2)
C(15)-C(14)-C(13) 123.0(3)
C(15)-C(14)-H(14A) 118.5
C(13)-C(14)-H(14A) 118.5
C(14)-C(15)-C(16) 117.7(3)
C(14)-C(15)-H(15A) 121.1
C(16)-C(15)-H(15A) 121.1
C(11)-C(16)-C(15) 120.5(3)
C(11)-C(16)-H(16A) 119.7
C(15)-C(16)-H(16A) 119.7
C(11)-C(17)-C(18) 112.1(2)
C(11)-C(17)-H(17A) 109.2
C(18)-C(17)-H(17A) 109.2
C(11)-C(17)-H(17B) 109.2
C(18)-C(17)-H(17B) 109.2
H(17A)-C(17)-H(17B) 107.9
N(18)-C(18)-C(17) 109.4(2)
N(18)-C(18)-H(18A) 109.8
C(17)-C(18)-H(18A) 109.8
N(18)-C(18)-H(18B) 109.8
C(17)-C(18)-H(18B) 109.8
H(18A)-C(18)-H(18B) 108.2
C(19)-N(18)-C(18) 124.59(16)
C(19)-N(18)-H(18N) 107.65(18)
C(18)-N(18)-H(18N) 126.56(16)
N(19)-C(19)-N(20) 118.6(2)
N(19)-C(19)-N(18) 121.4(2)
N(20)-C(19)-N(18) 120.0(2)
C(19)-N(19)-H(19A) 120.0
C(19)-N(19)-H(19B) 120.0
H(19A)-N(19)-H(19B) 120.0
C(19)-N(20)-O(20) 113.70(14)
C(19)-N(20)-H(20N) 117.67(18)
O(20)-N(20)-H(20N) 112.18(11)
N(20)-O(20)-H(20O) 114.76(11)
O(13)-C(20)-H(20A) 109.5
O(13)-C(20)-H(20B) 109.5
H(20A)-C(20)-H(20B) 109.5
O(13)-C(20)-H(20C) 109.5
H(20A)-C(20)-H(20C) 109.5
H(20B)-C(20)-H(20C) 109.5
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C(22)-C(21)-C(26) 118.4(2)
C(22)-C(21)-C(27) 120.6(2)
C(26)-C(21)-C(27) 120.8(3)
C(21)-C(22)-C(23) 122.4(3)
C(21)-C(22)-H(22A) 118.8
C(23)-C(22)-H(22A) 118.8
C(24)-C(23)-O(23) 116.6(2)
C(24)-C(23)-C(22) 118.4(3)
O(23)-C(23)-C(22) 125.0(2)
C(23)-O(23)-C(30) 117.2(2)
C(23)-C(24)-C(25) 122.3(3)
C(23)-C(24)-H(24A) 118.8
C(25)-C(24)-H(24A) 118.8
C(24)-C(25)-C(26) 117.6(3)
C(24)-C(25)-H(25A) 121.2
C(26)-C(25)-H(25A) 121.2
C(21)-C(26)-C(25) 120.9(3)
C(21)-C(26)-H(26A) 119.6
C(25)-C(26)-H(26A) 119.6
C(21)-C(27)-C(28) 110.9(2)
C(21)-C(27)-H(27A) 109.5
C(28)-C(27)-H(27A) 109.5
C(21)-C(27)-H(27B) 109.5
C(28)-C(27)-H(27B) 109.5
H(27A)-C(27)-H(27B) 108.0
N(28)-C(28)-C(27) 107.9(2)
N(28)-C(28)-H(28A) 110.1
C(27)-C(28)-H(28A) 110.1
N(28)-C(28)-H(28B) 110.1
C(27)-C(28)-H(28B) 110.1
H(28A)-C(28)-H(28B) 108.4
C(29)-N(28)-C(28) 125.79(16)
C(29)-N(28)-H(28N) 115.6(3)
C(28)-N(28)-H(28N) 117.7(2)
N(28)-C(29)-N(29) 123.1(2)
N(28)-C(29)-N(30) 120.9(2)
N(29)-C(29)-N(30) 115.9(2)
C(29)-N(29)-H(29A) 120.0
C(29)-N(29)-H(29B) 120.0
H(29A)-N(29)-H(29B) 120.0
C(29)-N(30)-O(30) 111.56(14)
C(29)-N(30)-H(30N) 115.43(17)
O(30)-N(30)-H(30N) 105.61(11)
N(30)-O(30)-H(30O) 99.99(12)
O(23)-C(30)-H(30A) 109.5
O(23)-C(30)-H(30B) 109.5
H(30A)-C(30)-H(30B) 109.5
O(23)-C(30)-H(30C) 109.5
H(30A)-C(30)-H(30C) 109.5
H(30B)-C(30)-H(30C) 109.5
C(36)-C(31)-C(32) 119.8(2)
C(36)-C(31)-C(37) 119.4(3)
C(32)-C(31)-C(37) 120.8(2)
C(33)-C(32)-C(31) 119.7(2)
C(33)-C(32)-H(32A) 120.2
C(31)-C(32)-H(32A) 120.2
O(33)-C(33)-C(32) 123.2(2)
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O(33)-C(33)-C(34) 116.7(2)
C(32)-C(33)-C(34) 120.1(2)
C(33)-O(33)-C(40) 118.6(2)
C(35)-C(34)-C(33) 117.7(2)
C(35)-C(34)-H(34A) 121.2
C(33)-C(34)-H(34A) 121.2
C(36)-C(35)-C(34) 123.7(3)
C(36)-C(35)-H(35A) 118.1
C(34)-C(35)-H(35A) 118.1
C(35)-C(36)-C(31) 118.9(3)
C(35)-C(36)-H(36A) 120.5
C(31)-C(36)-H(36A) 120.5
C(38)-C(37)-C(31) 113.3(2)
C(38)-C(37)-H(37A) 108.9
C(31)-C(37)-H(37A) 108.9
C(38)-C(37)-H(37B) 108.9
C(31)-C(37)-H(37B) 108.9
H(37A)-C(37)-H(37B) 107.7
N(38)-C(38)-C(37) 107.9(2)
N(38)-C(38)-H(38A) 110.1
C(37)-C(38)-H(38A) 110.1
N(38)-C(38)-H(38B) 110.1
C(37)-C(38)-H(38B) 110.1
H(38A)-C(38)-H(38B) 108.4
C(39)-N(38)-C(38) 125.30(16)
C(39)-N(38)-H(38N) 108.0(6)
C(38)-N(38)-H(38N) 126.7(6)
N(38)-C(39)-N(39) 124.5(2)
N(38)-C(39)-N(40) 117.9(2)
N(39)-C(39)-N(40) 117.6(2)
C(39)-N(39)-H(39A) 120.0
C(39)-N(39)-H(39B) 120.0
H(39A)-N(39)-H(39B) 120.0
C(39)-N(40)-O(40) 114.64(13)
C(39)-N(40)-H(40N) 95.54(14)
O(40)-N(40)-H(40N) 102.41(15)
N(40)-O(40)-H(40O) 112.59(13)
O(33)-C(40)-H(40A) 109.5
O(33)-C(40)-H(40B) 109.5
H(40A)-C(40)-H(40B) 109.5
O(33)-C(40)-H(40C) 109.5
H(40A)-C(40)-H(40C) 109.5
H(40B)-C(40)-H(40C) 109.5
_____________________________________________________________
Torsion angles [°] for (78)
________________________________________________________________
C(6)-C(1)-C(2)-C(3) 0.9(4)
C(7)-C(1)-C(2)-C(3) -176.8(2)
C(1)-C(2)-C(3)-O(3) 176.8(3)
C(1)-C(2)-C(3)-C(4) 2.4(4)
C(2)-C(3)-O(3)-C(10) -0.5(4)
C(4)-C(3)-O(3)-C(10) 174.3(3)
O(3)-C(3)-C(4)-C(5) 179.9(3)
C(2)-C(3)-C(4)-C(5) -5.2(4)
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C(3)-C(4)-C(5)-C(6) 4.9(5)
C(4)-C(5)-C(6)-C(1) -1.8(5)
C(2)-C(1)-C(6)-C(5) -1.3(4)
C(7)-C(1)-C(6)-C(5) 176.4(3)
C(6)-C(1)-C(7)-C(8) -77.6(3)
C(2)-C(1)-C(7)-C(8) 100.0(3)
C(1)-C(7)-C(8)-N(8) -57.7(3)
C(7)-C(8)-N(8)-C(9) 161.6(2)
C(8)-N(8)-C(9)-N(9) -0.4(3)
C(8)-N(8)-C(9)-N(10) 178.90(19)
N(8)-C(9)-N(10)-O(10) 20.6(2)
N(9)-C(9)-N(10)-O(10) -160.03(16)
C(16)-C(11)-C(12)-C(13) -0.2(4)
C(17)-C(11)-C(12)-C(13) 172.6(3)
C(11)-C(12)-C(13)-C(14) 2.0(4)
C(11)-C(12)-C(13)-O(13) 179.8(3)
C(14)-C(13)-O(13)-C(20) -178.2(3)
C(12)-C(13)-O(13)-C(20) 4.0(4)
O(13)-C(13)-C(14)-C(15) 178.4(3)
C(12)-C(13)-C(14)-C(15) -3.5(5)
C(13)-C(14)-C(15)-C(16) 3.0(5)
C(12)-C(11)-C(16)-C(15) -0.4(4)
C(17)-C(11)-C(16)-C(15) -173.0(3)
C(14)-C(15)-C(16)-C(11) -1.0(5)
C(12)-C(11)-C(17)-C(18) -99.8(3)
C(16)-C(11)-C(17)-C(18) 72.6(4)
C(11)-C(17)-C(18)-N(18) 58.7(3)
C(17)-C(18)-N(18)-C(19) -163.2(2)
C(18)-N(18)-C(19)-N(19) 1.7(3)
C(18)-N(18)-C(19)-N(20) -179.95(19)
N(19)-C(19)-N(20)-O(20) 162.21(16)
N(18)-C(19)-N(20)-O(20) -16.2(2)
C(26)-C(21)-C(22)-C(23) -0.4(4)
C(27)-C(21)-C(22)-C(23) -175.1(3)
C(21)-C(22)-C(23)-C(24) 0.9(4)
C(21)-C(22)-C(23)-O(23) 179.4(3)
C(24)-C(23)-O(23)-C(30) 176.4(3)
C(22)-C(23)-O(23)-C(30) -2.2(4)
O(23)-C(23)-C(24)-C(25) 179.7(3)
C(22)-C(23)-C(24)-C(25) -1.7(4)
C(23)-C(24)-C(25)-C(26) 1.9(4)
C(22)-C(21)-C(26)-C(25) 0.7(4)
C(27)-C(21)-C(26)-C(25) 175.3(3)
C(24)-C(25)-C(26)-C(21) -1.4(4)
C(22)-C(21)-C(27)-C(28) -97.3(3)
C(26)-C(21)-C(27)-C(28) 88.2(3)
C(21)-C(27)-C(28)-N(28) -179.0(2)
C(27)-C(28)-N(28)-C(29) 146.2(2)
C(28)-N(28)-C(29)-N(29) -0.6(4)
C(28)-N(28)-C(29)-N(30) 179.0(2)
N(28)-C(29)-N(30)-O(30) 14.2(3)
N(29)-C(29)-N(30)-O(30) -166.22(17)
C(36)-C(31)-C(32)-C(33) -0.4(4)
C(37)-C(31)-C(32)-C(33) 179.4(2)
C(31)-C(32)-C(33)-O(33) -176.9(2)
C(31)-C(32)-C(33)-C(34) 1.2(4)
C(32)-C(33)-O(33)-C(40) -6.5(4)
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C(34)-C(33)-O(33)-C(40) 175.4(2)
O(33)-C(33)-C(34)-C(35) 176.8(2)
C(32)-C(33)-C(34)-C(35) -1.4(4)
C(33)-C(34)-C(35)-C(36) 0.8(5)
C(34)-C(35)-C(36)-C(31) -0.1(5)
C(32)-C(31)-C(36)-C(35) -0.2(4)
C(37)-C(31)-C(36)-C(35) -179.9(3)
C(36)-C(31)-C(37)-C(38) -82.4(3)
C(32)-C(31)-C(37)-C(38) 97.8(3)
C(31)-C(37)-C(38)-N(38) 177.4(2)
C(37)-C(38)-N(38)-C(39) -151.2(2)
C(38)-N(38)-C(39)-N(39) 4.4(4)
C(38)-N(38)-C(39)-N(40) -178.12(19)
N(38)-C(39)-N(40)-O(40) -13.0(2)
N(39)-C(39)-N(40)-O(40) 164.61(18)
________________________________________________________________
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N-2-(4’-hydroxyphenyl)ethyl-N’-hydroxyguanidine hydrochloride (81)
Crystal data and structure refinement for (81)
Empirical formula C9H14ClN3O2 Index ranges
-6<=h<=6, -8<=k<=8,
-32<=l<=30
Formula weight 231.68 Reflections collected 9403
Temperature 93(2) K Independentreflections 3820 [R(int) = 0.1191]
Wavelength 0.71073 Å Completeness to theta= 25.00° 95.6 %
Crystal system Triclinic Absorption correction Multiscan
Space group P-1 Max. and min.transmission 1.0000 and 0.9169
Unit cell dimensions
a = 5.640(6) Å,
α= 90.39(3)°
b = 7.270(8) Å,
β= 95.16(3)°
c = 26.698(14) Å,
γ= 91.24(2)°
Refinement method Full-matrix least-squareson F2
Volume 1090.0(18) Å3 Data / restraints /parameters 3820 / 12 / 306
Z 4 Goodness-of-fit on F2 1.153
Density (calculated) 1.412 Mg/m3 Final R indices[I>2sigma(I)] R1 = 0.1164, wR2 = 0.3084
Absorption coefficient 0.335 mm-1 R indices (all data) R1 = 0.1339, wR2 = 0.3317
F(000) 488 Absolute structureparameter N/A
Crystal size 0.2000 x 0.1000 x 0.0100mm3 Extinction coefficient 0.002(8)
Theta range for data
collection 2.30 to 25.35°
Largest diff. peak and
hole 0.665 and -0.594 e.Å
-3
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Bond lengths [Å] and angles [°] for (81)
_____________________________________________________
C(1)-C(2) 1.374(8)
C(1)-C(6) 1.408(8)
C(1)-C(7) 1.502(7)
C(2)-C(3) 1.392(7)
C(2)-H(2A) 0.9500
C(3)-C(4) 1.376(8)
C(3)-H(3A) 0.9500
C(4)-C(5) 1.361(8)
C(4)-O(4) 1.384(6)
O(4)-H(4O) 0.980(3)
C(5)-C(6) 1.376(7)
C(5)-H(5A) 0.9500
C(6)-H(6A) 0.9500
C(7)-C(8) 1.505(8)
C(7)-H(7A) 0.9900
C(7)-H(7B) 0.9900
C(8)-N(8) 1.450(6)
C(8)-H(8A) 0.9900
C(8)-H(8B) 0.9900
N(8)-C(9) 1.321(7)
N(8)-H(8N) 0.980(3)
C(9)-N(9) 1.338(7)
C(9)-N(10) 1.356(7)
N(9)-H(9A) 0.980(3)
N(9)-H(9B) 0.980(3)
N(10)-O(10) 1.424(6)
N(10)-H(10N) 0.980(3)
O(10)-H(10O) 0.9800
C(11)-C(12) 1.393(8)
C(11)-C(16) 1.395(8)
C(11)-C(17) 1.512(7)
C(12)-C(13) 1.376(7)
C(12)-H(12A) 0.9500
C(13)-C(14) 1.405(8)
C(13)-H(13A) 0.9500
C(14)-O(14) 1.363(6)
C(14)-C(15) 1.375(8)
O(14)-H(14O) 0.980(3)
C(15)-C(16) 1.388(8)
C(15)-H(15A) 0.9500
C(16)-H(16A) 0.9500
C(17)-C(18) 1.523(8)
C(17)-H(17A) 0.9900
C(17)-H(17B) 0.9900
C(18)-N(18) 1.476(6)
C(18)-H(18A) 0.9900
C(18)-H(18B) 0.9900
N(18)-C(19) 1.319(7)
N(18)-H(18N) 0.980(3)
C(19)-N(19) 1.316(7)
C(19)-N(20) 1.360(7)
N(19)-H(19A) 0.980(3)
N(19)-H(19B) 0.980(3)
N(20)-O(20) 1.408(6)
N(20)-H(20N) 0.980(3)
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O(20)-H(20O) 0.980(3)
C(2)-C(1)-C(6) 117.1(5)
C(2)-C(1)-C(7) 124.2(5)
C(6)-C(1)-C(7) 118.7(5)
C(1)-C(2)-C(3) 121.7(5)
C(1)-C(2)-H(2A) 119.2
C(3)-C(2)-H(2A) 119.2
C(4)-C(3)-C(2) 119.3(5)
C(4)-C(3)-H(3A) 120.3
C(2)-C(3)-H(3A) 120.3
C(5)-C(4)-C(3) 120.6(5)
C(5)-C(4)-O(4) 118.5(5)
C(3)-C(4)-O(4) 120.9(5)
C(4)-O(4)-H(4O) 115(4)
C(4)-C(5)-C(6) 119.8(5)
C(4)-C(5)-H(5A) 120.1
C(6)-C(5)-H(5A) 120.1
C(5)-C(6)-C(1) 121.4(5)
C(5)-C(6)-H(6A) 119.3
C(1)-C(6)-H(6A) 119.3
C(1)-C(7)-C(8) 113.5(4)
C(1)-C(7)-H(7A) 108.9
C(8)-C(7)-H(7A) 108.9
C(1)-C(7)-H(7B) 108.9
C(8)-C(7)-H(7B) 108.9
H(7A)-C(7)-H(7B) 107.7
N(8)-C(8)-C(7) 113.2(4)
N(8)-C(8)-H(8A) 108.9
C(7)-C(8)-H(8A) 108.9
N(8)-C(8)-H(8B) 108.9
C(7)-C(8)-H(8B) 108.9
H(8A)-C(8)-H(8B) 107.8
C(9)-N(8)-C(8) 124.9(5)
C(9)-N(8)-H(8N) 97(4)
C(8)-N(8)-H(8N) 136(4)
N(8)-C(9)-N(9) 123.2(5)
N(8)-C(9)-N(10) 120.6(5)
N(9)-C(9)-N(10) 116.2(5)
C(9)-N(9)-H(9A) 109(4)
C(9)-N(9)-H(9B) 116(4)
H(9A)-N(9)-H(9B) 134(6)
C(9)-N(10)-O(10) 111.7(4)
C(9)-N(10)-H(10N) 120(4)
O(10)-N(10)-H(10N) 114(4)
N(10)-O(10)-H(10O) 109.5
C(12)-C(11)-C(16) 118.8(5)
C(12)-C(11)-C(17) 121.1(5)
C(16)-C(11)-C(17) 120.0(5)
C(13)-C(12)-C(11) 120.6(5)
C(13)-C(12)-H(12A) 119.7
C(11)-C(12)-H(12A) 119.7
C(12)-C(13)-C(14) 120.1(5)
C(12)-C(13)-H(13A) 120.0
C(14)-C(13)-H(13A) 120.0
O(14)-C(14)-C(15) 118.6(5)
O(14)-C(14)-C(13) 121.6(5)
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C(15)-C(14)-C(13) 119.7(5)
C(14)-O(14)-H(14O) 105(4)
C(14)-C(15)-C(16) 119.9(5)
C(14)-C(15)-H(15A) 120.0
C(16)-C(15)-H(15A) 120.0
C(15)-C(16)-C(11) 120.8(5)
C(15)-C(16)-H(16A) 119.6
C(11)-C(16)-H(16A) 119.6
C(11)-C(17)-C(18) 109.0(5)
C(11)-C(17)-H(17A) 109.9
C(18)-C(17)-H(17A) 109.9
C(11)-C(17)-H(17B) 109.9
C(18)-C(17)-H(17B) 109.9
H(17A)-C(17)-H(17B) 108.3
N(18)-C(18)-C(17) 110.9(5)
N(18)-C(18)-H(18A) 109.5
C(17)-C(18)-H(18A) 109.5
N(18)-C(18)-H(18B) 109.5
C(17)-C(18)-H(18B) 109.5
H(18A)-C(18)-H(18B) 108.1
C(19)-N(18)-C(18) 120.4(5)
C(19)-N(18)-H(18N) 117(4)
C(18)-N(18)-H(18N) 121(4)
N(19)-C(19)-N(18) 121.9(5)
N(19)-C(19)-N(20) 118.3(5)
N(18)-C(19)-N(20) 119.7(5)
C(19)-N(19)-H(19A) 119(4)
C(19)-N(19)-H(19B) 118(4)
H(19A)-N(19)-H(19B) 122(6)
C(19)-N(20)-O(20) 113.2(4)
C(19)-N(20)-H(20N) 111(4)
O(20)-N(20)-H(20N) 119(4)
N(20)-O(20)-H(20O) 94(5)
_____________________________________________________________
Torsion angles [°] for (81)
________________________________________________________________
C(6)-C(1)-C(2)-C(3) 0.8(8)
C(7)-C(1)-C(2)-C(3) -179.1(5)
C(1)-C(2)-C(3)-C(4) 0.4(8)
C(2)-C(3)-C(4)-C(5) -2.0(8)
C(2)-C(3)-C(4)-O(4) 179.8(5)
C(3)-C(4)-C(5)-C(6) 2.3(8)
O(4)-C(4)-C(5)-C(6) -179.4(5)
C(4)-C(5)-C(6)-C(1) -1.1(8)
C(2)-C(1)-C(6)-C(5) -0.5(7)
C(7)-C(1)-C(6)-C(5) 179.4(5)
C(2)-C(1)-C(7)-C(8) 14.9(7)
C(6)-C(1)-C(7)-C(8) -165.0(5)
C(1)-C(7)-C(8)-N(8) 178.1(4)
C(7)-C(8)-N(8)-C(9) -84.4(7)
C(8)-N(8)-C(9)-N(9) -0.2(9)
C(8)-N(8)-C(9)-N(10) -178.8(5)
N(8)-C(9)-N(10)-O(10) -13.7(7)
N(9)-C(9)-N(10)-O(10) 167.7(5)
C(16)-C(11)-C(12)-C(13) -0.4(8)
C(17)-C(11)-C(12)-C(13) 175.2(5)
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C(11)-C(12)-C(13)-C(14) -0.7(8)
C(12)-C(13)-C(14)-O(14) 179.3(5)
C(12)-C(13)-C(14)-C(15) 2.2(8)
O(14)-C(14)-C(15)-C(16) -179.7(5)
C(13)-C(14)-C(15)-C(16) -2.5(8)
C(14)-C(15)-C(16)-C(11) 1.4(8)
C(12)-C(11)-C(16)-C(15) 0.1(8)
C(17)-C(11)-C(16)-C(15) -175.6(5)
C(12)-C(11)-C(17)-C(18) -102.8(6)
C(16)-C(11)-C(17)-C(18) 72.7(7)
C(11)-C(17)-C(18)-N(18) -174.6(5)
C(17)-C(18)-N(18)-C(19) 171.2(5)
C(18)-N(18)-C(19)-N(19) 4.8(8)
C(18)-N(18)-C(19)-N(20) -177.3(5)
N(19)-C(19)-N(20)-O(20) -165.1(5)
N(18)-C(19)-N(20)-O(20) 16.9(7)
________________________________________________________________
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N-2-(3’-aminophenyl)ethyl-N’-hydroxyguanidine dihydrochloride (111)
Crystal data and structure refinement for (111)
Empirical formula C9H16Cl2N4O Index ranges
-16<=h<=14, -
13<=k<=12, -12<=l<=18
Formula weight 267.16 Reflections collected 13265
Temperature 93(2) K Independentreflections 2266 [R(int) = 0.0625]
Wavelength 0.71073 Å Completeness to theta= 25.00° 99.3 %
Crystal system Orthorhombic Absorption correction Multiscan
Space group Pbca Max. and min.transmission 1.0000 and 0.9541
Unit cell dimensions
a = 14.276(3) Å,
α= 90°
b = 11.091(3) Å,
β= 90°
c = 15.796(4) Å,
γ= 90°
Refinement method Full-matrix least-squareson F2
Volume 2501.2(11) Å3 Data / restraints /parameters 2266 / 0 / 149
Z 8 Goodness-of-fit on F2 1.171
Density (calculated) 1.419 Mg/m3 Final R indices[I>2sigma(I)] R1 = 0.0873, wR2 = 0.2595
Absorption coefficient 0.505 mm-1 R indices (all data) R1 = 0.1020, wR2 = 0.2772
F(000) 1120 Absolute structureparameter N/A
Crystal size 0.200 x 0.200 x 0.020 mm3 Extinction coefficient 0.002(2)
Theta range for data
collection 3.39 to 25.35°
Largest diff. peak and
hole 1.804 and -0.663 e.Å
-3
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Bond lengths [Å] and angles [°] for (111)
_____________________________________________________
C(1)-C(6) 1.385(7)
C(1)-C(2) 1.388(7)
C(1)-C(7) 1.505(7)
C(2)-C(3) 1.378(6)
C(2)-H(2A) 0.9500
C(3)-C(4) 1.388(7)
C(3)-N(3) 1.467(6)
N(3)-H(3A) 0.9801
N(3)-H(3B) 0.9801
N(3)-H(3C) 0.9801
C(4)-C(5) 1.380(7)
C(4)-H(4A) 0.9500
C(5)-C(6) 1.376(7)
C(5)-H(5A) 0.9500
C(6)-H(6A) 0.9500
C(7)-C(8) 1.522(7)
C(7)-H(7A) 0.9900
C(7)-H(7B) 0.9900
C(8)-N(8) 1.454(6)
C(8)-H(8A) 0.9900
C(8)-H(8B) 0.9900
N(8)-C(9) 1.310(6)
N(8)-H(8N) 0.9800
C(9)-N(9) 1.311(6)
C(9)-N(10) 1.373(7)
N(9)-H(9A) 0.9800
N(9)-H(9B) 0.9800
N(10)-O(10) 1.325(7)
N(10)-H(10N) 0.9800
O(10)-H(10O) 0.9800
C(6)-C(1)-C(2) 118.1(4)
C(6)-C(1)-C(7) 120.8(4)
C(2)-C(1)-C(7) 121.1(4)
C(3)-C(2)-C(1) 119.7(4)
C(3)-C(2)-H(2A) 120.2
C(1)-C(2)-H(2A) 120.2
C(2)-C(3)-C(4) 122.1(4)
C(2)-C(3)-N(3) 119.1(4)
C(4)-C(3)-N(3) 118.8(4)
C(3)-N(3)-H(3A) 109.5
C(3)-N(3)-H(3B) 109.5
H(3A)-N(3)-H(3B) 109.5
C(3)-N(3)-H(3C) 109.5
H(3A)-N(3)-H(3C) 109.5
H(3B)-N(3)-H(3C) 109.5
C(5)-C(4)-C(3) 118.0(4)
C(5)-C(4)-H(4A) 121.0
C(3)-C(4)-H(4A) 121.0
C(6)-C(5)-C(4) 120.1(4)
C(6)-C(5)-H(5A) 119.9
C(4)-C(5)-H(5A) 119.9
C(5)-C(6)-C(1) 122.0(4)
C(5)-C(6)-H(6A) 119.0
C(1)-C(6)-H(6A) 119.0
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C(1)-C(7)-C(8) 113.9(4)
C(1)-C(7)-H(7A) 108.8
C(8)-C(7)-H(7A) 108.8
C(1)-C(7)-H(7B) 108.8
C(8)-C(7)-H(7B) 108.8
H(7A)-C(7)-H(7B) 107.7
N(8)-C(8)-C(7) 113.3(4)
N(8)-C(8)-H(8A) 108.9
C(7)-C(8)-H(8A) 108.9
N(8)-C(8)-H(8B) 108.9
C(7)-C(8)-H(8B) 108.9
H(8A)-C(8)-H(8B) 107.7
C(9)-N(8)-C(8) 124.4(4)
C(9)-N(8)-H(8N) 117.8
C(8)-N(8)-H(8N) 117.8
N(8)-C(9)-N(9) 123.7(5)
N(8)-C(9)-N(10) 113.7(5)
N(9)-C(9)-N(10) 122.6(5)
C(9)-N(9)-H(9A) 120.0
C(9)-N(9)-H(9B) 120.0
H(9A)-N(9)-H(9B) 120.0
O(10)-N(10)-C(9) 112.4(5)
O(10)-N(10)-H(10N) 123.8
C(9)-N(10)-H(10N) 123.8
N(10)-O(10)-H(10O) 109.5
_____________________________________________________________
Torsion angles [°] for (111)
________________________________________________________________
C(6)-C(1)-C(2)-C(3) 0.8(6)
C(7)-C(1)-C(2)-C(3) -177.4(4)
C(1)-C(2)-C(3)-C(4) -0.9(6)
C(1)-C(2)-C(3)-N(3) -178.3(4)
C(2)-C(3)-C(4)-C(5) 0.5(7)
N(3)-C(3)-C(4)-C(5) 177.9(4)
C(3)-C(4)-C(5)-C(6) 0.1(7)
C(4)-C(5)-C(6)-C(1) -0.2(7)
C(2)-C(1)-C(6)-C(5) -0.2(7)
C(7)-C(1)-C(6)-C(5) 178.0(4)
C(6)-C(1)-C(7)-C(8) -100.4(5)
C(2)-C(1)-C(7)-C(8) 77.8(5)
C(1)-C(7)-C(8)-N(8) -65.9(5)
C(7)-C(8)-N(8)-C(9) -78.9(5)
C(8)-N(8)-C(9)-N(9) -0.6(7)
C(8)-N(8)-C(9)-N(10) -179.4(4)
N(8)-C(9)-N(10)-O(10) -173.8(4)
N(9)-C(9)-N(10)-O(10) 7.4(7)
________________________________________________________________
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N-(tert-butoxycarbonyl)-2-(4’-aminophenyl)ethylcyanamide (113)
Crystal data and structure refinement for (113)
Empirical formula C14H19N3O2 Index ranges
-9<=h<=6, -10<=k<=10, -
12<=l<=13
Formula weight 261.32 Reflections collected 4755
Temperature 93(2) K Independentreflections 2600 [R(int) = 0.0444]
Wavelength 0.71073 Å Completeness to theta= 25.00° 97.7 %
Crystal system Triclinic Absorption correction Multiscan
Space group P-1 Max. and min.transmission 1.0000 and 0.8793
Unit cell dimensions
a = 8.304(8) Å,
α= 98.592(11)°
b = 8.733(7) Å,
β= 102.328(13)°
c = 11.538(9) Å,
γ= 112.065(15)°
Refinement method Full-matrix least-squareson F2
Volume 732.8(11) Å3 Data / restraints /parameters 2600 / 2 / 182
Z 2 Goodness-of-fit on F2 1.075
Density (calculated) 1.184 Mg/m3 Final R indices[I>2sigma(I)] R1 = 0.0670, wR2 = 0.1642
Absorption coefficient 0.081 mm-1 R indices (all data) R1 = 0.0937, wR2 = 0.1842
F(000) 280 Absolute structureparameter N/A
Crystal size 0.2000 x 0.0500 x 0.300mm3 Extinction coefficient 0.044(9)
Theta range for data
collection 1.87 to 25.35°
Largest diff. peak and
hole 0.259 and -0.321 e.Å
-3
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Bond lengths [Å] and angles [°] for (113)
_____________________________________________________
C(1)-C(2) 1.378(4)
C(1)-C(6) 1.401(4)
C(1)-C(7) 1.512(3)
C(2)-C(3) 1.396(3)
C(2)-H(2A) 0.9500
C(3)-C(4) 1.389(4)
C(3)-H(3A) 0.9500
C(4)-C(5) 1.384(4)
C(4)-N(4) 1.425(3)
C(5)-C(6) 1.387(3)
C(5)-H(5A) 0.9500
C(6)-H(6A) 0.9500
C(7)-C(8) 1.534(4)
C(7)-H(7A) 0.9900
C(7)-H(7B) 0.9900
C(8)-N(8) 1.457(3)
C(8)-H(8A) 0.9900
C(8)-H(8B) 0.9900
N(8)-C(9) 1.347(3)
N(8)-H(8N) 0.979(3)
O(9)-C(9) 1.226(3)
C(9)-O(10) 1.346(3)
O(10)-C(11) 1.491(3)
C(11)-C(12) 1.514(3)
C(11)-C(14) 1.517(4)
C(11)-C(13) 1.523(4)
C(12)-H(12A) 0.9800
C(12)-H(12B) 0.9800
C(12)-H(12C) 0.9800
C(13)-H(13A) 0.9800
C(13)-H(13B) 0.9800
C(13)-H(13C) 0.9800
C(14)-H(14A) 0.9800
C(14)-H(14B) 0.9800
C(14)-H(14C) 0.9800
N(4)-C(15) 1.327(4)
N(4)-H(4N) 0.980(3)
C(15)-N(15) 1.153(3)
C(2)-C(1)-C(6) 118.1(2)
C(2)-C(1)-C(7) 121.2(2)
C(6)-C(1)-C(7) 120.7(2)
C(1)-C(2)-C(3) 122.0(2)
C(1)-C(2)-H(2A) 119.0
C(3)-C(2)-H(2A) 119.0
C(4)-C(3)-C(2) 118.8(2)
C(4)-C(3)-H(3A) 120.6
C(2)-C(3)-H(3A) 120.6
C(5)-C(4)-C(3) 120.4(2)
C(5)-C(4)-N(4) 118.6(2)
C(3)-C(4)-N(4) 121.0(2)
C(4)-C(5)-C(6) 119.9(2)
C(4)-C(5)-H(5A) 120.1
C(6)-C(5)-H(5A) 120.1
C(5)-C(6)-C(1) 120.9(2)
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C(5)-C(6)-H(6A) 119.6
C(1)-C(6)-H(6A) 119.6
C(1)-C(7)-C(8) 112.9(2)
C(1)-C(7)-H(7A) 109.0
C(8)-C(7)-H(7A) 109.0
C(1)-C(7)-H(7B) 109.0
C(8)-C(7)-H(7B) 109.0
H(7A)-C(7)-H(7B) 107.8
N(8)-C(8)-C(7) 112.5(2)
N(8)-C(8)-H(8A) 109.1
C(7)-C(8)-H(8A) 109.1
N(8)-C(8)-H(8B) 109.1
C(7)-C(8)-H(8B) 109.1
H(8A)-C(8)-H(8B) 107.8
C(9)-N(8)-C(8) 123.1(2)
C(9)-N(8)-H(8N) 117.6(14)
C(8)-N(8)-H(8N) 118.7(14)
O(9)-C(9)-O(10) 124.6(2)
O(9)-C(9)-N(8) 125.2(2)
O(10)-C(9)-N(8) 110.2(2)
C(9)-O(10)-C(11) 121.13(19)
O(10)-C(11)-C(12) 109.74(18)
O(10)-C(11)-C(14) 110.10(19)
C(12)-C(11)-C(14) 113.2(2)
O(10)-C(11)-C(13) 101.69(19)
C(12)-C(11)-C(13) 110.6(2)
C(14)-C(11)-C(13) 110.9(2)
C(11)-C(12)-H(12A) 109.5
C(11)-C(12)-H(12B) 109.5
H(12A)-C(12)-H(12B) 109.5
C(11)-C(12)-H(12C) 109.5
H(12A)-C(12)-H(12C) 109.5
H(12B)-C(12)-H(12C) 109.5
C(11)-C(13)-H(13A) 109.5
C(11)-C(13)-H(13B) 109.5
H(13A)-C(13)-H(13B) 109.5
C(11)-C(13)-H(13C) 109.5
H(13A)-C(13)-H(13C) 109.5
H(13B)-C(13)-H(13C) 109.5
C(11)-C(14)-H(14A) 109.5
C(11)-C(14)-H(14B) 109.5
H(14A)-C(14)-H(14B) 109.5
C(11)-C(14)-H(14C) 109.5
H(14A)-C(14)-H(14C) 109.5
H(14B)-C(14)-H(14C) 109.5
C(15)-N(4)-C(4) 122.0(2)
C(15)-N(4)-H(4N) 118.6(16)
C(4)-N(4)-H(4N) 119.2(17)
N(15)-C(15)-N(4) 179.4(3)
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Torsion angles [°] for (113)
________________________________________________________________
C(6)-C(1)-C(2)-C(3) 0.7(4)
C(7)-C(1)-C(2)-C(3) 178.7(2)
C(1)-C(2)-C(3)-C(4) -1.2(4)
C(2)-C(3)-C(4)-C(5) 0.6(4)
C(2)-C(3)-C(4)-N(4) 179.9(2)
C(3)-C(4)-C(5)-C(6) 0.5(4)
N(4)-C(4)-C(5)-C(6) -178.9(2)
C(4)-C(5)-C(6)-C(1) -0.9(4)
C(2)-C(1)-C(6)-C(5) 0.3(4)
C(7)-C(1)-C(6)-C(5) -177.7(2)
C(2)-C(1)-C(7)-C(8) -96.6(3)
C(6)-C(1)-C(7)-C(8) 81.4(3)
C(1)-C(7)-C(8)-N(8) 65.5(3)
C(7)-C(8)-N(8)-C(9) -106.5(3)
C(8)-N(8)-C(9)-O(9) -2.7(4)
C(8)-N(8)-C(9)-O(10) 177.8(2)
O(9)-C(9)-O(10)-C(11) -5.7(4)
N(8)-C(9)-O(10)-C(11) 173.77(18)
C(9)-O(10)-C(11)-C(12) 68.2(3)
C(9)-O(10)-C(11)-C(14) -57.1(3)
C(9)-O(10)-C(11)-C(13) -174.7(2)
C(5)-C(4)-N(4)-C(15) -168.8(2)
C(3)-C(4)-N(4)-C(15) 11.8(4)
C(4)-N(4)-C(15)-N(15) 14(32)
________________________________________________________________
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N,N-dimethyl-N’-phenylethyl urea (126)
Crystal data and structure refinement for (126)
Empirical formula C11H16N2O Index ranges
-12<=h<=9, -11<=k<=10,
-22<=l<=24
Formula weight 192.26 Reflections collected 11892
Temperature 93(2) K Independentreflections 1887 [R(int) = 0.0220]
Wavelength 0.71073 Å Completeness to theta= 25.00° 96.3 %
Crystal system Orthorhombic Absorption correction Multiscan
Space group Pbca Max. and min.transmission 1.0000 and 0.5917
Unit cell dimensions
a = 10.417(2) Å,
α= 90°
b = 9.860(2) Å,
β= 90°
c = 20.882(5) Å,
γ= 90°
Refinement method Full-matrix least-squareson F2
Volume 2144.7(8) Å3 Data / restraints /parameters 1887 / 1 / 134
Z 8 Goodness-of-fit on F2 1.064
Density (calculated) 1.191 Mg/m3 Final R indices[I>2sigma(I)] R1 = 0.0443, wR2 = 0.1200
Absorption coefficient 0.078 mm-1 R indices (all data) R1 = 0.0462, wR2 = 0.1220
F(000) 832 Absolute structureparameter N/A
Crystal size 0.1500 x 0.1500 x 0.0300mm3 Extinction coefficient N/A
Theta range for data
collection 2.76 to 25.34°
Largest diff. peak and
hole 0.249 and -0.250 e.Å
-3
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N-phenylethylaminoiminomethanesulfonic acid (137)
Crystal data and structure refinement for (137)
Empirical formula C9H12N2O3S Index ranges
-6<=h<=5, -8<=k<=10, -
10<=l<=13
Formula weight 228.27 Reflections collected 3126
Temperature 93(2) K Independentreflections 1495 [R(int) = 0.0133]
Wavelength 0.71073 Å Completeness to theta= 25.00° 93.4 %
Crystal system Monoclinic Absorption correction Multiscan
Space group P2(1) Max. and min.transmission 1.0000 and 0.8547
Unit cell dimensions
a = 5.3683(12) Å,
α= 90°
b = 8.428(2) Å,
β= 92.506(7)°
c = 11.189(3) Å,
γ= 90°
Refinement method Full-matrix least-squareson F2
Volume 505.7(2) Å3 Data / restraints /parameters 1495 / 4 / 149
Z 2 Goodness-of-fit on F2 1.043
Density (calculated) 1.499 mg/m3 Final R indices[I>2sigma(I)] R1 = 0.0191, wR2 = 0.0474
Absorption coefficient 0.308 mm-1 R indices (all data) R1 = 0.0192, wR2 = 0.0475
F(000) 240 Absolute structureparameter 0.03(5)
Crystal size 0.1000 x 0.1000 x 0.1000mm3 Extinction coefficient N/A
Theta range for data
collection 3.03 to 25.37°
Largest diff. peak and
hole 0.265 and -0.186 e.Å
-3
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Bond lengths [Å] and angles [°] for (137)
_____________________________________________________
C(1)-C(6) 1.384(2)
C(1)-C(2) 1.394(2)
C(1)-C(7) 1.516(2)
C(2)-C(3) 1.388(2)
C(2)-H(2A) 0.9500
C(3)-C(4) 1.381(3)
C(3)-H(3A) 0.9500
C(4)-C(5) 1.387(2)
C(4)-H(4A) 0.9500
C(5)-C(6) 1.391(2)
C(5)-H(5A) 0.9500
C(6)-H(6A) 0.9500
C(7)-C(8) 1.523(2)
C(7)-H(7A) 0.9900
C(7)-H(7B) 0.9900
C(8)-N(8) 1.4803(18)
C(8)-H(8A) 0.9900
C(8)-H(8B) 0.9900
N(8)-C(9) 1.301(2)
N(8)-H(8N) 0.978(3)
C(9)-N(9) 1.305(2)
C(9)-S(9) 1.8242(15)
N(9)-H(9A) 0.979(3)
N(9)-H(9B) 0.978(3)
S(9)-O(2) 1.4403(12)
S(9)-O(3) 1.4432(12)
S(9)-O(1) 1.4466(12)
C(6)-C(1)-C(2) 119.12(15)
C(6)-C(1)-C(7) 121.22(14)
C(2)-C(1)-C(7) 119.65(16)
C(3)-C(2)-C(1) 120.21(16)
C(3)-C(2)-H(2A) 119.9
C(1)-C(2)-H(2A) 119.9
C(4)-C(3)-C(2) 120.49(15)
C(4)-C(3)-H(3A) 119.8
C(2)-C(3)-H(3A) 119.8
C(3)-C(4)-C(5) 119.50(15)
C(3)-C(4)-H(4A) 120.2
C(5)-C(4)-H(4A) 120.2
C(4)-C(5)-C(6) 120.14(16)
C(4)-C(5)-H(5A) 119.9
C(6)-C(5)-H(5A) 119.9
C(1)-C(6)-C(5) 120.52(15)
C(1)-C(6)-H(6A) 119.7
C(5)-C(6)-H(6A) 119.7
C(1)-C(7)-C(8) 112.29(13)
C(1)-C(7)-H(7A) 109.1
C(8)-C(7)-H(7A) 109.1
C(1)-C(7)-H(7B) 109.1
C(8)-C(7)-H(7B) 109.1
H(7A)-C(7)-H(7B) 107.9
N(8)-C(8)-C(7) 108.35(13)
N(8)-C(8)-H(8A) 110.0
C(7)-C(8)-H(8A) 110.0
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N(8)-C(8)-H(8B) 110.0
C(7)-C(8)-H(8B) 110.0
H(8A)-C(8)-H(8B) 108.4
C(9)-N(8)-C(8) 124.75(13)
C(9)-N(8)-H(8N) 119.8(11)
C(8)-N(8)-H(8N) 115.4(11)
N(8)-C(9)-N(9) 126.48(13)
N(8)-C(9)-S(9) 116.07(11)
N(9)-C(9)-S(9) 117.42(11)
C(9)-N(9)-H(9A) 118.7(14)
C(9)-N(9)-H(9B) 123.5(13)
H(9A)-N(9)-H(9B) 118(2)
O(2)-S(9)-O(3) 114.96(7)
O(2)-S(9)-O(1) 113.95(7)
O(3)-S(9)-O(1) 114.81(7)
O(2)-S(9)-C(9) 104.76(7)
O(3)-S(9)-C(9) 102.29(7)
O(1)-S(9)-C(9) 104.05(7)
_____________________________________________________________
Torsion angles [°] for (137)
________________________________________________________________
C(6)-C(1)-C(2)-C(3) -1.0(2)
C(7)-C(1)-C(2)-C(3) -179.99(15)
C(1)-C(2)-C(3)-C(4) 1.2(3)
C(2)-C(3)-C(4)-C(5) -0.5(3)
C(3)-C(4)-C(5)-C(6) -0.5(3)
C(2)-C(1)-C(6)-C(5) 0.0(2)
C(7)-C(1)-C(6)-C(5) 179.01(15)
C(4)-C(5)-C(6)-C(1) 0.7(2)
C(6)-C(1)-C(7)-C(8) 104.53(18)
C(2)-C(1)-C(7)-C(8) -76.50(19)
C(1)-C(7)-C(8)-N(8) 175.02(13)
C(7)-C(8)-N(8)-C(9) -171.64(14)
C(8)-N(8)-C(9)-N(9) -1.6(2)
C(8)-N(8)-C(9)-S(9) -179.73(12)
N(8)-C(9)-S(9)-O(2) -61.96(13)
N(9)-C(9)-S(9)-O(2) 119.76(12)
N(8)-C(9)-S(9)-O(3) 58.31(13)
N(9)-C(9)-S(9)-O(3) -119.96(12)
N(8)-C(9)-S(9)-O(1) 178.13(11)
N(9)-C(9)-S(9)-O(1) -0.15(13)
________________________________________________________________
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N-methyl-N’-phenylethylaminoiminomethanesulfonic acid (132)
Crystal data and structure refinement for (132)
Empirical formula C10H14N2O3S Index ranges
-13<=h<=13, -
13<=k<=12, -9<=l<=8
Formula weight 242.29 Reflections collected 6525
Temperature 93(2) K Independentreflections 1931 [R(int) = 0.0249]
Wavelength 0.71073 Å Completeness to theta= 25.00° 96.6 %
Crystal system Orthorhombic Absorption correction Multiscan
Space group Pna2(1) Max. and min.transmission 1.0000 and 0.7812
Unit cell dimensions
a = 11.814(2) Å,
α= 90°
b = 11.656(2) Å,
β= 90°
c = 8.6208(16) Å,
γ= 90°
Refinement method Full-matrix least-squareson F2
Volume 1187(4) Å3 Data / restraints /parameters 1931 / 3 / 156
Z 4 Goodness-of-fit on F2 1.051
Density (calculated) 1.356 mg/m3 Final R indices[I>2sigma(I)] R1 = 0.0232, wR2 = 0.0576
Absorption coefficient 0.267 mm-1 R indices (all data) R1 = 0.0245, wR2 = 0.0582
F(000) 512 Absolute structureparameter -0.03(6)
Crystal size 0.080 x 0.080 x 0.080 mm3 Extinction coefficient 0.0023(12)
Theta range for data
collection 2.45 to 25.33°
Largest diff. peak and
hole 0.207 and -0.174 e.Å
-3
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Bond lengths [Å] and angles [°] for (132)
_____________________________________________________
C(1)-C(2) 1.386(3)
C(1)-C(6) 1.395(3)
C(1)-C(7) 1.505(3)
C(2)-C(3) 1.385(3)
C(2)-H(2A) 0.9500
C(3)-C(4) 1.369(4)
C(3)-H(3A) 0.9500
C(4)-C(5) 1.382(4)
C(4)-H(4A) 0.9500
C(5)-C(6) 1.386(4)
C(5)-H(5A) 0.9500
C(6)-H(6A) 0.9500
C(7)-C(8) 1.520(2)
C(7)-H(7A) 0.9900
C(7)-H(7B) 0.9900
C(8)-N(8) 1.468(2)
C(8)-H(8A) 0.9900
C(8)-H(8B) 0.9900
N(8)-C(9) 1.311(2)
N(8)-H(8N) 0.979(3)
C(9)-N(9) 1.303(2)
C(9)-S(9) 1.8147(17)
N(9)-C(10) 1.455(2)
N(9)-H(9N) 0.978(3)
C(10)-H(10A) 0.9800
C(10)-H(10B) 0.9800
C(10)-H(10C) 0.9800
S(9)-O(3) 1.4341(13)
S(9)-O(1) 1.4369(14)
S(9)-O(2) 1.4442(13)
C(2)-C(1)-C(6) 118.36(19)
C(2)-C(1)-C(7) 121.03(16)
C(6)-C(1)-C(7) 120.60(16)
C(3)-C(2)-C(1) 121.24(19)
C(3)-C(2)-H(2A) 119.4
C(1)-C(2)-H(2A) 119.4
C(4)-C(3)-C(2) 120.0(2)
C(4)-C(3)-H(3A) 120.0
C(2)-C(3)-H(3A) 120.0
C(3)-C(4)-C(5) 119.8(2)
C(3)-C(4)-H(4A) 120.1
C(5)-C(4)-H(4A) 120.1
C(4)-C(5)-C(6) 120.6(2)
C(4)-C(5)-H(5A) 119.7
C(6)-C(5)-H(5A) 119.7
C(5)-C(6)-C(1) 120.0(2)
C(5)-C(6)-H(6A) 120.0
C(1)-C(6)-H(6A) 120.0
C(1)-C(7)-C(8) 111.92(14)
C(1)-C(7)-H(7A) 109.2
C(8)-C(7)-H(7A) 109.2
C(1)-C(7)-H(7B) 109.2
C(8)-C(7)-H(7B) 109.2
H(7A)-C(7)-H(7B) 107.9
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N(8)-C(8)-C(7) 110.88(13)
N(8)-C(8)-H(8A) 109.5
C(7)-C(8)-H(8A) 109.5
N(8)-C(8)-H(8B) 109.5
C(7)-C(8)-H(8B) 109.5
H(8A)-C(8)-H(8B) 108.1
C(9)-N(8)-C(8) 127.62(15)
C(9)-N(8)-H(8N) 118.8(13)
C(8)-N(8)-H(8N) 113.1(13)
N(9)-C(9)-N(8) 122.89(16)
N(9)-C(9)-S(9) 115.54(13)
N(8)-C(9)-S(9) 121.56(14)
C(9)-N(9)-C(10) 123.09(15)
C(9)-N(9)-H(9N) 118.7(13)
C(10)-N(9)-H(9N) 118.0(13)
N(9)-C(10)-H(10A) 109.5
N(9)-C(10)-H(10B) 109.5
H(10A)-C(10)-H(10B) 109.5
N(9)-C(10)-H(10C) 109.5
H(10A)-C(10)-H(10C) 109.5
H(10B)-C(10)-H(10C) 109.5
O(3)-S(9)-O(1) 114.42(8)
O(3)-S(9)-O(2) 115.43(8)
O(1)-S(9)-O(2) 113.87(8)
O(3)-S(9)-C(9) 103.63(8)
O(1)-S(9)-C(9) 105.31(8)
O(2)-S(9)-C(9) 102.15(7)
_____________________________________________________________
Torsion angles [°] for (132)
________________________________________________________________
C(6)-C(1)-C(2)-C(3) 0.3(3)
C(7)-C(1)-C(2)-C(3) 179.33(17)
C(1)-C(2)-C(3)-C(4) -0.2(3)
C(2)-C(3)-C(4)-C(5) 0.0(3)
C(3)-C(4)-C(5)-C(6) 0.2(4)
C(4)-C(5)-C(6)-C(1) -0.1(4)
C(2)-C(1)-C(6)-C(5) -0.2(3)
C(7)-C(1)-C(6)-C(5) -179.2(2)
C(2)-C(1)-C(7)-C(8) 103.07(18)
C(6)-C(1)-C(7)-C(8) -77.9(2)
C(1)-C(7)-C(8)-N(8) -177.50(14)
C(7)-C(8)-N(8)-C(9) -96.89(19)
C(8)-N(8)-C(9)-N(9) 177.79(17)
C(8)-N(8)-C(9)-S(9) -3.7(2)
N(8)-C(9)-N(9)-C(10) 1.6(3)
S(9)-C(9)-N(9)-C(10) -177.02(13)
N(9)-C(9)-S(9)-O(3) -11.65(15)
N(8)-C(9)-S(9)-O(3) 169.74(14)
N(9)-C(9)-S(9)-O(1) -132.15(14)
N(8)-C(9)-S(9)-O(1) 49.25(16)
N(9)-C(9)-S(9)-O(2) 108.63(14)
N(8)-C(9)-S(9)-O(2) -69.97(15)
________________________________________________________________
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N-dimethyl-N’-phenylethylaminoiminomethanesulfonic acid (133)
Crystal data and structure refinement for (133)
Empirical formula C11H16N2O3S Index ranges
-25<=h<=21, -10<=k<=8,
-12<=l<=14
Formula weight 256.32 Reflections collected 13988
Temperature 93(2) K Independentreflections 3991 [R(int) = 0.0322]
Wavelength 0.71073 Å Completeness to theta= 25.00° 98.0 %
Crystal system Orthorhombic Absorption correction Multiscan
Space group Pca2(1) Max. and min.transmission 1.0000 and 0.8622
Unit cell dimensions
a = 21.828(3) Å,
α= 90°
b = 9.0868(13) Å,
β= 90°
c = 12.3809(19) Å,
γ= 90°
Refinement method Full-matrix least-squareson F2
Volume 2455.7(6) Å3 Data / restraints /parameters 3991 / 3 / 321
Z 8 Goodness-of-fit on F2 1.057
Density (calculated) 1.387 mg/m3 Final R indices[I>2sigma(I)] R1 = 0.0403, wR2 = 0.0855
Absorption coefficient 0.262 mm-1 R indices (all data) R1 = 0.0497, wR2 = 0.0898
F(000) 1088 Absolute structureparameter 0.33(8)
Crystal size 0.100 x 0.100 x 0.030 mm3 Extinction coefficient 0.0015(3)
Theta range for data
collection 2.92 to 25.35°
Largest diff. peak and
hole 0.317 and -0.391 e.Å
-3
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Bond lengths [Å] and angles [°] for (133)
_____________________________________________________
C(1)-C(6) 1.374(5)
C(1)-C(2) 1.395(6)
C(1)-C(7) 1.521(6)
C(2)-C(3) 1.401(5)
C(2)-H(2A) 0.9500
C(3)-C(4) 1.370(5)
C(3)-H(3A) 0.9500
C(4)-C(5) 1.380(5)
C(4)-H(4A) 0.9500
C(5)-C(6) 1.381(5)
C(5)-H(5A) 0.9500
C(6)-H(6A) 0.9500
C(7)-C(8) 1.367(7)
C(7)-H(7A) 0.9900
C(7)-H(7B) 0.9900
C(8)-N(8) 1.475(6)
C(8)-H(8A) 0.9900
C(8)-H(8B) 0.9900
N(8)-C(9) 1.320(5)
N(8)-H(8N) 0.979(3)
C(9)-N(9) 1.309(4)
C(9)-S(9) 1.839(3)
S(9)-O(2) 1.436(2)
S(9)-O(3) 1.440(2)
S(9)-O(1) 1.441(2)
N(9)-C(11) 1.458(4)
N(9)-C(10) 1.468(4)
C(10)-H(10A) 0.9800
C(10)-H(10B) 0.9800
C(10)-H(10C) 0.9800
C(11)-H(11A) 0.9800
C(11)-H(11B) 0.9800
C(11)-H(11C) 0.9800
C(21)-C(22) 1.386(4)
C(21)-C(26) 1.396(5)
C(21)-C(27) 1.512(5)
C(22)-C(23) 1.404(5)
C(22)-H(22A) 0.9500
C(23)-C(24) 1.369(5)
C(23)-H(23A) 0.9500
C(24)-C(25) 1.374(5)
C(24)-H(24A) 0.9500
C(25)-C(26) 1.386(5)
C(25)-H(25A) 0.9500
C(26)-H(26A) 0.9500
C(27)-C(28) 1.520(5)
C(27)-H(27A) 0.9900
C(27)-H(27B) 0.9900
C(28)-N(28) 1.477(5)
C(28)-H(28A) 0.9900
C(28)-H(28B) 0.9900
N(28)-C(29) 1.311(4)
N(28)-H(28N) 0.979(3)
C(29)-N(29) 1.317(4)
C(29)-S(29) 1.844(3)
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S(29)-O(5) 1.435(2)
S(29)-O(6) 1.439(2)
S(29)-O(4) 1.448(2)
N(29)-C(30) 1.467(4)
N(29)-C(31) 1.475(4)
C(30)-H(30A) 0.9800
C(30)-H(30B) 0.9800
C(30)-H(30C) 0.9800
C(31)-H(31A) 0.9800
C(31)-H(31B) 0.9800
C(31)-H(31C) 0.9800
C(6)-C(1)-C(2) 118.3(4)
C(6)-C(1)-C(7) 119.6(4)
C(2)-C(1)-C(7) 122.1(4)
C(1)-C(2)-C(3) 120.4(4)
C(1)-C(2)-H(2A) 119.8
C(3)-C(2)-H(2A) 119.8
C(4)-C(3)-C(2) 119.9(4)
C(4)-C(3)-H(3A) 120.0
C(2)-C(3)-H(3A) 120.0
C(3)-C(4)-C(5) 119.8(3)
C(3)-C(4)-H(4A) 120.1
C(5)-C(4)-H(4A) 120.1
C(4)-C(5)-C(6) 120.1(4)
C(4)-C(5)-H(5A) 119.9
C(6)-C(5)-H(5A) 119.9
C(1)-C(6)-C(5) 121.4(4)
C(1)-C(6)-H(6A) 119.3
C(5)-C(6)-H(6A) 119.3
C(8)-C(7)-C(1) 118.2(4)
C(8)-C(7)-H(7A) 107.8
C(1)-C(7)-H(7A) 107.8
C(8)-C(7)-H(7B) 107.8
C(1)-C(7)-H(7B) 107.8
H(7A)-C(7)-H(7B) 107.1
C(7)-C(8)-N(8) 114.3(4)
C(7)-C(8)-H(8A) 108.7
N(8)-C(8)-H(8A) 108.7
C(7)-C(8)-H(8B) 108.7
N(8)-C(8)-H(8B) 108.7
H(8A)-C(8)-H(8B) 107.6
C(9)-N(8)-C(8) 130.6(4)
C(9)-N(8)-H(8N) 110(3)
C(8)-N(8)-H(8N) 119(3)
N(9)-C(9)-N(8) 127.0(3)
N(9)-C(9)-S(9) 119.4(3)
N(8)-C(9)-S(9) 113.6(2)
O(2)-S(9)-O(3) 114.97(16)
O(2)-S(9)-O(1) 114.58(15)
O(3)-S(9)-O(1) 114.24(15)
O(2)-S(9)-C(9) 103.19(15)
O(3)-S(9)-C(9) 104.62(14)
O(1)-S(9)-C(9) 103.21(14)
C(9)-N(9)-C(11) 123.0(3)
C(9)-N(9)-C(10) 124.1(3)
C(11)-N(9)-C(10) 112.6(3)
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N(9)-C(10)-H(10A) 109.5
N(9)-C(10)-H(10B) 109.5
H(10A)-C(10)-H(10B) 109.5
N(9)-C(10)-H(10C) 109.5
H(10A)-C(10)-H(10C) 109.5
H(10B)-C(10)-H(10C) 109.5
N(9)-C(11)-H(11A) 109.5
N(9)-C(11)-H(11B) 109.5
H(11A)-C(11)-H(11B) 109.5
N(9)-C(11)-H(11C) 109.5
H(11A)-C(11)-H(11C) 109.5
H(11B)-C(11)-H(11C) 109.5
C(22)-C(21)-C(26) 118.5(3)
C(22)-C(21)-C(27) 121.6(3)
C(26)-C(21)-C(27) 119.8(3)
C(21)-C(22)-C(23) 120.5(3)
C(21)-C(22)-H(22A) 119.8
C(23)-C(22)-H(22A) 119.8
C(24)-C(23)-C(22) 119.9(3)
C(24)-C(23)-H(23A) 120.0
C(22)-C(23)-H(23A) 120.0
C(23)-C(24)-C(25) 120.1(3)
C(23)-C(24)-H(24A) 119.9
C(25)-C(24)-H(24A) 119.9
C(24)-C(25)-C(26) 120.6(3)
C(24)-C(25)-H(25A) 119.7
C(26)-C(25)-H(25A) 119.7
C(25)-C(26)-C(21) 120.4(3)
C(25)-C(26)-H(26A) 119.8
C(21)-C(26)-H(26A) 119.8
C(21)-C(27)-C(28) 110.8(3)
C(21)-C(27)-H(27A) 109.5
C(28)-C(27)-H(27A) 109.5
C(21)-C(27)-H(27B) 109.5
C(28)-C(27)-H(27B) 109.5
H(27A)-C(27)-H(27B) 108.1
N(28)-C(28)-C(27) 110.0(3)
N(28)-C(28)-H(28A) 109.7
C(27)-C(28)-H(28A) 109.7
N(28)-C(28)-H(28B) 109.7
C(27)-C(28)-H(28B) 109.7
H(28A)-C(28)-H(28B) 108.2
C(29)-N(28)-C(28) 128.9(3)
C(29)-N(28)-H(28N) 117(2)
C(28)-N(28)-H(28N) 114(2)
N(28)-C(29)-N(29) 126.5(3)
N(28)-C(29)-S(29) 113.9(2)
N(29)-C(29)-S(29) 119.7(2)
O(5)-S(29)-O(6) 115.20(15)
O(5)-S(29)-O(4) 114.33(14)
O(6)-S(29)-O(4) 113.91(14)
O(5)-S(29)-C(29) 104.75(15)
O(6)-S(29)-C(29) 104.39(14)
O(4)-S(29)-C(29) 102.29(15)
C(29)-N(29)-C(30) 123.4(3)
C(29)-N(29)-C(31) 123.7(3)
C(30)-N(29)-C(31) 112.9(3)
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N(29)-C(30)-H(30A) 109.5
N(29)-C(30)-H(30B) 109.5
H(30A)-C(30)-H(30B) 109.5
N(29)-C(30)-H(30C) 109.5
H(30A)-C(30)-H(30C) 109.5
H(30B)-C(30)-H(30C) 109.5
N(29)-C(31)-H(31A) 109.5
N(29)-C(31)-H(31B) 109.5
H(31A)-C(31)-H(31B) 109.5
N(29)-C(31)-H(31C) 109.5
H(31A)-C(31)-H(31C) 109.5
H(31B)-C(31)-H(31C) 109.5
_____________________________________________________________
Torsion angles [°] for (133)
________________________________________________________________
C(6)-C(1)-C(2)-C(3) -0.1(6)
C(7)-C(1)-C(2)-C(3) -178.7(4)
C(1)-C(2)-C(3)-C(4) -0.1(6)
C(2)-C(3)-C(4)-C(5) -0.3(5)
C(3)-C(4)-C(5)-C(6) 0.7(5)
C(2)-C(1)-C(6)-C(5) 0.5(6)
C(7)-C(1)-C(6)-C(5) 179.2(4)
C(4)-C(5)-C(6)-C(1) -0.9(5)
C(6)-C(1)-C(7)-C(8) 147.3(6)
C(2)-C(1)-C(7)-C(8) -34.1(8)
C(1)-C(7)-C(8)-N(8) -168.5(5)
C(7)-C(8)-N(8)-C(9) -117.3(6)
C(8)-N(8)-C(9)-N(9) -14.1(7)
C(8)-N(8)-C(9)-S(9) 166.8(4)
N(9)-C(9)-S(9)-O(2) -51.4(3)
N(8)-C(9)-S(9)-O(2) 127.8(3)
N(9)-C(9)-S(9)-O(3) 69.2(3)
N(8)-C(9)-S(9)-O(3) -111.6(3)
N(9)-C(9)-S(9)-O(1) -170.9(3)
N(8)-C(9)-S(9)-O(1) 8.2(3)
N(8)-C(9)-N(9)-C(11) -15.9(5)
S(9)-C(9)-N(9)-C(11) 163.1(3)
N(8)-C(9)-N(9)-C(10) 171.3(3)
S(9)-C(9)-N(9)-C(10) -9.7(4)
C(26)-C(21)-C(22)-C(23) 0.0(5)
C(27)-C(21)-C(22)-C(23) 179.0(3)
C(21)-C(22)-C(23)-C(24) 0.8(5)
C(22)-C(23)-C(24)-C(25) -1.3(5)
C(23)-C(24)-C(25)-C(26) 1.0(5)
C(24)-C(25)-C(26)-C(21) -0.1(5)
C(22)-C(21)-C(26)-C(25) -0.4(5)
C(27)-C(21)-C(26)-C(25) -179.3(3)
C(22)-C(21)-C(27)-C(28) 113.1(3)
C(26)-C(21)-C(27)-C(28) -67.9(4)
C(21)-C(27)-C(28)-N(28) 179.9(3)
C(27)-C(28)-N(28)-C(29) 146.2(3)
C(28)-N(28)-C(29)-N(29) 22.2(5)
C(28)-N(28)-C(29)-S(29) -158.8(2)
N(28)-C(29)-S(29)-O(5) -124.8(2)
N(29)-C(29)-S(29)-O(5) 54.3(3)
N(28)-C(29)-S(29)-O(6) 113.8(2)
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N(29)-C(29)-S(29)-O(6) -67.2(3)
N(28)-C(29)-S(29)-O(4) -5.2(3)
N(29)-C(29)-S(29)-O(4) 173.9(2)
N(28)-C(29)-N(29)-C(30) -167.1(3)
S(29)-C(29)-N(29)-C(30) 14.0(4)
N(28)-C(29)-N(29)-C(31) 13.8(5)
S(29)-C(29)-N(29)-C(31) -165.1(2)
________________________________________________________________
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N-phenylethyl-N’-hydroxyguanidine hydrochloride (120)
Crystal data and structure refinement for (120)
Empirical formula C9H14ClN3O Index ranges
-14<=h<=10, -8<=k<=7, -
28<=l<=29
Formula weight 215.68 Reflections collected 10496
Temperature 93(2) K Independentreflections 3283 [R(int) = 0.0317]
Wavelength 0.71073 Å Completeness to theta= 25.00° 84.7 %
Crystal system Monoclinic Absorption correction Multiscan
Space group P2(1)/c Max. and min.transmission 1.0000 and 0.8445
Unit cell dimensions
a = 11.980(3) Å,
α= 90°
b = 7.3875(15) Å,
β= 99.080(6)°
c = 24.609(7) Å
γ= 90°
Refinement method Full-matrix least-squareson F2
Volume 2150.6(10) Å3 Data / restraints /parameters 3283 / 10 / 295
Z 8 Goodness-of-fit on F2 0.910
Density (calculated) 1.332 Mg/m3 Final R indices[I>2sigma(I)] R1 = 0.0675, wR2 = 0.1366
Absorption coefficient 0.328 mm-1 R indices (all data) R1 = 0.0750, wR2 = 0.1404
F(000) 912 Absolute structureparameter N/A
Crystal size 0.1000 x 0.1000 x 0.0100mm3 Extinction coefficient 0.0018(4)
Theta range for data
collection 2.21 to 25.32°
Largest diff. peak and
hole 0.503 and -0.350 e.Å
-3
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Bond lengths [Å] and angles [°] for (120)
_____________________________________________________
C(1)-C(2) 1.381(6)
C(1)-C(6) 1.400(6)
C(1)-C(7) 1.514(6)
C(2)-C(3) 1.385(6)
C(2)-H(2A) 0.9500
C(3)-C(4) 1.377(7)
C(3)-H(3A) 0.9500
C(4)-C(5) 1.386(7)
C(4)-H(4A) 0.9500
C(5)-C(6) 1.383(6)
C(5)-H(5A) 0.9500
C(6)-H(6A) 0.9500
C(7)-C(8) 1.512(6)
C(7)-H(7A) 0.9900
C(7)-H(7B) 0.9900
C(8)-N(8) 1.467(5)
C(8)-H(8A) 0.9900
C(8)-H(8B) 0.9900
N(8)-C(9) 1.323(5)
N(8)-H(8N) 0.969(19)
C(9)-N(9) 1.329(5)
C(9)-N(10) 1.360(5)
N(9)-H(9A) 0.983(19)
N(9)-H(9B) 0.968(19)
N(10)-O(10) 1.412(5)
N(10)-H(10N) 0.97(2)
O(10)-H(10O) 0.97(2)
C(11)-C(16) 1.384(6)
C(11)-C(12) 1.398(6)
C(11)-C(17) 1.516(5)
C(12)-C(13) 1.386(6)
C(12)-H(12A) 0.9500
C(13)-C(14) 1.385(7)
C(13)-H(13A) 0.9500
C(14)-C(15) 1.381(6)
C(14)-H(14A) 0.9500
C(15)-C(16) 1.393(6)
C(15)-H(15A) 0.9500
C(16)-H(16A) 0.9500
C(17)-C(18) 1.521(6)
C(17)-H(17A) 0.9900
C(17)-H(17B) 0.9900
C(18)-N(18) 1.470(5)
C(18)-H(18A) 0.9900
C(18)-H(18B) 0.9900
N(18)-C(19) 1.327(5)
N(18)-H(18N) 0.97(2)
C(19)-N(19) 1.321(5)
C(19)-N(20) 1.350(5)
N(19)-H(19A) 0.97(2)
N(19)-H(19B) 0.98(2)
N(20)-O(20) 1.412(5)
N(20)-H(20N) 0.962(19)
O(20)-H(20O) 0.97(2)
APPENDIX
298
C(2)-C(1)-C(6) 119.2(4)
C(2)-C(1)-C(7) 121.6(4)
C(6)-C(1)-C(7) 119.1(4)
C(1)-C(2)-C(3) 120.9(4)
C(1)-C(2)-H(2A) 119.6
C(3)-C(2)-H(2A) 119.6
C(4)-C(3)-C(2) 119.9(5)
C(4)-C(3)-H(3A) 120.1
C(2)-C(3)-H(3A) 120.1
C(3)-C(4)-C(5) 119.8(4)
C(3)-C(4)-H(4A) 120.1
C(5)-C(4)-H(4A) 120.1
C(6)-C(5)-C(4) 120.7(4)
C(6)-C(5)-H(5A) 119.6
C(4)-C(5)-H(5A) 119.6
C(5)-C(6)-C(1) 119.5(4)
C(5)-C(6)-H(6A) 120.2
C(1)-C(6)-H(6A) 120.2
C(8)-C(7)-C(1) 112.8(4)
C(8)-C(7)-H(7A) 109.0
C(1)-C(7)-H(7A) 109.0
C(8)-C(7)-H(7B) 109.0
C(1)-C(7)-H(7B) 109.0
H(7A)-C(7)-H(7B) 107.8
N(8)-C(8)-C(7) 109.0(4)
N(8)-C(8)-H(8A) 109.9
C(7)-C(8)-H(8A) 109.9
N(8)-C(8)-H(8B) 109.9
C(7)-C(8)-H(8B) 109.9
H(8A)-C(8)-H(8B) 108.3
C(9)-N(8)-C(8) 123.9(4)
C(9)-N(8)-H(8N) 112(3)
C(8)-N(8)-H(8N) 123(3)
N(8)-C(9)-N(9) 122.6(4)
N(8)-C(9)-N(10) 119.4(4)
N(9)-C(9)-N(10) 118.0(4)
C(9)-N(9)-H(9A) 118(3)
C(9)-N(9)-H(9B) 115(3)
H(9A)-N(9)-H(9B) 120(4)
C(9)-N(10)-O(10) 112.7(3)
C(9)-N(10)-H(10N) 107(3)
O(10)-N(10)-H(10N) 123(3)
N(10)-O(10)-H(10O) 106(4)
C(16)-C(11)-C(12) 118.6(4)
C(16)-C(11)-C(17) 121.0(4)
C(12)-C(11)-C(17) 120.3(4)
C(13)-C(12)-C(11) 120.4(4)
C(13)-C(12)-H(12A) 119.8
C(11)-C(12)-H(12A) 119.8
C(14)-C(13)-C(12) 120.3(4)
C(14)-C(13)-H(13A) 119.8
C(12)-C(13)-H(13A) 119.8
C(15)-C(14)-C(13) 119.7(4)
C(15)-C(14)-H(14A) 120.1
C(13)-C(14)-H(14A) 120.1
C(14)-C(15)-C(16) 119.9(4)
C(14)-C(15)-H(15A) 120.0
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C(16)-C(15)-H(15A) 120.0
C(11)-C(16)-C(15) 120.9(4)
C(11)-C(16)-H(16A) 119.5
C(15)-C(16)-H(16A) 119.5
C(11)-C(17)-C(18) 115.2(4)
C(11)-C(17)-H(17A) 108.5
C(18)-C(17)-H(17A) 108.5
C(11)-C(17)-H(17B) 108.5
C(18)-C(17)-H(17B) 108.5
H(17A)-C(17)-H(17B) 107.5
N(18)-C(18)-C(17) 110.7(3)
N(18)-C(18)-H(18A) 109.5
C(17)-C(18)-H(18A) 109.5
N(18)-C(18)-H(18B) 109.5
C(17)-C(18)-H(18B) 109.5
H(18A)-C(18)-H(18B) 108.1
C(19)-N(18)-C(18) 122.1(4)
C(19)-N(18)-H(18N) 117(4)
C(18)-N(18)-H(18N) 121(4)
N(19)-C(19)-N(18) 122.3(4)
N(19)-C(19)-N(20) 117.8(4)
N(18)-C(19)-N(20) 119.9(4)
C(19)-N(19)-H(19A) 128(4)
C(19)-N(19)-H(19B) 117(3)
H(19A)-N(19)-H(19B) 108(5)
C(19)-N(20)-O(20) 114.9(3)
C(19)-N(20)-H(20N) 110(3)
O(20)-N(20)-H(20N) 123(3)
N(20)-O(20)-H(20O) 105(4)
_____________________________________________________________
Torsion angles [°] for (120)
________________________________________________________________
C(6)-C(1)-C(2)-C(3) -1.2(7)
C(7)-C(1)-C(2)-C(3) -179.4(4)
C(1)-C(2)-C(3)-C(4) 0.1(7)
C(2)-C(3)-C(4)-C(5) 1.2(7)
C(3)-C(4)-C(5)-C(6) -1.4(7)
C(4)-C(5)-C(6)-C(1) 0.4(7)
C(2)-C(1)-C(6)-C(5) 0.9(7)
C(7)-C(1)-C(6)-C(5) 179.2(4)
C(2)-C(1)-C(7)-C(8) 73.9(6)
C(6)-C(1)-C(7)-C(8) -104.3(5)
C(1)-C(7)-C(8)-N(8) 161.3(4)
C(7)-C(8)-N(8)-C(9) -161.5(4)
C(8)-N(8)-C(9)-N(9) -8.2(6)
C(8)-N(8)-C(9)-N(10) 171.9(4)
N(8)-C(9)-N(10)-O(10) -19.6(5)
N(9)-C(9)-N(10)-O(10) 160.5(3)
C(16)-C(11)-C(12)-C(13) -1.3(6)
C(17)-C(11)-C(12)-C(13) 176.5(4)
C(11)-C(12)-C(13)-C(14) 0.6(7)
C(12)-C(13)-C(14)-C(15) 1.4(7)
C(13)-C(14)-C(15)-C(16) -2.8(7)
C(12)-C(11)-C(16)-C(15) 0.0(7)
C(17)-C(11)-C(16)-C(15) -177.8(4)
C(14)-C(15)-C(16)-C(11) 2.1(7)
APPENDIX
300
C(16)-C(11)-C(17)-C(18) -116.0(5)
C(12)-C(11)-C(17)-C(18) 66.2(5)
C(11)-C(17)-C(18)-N(18) 71.9(4)
C(17)-C(18)-N(18)-C(19) 179.9(3)
C(18)-N(18)-C(19)-N(19) 7.3(6)
C(18)-N(18)-C(19)-N(20) -172.0(4)
N(19)-C(19)-N(20)-O(20) 165.2(3)
N(18)-C(19)-N(20)-O(20) -15.4(5)
________________________________________________________________
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N,N-dimethyl-N’-phenylethyl-N-hydroxyguanidine hydrochloride (122)
Crystal data and structure refinement for (122)
Empirical formula C11H18ClN3O Index ranges
-5<=h<=8, -7<=k<=9, -
14<=l<=15
Formula weight 243.73 Reflections collected 3917
Temperature 93(2) K Independentreflections 2097 [R(int) = 0.0327]
Wavelength 0.71073 Å Completeness to theta= 25.00° 92.9 %
Crystal system Triclinic Absorption correction Multiscan
Space group P-1 Max. and min.transmission 1.0000 and 0.6247
Unit cell dimensions
a = 6.9008(16) Å,
α= 78.99(2)°
b = 7.6974(18) Å,
β= 75.15(2)°
c = 12.576(3) Å
γ= 76.77(3)°
Refinement method Full-matrix least-squareson F2
Volume 622.3(3) Å3 Data / restraints /parameters 2097 / 3 / 161
Z 2 Goodness-of-fit on F2 1.006
Density (calculated) 1.301 Mg/m3 Final R indices[I>2sigma(I)] R1 = 0.0407, wR2 = 0.0724
Absorption coefficient 0.292 mm-1 R indices (all data) R1 = 0.0538, wR2 = 0.0783
F(000) 260 Absolute structureparameter N/A
Crystal size 0.1500 x 0.0500 x 0.0500mm3 Extinction coefficient 0.0012(16)
Theta range for data
collection 2.75 to 25.32°
Largest diff. peak and
hole 0.231 and -0.237 e.Å
-3
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Bond lengths [Å] and angles [°] for (122)
_____________________________________________________
C(1)-C(2) 1.386(3)
C(1)-C(6) 1.391(2)
C(1)-C(7) 1.515(2)
C(2)-C(3) 1.396(3)
C(2)-H(2A) 0.9500
C(3)-C(4) 1.372(3)
C(3)-H(3A) 0.9500
C(4)-C(5) 1.378(3)
C(4)-H(4A) 0.9500
C(5)-C(6) 1.383(3)
C(5)-H(5A) 0.9500
C(6)-H(6A) 0.9500
C(7)-C(8) 1.518(3)
C(7)-H(7A) 0.9900
C(7)-H(7B) 0.9900
C(8)-N(8) 1.461(2)
C(8)-H(8A) 0.9900
C(8)-H(8B) 0.9900
N(8)-C(9) 1.334(2)
N(8)-H(8N) 0.979(3)
C(9)-N(9) 1.335(2)
C(9)-N(10) 1.348(2)
N(9)-C(11) 1.457(2)
N(9)-C(10) 1.466(2)
C(10)-H(10A) 0.9800
C(10)-H(10B) 0.9800
C(10)-H(10C) 0.9800
C(11)-H(11A) 0.9800
C(11)-H(11B) 0.9800
C(11)-H(11C) 0.9800
N(10)-O(10) 1.4117(19)
N(10)-H(10N) 0.979(3)
O(10)-H(10O) 0.979(3)
C(2)-C(1)-C(6) 117.90(18)
C(2)-C(1)-C(7) 123.42(17)
C(6)-C(1)-C(7) 118.69(18)
C(1)-C(2)-C(3) 120.50(18)
C(1)-C(2)-H(2A) 119.8
C(3)-C(2)-H(2A) 119.8
C(4)-C(3)-C(2) 120.7(2)
C(4)-C(3)-H(3A) 119.6
C(2)-C(3)-H(3A) 119.6
C(3)-C(4)-C(5) 119.26(18)
C(3)-C(4)-H(4A) 120.4
C(5)-C(4)-H(4A) 120.4
C(4)-C(5)-C(6) 120.25(19)
C(4)-C(5)-H(5A) 119.9
C(6)-C(5)-H(5A) 119.9
C(5)-C(6)-C(1) 121.4(2)
C(5)-C(6)-H(6A) 119.3
C(1)-C(6)-H(6A) 119.3
C(1)-C(7)-C(8) 114.69(16)
C(1)-C(7)-H(7A) 108.6
C(8)-C(7)-H(7A) 108.6
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C(1)-C(7)-H(7B) 108.6
C(8)-C(7)-H(7B) 108.6
H(7A)-C(7)-H(7B) 107.6
N(8)-C(8)-C(7) 108.77(16)
N(8)-C(8)-H(8A) 109.9
C(7)-C(8)-H(8A) 109.9
N(8)-C(8)-H(8B) 109.9
C(7)-C(8)-H(8B) 109.9
H(8A)-C(8)-H(8B) 108.3
C(9)-N(8)-C(8) 124.92(16)
C(9)-N(8)-H(8N) 114.5(13)
C(8)-N(8)-H(8N) 118.1(13)
N(8)-C(9)-N(9) 119.66(17)
N(8)-C(9)-N(10) 119.19(16)
N(9)-C(9)-N(10) 121.12(16)
C(9)-N(9)-C(11) 120.72(15)
C(9)-N(9)-C(10) 123.10(15)
C(11)-N(9)-C(10) 115.43(14)
N(9)-C(10)-H(10A) 109.5
N(9)-C(10)-H(10B) 109.5
H(10A)-C(10)-H(10B) 109.5
N(9)-C(10)-H(10C) 109.5
H(10A)-C(10)-H(10C) 109.5
H(10B)-C(10)-H(10C) 109.5
N(9)-C(11)-H(11A) 109.5
N(9)-C(11)-H(11B) 109.5
H(11A)-C(11)-H(11B) 109.5
N(9)-C(11)-H(11C) 109.5
H(11A)-C(11)-H(11C) 109.5
H(11B)-C(11)-H(11C) 109.5
C(9)-N(10)-O(10) 116.86(13)
C(9)-N(10)-H(10N) 123.3(12)
O(10)-N(10)-H(10N) 110.2(12)
N(10)-O(10)-H(10O) 105.7(13)
_____________________________________________________________
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Torsion angles [°] for (122)
________________________________________________________________
C(6)-C(1)-C(2)-C(3) 0.4(3)
C(7)-C(1)-C(2)-C(3) -179.89(17)
C(1)-C(2)-C(3)-C(4) 0.2(3)
C(2)-C(3)-C(4)-C(5) -0.4(3)
C(3)-C(4)-C(5)-C(6) 0.1(3)
C(4)-C(5)-C(6)-C(1) 0.4(3)
C(2)-C(1)-C(6)-C(5) -0.7(3)
C(7)-C(1)-C(6)-C(5) 179.59(18)
C(2)-C(1)-C(7)-C(8) -0.1(3)
C(6)-C(1)-C(7)-C(8) 179.63(17)
C(1)-C(7)-C(8)-N(8) -178.88(15)
C(7)-C(8)-N(8)-C(9) 159.21(17)
C(8)-N(8)-C(9)-N(9) -163.22(17)
C(8)-N(8)-C(9)-N(10) 19.0(3)
N(8)-C(9)-N(9)-C(11) 18.3(3)
N(10)-C(9)-N(9)-C(11) -164.03(16)
N(8)-C(9)-N(9)-C(10) -151.36(18)
N(10)-C(9)-N(9)-C(10) 26.3(3)
N(8)-C(9)-N(10)-O(10) -147.57(16)
N(9)-C(9)-N(10)-O(10) 34.7(2)
________________________________________________________________
APPENDIX
305
3-phenylpropionohydroxamic acid (139)
Crystal data and structure refinement for (139)
Empirical formula C9H11NO2 Index ranges
-9<=h<=9, -8<=k<=8, -
30<=l<=30
Formula weight 165.19 Reflections collected 14529
Temperature 93(2) K Independentreflections 1286 [R(int) = 0.1240]
Wavelength 1.54178 Å Completeness to theta= 25.00° 96.2 %
Crystal system Orthorhombic Absorption correction Multiscan
Space group Pbca Max. and min.transmission 1.0000 and 0.7177
Unit cell dimensions
a = 10.5232(9) Å,
α= 90°
b = 9.5588(9) Å,
β= 90°
c = 33.738(3) Å
γ= 90°
Refinement method Full-matrix least-squareson F2
Volume 3393.7(5) Å3 Data / restraints /parameters 1286 / 4 / 235
Z 16 Goodness-of-fit on F2 1.053
Density (calculated) 1.293 mg/m3 Final R indices[I>2sigma(I)] R1 = 0.0606, wR2 = 0.1562
Absorption coefficient 0.753 mm-1 R indices (all data) R1 = 0.0646, wR2 = 0.1607
F(000) 1408 Absolute structureparameter N/A
Crystal size 0.100 x 0.100 x 0.010 mm3 Extinction coefficient 0.0011(3)
Theta range for data
collection 4.95 to 44.67°
Largest diff. peak and
hole 0.217 and -0.227 e.Å
-3
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Bond lengths [Å] and angles [°] for (139)
_____________________________________________________
C(1)-C(6) 1.380(5)
C(1)-C(2) 1.387(5)
C(1)-C(7) 1.499(5)
C(2)-C(3) 1.363(5)
C(2)-H(2A) 0.9500
C(3)-C(4) 1.371(6)
C(3)-H(3A) 0.9500
C(4)-C(5) 1.368(5)
C(4)-H(4A) 0.9500
C(5)-C(6) 1.391(5)
C(5)-H(5A) 0.9500
C(6)-H(6A) 0.9500
C(7)-C(8) 1.530(5)
C(7)-H(7A) 0.9900
C(7)-H(7B) 0.9900
C(8)-C(9) 1.492(5)
C(8)-H(8A) 0.9900
C(8)-H(8B) 0.9900
C(9)-O(9) 1.251(4)
C(9)-N(9) 1.314(4)
N(9)-O(10) 1.394(3)
N(9)-H(9N) 0.979(3)
O(10)-H(10O) 0.980(3)
C(11)-C(12) 1.388(5)
C(11)-C(16) 1.392(5)
C(11)-C(17) 1.506(5)
C(12)-C(13) 1.379(5)
C(12)-H(12A) 0.9500
C(13)-C(14) 1.387(5)
C(13)-H(13A) 0.9500
C(14)-C(15) 1.379(5)
C(14)-H(14A) 0.9500
C(15)-C(16) 1.373(5)
C(15)-H(15A) 0.9500
C(16)-H(16A) 0.9500
C(17)-C(18) 1.544(5)
C(17)-H(17A) 0.9900
C(17)-H(17B) 0.9900
C(18)-C(19) 1.486(5)
C(18)-H(18A) 0.9900
C(18)-H(18B) 0.9900
C(19)-O(19) 1.257(4)
C(19)-N(19) 1.316(5)
N(19)-O(20) 1.405(4)
N(19)-H(19N) 0.980(3)
O(20)-H(20O) 0.980(3)
C(6)-C(1)-C(2) 117.1(3)
C(6)-C(1)-C(7) 121.9(3)
C(2)-C(1)-C(7) 121.0(3)
C(3)-C(2)-C(1) 122.1(4)
C(3)-C(2)-H(2A) 118.9
C(1)-C(2)-H(2A) 118.9
C(2)-C(3)-C(4) 120.4(4)
C(2)-C(3)-H(3A) 119.8
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C(4)-C(3)-H(3A) 119.8
C(5)-C(4)-C(3) 119.1(4)
C(5)-C(4)-H(4A) 120.5
C(3)-C(4)-H(4A) 120.5
C(4)-C(5)-C(6) 120.5(4)
C(4)-C(5)-H(5A) 119.7
C(6)-C(5)-H(5A) 119.7
C(1)-C(6)-C(5) 120.8(4)
C(1)-C(6)-H(6A) 119.6
C(5)-C(6)-H(6A) 119.6
C(1)-C(7)-C(8) 114.8(3)
C(1)-C(7)-H(7A) 108.6
C(8)-C(7)-H(7A) 108.6
C(1)-C(7)-H(7B) 108.6
C(8)-C(7)-H(7B) 108.6
H(7A)-C(7)-H(7B) 107.5
C(9)-C(8)-C(7) 113.3(3)
C(9)-C(8)-H(8A) 108.9
C(7)-C(8)-H(8A) 108.9
C(9)-C(8)-H(8B) 108.9
C(7)-C(8)-H(8B) 108.9
H(8A)-C(8)-H(8B) 107.7
O(9)-C(9)-N(9) 122.7(3)
O(9)-C(9)-C(8) 121.4(4)
N(9)-C(9)-C(8) 115.9(4)
C(9)-N(9)-O(10) 118.9(3)
C(9)-N(9)-H(9N) 127.3(17)
O(10)-N(9)-H(9N) 113.2(17)
N(9)-O(10)-H(10O) 102(2)
C(12)-C(11)-C(16) 117.6(3)
C(12)-C(11)-C(17) 122.4(4)
C(16)-C(11)-C(17) 120.0(3)
C(13)-C(12)-C(11) 121.2(4)
C(13)-C(12)-H(12A) 119.4
C(11)-C(12)-H(12A) 119.4
C(12)-C(13)-C(14) 120.4(4)
C(12)-C(13)-H(13A) 119.8
C(14)-C(13)-H(13A) 119.8
C(15)-C(14)-C(13) 118.9(4)
C(15)-C(14)-H(14A) 120.5
C(13)-C(14)-H(14A) 120.5
C(16)-C(15)-C(14) 120.5(4)
C(16)-C(15)-H(15A) 119.7
C(14)-C(15)-H(15A) 119.7
C(15)-C(16)-C(11) 121.4(3)
C(15)-C(16)-H(16A) 119.3
C(11)-C(16)-H(16A) 119.3
C(11)-C(17)-C(18) 116.5(3)
C(11)-C(17)-H(17A) 108.2
C(18)-C(17)-H(17A) 108.2
C(11)-C(17)-H(17B) 108.2
C(18)-C(17)-H(17B) 108.2
H(17A)-C(17)-H(17B) 107.3
C(19)-C(18)-C(17) 112.5(3)
C(19)-C(18)-H(18A) 109.1
C(17)-C(18)-H(18A) 109.1
C(19)-C(18)-H(18B) 109.1
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C(17)-C(18)-H(18B) 109.1
H(18A)-C(18)-H(18B) 107.8
O(19)-C(19)-N(19) 121.7(3)
O(19)-C(19)-C(18) 122.8(3)
N(19)-C(19)-C(18) 115.4(3)
C(19)-N(19)-O(20) 118.9(3)
C(19)-N(19)-H(19N) 123.1(19)
O(20)-N(19)-H(19N) 116.4(19)
N(19)-O(20)-H(20O) 106(3)
_____________________________________________________________
Torsion angles [°] for (139)
________________________________________________________________
C(6)-C(1)-C(2)-C(3) -0.1(5)
C(7)-C(1)-C(2)-C(3) 179.3(3)
C(1)-C(2)-C(3)-C(4) -0.3(6)
C(2)-C(3)-C(4)-C(5) 0.3(6)
C(3)-C(4)-C(5)-C(6) 0.1(6)
C(2)-C(1)-C(6)-C(5) 0.5(5)
C(7)-C(1)-C(6)-C(5) -178.9(3)
C(4)-C(5)-C(6)-C(1) -0.5(6)
C(6)-C(1)-C(7)-C(8) 74.2(4)
C(2)-C(1)-C(7)-C(8) -105.2(4)
C(1)-C(7)-C(8)-C(9) -74.1(4)
C(7)-C(8)-C(9)-O(9) -55.3(4)
C(7)-C(8)-C(9)-N(9) 125.6(3)
O(9)-C(9)-N(9)-O(10) 3.1(5)
C(8)-C(9)-N(9)-O(10) -177.8(2)
C(16)-C(11)-C(12)-C(13) -1.1(5)
C(17)-C(11)-C(12)-C(13) 177.1(3)
C(11)-C(12)-C(13)-C(14) -0.2(5)
C(12)-C(13)-C(14)-C(15) 0.5(5)
C(13)-C(14)-C(15)-C(16) 0.4(5)
C(14)-C(15)-C(16)-C(11) -1.8(5)
C(12)-C(11)-C(16)-C(15) 2.1(5)
C(17)-C(11)-C(16)-C(15) -176.1(3)
C(12)-C(11)-C(17)-C(18) 28.3(5)
C(16)-C(11)-C(17)-C(18) -153.5(3)
C(11)-C(17)-C(18)-C(19) 62.4(4)
C(17)-C(18)-C(19)-O(19) 59.8(4)
C(17)-C(18)-C(19)-N(19) -120.9(3)
O(19)-C(19)-N(19)-O(20) -5.4(4)
C(18)-C(19)-N(19)-O(20) 175.3(3)
________________________________________________________________
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4-(trifluoromethyl)phenylacetohydroxamic acid (141)
Crystal data and structure refinement for (141)
Empirical formula C9H8F3NO2 Index ranges
-32<=h<=42, -6<=k<=4, -
11<=l<=11
Formula weight 219.16 Reflections collected 5651
Temperature 93(2) K Independentreflections 1697 [R(int) = 0.1554]
Wavelength 1.54178 Å Completeness to theta= 25.00° 98.7 %
Crystal system Monoclinic Absorption correction Multiscan
Space group C2/c Max. and min.transmission 1.0000 and 0.9676
Unit cell dimensions
a = 35.291(7) Å,
α= 90°
b = 5.6375(11) Å,
β= 95.27(3)°
c = 9.4844(19) Å
γ= 90°
Refinement method Full-matrix least-squareson F2
Volume 1878.9(6) Å3 Data / restraints /parameters 1697 / 2 / 145
Z 8 Goodness-of-fit on F2 1.046
Density (calculated) 1.550 mg/m3 Final R indices[I>2sigma(I)] R1 = 0.1194, wR2 = 0.3016
Absorption coefficient 0.148 mm-1 R indices (all data) R1 = 0.1947, wR2 = 0.3619
F(000) 896 Absolute structureparameter N/A
Crystal size 0.3000 x 0.1000 x 0.0100mm3 Extinction coefficient N/A
Theta range for data
collection 2.32 to 25.40°
Largest diff. peak and
hole 0.439 and -0.425 e.Å
-3
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Bond lengths [Å] and angles [°] for (141)
_____________________________________________________
C(1)-C(6) 1.384(10)
C(1)-C(2) 1.397(9)
C(1)-C(7) 1.523(9)
C(2)-C(3) 1.375(9)
C(2)-H(2A) 0.9500
C(3)-C(4) 1.386(10)
C(3)-H(3A) 0.9500
C(4)-C(5) 1.401(9)
C(4)-C(9) 1.482(10)
C(5)-C(6) 1.360(10)
C(5)-H(5A) 0.9500
C(6)-H(6A) 0.9500
C(7)-C(8) 1.503(9)
C(7)-H(7A) 0.9900
C(7)-H(7B) 0.9900
C(8)-O(8) 1.248(8)
C(8)-N(8) 1.317(9)
N(8)-O(9) 1.398(7)
N(8)-H(8N) 0.980(3)
O(9)-H(9O) 0.980(3)
C(9)-F(1) 1.323(9)
C(9)-F(2) 1.326(8)
C(9)-F(3) 1.366(9)
C(6)-C(1)-C(2) 118.6(6)
C(6)-C(1)-C(7) 120.9(6)
C(2)-C(1)-C(7) 120.5(6)
C(3)-C(2)-C(1) 121.1(7)
C(3)-C(2)-H(2A) 119.4
C(1)-C(2)-H(2A) 119.4
C(2)-C(3)-C(4) 119.5(6)
C(2)-C(3)-H(3A) 120.2
C(4)-C(3)-H(3A) 120.2
C(3)-C(4)-C(5) 119.5(6)
C(3)-C(4)-C(9) 121.8(6)
C(5)-C(4)-C(9) 118.6(7)
C(6)-C(5)-C(4) 120.3(6)
C(6)-C(5)-H(5A) 119.9
C(4)-C(5)-H(5A) 119.9
C(5)-C(6)-C(1) 121.0(6)
C(5)-C(6)-H(6A) 119.5
C(1)-C(6)-H(6A) 119.5
C(8)-C(7)-C(1) 114.8(6)
C(8)-C(7)-H(7A) 108.6
C(1)-C(7)-H(7A) 108.6
C(8)-C(7)-H(7B) 108.6
C(1)-C(7)-H(7B) 108.6
H(7A)-C(7)-H(7B) 107.5
O(8)-C(8)-N(8) 123.5(6)
O(8)-C(8)-C(7) 122.8(6)
N(8)-C(8)-C(7) 113.7(6)
C(8)-N(8)-O(9) 122.2(6)
C(8)-N(8)-H(8N) 122(3)
O(9)-N(8)-H(8N) 115(3)
N(8)-O(9)-H(9O) 94(6)
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F(1)-C(9)-F(2) 107.4(6)
F(1)-C(9)-F(3) 105.6(6)
F(2)-C(9)-F(3) 104.3(6)
F(1)-C(9)-C(4) 113.7(7)
F(2)-C(9)-C(4) 114.0(5)
F(3)-C(9)-C(4) 111.1(6)
_____________________________________________________________
Torsion angles [°] for (141)
________________________________________________________________
C(6)-C(1)-C(2)-C(3) 1.5(10)
C(7)-C(1)-C(2)-C(3) -177.7(6)
C(1)-C(2)-C(3)-C(4) -0.1(11)
C(2)-C(3)-C(4)-C(5) -0.2(10)
C(2)-C(3)-C(4)-C(9) 177.9(7)
C(3)-C(4)-C(5)-C(6) -1.0(10)
C(9)-C(4)-C(5)-C(6) -179.2(7)
C(4)-C(5)-C(6)-C(1) 2.6(10)
C(2)-C(1)-C(6)-C(5) -2.8(10)
C(7)-C(1)-C(6)-C(5) 176.5(6)
C(6)-C(1)-C(7)-C(8) 118.0(7)
C(2)-C(1)-C(7)-C(8) -62.8(9)
C(1)-C(7)-C(8)-O(8) -40.8(9)
C(1)-C(7)-C(8)-N(8) 139.1(6)
O(8)-C(8)-N(8)-O(9) -1.6(10)
C(7)-C(8)-N(8)-O(9) 178.5(5)
C(3)-C(4)-C(9)-F(1) 8.0(10)
C(5)-C(4)-C(9)-F(1) -173.9(6)
C(3)-C(4)-C(9)-F(2) 131.5(7)
C(5)-C(4)-C(9)-F(2) -50.4(9)
C(3)-C(4)-C(9)-F(3) -111.0(8)
C(5)-C(4)-C(9)-F(3) 67.1(8)
________________________________________________________________
